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ABSTRACT 
 
M. ELIZABETH HODGSON:  The Case-only Method for Gene-Environment Interaction 
Studies:  The Independence Assumption Illustrated with Empirical Data from the Published 
literature and Two Population-based Control groups, the Carolina Breast Cancer Study and 
the North Carolina Colon Cancer Study 
 
(Under the direction of Robert C. Millikan) 
 
Gene-environment interaction in the etiology of disease is a topic of on-going 
interest.  While there has been increasing use of the case-only study design to investigate 
gene-environment interaction in cancer, as well as other disease areas, concerns about the 
underlying assumption that the genetic and environmental exposures are independent in the 
underlying population (the independence assumption) have not been adequately addressed.  
The case-only study design requires only cases, no population controls or cohort, to estimate 
statistical interaction.  This design has obvious cost advantages, as well as some 
methodological and ethical advantages.  However, for results to be valid the independence 
assumption must be met.  There has been little investigation into the frequency and 
magnitude of independence assumption violation for DNA repair genes and smoking, an 
interaction of particular interest in cancer.  Nor have optimal methods for validating the 
independence assumption received much attention. 
Empirical data of two types were used to evaluate the independence assumption for 
selected genetic variants and smoking behavior.  A systematic review of the literature 
identified 55 studies that presented the joint distribution of smoking and SNPs in 3 DNA 
repair genes (XRCC1 Arg399Gln, Arg194Trp, or Arg280His, XPD Lys751Gln, and 
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Asp312Asn, and XRCC3 Thr241Met).  Measures of smoking were ever/never smoking, 
current/not current smoker, duration of smoking (<=10 years, 11-20 years, >20 years), 
intensity (<1/2 pack/day, ½-1 pack/day, >1 pack/day), and pack-years (<=35 pack-years, >35 
pack-years).  The odds ratio for SNP-smoking association in controls (ORz) was used to 
estimate the gene-environment association in the underlying population.  Results showed that 
ORz was not reliably null for any of the SNP-smoking combinations.  Studies with XRCC1 
399 / ever-never smoking and XPD 751 / pack-years were too heterogeneous for summary 
estimates [ranges, ORz (95% confidence interval (CI)): 0.7 (0.4, 1.2) – 1.9 (1.2, 2.8) and 0.8 
(0.5, 1.3) – 2.3 (0.8, 6.1), respectively).  In addition, estimates for studies considered 
homogeneous (Cochran’s Q p-value <0.10) varied 2- to 5-fold within meta-analysis.  No 
study characteristics were identified that could explain heterogeneity.  
Data from two population-based control groups, the Carolina Breast Cancer Study 
and the North Carolina Colon Cancer Study, were used to evaluate the independence 
assumption for smoking and a panel of eight metabolic and 26 DNA repair genes plausibly 
related to smoking behavior.  ORz was not consistent across smoking measures precluding 
the use of one smoking measure (e.g. ever-never) as a substitute for evaluating other 
measures such as duration and dose.  In particular, results for smoking status were most often 
near the null, while measures of smoking amount for the same SNPs were of sufficient 
magnitude to cause appreciable bias in the case-only estimates (ORz<=0.7 or >=1.4) 
approximately half of the time.  There were no strong patterns of the magnitude or direction 
of ORz differing by race, age, gender or biological pathway (xenobiotic metabolism, DNA 
repair).  
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Taken together, results suggest that ORz should be considered population-specific. 
Therefore, the independence assumption should be evaluated in the population underlying a 
case-only study, rather than in a proxy control group(s) or pooled controls.  A systematic 
search for relevant literature and control data, in addition to a comprehensive evaluation of 
all smoking measures used in the case-only analysis are essential for evaluation of the 
independence assumption. 
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I. INTRODUCTION 
The case-only study design as proposed by Prentice (1984) and popularized by 
Piegorsch (1994) and Khoury (1996) has become increasingly popular over the last decade, 
especially for studies of gene-environment interaction (GxE) in cancer.  It is used in 
epidemiologic studies to estimate the magnitude of statistical interaction between two 
measured exposures with respect to a given outcome [1-3].  This method requires only cases, 
no population controls or cohort.  Provided the design assumptions are met, the case-only 
study can estimate statistical interactions that deviate from the multiplicative null.  The 
relationship between gene-environment interaction estimated by the case-only odds ratio 
(COR) and the same gene-environment interaction estimated by a case-control study can be 
expressed as follows (OR=odds ratio): 
OR gene*env, case-only = OR gene*envr, case-control /(OR gene, case-control * OR envr, case-control)   *  Z 
where Z (estimated by ORz) is the association between the gene and the environmental 
exposure in the control group of a case-control study [3].  The quantity [OR gene*envr, case-control 
/(OR gene, case-control * OR envr, case-control)] is sometimes referred to as the synergy index on a 
multiplicative scale, or synergy index on a multiple scale (SIM).  When there is no association 
between the genetic exposure and the environmental exposure in the population (i.e. Z=1), the 
case-only OR is equivalent to the (multiplicative) deviation from a (perfectly) multiplicative 
relationship between the genetic and environmental exposures (i.e. COR = SIM).  Using these 
abbreviations, the relationship can be expressed succinctly as:  
COR = SIM * ORz. 
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There are a number of possible causal and non-causal reasons for Z to take on values 
other than one. Values of Z greater or less than 1 can be due to a biological relationship 
between the gene and the exposure, either because the polymorphism itself is a causal variant 
of the gene or because it is in linkage disequilibrium (LD) with a causal variant.  One non-
causal reason for Z to vary from the null is that environmental and genetic exposures may 
have been non-differentially misclassified with respect to each other, as can happen when 
population stratification is present [4].  Non-random misclassification of either the genetic 
exposure (e.g. through linkage disequilibrium) or the environmental exposure (e.g. heavy 
smokers underreport smoking more than light smokers) can also create apparent association in 
a study population.  Selection bias can also cause association between two exposures in a 
study population.  For instance, if smokers with a family history of the outcome are less likely 
to participate as controls than smokers without a family history or non-smokers with a family 
history, a spurious inverse control group association could be created between smoking and 
any genetic exposure related to family history.  
Conversely, a positive association could be seen in the study, even though there is no 
association in the underlying population, if smokers with a family history are more likely to 
participate than non-smokers with a family history or smokers without a family history.  
Cohort effects could affect control group associations if, for instance, a genetic exposure is 
associated with longevity, and the environmental exposure is one that has changed prevalence 
in the population over time, such as smoking or dietary patterns.  Chance can also play a role.  
Since the expectation that Z=1 is a large sample asymptotic approximation, as sample size 
decreases, Z will deviate from the null with increasing frequency through random error alone 
[5].  Consequently, as Z is evaluated in subgroups, and sample size drops, Z can deviate from 
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unity by chance alone.  Further, as sample size decreases, the power to detect interaction also 
drops sharply [6].  The assumption that Z=1 can only be evaluated if both exposures have 
been measured in the population at risk or, in the context of a case-control study, in an 
appropriate control population.  
There are clear advantages to the case-only method in several settings.  The lack of 
requirement for a control group reduces costs, but there are methodological and ethical 
advantages as well.  Differential recruiting success between cases and controls raises 
questions of selection bias and the difficulty of establishing an appropriate control group for 
hospital-based studies of rare diseases is well known [7].  Because only cases are used in the 
analysis, recall bias generated by differential recall between cases and controls cannot affect 
case-only studies, although differential recall among cases by genetic and/or environmental 
factors is still possible. Estimation of the interaction parameter from case-only analyses is 
more efficient than for a traditional case-control study (i.e. fewer cases are required for 
similar precision of estimate) [8].  Invasive procedures that are part of cases’ diagnosis or 
treatment often cannot be done ethically in healthy volunteers, especially with vulnerable 
populations such as children [9].  Additionally, the cost/benefit balance for controls in a study 
that collects genetic information is different than for a study that does not collect genetic 
information.  That is, there are potentially greater costs (e.g. potential misuse of information, 
potential for unwanted information about genetically related individuals to be revealed etc.) 
for the same benefits.  
Further, questions of sample size have a strong albeit controversial ethical dimension, 
with some arguing that smaller studies are more ethical due to a more favorable risk/benefit 
ratio [10-11], and others arguing that under-powered studies are unethical [12-13].  This is 
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particularly relevant for gene-environment interaction research, where the traditional case-
control approach requires large sample sizes, and there is ongoing interest in exploring valid 
alternative methodologies such as sequential testing, or case-only studies [3, 14-15].   
But these advantages come at a cost. A case-only study only estimates interaction on a 
multiplicative scale, and cannot estimate the independent effect of either exposure, or additive 
joint effects, limiting its use to situations where the independent or additive effects of the two 
exposures are not of interest. However, where independent effects are already well described 
(e.g. smoking and lung cancer) or thought to be negligible (e.g. low penetrance polymorphic 
genes) this may still be an attractive design [2].  It has been proposed as a screening method to 
identify candidate genes, or gene-environment or gene-gene interactions that may be 
etiologically important for further investigation [5, 16-17]. 
In addition to limits on the estimates that can be obtained, the validity of case-only 
studies is limited by multiple design assumptions.  Many are common to all epidemiologic 
study designs; no misclassification of exposure or disease, no selection bias, no uncontrolled 
confounding and a sufficient sample size are examples.  In addition, however, the validity of 
the case-only estimate of interaction rests on the assumption that the two exposures are 
independent in the population from which the cases arose [2], referred to henceforth as the 
independence assumption.  
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II. REVIEW OF THE LITERATURE 
A. Published case-only analyses 
To date, numerous studies have been published using the case-only method of 
assessing interaction.  Although the case-only study design is theoretically applicable to 
studying statistical interaction between any two exposures for a given case definition, it has 
been proposed as particularly useful for gene-environment interaction or gene-gene 
interaction [3].  The distribution of published reports bears this out.  Of the 27 case-only 
interaction studies found in PubMed from Jan 1, 2007- Sept 21, 2009 [search term:  “case-
only” , Limits: English, Human], 25 contained assessments of gene-environment interaction, 
with strongest interest in cancer outcomes (18 publications).  Two included gene-gene 
interaction; four included environment-environment interaction where environment was 
broadly defined as any non-genotypic factor.   
Of the 15 most recent case-only interaction analyses published (2008-2009) 11 were 
nested in existing case-control studies, one was nested in a cohort although genetic data were 
not available for non-cases and three were stand-alone case-only studies (no controls or 
cohort). For approximately half of the nested analyses, both the case-only estimates of 
interaction (COR) and case-control estimates of interaction [SIM or interaction odds ratio 
(IOR)] were presented.  Case-only analyses fully nested in case-control studies (also called 
adjunct case-only analyses) are generally performed to take advantage of the increased 
precision afforded by the case-only approach, or address potential shortcomings in the 
controls, such as differential recall between cases and controls [18] or a low response rate in 
controls [19].  In fact, over the last decade, at least two variations on the case-only approach 
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have been implemented:  partially nested extensions of case-control studies, (additional cases 
added to the cases in a case-control study) [20-22], interaction of time-varying population-
level factors and fixed individual-level factors [23-24]. 
Smoking behavior and/or tobacco use is the single most frequently examined 
environmental exposure in case-only interaction analyses. It was assessed in approximately 
half of the case-only analyses in the last two years, most often in conjunction with xenobiotic 
metabolizing genes [e.g. GSTs (glutathione S-transferases), CYP1A1 (cytochrome P450, 
family 1, subfamily A, polypeptide 1)].  DNA repair genes are often examined in traditional 
interaction studies, frequently with smoking, however, there have only been two case-only 
interaction analyses of DNA repair genes between Jan 1, 2007 and Sept 23, 2009 and neither 
examined smoking [25-26].  
  In the recent literature (2008-2009), in addition to nested case-only studies, there 
have been three stand-alone case-only analyses (i.e. no controls, no relevant data for controls 
and/or no case-control estimates presented [25, 27-28].  Studies designed as case-only (no 
controls) have been employed to address a range of issues beyond increased precision or 
reduced cost.  Case-only studies can address the ethical problem of carrying out invasive or 
frightening exposure measurements on healthy participants, particularly children [9, 25, 29-
32].  They have been used to examine interaction when a control group is not easily 
identifiable, as in the case of very rare diseases where cases are collected over several 
population [33-34], where appropriate controls are prohibitively expensive to identify [35] or 
for special populations such as centenarians [16, 36].  When the genetic exposure is both rare 
and highly penetrant, such as BRCA1/2, it may be prohibitively difficult to collect sufficient 
controls for interaction analyses [34, 37-39].   
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An important distinction among the case-only studies of gene-environment interaction 
is their approach to verifying the source population assumption of independence.  At the 
extremes, approaches range from no explicit mention of the independence assumption [19, 37, 
40] to assessment in a sample of a geographically and demographically similar population 
[25, 41].  Justification is often based on the plausibility of the independence assumption alone 
[9, 18, 27, 34, 42-48].  However, a number of studies have undertaken more quantitative 
evaluations of the independence assumption [20-22, 25-26, 35, 41, 49-53].  Among the case-
only studies published in 2008-2009, only one presented the control-only estimates (ORz) for 
the relevant analyses [35].  Two of the three stand-alone case studies justified the 
independence assumption:  1) Smits (2008) referenced a large study of pooled GSEC controls 
[28, 54] and 2) Yang (2008) used subjects “randomly selected from the same population” 
[25].  Not surprisingly, most case-only studies that presented a quantitative or semi-
quantitative assessment of the independence assumption were at least partially nested within 
case-control studies.  Although nested case-only studies can assess the independence 
assumption most rigorously, assuming the control group adequately represents the underlying 
population, the fact that they have a control group means that cannot realize the full cost or 
ethical advantages that help make the case-only study design attractive.    
A number of approaches have been taken for quantitative assessment of the 
independence assumption, whether the independence assumption is being evaluated in study 
control groups and/or in ancillary data (i.e. data external to the published study), although all 
approaches have ultimately relied almost exclusively on statistical significance.  Some studies 
assessed the independence assumption using the χ2 test for categorical variables at α=0.05, 
while others simply stated that no significant associations were found, without specifying 
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method of assessment.  Few studies provided information on the magnitude of any 
associations between genotype and environmental exposure from control groups or ancillary 
data.  However, even in the most thorough presentations of control-only data, statistical 
significance is the paramount concern.    For example, in Egan (2003), where equivalently 
adjusted case-only and control-only analyses of each categorization of environmental 
exposure and subgroup examined were presented side by side [52], the magnitude of the ORzs 
in controls varied from 0.5 to 1.1, yet only the sole statistically significant association was 
considered problematic.  Similarly, data presented in Marcus et. al. (2000) allowed calculation 
of control group ORzs for each study included in the pooled analysis, which showed wide 
variation in the magnitude of ORzs (0.5 - 1.8). 
Stand-alone case-only studies often do not present any quantitative assessment of the 
independence assumption.  One stand-alone study to do so calculated unadjusted ORz 
(95%CI)s from published control group cross-classifications of genotype [CYP1B1 
Val432Leu, catechol-O-methyltransferase (COMT) Val108Met and sulfotransferase 1A, 
member 1 (SULT1A1) Arg213His] and environmental exposure (smoking, ever/never) and 
presented an ORz (95% CI) for each of the 3 associations studied [53].  All associations 
between ever smoking and variant genotype were weakly inverse and none were statistically 
significant: ORz (95%CI) = 0.77 (0.19, 3.10) for CYP1B1 (Leu/Leu vs. any Val), 0.90 (0.45, 
1.81) for COMT (Val/Val vs. any Met), and 0.72 (0.38, 1.34) for SULT1A1 (Arg/Arg vs. any 
His).  The control group associations for CYP1B1 and COMT were from a population-based 
study of ovarian cancer conducted in Hawaii among women of 3 different ethnicities 
(Ncontrol=144) [55]; the SULT1A1 control group association examined was from a study of 
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lung cancer conducted in Texas that used managed care enrollees as controls (Ncontrol=444) 
[56].   
Since publication of the Saintot et. al. (2003) study, an Italian hospital-based study of 
male bladder cancer (N=214) has been published with appropriate control group data to assess 
the independence assumption for CYP1B1 Val432Leu and smoking [57].  When control group 
associations were calculated for CYP1B1 genotype as Val/Val (ref) vs. any Leu, however, the 
ORz(95%CI) for CYP1B1 and smoking are 1.4(0.6, 3.3), 1.2(0.5, 3.2) and 1.7(0.6, 4.7) for 
never/ever, never/light smoking, and never/heavy smoking respectively.  With statistical 
significance as the sole criterion, the independence assumption would be met in all cases.  
However, insofar as the associations in these ancillary data accurately represent associations 
in the underlying population in the Saintot et. al. study, this shows that the COR for smoking 
and CYP1B1 Val432Leu genotype in Saintot (2003) could be biased to a greater or lesser 
degree, and in either direction, depending on the specific case-only analysis done (genotype 
category, smoking categories etc.).    In addition, other criteria may need to be examined for 
control populations including, but not limited to, existence of Hardy-Weinberg equilibrium in 
controls, demographic similarity to case-only population (gender, age, ethnicity etc.) and 
study design. 
B. Validity of independence assumption 
Gene-environment associations in populations can be causal or non-causal. When the 
‘implausibility’ of specific G-E association is argued in published case-only analyses, 
however, it is generally considered only within the framework of causality.  Interest in genetic 
influences on behavioral traits is long-standing and there is an extensive and increasing 
literature in behavioral genetics.  One essay on the future of behavioral genetics in the era of 
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genomics states that ‘nearly all behavioral variation reflects some genetic influence’ [58].  
While there are currently only a limited number of established associations between genotype 
and behavior, research in the areas of personality, psychiatric disorders and addiction is 
flourishing [59-61].  Genes being investigated for impact on behaviors that influence health 
outcomes include: monoamine oxidase A (MAO-A) and antisocial behavior, serotonin 
transporter (SLC6A4) and anxiety and depression, COMT and frontal lobe function, brain-
derived neurotropic factor (BDNF) and long-term memory, and dopamine receptor D2 
(DRD2) and substance abuse, gambling and alcoholism, among many others [60-61].  Most of 
these genes, if not all, function in multiple pathways with poorly characterized effects.  
COMT, for instance, because of its role in the dopamine pathway and hormone metabolism 
has been studied in conjunction with schizophrenia [62], attention deficit hyperactivity 
disorder [63], smoking [64], alcoholism [65], cataract  [66], Alzheimer disease [67], and 
breast [68-69], ovarian [55], hepatocellular [70], and bladder cancer [71].  These are widely 
divergent health outcomes and many have strong behavioral and exposure-related 
components.   
Given the current limited state of knowledge of genetic influences on health-related 
behaviors and exposures, and the wide variety of gene-behavior associations considered 
plausible enough to be under investigation, it seems unwise to argue the validity of the 
independence assumption based entirely on the implausibility of a causal association.  A more 
prudent approach would be to thoroughly examine any empirical evidence for or against 
causal association between the relevant gene and exposure before proceeding.  In this section, 
I will discuss two examples of gene-exposure association that there is empirical evidence for, 
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in order to illustrate various ways gene-exposure association can be problematic for case-only 
analysis, and for the process of evaluating the independence assumption. 
The strongest example of an independence assumption violation is the association 
between aldehyde dehydrogenase 2 (ALDH2) genotype and alcohol consumption [72].  This 
association in the underlying population means that a case-only study of the interaction of 
ALDH2 and alcohol consumption would be invalid.  The ALDH2*1 allele codes for normally 
functioning aldehyde dehydrogenase, a rate-limiting enzyme in the ethanol metabolism 
pathway.  ALDH2*2 is a variant allele coding for a much lower activity form of aldehyde 
dehydrogenase.  Individuals homozygous for the ALDH2*2 allele experience flushing, 
tachycardia, headache and nausea after consuming alcohol. Consequently, these individuals 
tend not to consume alcohol, and have virtually no risk of alcoholism [73-74].  Heterozygotes 
(ALDH2*1/2) can also experience aversive reactions, although with widely varying severity. 
Consequently, individuals heterozygous for ALDH2 tend to consume less alcohol overall [75], 
consume fewer drinks at one sitting and engage in binge drinking less often than ALDH2*1/1 
homozygotes [76].  Additionally, research on the subjective experience of alcohol 
consumption demonstrates that reactions vary by ALDH2 genotype.  In a sample of college-
age Asian men and women with equivalent blood alcohol levels, heterozygotes (ALDH2*1/2) 
reported a more intense subjective reaction to alcohol, as well as more flushing and higher 
cortisol levels, than those homozygous for the wild type allele (ALDH2*1/1) [72, 77].  In 
another study, participants rated a panel of subjective responses to alcohol consumption with 
heterozygous individuals reporting more dizziness, higher intensity of effect and more facial 
warming than ALDH2*1/1 individuals [78].  Despite the protection from alcoholism that 
aversion to excess and/or habitual consumption of alcohol provides, it has been shown that 
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individuals with the ALDH2*2 allele who do consume alcohol are at higher, rather than lower, 
risk of many of the negative consequences of alcohol consumption.  These can include 
neurocognitive impairments [79] and esophageal cancer [80].  It has been hypothesized that 
this occurs through the high levels of acetaldehyde built up after drinking [78, 81], leading to 
increased oxidative stress[82]. 
This ALDH2 polymorphism has also been variously associated with poor glycemic 
control in Type II diabetics who are light to moderate drinkers [83], gout [84], and HDL [85], 
and cortisol [86] and lipid peroxide responses [82] to alcohol consumption.  Any one of these 
environmental exposures could be a plausible candidate for a future gene-environment 
interaction study with ALDH2, either directly or by proxy, for a number of common disease 
outcomes (e.g. cardiovascular disease, cancers). For example, the interaction of alcohol 
metabolizing genes and stress (whether measured by blood cortisol levels, life events 
questionnaires or other means) would be of interest for studies of cardiovascular disease, 
breast cancer and esophageal cancer. The interaction of alcohol metabolizing genes and 
glycemic control would be of interest in studies of insulin resistance, time to initiation of 
insulin use or severity of Type II diabetes.  Association in the control group between the 
ALDH2 polymorphism and any of these exposures has the potential to violate the 
independence assumption and invalidate or bias a case-only analysis of that interaction.   
Although the ALDH2-alcohol consumption association is well documented and the 
non-independence of these two exposures clearly makes a case-only analysis of interaction 
inappropriate, researchers more often find the association of interest less well understood.  For 
example, the association (or lack thereof) between CYP2A6 and various aspects of smoking 
behavior has received considerable attention in the last 15 years [87-90].  CYP2A6 is a 
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polymorphic gene coding for the enzyme (cytochrome P450 2A6) that is responsible for the 
bulk (~80%) of the biotransformation of nicotine to cotinine (the major breakdown product of 
nicotine), then on to 3’hydroxycotinine [91-92].  As of 2002, there were 10 known variants of 
CYP2A6, coding for enzymes with no activity (or deletions), reduced activity or enhanced 
activity [93].   
Because people usually smoke to raise nicotine levels in the blood and brain, it has 
been proposed that fast metabolizers of nicotine need to smoke more than slow metabolizers 
to achieve the same steady-state nicotine levels [94-96]. The relationship between CYP2A6 
polymorphisms and altered nicotine metabolism has been demonstrated in experimental 
studies that followed similar protocols [93, 97-98].  In these studies, it was shown that 
CYP2A6 genotype was closely and consistently correlated with enzyme activity as measured 
by nicotine and cotinine levels after nicotine administration.  For CYP2A6*1/*1 individuals 
(‘normal’ wild-type metabolizers), plasma nicotine levels were higher and cotinine levels 
lower than for all other genotypes, except gene duplications.  
The relationship between CYP2A6 activity and altered smoking behavior has also been 
investigated in vivo.  A double-blind placebo-controlled experiment reported by Sellers 
demonstrated that administration of a CYP2A6 inhibitor (oral methoxsalen) together with oral 
nicotine caused a consistent and stepwise reduction in smoking behavior when participants 
were given a ‘free smoking period’ after drug administration [95].  All smoking indices tested  
(breath carbon monoxide increase, number of cigarettes smoked, time to next cigarette, 
number of total puffs, nicotine/cotinine ratio, carbon monoxide increase/puff, and self-rated 
desire to smoke) were consistent with a reduction in smoking behavior for participants with 
impaired CYP2A6 function [95].   
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Despite experimental evidence for a strong CYP2A6 genetic component to smoking 
behavior, epidemiological evidence has been more equivocal, although consensus has begun 
to emerge that at least some aspects of adult smoking behavior are influenced by CYP2A6 
variation (recently reviewed in Ray (2009) [89]).  However, as recently as 2003, there was no 
firm consensus as to whether CYP2A6 influenced smoking behavior [88]. In a 2003 review by 
Tricker et.al., eight out of 12 studies showed results consistent with the hypothesis that 
individuals with variant genotypes would score lower on measures of smoking behavior [99-
105].  However, few were able to demonstrate statistical significance [99, 101-102] and one 
of the three had technical difficulties with genotyping [101].  Only two of the 12 [102, 106] 
were able to use biomarkers of cigarette consumption rather than self-reported measures of 
smoking status and behavior, one positive [102] and the other null [106].  Further, a meta-
analysis of CYP2A6 genotype and smoking behavior, which included 11 of the 12 studies 
reviewed by Tricker (Pianzella 1998 was excluded), failed to provide evidence of an 
association between CYP2A6 genotype and smoking status [87].  Unfortunately, the authors 
were only able to categorize smoking into crude categories of SMOKE (higher tobacco use or 
dependence) vs. NO SMOKE (no tobacco use or non-dependent smoking) and SMOKE more 
vs. SMOKE less.  In contrast to the overall results, the most methodologically rigorous study 
[102], showed a clear trend for those with lower activity level genotypes to have lower breath 
carbon monoxide levels, lower cotinine levels, and a higher nicotine/cotinine ratio than 
smokers with a more active genotype. This supports the hypothesis that slow nicotine 
metabolizers require less cigarette consumption to maintain nicotine levels than faster 
metabolizers.  Given a behavior as complex as smoking, and the level of detail available, it is 
not surprising that subtle or specific effects were not evident in this meta-analysis [87].   
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Clearly, as of 2003, there was more to be done before the putative association between 
indices of smoking behavior and variation in the CYP2A6 gene could be convincingly 
demonstrated or a determination made about whether the independence assumption would be 
violated in a case-only analysis of CYP2A6 variation and smoking behavior.   However, if the 
only the criterion for verifying the independence assumption is the statistical significance of 
the putative relationship between CYP2A6 and smoking in controls, an investigator would 
have been justified proceeding with a case-only study of CYP2A6, smoking and lung cancer at 
this point in time.    
If the independence assumption were verified, a case-only study of the interaction of 
CYP2A6 and smoking would be attractive for a number of reasons.  It is hypothesized that, in 
addition to the protective effect of smoking less, individuals with lower CYP2A6 activity are 
at lower risk of lung cancer from smoking than those with higher activity enzymes because of 
reduced procarginogen activation.  CYP2A6 is able to metabolize 4-(methylnitrosamino)-1-(3-
pyridyl)-1-buanone (NNK), a component of cigarette smoke, to a reactive mutagenic 
compound.  When CYP2A6 is inhibited by methoxsalen in CYP2A6*1/*1 individuals, 
production of the reactive metabolite is reduced and NNK metabolism is shifted to NNAL and 
NNAL-glucuronide, non-mutagenic and readily excretable compounds [89, 107-108], 
decreasing exposure to carcinogenic intermediates.  There have also been investigations of 
possible behavioral mechanisms by which cancer risk is reduced in slow metabolizers [109].  
Consequently, the interaction of CYP2A6 variants and smoking is of high interest, both for 
public health and clinical practice, and a number of traditional case-control studies have 
examined this [103, 110-112]. 
  16
The case-only study has several advantages over a traditional case-control study in this 
context.  No controls need to be recruited, interviewed, genotyped or phenotyped.  This is 
especially appealing for a study in a Caucasian or African-American population because the 
frequency of variant alleles for CYP2A6 is generally quite low [<5% [93, 113]] and large 
numbers of controls would be needed for an interaction analysis.  A case-only study would 
not generate ORs for the main effects of smoking or CYP2A6 variation but this might not be 
seen as a severe limitation.  For many cancers, particularly lung cancer, the main effects of 
smoking are well established.  The CYP2A6 enzyme has a limited number of substrates, 
primarily exogenous [88], and is therefore unlikely to have a substantial main effect in the 
absence of environmental exposure.  Selection bias due to differential non-participation of 
smokers as controls would not be a factor.  Although selection bias related to case recruitment 
would still remain a consideration, recruitment of cases is generally more successful than for 
controls and the potential for selection bias should be lower.  Lastly, a case-only study would 
eliminate the potential for differential recall between cases and controls, a concern with 
behavioral risk factors such as smoking where participants believe that exposure have could 
affected their case status.  If the only the criterion for verifying the independence assumption 
is the statistical significance of the putative relationship between CYP2A6 and smoking in 
controls, an investigator in 2003 would be justified proceeding with a case-only study of 
CYP2A6, smoking and lung cancer, despite the gathering experimental and epidemiological 
evidence of association.  However, from the current vantage point, it is clear that this would 
have led to biased estimates of interaction.  It is also clear that more than statistical 
significance is needed to guide evaluation of the independence assumption. 
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C. The independence assumption in empirical data 
Outside of investigators conducting specific case-only analyses, as discussed 
previously, relatively little work has been done directly assessing particular control group G-E 
associations likely to be important in interaction studies.  Two notable exceptions are the 
recent large analyses of smoking and metabolic gene polymorphisms by Smits et. al. [54] and 
a similar study of metabolic gene polymorphisms and alcohol consumption by Raimondi et. 
al. [114].  The former study examined associations between polymorphisms in five xenobiotic 
metabolizing genes, CYP1A1, GSTM1, GSTT1, GSTP1 and NAT2 and tobacco consumption 
in pooled controls from case-control studies included in the International Collaborative Study 
on Genetic Susceptibility to Environmental Carcinogens (GSEC), and the latter examined 
associations between polymorphisms in CYP2E1 RsaI, CYP2E1 DraI, ADH1C and NQO1 and 
alcohol consumption in the same data. The GSEC includes individual level data from both 
published and unpublished case-control studies of gene-environment interaction in cancer 
[115-116].   
In the study of metabolic polymorphisms and smoking, the number of subjects 
included in each analysis varied from 2,792 for GSTP1 to 10,719 for CYP1A1.  Although the 
sample size was large, the study had several important limitations.  The authors were only 
able to categorize smoking crudely, as never/current/former for the bulk of their data, and had 
information on dose for less than half of those (35.5%-47.3%).  Smokers may refuse to be 
controls more often than non-smokers, and refusal could also be associated with family 
history and therefore genetic factors.  Although this would be more problematic for high 
penetrance genes that track more closely with family history than is likely for single 
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nucleotide polymorphisms (SNPs), selection bias may have been present, a limitation not 
addressed by the authors.   
Bias due to non-participation by smokers can vary between populations. For example, 
studies done in Canada, the US and Europe have shown both over-participation and under-
participation by smokers.  As an example of over-participation by smokers, Morabia et. al 
reported a higher prevalence of current smoking among male and female neighborhood 
controls (42% and 38%, respectively) than hospital-based controls (29% and 24%) or in the 
US overall (30% and 25%) [117].  Similarly, Ramos et. al. found higher  proportions of 
current  and former smokers in women who participated in a population-based study of 
myocardial infarction (12% and 10%, respectively) than in those who did not fully participate 
(7% and 4%, respectively) [118].  Conversely, Holt et. al (1997) found that women who 
smoked during pregnancy were more likely (24%) than non-smokers (13%) to refuse 
participation in a post-partum survey (24% and 13% refusals, respectively) [119].  Heilbrun 
et. al. (1982) found 57% of participants in a prospective study of cancer in Hawaii were 
current smokers while 61% of the men who refused were current smokers [120].   In a 
Canadian study of mammography, current smokers were underrepresented among women 
having time-appropriate mammograms [121].   
Probably most important for the evaluation of the independence assumption, the 
controls in a pooled study do not represent any particular population at risk from which cases 
might arise.  Identifying a relevant population base in which to assess the independence 
assumption is of fundamental importance to the validity of case-only studies.  It is not often 
appreciated that populations might vary in ways that affect the independence assumption and 
thus the validity of case-only studies conducted in those populations.   The independence 
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assumption pertains to unconfounded G-E association and different populations may well 
have different constellations of G-E confounders.  In this context, it is extremely difficult, if 
not impossible, to use results from pooled studies to answer to the question of whether a 
specific case-only study might be valid in one or more of these populations.  In Smits et. al. 
(2004) non-hospital (“healthy”) and hospital controls from GSEC studies were pooled (66% 
and 38%, respectively) for overall analyses.  Overall estimates were adjusted for study, 
gender, age, and ethnicity. This could be problematic for at least gender, age and ethnicity if 
these variables are proxies for different exposures in different populations.  Participants were 
primarily Caucasian (72.6%), with smaller proportions of Asians (11.6%) and African-
Americans (5.2%).  However, given that race/ethnicity is largely a socially constructed 
variable [122-123], it is unclear what meaning this has when taken out of the appropriate 
social context.  Nonetheless, for this pooled analysis the authors conclude that “The use of the 
case-only design for epidemiologic studies including these polymorphisms is therefore 
justified, at least when studying smoking habits.”  This conclusion was based on the paucity 
of statistical significance and lack of strong associations (all ORs were <1.3 or >0.8 for 
healthy controls, < 1.4 or >0.6 for hospital controls).  In view of the study limitations 
discussed, however, this conclusion does not seem fully justified.   
In a smaller (N=339) population-based study of Japanese males 40-49 years of age, 
the authors assessed association between ‘habitual smoking’ (ever/never) and drinking 
(drinker/non-drinker), and a panel of 153 single nucleotide polymorphisms (SNPs) in 40 
candidate genes [64]. Genes chosen were those coding for xenobiotic metabolizing enzymes, 
DNA repair enzymes and ‘other stress-related proteins’. The xenobiotic metabolizing 
enzymes included the cytochrome P-450s CYP1A1, CYP1B1, CYP2C9, CYP2C19, CYP2E1, 
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CYP17A1, and CYP19A1, glutathione transferases GSTM2, GSTM3, GSTT2, and GSTP1, N- 
acetyl transferases NAT1 and NAT2, alcohol dehydrogenases ADH1A, ADH1B, and ADH1C, 
aldehyde dehydrogenase ALDH2, and epoxide hydrolases EPHX1 and EPHX2.  The DNA 
repair enzymes were OGG1 and NUDT1 (MTH1).  The other genes included, but were not 
limited to: the estrogen and progesterone metabolism genes, ESR1, ESR2, ERRRG, PGR, 
COMT, HSP17B2, and HSP17B3, serotonin transporter gene SLC6A4, glucocorticoid receptor 
NR3C1, nitric oxide synthase NOS2A and NOS3 and dopamine receptor genes DRD2, DRD3, 
and DRD4.  The SNPs analyzed were chosen from a larger pool of SNPs (N=289) after 
elimination of SNPs with a minor allele frequency of <1% and SNPs not in Hardy Weinberg 
equilibrium (HWE).  Consistent with study goals, all genes were chosen because they were 
considered important candidates for future interaction studies, rather than because they were 
particularly likely candidates for gene-smoking/drinking association in a healthy population.  
Plausibility of individual gene-environment associations was discussed only for SNPs with 
statistically significant results.   
For the DNA repair genes examined, OGG1 and NUDT1, associations were found 
between smoking and three of four of the SNPs in OGG1 (0.4-0.6, borderline statistical 
significance, variant carrier vs. variant non-carrier) but no statistically significant associations 
were found for either SNP of NUDT1.  After adjustment for drinking status 
(never/former/current drinker), significant associations were reported for smoking and at least 
one SNP in five of the 40 genes tested [OGG1 (DNA repair), SLC6A4 (serotonin transport), 
CYP17A1 (xenobiotic metabolism), EPHX1 (xenobiotic metabolism) and ESR1 (estrogen 
metabolism)].  The associations with smoking and OGG1, CYP17A1 and EPHX1 were novel 
findings with uncertain plausibility that must be replicated.   
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This study has several important limitations [64].  Because of sample size, smoking 
was dichotomous in all analyses:  ever/never for the unadjusted estimates for each SNP, 
current/non-smokers and current vs. never smokers for adjusted estimates.  Data were 
insufficient for estimates of effect for smoking dose or duration and dose-response 
relationships could not be explored. Functional data was lacking for most of the SNPs 
examined.  The DNA samples included in this study were the subset of samples from a 
previous study with enough DNA remaining for further testing (53.5%), raising the possibility 
of selection bias.  Overall, before calculating the adjusted estimates, the authors examined 153 
SNPs for association with 2 exposures (smoking, drinking) using 2 models for each 
comparison (variant dominant, variant recessive) for a minimum of 612 comparisons.  
Statistically significant association was found for 29 (4.7%) of the comparisons.  Given the 
limitations (high number of comparisons, limited sample size, gender- and age-restricted 
population and crude environmental exposure measurements), results for this particular panel 
of  ‘stress-related proteins’ must be replicated before the associations are considered robust.  
Although these limitations were not discussed (other than sample size), the authors state that 
the study provides basic but essential information for future case-only studies (i.e. that some 
particular SNPs may be associated with smoking and others likely are not), a conclusion 
which seems warranted if results are considered with appropriate caution.   
Finally, in a more limited exploration of G-E control group associations, a different 
group of investigators examined associations in four studies from Johns Hopkins University 
[124].  They found ‘very few’ statistically significant G-E associations among controls, 
though they specified neither the particular associations examined nor the magnitude of the 
associations.  They did note, however, that 5 of the 7 significant interactions that were found 
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in case-control analyses were not found in the corresponding case-only analyses, primarily 
due to non-significant G-E control group associations that were in the opposite direction to  
the interaction effect. This phenomenon was also demonstrated in a 1999 study by Hamajima 
et. al., using data from 4 published studies of gene-smoking interaction [125].  In this paper, 
ORzs from all 4 studies (range: 0.6-2.3) were non-significant and in the opposite direction 
from the SIM, causing all of the CORs to be closer to the null than the case-control estimates 
of interaction.  In these studies, the tests of statistical significance (at α=0.05) of the COR and 
SIM were concordant, although the magnitude of the COR and SIM were different.  The most 
extreme example was from the study of NAT2 and smoking in bladder cancer, where ORz was 
0.69 (95% confidence interval (CI) 0.37, 1.29), the COR was 0.83 (95% confidence interval 
(CI) 0.42, 1.66) and the SIM was 1.20 (95% CI 0.49, 2.96).  Both of these studies of G-E 
association in control groups serve to illustrate the necessity of further exploration of 
empirical evidence of independence assumption violation and its effects on interaction studies 
and the interpretation of interaction estimates from different study designs.  
D. Effect of independence assumption violation in data simulation 
Data simulations have demonstrated that even small violations of the independence 
assumption can strongly bias the case-only interaction parameter [5].   Using logistic models, 
Albert et. al. (2001) varied the magnitude of control group G-E association to explore the 
effect of independence assumption violation on case-only interaction estimates.  As expected 
from the previously presented equation (COR = SIM * ORz), as values of ORz above the null 
increased, the COR was biased away from the SIM in a multiplicative fashion.  Using data 
from a study of XRCC1 genotype and lung cancer by Ratnasinghe et. al. (2001), they showed 
that a control group association between genotype and pack-years of tobacco use of ORz=2.03 
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created a bias in the COR of 105% [COR=0.90 (95% CI 0.41, 1.94), SIM= 0.44 (95% CI 
0.17, 1.16)] [126].  An ORz of 1.2, the association between genotype and alcohol drinking 
status (ever/never), biased the COR by nearly 30% in another example.   
Further, violations of the independence assumption may cause the Type II error rate 
(false negatives) to be high.  When control-group G-E associations are of similar magnitude 
but opposite in direction to the interaction effect, a case-only study may not detect interaction 
effects [5, 124].  Type II error when evaluating the independence assumption means that true 
Zs of sufficient magnitude to bias the COR are not detected.  Depending on the magnitude of 
bias in the COR from this source, these CORs could be extremely misleading in the context of 
screening for interaction or candidate genes for further investigation. Little work has been 
done to explore this possibility. 
E. Independence assumption verification methods 
Although the validity of case-only estimates rests heavily on the independence 
assumption, and case-only studies, particularly stand-alone case-only studies, have many 
advantages over traditional study designs for interaction analysis,  there is relatively little the 
literature on methods of independence assumption verification.  The previously discussed 
work by Albert et. al. (2001) which partially quantified, largely through data simulation, the 
magnitude of bias and effect on the Type I error rate of even modest G-E association in 
controls is one example.  Another notable paper to focus on independence assumption 
evaluation is a recent paper by Gatto et. al. which elucidates conditions under which a control 
group is an appropriate proxy for the underlying study population when validating the 
independence assumption [127].  They conclude, also primarily from data simulations, that a 
control group can be used for this purpose only when 1) the baseline risk of disease is very 
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low [ p(Disease | G-E-) < 0.1%] or 2) the baseline risk of disease is low [ p(Disease | G-E-) <= 
1.0 %] and the independent effect of the gene is weak (RRgene<= 2.0).  If this is not the case, 
the magnitude of the control group G-E OR (ORz) diverges substantially from the G-E RR in 
the underlying cohort (RRz), which is what the independence assumption is based on.  
Although the data simulations in this study are framed in terms of gene-environment 
interaction, the conclusions apply to any two exposures examined in a case-only interaction 
study.  In practice, because the case-only design cannot estimate main effects, it would not be 
on optimal choice for investigation of a gene expected to have an appreciable main effect, an 
important consideration.   
Some empirical work on independence assumption evaluation has been done with 
pooled data, and with existing case-control studies, but has focused on quantifying specific 
independence assumption associations [54, 114], or  on assessing the frequency of 
independence assumption violation [124], rather than on methods of independence 
assumption assessment.  In practice, some published case-only studies have used only 
arguments about the plausibility of the independence assumption; others have gone further 
and attempted quantitative assessment of the independence assumption in control groups or 
other ancillary data.  Quantitative assessments have relied on statistical significance of ORz as 
the sole criterion of the validity of the independence assumption regardless of the method of 
assessing the G-E association.  However, the practical effects of relying on statistical 
significance to evaluate estimates of Z, in particular the effects on bias in the COR remain to 
be elucidated.   
A further difficulty is that methodological work that has been done generally assumes 
case-only analyses are fully nested within case-control studies. Although nested case-only 
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analyses of interaction, if properly conducted, do produce more precise estimates than case-
control analyses of interaction, they cannot realize other important advantages of the case-
only design such as smaller sample size, no risk to controls and cost reduction.  By necessity, 
evaluating ancillary data for use in independence assumption validation must include 
considerations of the appropriateness of the control data to the case-series.  Because the two 
most prominent studies to date that have explicitly considered ancillary control data have 
pooled controls (GSEC controls) [54], or consider a very limited population (Japanese men, 
40-49 years of age) [64], very little light has been shed on what study characteristics a control 
group should possess in order to be a valid proxy for population controls for a given case-
series.  While Albert et. al.  (2001) have proposed, and partially evaluated, a method for using 
a sample of controls for independence assumption validation, no analogous work has been 
done on the optimal method(s) of evaluating the independence assumption in ancillary data.  
So, although many aspects of independence assumption evaluation can presumably be 
generalized from nested case-only studies, more work needs to be done to ascertain which 
aspects can be generalized, and what additional practices are needed for independence 
assumption verification in stand-alone case-only studies. 
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III. STATEMENT OF SPECIFIC AIMS 
A. Specific aims 
Aim 1:  Meta-analysis 
To characterize specific gene-smoking associations in control groups found by systematic 
review of the published literature using meta-analytic techniques when appropriate.  
 
1. To estimate the control group/population associations for a set of DNA repair gene 
variant-smoking pairs (ORz) using published data.  To estimate a summary ORz where 
appropriate.  
 
Association was estimated by calculating an unadjusted odds ratio and 95% confidence 
interval [OR (95% CI)] from published data.  Genetic exposures were XRCC1 [Arg399Gln 
(rs25487), Arg194Trp (rs179872), Arg280His(rs25489)], XPD [Lys751Gln (rs13181), 
Asp312Asn (rs1799793)] and XRCC3 [Thr241Met(rs861539)].  Smoking exposures included, 
wherever possible, smoking status: current, former, never, not current smokers, and smoking 
amount: duration, intensity and pack-years of smoking. 
 
2. To use meta-regression to evaluate study characteristics as potential predictors of 
heterogeneity.   
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Study characteristics included study-level characteristics such as: Hardy-Weinberg 
equilibrium in controls, geographic study area, study design, mean/median age of study 
population, proportion male gender and ethnicity.   
 
Aim 2:  Carolina Breast Cancer Study (CBCS) and North Carolina Colon Cancer Study   
(NCCCS) control group associations 
To estimate gene variant-smoking associations in CBCS and NCCCS control groups overall, 
where appropriate, and within race, categorical age and gender, for all SNPs in CBCS or 
NCCCS plausibly biologically related to smoking behavior. 
 
1. By race, age, gender and overall:  To estimate gene variant-smoking associations 
[unadjusted ORz (95% CI)] in CBCS (Phase I and II, CIS) and NCCCS control groups 
using unconditional logistic regression. 
 
2. To evaluate effect measure modification by race, age or gender (NCCCS only) using the 
likelihood ratio test (at α=0.05) for models with and without a race/age/gender x smoking 
term.  To estimate ORzs adjusted for the sampling variables race, age and gender when 
there was no appreciable effect measure modification.  To test for Hardy Weinberg 
equilibrium within race for each polymorphism. 
 
3. To assess potential patterns in independence assumption violation across gene pathway 
groups:  SNPs were grouped by gene pathways (e.g. DNA repair, xenobiotic metabolism) 
for analysis as above, by race, age or overall. 
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4. To evaluate potential confounders of ORz:  To evaluate sampling variables [age at 
selection, race, gender (NCCCS only)], all individual level factors identified in the meta-
analysis as potentially important [age, race], and other variables identified using directed 
acyclic graphs [family history of any cancer, family income] as potential confounders. 
 
Aim 3:  Environmental misspecification 
To evaluate the impact of environmental exposure misspecification on independence 
assumption evaluation using CBCS/NCCCS control group data. 
 
1. To evaluate the effect of error due to smoking misspecification:  To describe the 
frequency, magnitude and direction of undetected bias in the COR when significance 
testing or the magnitude of ORz were used to assess independence for a given 
specification of smoking such as ever smoking, but the COR would have been calculated 
for a different specification of smoking, such as intensity (packs/day). 
B. Hypotheses 
The primary hypothesis was that the independence assumption would be violated (i.e. 
ORz ≠ 1) for smoking behavior and a proportion of the genetic variants greater than would be 
expected by chance alone both in the meta-analysis and in the CBCS and NCCCS control 
groups.  Further, that the violation(s) will be of sufficient magnitude to cause appreciable bias 
(>15%) in the COR.  Secondary hypotheses are that 1) violations of the independence 
assumption will occur more frequently for measures of smoking amount (duration, dose or 
PY) than for smoking status (ever or current smoking), 2) misspecification of smoking 
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exposure (using a different smoking measure to evaluate the independence assumption than 
the smoking measure used in the case-only analysis) will lead to undetected bias in the COR 
and 3) the magnitude and direction of ORz for SNPs assayed in the CBCS and NCCCS 
controls will agree more often than expected by chance.   
The study characteristics that were expected to be influential predictors of the 
magnitude of ORz were HWE status, population- vs. hospital/patient-based controls and older 
age.  Assessment of Hardy Weinberg equilibrium provides some indication of possible 
population stratification by ethnicity, misclassification of genotype and/or selection bias in the 
control group [128] and these may induce G-E association.  Since smoking can increase risk 
for numerous diseases, hospital-based controls are likely to have G-E associations not found 
in the general population.  Similarly, for any genes associated with longevity, average age of 
the study population was expected to influence G-E association, particularly for an exposure 
such as smoking where patterns of use have changed over time, and continue to change.  
There is an extensive and rapidly expanding literature on the genetics of longevity [129-132].  
Many different functional categories of genes are being examined including DNA repair 
genes, xenobiotic-metabolizing genes and genes involved in defense against reactive oxygen 
species (ROS).  Not surprisingly these are many of the same genes being investigated for their 
potential as cancer susceptibility genes. 
C. Rationale 
The primary aim of the studies described in Chapters V-A and V-B was to enable 
investigators considering a stand-alone case-only study of gene-environment interaction to 
evaluate the independence assumption more rigorously than has been done previously and 
identify situations where case-only estimates are not valid.  Although the case-only design can 
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be used to evaluate statistical (multiplicative) interaction between any two exposures, it is 
most commonly used for gene-environment interaction.  In order to explore the independence 
assumption in empirical data, a model environmental exposure (smoking behavior) and a 
panel of genetic variants were chosen.  Briefly, smoking behavior was chosen because of its 
importance in public health, and because smoking measures are very commonly collected.  
Polymorphic genes plausibly biologically related to smoking, primarily DNA repair genes, 
were the genetic exposures of interest.  The study described in Chapter V-A was a systematic 
review including a series of meta-analyses of six DNA repair SNPs and smoking.  The second 
study (Chapter V-B) was an exploration of control group gene-smoking associations (ORz), 
including but not limited to the DNA repair genes in the systematic review, in two population-
based control groups.   
1. Smoking and genes 
Interest in genetic influences on behavioral traits is long-standing and there is an 
extensive and burgeoning literature in behavioral genetics.  While there are currently only a 
limited number of established associations between genotype and behavior, research in areas 
related to smoking behavior, including addiction, personality, and psychiatric disorders, is 
flourishing [59-61].  Most of these genes function in multiple pathways with poorly 
characterized effects.  COMT, for instance, because of its role in the dopamine pathway and 
hormone metabolism has been studied in conjunction with widely divergent outcomes, many 
with behavioral components, such as schizophrenia, attention deficit hyperactivity disorder, 
alcoholism, cataract, blood pressure, Alzheimer disease  and breast, ovarian,  hepatocellular, 
and bladder cancer as well as smoking behavior [55, 62-71, 133].   
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Strong interest in examining smoking in gene-environment studies comes from a 
number of sources.  Smoking is a highly prevalent exposure.  Data from the 2003 Behavioral 
Risk Factor Surveillance System (BRFSS) survey indicated a median prevalence of 22.1% for 
current smoking among US adults with a range of 12%-31% by state [134].  In China, the 
prevalence of smoking and tobacco-related deaths has risen dramatically over the last 
decades, and is projected to increase in other developing countries in the coming decades, 
perhaps causing as many as 10 million deaths globally (out of a projected 60 million) by the 
year 2030 [135].  Tobacco smoking has a well-documented causal relationship with many 
cancers (e.g. lung and bladder), and is believed to contribute to other cancers (e.g. colon, 
kidney and prostate). However, variation in disease outcome with similar exposure does exist 
and the development of cancer is not an inevitable outcome even for heavy smokers.  This is 
not surprising, given that tobacco smoke constituents (including carcinogens) are metabolized 
by xenobiotic-metabolizing enzymes encoded by highly polymorphic genes and that the 
genotoxic effects of tobacco smoke constituents [136] are modified by highly polymorphic 
DNA repair enzyme genes [137].  Consequently, gene-smoking interaction studies are of 
significant public health importance. However, they may be problematic for case-only studies 
if the genetic exposures under study, or genes in linkage disequilibrium with them, are 
causally or non-causally associated with aspects of smoking behavior.  
Twin, adoption and linkage studies all demonstrate that there is a heritable (i.e. 
genetic) component to smoking behavior.  Evidence from twin studies and association studies 
suggest that there are genetic influences on at least three aspects of smoking history: smoking 
initiation, nicotine addiction and success of smoking cessation [90, 138].  There is, however, 
substantial variation among populations with respect to the relative contributions of genetic 
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vs. environmental influences [139].  Interest has focused on variation in constituents of the 
dopamine pathway (e.g. DRD2, COMT), nicotine metabolism (e.g. CYP2A6), the serotonin 
pathway (5HTT), xenobiotic metabolizing pathways (e.g. CYPs, GSTs) and nicotinic 
acetylcholine receptors (e.g. CHRNA4) [139].  Despite the many candidate gene studies, few 
robust gene-smoking associations have been found.  In fact, in a recent study designed to 
evaluate genetic screening for risk of smoking initiation, the criteria for choosing 
polymorphisms to include in the screening panel (positive results in at least three independent 
samples and a pooled OR of >1.1 for ever smoking) identified only five gene variants:  DRD2 
TAQ1A, TPH C779A, 5-HTTLPR, MAO-B A644G intron 13, and COMT Val158Met [140]. 
Metabolic genes and smoking:  There is an extensive epidemiologic literature on 
smoking and metabolic genes, [i.e. those coding for enzymes that metabolize nicotine or other 
tobacco smoke constituents such as polycyclic aromatic hydrocarbons (PAH) or aromatic 
amines] [108, 141].  These are largely case-control studies focused on the potential of the 
genes to modify risk of disease for smokers.  In addition to cancer, this has been an especially 
active area of research for cardiovascular disease and birth outcomes [142-143].  Smoking 
directly exposes the lungs to a range of toxic xenobiotics and is addictive; exposure to tobacco 
smoke constituents can last for decades, even through the entire lifespan via exposure to 
maternal smoking.   Tobacco smoke constituents, including nicotine and PAHs are 
metabolized to toxic intermediates and/or carcinogens by phase I (activation) and phase II 
(conjugation) enzymes [141].  Variation in these polymorphic genes can alter enzyme 
activity, regulation or expression, [144-146] plausibly increasing or decreasing risk of disease 
or influencing smoking behaviors, such as the number cigarettes consumed daily or years as a 
smoker.   
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Among the gene variants included in the current project, COMT Val158Met SNP 
(rs4680) is the only SNP that has been extensively studied with respect to its possible 
influence on smoking behavior, most often smoking cessation [147].  Results have been 
equivocal with two recent large population-based European studies coming to different 
conclusion [148-149].  Omidvar et. al. found a 20% reduction in incident smoking cessation, 
and 30% lower odds of prevalent quitting  for the carriers of the low activity form of the allele 
(Met carriers) whereas Breitling et. al. found no association [ORz=0.97 (95% CI 0.83, 1.12)].  
For other included xenobiotic metabolism genes, there is little research.  For CYP1A1, Chen 
et. al. demonstrated, in a population of pregnant women (N=165), that having at least one 
CYP1A1*2A allele was associated with smoking reduction [OR(95% CI)=2.2(1.0-4.6)] and 
increased quitting [OR(95% CI)=1.7(1.0,2.9)] during pregnancy [150].  There was no 
association between GSTM1 and reducing or quitting smoking found by Chen et. al. [150]. 
DNA repair genes and smoking:  Analogous work has not yet been done for DNA 
repair genes.  Although polymorphisms in the xenobiotic-metabolizing genes can influence 
the level of reactive metabolites and hence the amount of DNA damage, ultimately it is only 
DNA damage that is left unrepaired and allowed to continue through the cell cycle that can 
contribute to the genomic instability necessary for the development of cancer.  The 
carcinogenic ability of an environmental agent may therefore be mediated by an individual’s 
DNA repair capacity.  DNA repair enzymes are a group of proteins largely responsible for 
maintaining genomic integrity by repairing damage to DNA caused by endogenous metabolic 
intermediates and by-products, reactive intermediates of xenobiotic metabolism, including 
pharmaceuticals, and ionizing radiation.   
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Proteins in the DNA repair system, and their genes, fall into 4 broad functional 
categories, defined by the major type of damage each repairs.  They are the nucleotide 
excision repair (NER) pathway genes, base excision repair (BER) pathway genes, double 
strand break (DSB) pathway genes and mismatch repair pathway genes.  The base excision 
repair (BER) pathway is responsible for the removal of individual damaged bases and 
restoration of the sugar-phosphate backbone.  It uses the undamaged strand as a template for 
restoring the correct base.  The nucleotide excision repair (NER), in contrast to the BER, 
recognizes and removes bulky lesions from one strand of the DNA and restores stretches of 
DNA 25 nucleotides or more in length using the intact strand as a template as in BER.  The 
double-strand break (DSB), as the name implies, is responsible for rejoining sections of DNA 
that have been broken across both strands, leaving no intact template for repair.  DSB repair 
can be accomplished either through non-homologous end-joining, where the ends of two 
unrelated chromosomes are joined and some genetic material is lost, or homologous end 
joining, where the homologous chromosome is used as a template for repair.  The BER 
pathway is largely responsible for repair of oxidative damage and the NER pathway for repair 
of bulky DNA adducts, both types of damage produced by constituents of tobacco smoke 
[151].  Cigarette smoke is genotoxic, with multiple studies showing smokers have increased 
rates of sister chromatid exchange and micronuclei formation in lymphocytes, increased DNA 
strand breaks in lymphocytes, buccal cells and urothelial cells, and for heavy smokers, 
oxidative damage to DNA in germ cells [136].  The DNA repair genes in the BER, NER and 
DSB pathways are highly polymorphic [151-152], and this variation is thought to contribute 
to cancer risk.   
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In addition to the importance of DNA repair gene polymorphisms, smoking, and their 
likely interaction in cancer etiology and public health, for a case-only study it is also 
important to consider whether there could be a causal association between DNA repair genes 
and smoking in healthy individuals.  While there are no firm data in this area, and this is not 
currently an area of active investigation, plausible mechanisms exist for variability in DNA 
repair capacity (as measured by genotype) to be associated with smoking behavior, especially 
smoking dose.  Smoking induces DNA repair, presumably through DNA damage caused by 
smoking.  When there is reduced capacity for DNA repair, as may occur when an individual 
has an alleles for a lower activity form of a DNA repair enzyme, any physiological effects of 
non-repaired DNA will be exhibited at a lower level of the damaging exposure (smoking in 
this case) than when DNA repair is optimal.  Although no detailed work on the physiological 
effects of non-repaired DNA produced by smoking and the DNA repair genes that will be 
investigated in this project has been done, there is related evidence that there are physiological 
processed that could affect smoking behavior.   
Patients with xeroderma pigmentosum (XP), who lack NER DNA repair, suffer from 
high cancer rates but can also show neurodegenerative effects, which are believed to be the 
result of accumulation of unrepaired DNA lesions and cell death [153], possibly due to 
oxidative damage [154].  Patients with Cockayne syndrome (CS), another inherited disorder 
of DNA repair, can exhibit symptoms of neurological degeneration in addition to premature 
aging and patients while patients with ataxia telangiectasia, an inherited neurological disorder, 
have increased cancer susceptibility and impaired DNA repair [155].   
The pleasurable aspects of smoking, as well as smoking addiction, operate through 
neurological pathways, particularly through the nicotinic acetylcholine receptors, and 
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perturbations in this system could easily affect smoking dose and/or smoking cessation rates.  
Smoking is being actively investigated with respect to possible protective effects on risk of 
Parkinson’s and Alzheimer’s disease [156] and it has been proposed that pharmacologic 
stimulation of DNA repair via the ataxia telangiectasia-mutated (ATM) gene may be 
beneficial in Parkinson’s [157].   
In addition to possible interaction between smoking behavior and DNA repair through 
neurological mechanisms, more direct mechanisms are possible.  It has recently been shown 
that mice without the CSB gene (the defect in Cockayne syndrome) were especially 
vulnerable to oxidative damage from paraquat exposure [158].  Consistent with this 
observation, it has also been shown, using cells from XP patients, that unrepaired oxidative 
damage can appreciably affect transcription and reduce gene expression [159].  Exposure to 
cigarette smoke is a source of oxidative damage.  In patients with severe neurological 
manifestations of XP, death is often due to respiratory complications in childhood [160], 
although subtle manifestations of neurological effects are possible in adulthood [161-162].  
Further, it has been hypothesized that DNA repair may play a role in idiopathic pulmonary 
fibrosis [163-164], and that accumulated DNA damage may play a role in chronic obstructive 
pulmonary disease [165-167].  Development of respiratory effects related to poor repair of 
oxidative DNA damage could plausibly influence smoking dose, smoking duration and/or 
smoking cessation rates.   
A population-based study examining multiple SNPs (single nucleotide 
polymorphisms) for a panel of ‘lifestyle-associated’ genes in Japanese men (N=339) reported 
inverse associations (range of ORs= 0.4-0.6) between smoking status (smoker/non-smoker) 
and 3 different polymorphisms in OGG1, a DNA repair enzyme active in the BER pathway 
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[64].  Consistent with this observation, an  in vitro study has shown that transcription-linked 
subcellular localization and expression of OGG1 during the cell cycle was markedly different 
for wild-type hOGG1 and hOGG1 Ser326cys [168], one of the polymorphisms assessed by 
Liu et al. (2005).  The other DNA repair gene measured in the Liu et al. study was NUDT1.  
For NUDT1, homozygosity at one SNP was inversely associated with drinking status 
[drinker/non-drinker: 0.1(0.0-0.8)], although sample size was small (four homozygotes). 
Although the authors had insufficient data to assess the possible relationship between more 
complex aspects of smoking (e. g. dose) and DNA repair genes their results are consistent 
with a possible causal relationship between DNA repair genes and smoking behavior. 
As discussed previously, very little systematic work has been done aimed specifically 
at improving the conduct of stand-alone case-only studies.  Briefly, a pooled analysis has been 
conducted for several xenobiotic-metabolizing genes and smoking, but was limited to crude 
categorizations of smoking pooled across possibly disparate populations [54].  A similar study 
was conducted with xenobiotic-metabolizing genes and alcohol consumption and had similar 
limitations [114].  The small population-based Japanese study discussed earlier reported on a 
panel of 40 genes plausibly related to smoking or alcohol consumption and their association 
with smoking and/or drinking status, respectively, but was limited to males [64].  No attempt 
was made in any of these studies to evaluate characteristics of the data that might make it 
appropriate (or not) for evaluation of the independence assumption.   
Consequently, two studies were undertaken to address G-E association in empirical 
data: 1) a systematic review and meta-analysis of gene-smoking ORzs in published control 
data, and 2) an analysis of gene-smoking ORzs in two population-based control groups.  The 
studies are described in Chapters V-A and V-B, respectively.  The particular exposures 
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evaluated in these two studies (smoking and genes relevant to smoking and cancer) were 
chosen to provide immediately useful information for public health research, particularly 
cancer research, as well as provide a context for further exploration of associations that, if 
found in one or more populations, would prove problematic for gene-environment interaction 
studies in other populations.   
The six SNPs that were chosen for the systematic review are in three DNA repair 
genes that operate in different genetic pathways.  The genes were X-ray cross complementing 
gene 1 (XRCC1), xeroderma pigmentosum complementation group D [XPD, previously 
excision repair complementing defective 2 (ERCC2)] and X-ray cross-complementing gene 3 
(XRCC3).  Each gene is polymorphic, and each SNP has a minor allele frequency > 10% in 
most studied populations.  XRCC1 participates in the base excision repair (BER) pathway.  
Three important non-synonymous single nucleotide changes (Arg194Trp, Arg280His and 
Arg399Gln) have been identified in XRCC1.  XPD is active in the nucleotide excision repair 
(NER) pathway.  A single nucleotide change (SNP) in XPD exon 10 (Asp312Asn) and 
another in exon 23 (Lys751Gln) have been studied.  XRCC3 is in the double strand break 
(DSB) pathway.  XRCC3 is believed to code for an accessory protein in the process of 
homologous joining of broken double stranded DNA. In this case, the appropriate stretch of 
DNA on the homologous chromosome serves as a template for repair.  XRCC3 has one 
studied variant, a Thr241Met variant [169].  With the exception of the XRCC1 Arg194Trp 
[170], the variants are thought to code for reduced DNA repair capacity, although in no case 
has this been definitely established [170-174]. 
For the control group analyses, a convenience panel of gene variants plausibly related 
to smoking was chosen.  These included variants in xenobiotic metabolizing genes, DNA 
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repair genes, and variants in genes that respond to oxidative stress.  All genes were relevant to 
gene-environment interaction in cancer; the parent studies are case-control studies of breast 
cancer and colorectal caner.  Most of the genes have a minor allele frequency >10%.   
2. Meta-analyses 
 
Systematic review of control group G-E associations can assist in evaluation of the 
independence assumption at multiple levels.  Rigorous evaluation of the independence 
assumption for a proposed case-only study should include a thorough search of the published 
literature for relevant control group or cohort data, then evaluation of the magnitude of 
independence assumption violation in individual studies, both overall and in relevant 
subgroups.  A systematic search, at a minimum, can inform the investigator that there are no 
control data on the G-E association of interest in the literature, and therefore no empirical data 
available to evaluate the independence assumption.  This should preclude conducting a stand-
alone case-only study.   If the literature is scant and/or heterogeneous, one can nonetheless 
assess the potential range of bias that may be introduced into a case-only study.  Specifically, 
the meta-analysis includes assessing the magnitude, direction, precision and statistical 
significance of each study-specific gene-smoking ORz, as well as assessing heterogeneity of 
the ORzs across studies.  Since the magnitude of ORz is an estimate of the magnitude of bias 
in the COR, it is the key parameter.  Finally, if ORzs from published studies are both 
homogeneous and within an acceptably narrow range for the purposes of the case-only study, 
meta-analysis provides an estimate of the magnitude of bias likely to be introduced into the 
COR.  When studies are heterogeneous, or the range of ORzs is wide enough to cause a 
substantive difference in the COR, stratifying studies by design or study population 
characteristics can illuminate the sources of heterogeneity.  Lastly, meta-regression can be 
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used to formally estimate the strength of association between specific predictors, such as 
control group Hardy Weinberg equilibrium (HWE) status, population ethnicity, average age 
etc. and the magnitude of ORzs.  Understanding the relationship between important study 
characteristics and the magnitude of ORz can help determine what, if any, ancillary data are 
appropriate to evaluate the independence assumption. Using these tools, meta-analysis 
provides context for evaluation of the independence assumption not currently available.   
3. CBCS and NCCCS control groups 
The second study (see Chapter V-B) was an exploration of gene-environment 
association in two population-based control groups.  The studies were the Carolina Breast 
Cancer Study (CBCS) and the North Carolina Colon Cancer Study (NCCCS).  As in the meta-
analysis (Chapter V-A) smoking was the model environmental exposure. ORz was estimated 
for all genetic variants related to smoking that had been assayed for these control groups.  
This included all of the SNPs in the meta-analysis.  Genes were grouped a priori based on the 
biologic function of the gene (e.g. xenobiotic-metabolizing genes, DNA repair genes etc.) and 
associations were examined by group.   
The CBCS and the NCCCS are large population-based case-control studies done in 
central North Carolina during the mid- to late 1990’s which included urban, suburban and 
rural areas (CBCS: Ncases=2311, Ncontrols=2022;  NCCCS: Ncases=646, Ncontrols=1053 [175-180].  
Both studies over-sampled African Americans to increase power for subgroup analyses.  The 
NCCCS included male and female participants. Potential participants were selected from NC 
Division of Motor Vehicles lists (<65 years of age) and Health Care Financing Administration 
lists (>=65 years of age), and randomized recruitment was used to select to potential 
participants to frequency match on relevant characteristics in each study [181].  CBCS 
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participants were all female, with approximately half African American and half <50 years of 
age.  NCCCS participants were sampled such that the race, age and gender distribution of 
randomly selected cases is similar for controls (approximately 1:1 for gender and race). 
The CBCS and NCCCS data offered a rich resource for this project for several 
reasons.  First, both are population-based case-control studies.  Conceptually, the 
independence assumption is an assumption about the underlying population from which cases 
arose (control groups are used as surrogates for the underlying population); population-based 
control groups should be a better approximation of the underlying population than hospital-
based control groups or convenience samples.  Ideally, a large population survey or 
population-based cohort would be preferable, but in practice there are few of these available.  
Investigators rely on control groups from case-control studies such as the CBCS and NCCCS 
for independence evaluation.  In addition, the CBCS and NCCCS draw from approximately 
the same underlying population, using the same sampling method, so results could be 
compared for the 15 polymorphisms that were assayed in both control groups.  Ascertaining 
the level of agreement between two studies using the same sampling methods, sampling from 
an underlying population in largely overlapping geographic area, during overlapping time 
periods, but with different study outcomes (breast and colorectal cancer) provides a window 
into the population-specific nature of the independence assumption in practice. 
Second, both the CBCS and NCCCS collected extensive data on tobacco smoking 
behaviors.  In the CBCS there were data such that smoking could be categorized as 
ever/never, former/current/never, total duration of smoking, average amount smoked per day 
during periods of smoking and pack-years.  In the NCCCS there are data on smoking status 
(never, current and former), duration, and intensity as well. This level of detail 
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than what is usually published in the ancillary studies that must be used for independence 
assumption evaluation.  
Not only did this level of detail allow for estimation of ORz for measures of smoking 
amount (duration, dose and PY), it allowed investigation into the effect of smoking 
misspecification on independence assumption evaluation (see Chapter V-B).  The term 
‘misspecification’ was used in this study, rather than the term ‘misclassification’, because the 
underlying conceptualization of this problem was that of variable misspecification in 
modeling, rather than measurement error.  When a stand-alone case-only study is undertaken, 
the independence assumption must be examined in ancillary data.  As would be expected from 
the differing study goals, in ancillary data the categorizations used in tables for the joint 
distribution of genotype and smoking are generally more crude than those that will be 
analyzed in the proposed case-only study.  In the case of a polymorphic gene with 2 alleles at 
the locus of interest, this means that published data is often collapsed to 2 categories, carriers 
and non-carriers of the allele of interest, rather than published as 3 categories, 1 each for 
homozygotes of each allele and another for heterozygotes.  For smoking, the only 
categorization that can be consistently found across studies is the dichotomous ‘ever/never’ 
smoker.  Using one specification of exposure for independence assumption evaluation (e.g. 
ever/never)  and a different one for case-only interaction analysis (e.g. packs/day) is precisely 
analogous to doing a case-control interaction study with a model that has the same exposure 
specified as binary for controls and continuous for cases.  No work has been published to date 
on the validity of using different exposure specifications for independence assumption 
evaluation and case-only analysis.   
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The exposure misspecification results will be useful to researchers considering 
specific case-only studies, particularly with genes expected to interact with aspects of 
smoking amount.  If case-only studies are to be used to ‘screen’ for genes that interact with 
smoking, these results can help identify ancillary studies with appropriate data for valid 
independence assumption assessment.  Again, because of the wide range of research on 
smoking behavior, both in terms of smoking cessation and other modifications of smoking 
behavior, and on health outcomes, the utility of these results will not be limited to cancer 
research.  Results from these studies should raise awareness of this shortcoming in the 
ancillary data currently available to researchers.  Ideally, it will encourage research practices 
that make more detailed control data available for independence assumption evaluation. 
Additionally, a wide range of genetic polymorphisms have been examined in both 
studies.  The CBCS had data on polymorphisms in 17 DNA repair genes, 7 xenobiotic-
metabolizing genes, and 5 other genes related to cell growth and oxidative damage defense.  
The NCCCS had genotype data for 15 DNA repair genes, 3 xenobiotic metabolism genes and 
1 oxidative stress gene. (For a complete list of gene see Chapter V-B.)   
Because both studies over-sampled African Americans there were sufficient white and 
African American participants we were able to perform subgroup analyses by stratified by 
race.  Stratification by race allows population stratification to be addressed, at least crudely.  
Population stratification is a potentially important source of bias in genetic association studies 
[182].   
Finally, these studies provided a large sample size for evaluating the independence 
assumption (CBCS controls: N=2022, NCCCS: N=1053).  Since the independence 
assumption is a large sample approximation, it is crucial to evaluate it in samples with 
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sufficient power to detect relevant effect sizes.  Across the range of smoking prevalences in 
CBCS and NCCCS controls and several control subgroups (African American in CBCS, >=50 
years of age in CBCS and NCCCS, males in NCCCS), and at gene carrier prevalences of 20% 
or more, there was good power to detect ORzs of 1.6-1.7 and above, the magnitude of 
associations that previous data simulations have indicated to be problematic for case-only 
studies [5].  This is true for many of the measured genetic polymorphisms in these studies, 
which generally have carrier prevalences of >=10%.  In particular, there was excellent power 
to detect ORzs of 1.6-1.7 and above for the 6 polymorphisms examined in the meta-analysis, 
either overall or in subgroups.  
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IV.  METHODS 
A. Overview 
The methods used in the two studies that comprise the dissertation complement and 
support each other.  Both studies were an examination of empirical data used to evaluate the 
independence assumption.  The systematic review and meta-analysis gave a broad overview of 
the range of ORzs to be found for the selected DNA repair gene SNPs.  A systematic review 
shows the broad range of study types that have collected, but not necessarily presented, data that 
can be can be used for independence assumption evaluation. The magnitude of ORz can be 
compared across numerous study-level characteristics such as design and HWE status.  Methods 
of individual-level data analysis used for the CBCS and NCCCS control groups allow exploration 
of effect measure modification and confounding, information not available in a meta-analysis.  
Further, using two population-based control groups with detailed data on smoking provides a way 
to examine the effects of misspecification on independence assumption evaluation and level of 
agreement across studies, using a different method than comparison in a meta-analysis. Because 
the 6 SNPs in the meta-analysis are also assayed in the CBCS and NCCCS control groups results 
can be compared for the two methodologies.  Use of these two approaches to explore 
independence assumption evaluation from different viewpoints enhances understanding of the 
methods necessary for valid evaluation of the assumption.  
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B. Literature-based analysis of the independence assumption 
1. Overview 
The first phase of this dissertation project was a systematic review and literature-based 
series of meta-analyses of specific gene-environment associations in control groups, cohorts, 
cross-sectional and convenience studies, with the goal of better understanding heterogeneity 
within specific gene-smoking associations.  The environmental exposure was smoking and 
aspects of smoking behavior, such as dose and duration.  The genetic exposures were 
polymorphisms in 3 genes coding for DNA repair enzymes: XRCC1, XRCC3 and XPD. 
Meta-analytic techniques can be used to quantify the magnitude and heterogeneity of 
the multiple gene-environment associations found in the published literature.  It is a 
quantitative technique that can be used as part of a systematic review.  In a meta-analysis, 
data from multiple studies addressing the same question undergo formal qualitative and 
quantitative assessment.  It differs from a traditional narrative review in several important 
respects.  First, the literature on the topic of interest is searched in a more systematic and 
explicit manner, with a priori inclusion and exclusion criteria for studies. Second, data from 
multiple studies is both quantitatively and qualitatively compared, and can be combined under 
certain conditions, unlike a traditional review, which is primarily qualitative.  Where 
appropriate, summary estimates of effect that take sample size of the individual studies into 
account can be calculated.  Meta-regression can be used to formally explore sources of 
heterogeneity between studies, usually an informal subjective process in the narrative review.   
Meta-analyses have the advantage of making the literature search process, at least, more 
explicit and, at best, more thorough as well.  Additionally, meta-analysis is a more explicit 
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and objective way to compare study characteristics, and the only way to do it quantitatively 
[183].   
Meta-analytic techniques are used for two broad purposes.  One possible goal of meta-
analysis is to produce a summary estimate of effect across studies.  Provided certain criteria 
are met, this technique can be used to combine results from underpowered randomized 
clinical trials to produce a more precise estimate than otherwise available.  Summary 
estimates can be generated either from weighted pooling of the raw data from multiple studies 
or, less directly, from combining the individual study estimates with appropriate weighting.  
These techniques can also be used with observational studies, however the criteria for 
producing a valid summary estimate are more difficult to meet and a summary estimate is 
often not of primary interest.   
When a summary estimate is inappropriate (e.g. the studies are too heterogeneous to 
combine), or not desired, another possible goal of meta-analysis is to explore the sources of 
study heterogeneity [184-185].  This is most often done when there are multiple observational 
studies attempting to answer essentially the same question but results are inconsistent.  In this 
situation the primary goal is to understand differences between the studies.  Heterogeneity 
among studies can arise from both methodological and population factors [186-187].  
Methodological factors that can produce heterogeneity include study design, method of 
exposure ascertainment, and outcome definition.  As a hypothetical example, before 
widespread PSA (prostate specific antigen) screening, a study of race and prostate cancer 
including only screen-detected cases would be expected to yield a different (lower) magnitude 
of association than one that included only symptomatic cases, because race was associated 
with screening behavior.  Another possible source of study heterogeneity is differences 
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between the study populations.  A hypothetical example of this scenario would be if results 
from observational studies looking at the association of body mass index (BMI) and all-cause 
mortality done in sub-Saharan Africa differed from results from similar studies conducted in 
Western Europe, with higher BMI inversely associated with mortality in the former and 
positively associated in the latter.  It would clearly be inappropriate to combine these studies 
to derive a summary estimate.   
Meta-regression, which is analogous to standard regression techniques in most 
respects, is used to explore the influence of, and estimate the strength of, potential sources of 
heterogeneity [187].  In meta-regression, the unit of observation is the individual study, the 
outcome for each study is its effect estimate, and the independent predictors consist of defined 
values for each of the potential sources of variability.  For instance, a meta-regression 
performed on 10 studies of lead exposure and kidney cancer would have an N of 10, the 
outcome for each study would be the magnitude of the association between lead and kidney 
cancer, and some independent variables could be study design (case-control v. cohort), study 
site, year study was performed, and method of exposure measurement (blood lead levels/bone 
lead levels).  In meta-regression, outcome data on each observation (study) is weighted by the 
inverse of its variance, and can be further weighted by any additional factors the investigator 
considers important. The variance component can be deconstructed into two components, 
within study variance and residual variance.  The residual variance is the variance not 
accounted for by the independent variables, called the between-study variance.  Between-
study variance can be considered equal across studies if the given group of studies can be 
considered repeated trials of the same study.  In this case a ‘fixed effects’ model, which sets 
the between-study variance to 0, may be used.  Although it has been argued that studies of 
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genetic exposures may be a special case [188], this approach is often not considered 
appropriate for groups of observational studies as it can be difficult to conceptualize them as 
repeated trials of the same study.  Without this assumption, the between-study variance is 
allowed to vary, with a concomitant decrease in the precision of the summary estimate.  This 
is known as a random-effects model, and is often used with observational studies.  It assumes 
that each study comes from a distribution of studies, each with their own ‘true’ ORz.  This is 
in contrast to the fixed-effects model where each study is assumed to be an estimate of one 
underlying ‘true’ ORz. The choice of random- or fixed-effects models for meta-analysis is a 
conceptual, rather than mechanistic, choice.   
Stratified analysis, in conjunction with meta-regression, can help the investigator 
begin to identify which of the hypothesized sources of heterogeneity contribute to the 
variation in study results, as well as begin to quantify the relative strength and direction of 
those contributions.  Stratified analysis provides separate summary estimates by study 
characteristic and meta-regression provides a measure of each stratum relative to the reference 
stratum (e.g. hospital-based case control studies relative to population-based case-control 
studies). 
2. Literature Search  
After consultation with Lynne Morris, a reference librarian at UNC’s Health Sciences 
Library, I identified appropriate keywords and databases for a thorough search of the 
published genetic literature.  I used the CDC Genomics and Disease Prevention database 
(GDPInfo), PubMed, and the ISI Web of Science as the primary databases.  Keywords for the 
CDC database were from the ‘Factor Menu’ keyword list and were as follows: smoking 
behavior; smoke (tobacco), passive; smoking (tobacco), bidi; smoking (tobacco); smoking 
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(tobacco), maternal; tobacco.  I used the CDC Genomics and Disease Prevention database to 
determine the frequency with which various polymorphic genes are examined in conjunction 
with smoking.  Because the focus of the meta-analysis was association in the control groups 
rather than the interaction, the search included studies with any outcome.  The CDC database 
is limited to human studies, and has a strong focus on gene-environment interaction literature.  
After assessing the relative contribution of different genes to the gene-environment literature 
for smoking, a panel of genes for further searches was developed, emphasizing genes highly 
relevant to interaction analyses.   
It was not expected that the CDC database would produce an exhaustive list of the 
relevant gene-environment literature, but instead would provide a guide to the polymorphic 
genes most frequently studied in conjunction with smoking.  The preliminary CDC database 
search for XRCC1 and smoking produced 25 references.  The same search on PubMed, with 
the appropriate keywords for that database, produced 47 references and an analogous ISI Web 
of Science search found 64 publications.  There were 73 distinct publications in the combined 
list of 136 references, but only 21 papers referenced by all 3 databases.   Two papers were 
found only in the CDC database, 7 papers only in PubMed and 23 only in the Web of Science.  
Although each database has its strengths (CDC is appropriately focused for the current 
project, PubMed is more comprehensive but easily limited to relevant publications, and the 
Web of Science is the most comprehensive and current), it was clear that none alone would be 
sufficient for a thorough search of the literature. Each database captured a different subset of 
publications within the relevant time period (1999 forward) for the genetic polymorphisms of 
interest.   
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The goal for the final searches was to identify studies that  presented the joint 
distribution of the polymorphisms of interest and smoking in non-cases (hereafter referred to 
as controls) in a form that allowed estimation of the gene-smoking ORz(95%CI).  Final 
searches were done in PubMed, ISI Web of Science and CDC databases to capture as much of 
the relevant literature on each gene of interest and smoking as possible.  PubMed, ISI Web of 
Science and the CDC Genomics and Disease Prevention databases were searched up to March 
6, 2007 for peer-reviewed literature likely to contain data on the joint distribution of any of 
the polymorphisms of interest [single nucleotide polymorphisms XRCC1 Arg399Gln, 
Arg194Trp, and Arg280His, ERCC2(XPD) Lys751Gln and Asp312Asn, and XRCC3 
Thr241Met] and smoking behavior in non-case groups. Non-case groups were defined as any 
group not selected as the index group based on disease status (e.g. cohorts, convenience 
samples and control groups from case-control studies).  For simplicity all non-case groups 
will be referred to as controls throughout this document. 
For PubMed searches the terms ‘(smoking OR tobacco OR tobacco smoke OR 
tobacco smoke pollution)’, ‘(polymorphism OR polymorphism, genetic)’ and a gene-specific 
keyword (e.g. XRCC1) were used together to identify papers that included the polymorphisms 
of interest and smoking.  ISI keywords were (‘smok*’ OR  ‘tobacco’) and the gene-specific 
keyword.  The searches used the ‘general search’ and ‘by topic’ options that search the 
abstract and title text, not just the title.  Searches included all document types and in all 
languages.  PubMed, ISI Web of Science and GDPInfo databases were searched up to March 
6, 2007 for relevant peer-reviewed literature.   
Two types of studies contributed information on gene-smoking associations.  The first 
were ‘main effect’ studies, that is, studies that focused on the association between the given 
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genetic exposure and smoking behavior.  For example, this included studies of DNA repair 
genotypes and degree of genetic damage in blood cells of healthy volunteers, smokers and 
nonsmokers.  The second type of study that provided information for calculating ORz was 
gene-environment interaction studies of the polymorphism of interest and smoking.  These 
gene-environment interaction studies often contained tables of the joint distribution (in cases 
and controls) of the polymorphism and some aspect of smoking behavior.  In order to further 
the goal of examining heterogeneity between studies, the inclusion criteria were broad.  To be 
included a study had to present either 1) control data on the joint distribution of any of the 
genotypes of interest and any measure of smoking such that ORz (95% CI) could be 
calculated or 2) an estimate of the ORz and 95% CI in controls.  Further, each study had to 
provide enough information on the specific polymorphism and genotyping method to be 
certain the same polymorphisms had been assayed across studies.  SNP designations 
considered equivalent are in shown below (Table IV.1).  
 
Table IV.1  SNP designations for data abstraction 
XRCC1 XRCC1 XRCC1 XPD (ERCC2) XPD (ERCC2) XRCC3 
Arg399Gln  Arg194Trp Arg280His Lys751Gln Asp312Asn Thr241Met 
G28152A C26304T  G27466A A35931C G23591A C18067T 
exon 10 exon 6 exon 9 exon 23 exon 10 exon 7 
 rs25487 rs1799782  rs25489 rs13181 rs1799793 rs861539   
R399Q R194W R280H   K751Q D312N  T241M 
      ERCC2_18880_A>C ERCC2_6540_G>A   
 
Data used in more than one published analysis was only included once in any given 
meta-analysis.  Abstracts were excluded. There were no language restrictions on the searches.   
After searches were complete, abstracts were screened to ascertain that the study had smoking 
exposure, one of the SNPs of interest and non-cases.  Full text versions were obtained for all 
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articles meeting these criteria except the one non-English paper.  Non-English articles were 
included in the search to ascertain the proportion of missing studies caused by the language 
exclusion.  Full text articles were evaluated for appropriate control data.  All articles were 
screened and abstracted by E. Hodgson. 
3. Data abstraction  
If an abstract was not excluded by the initial screening, the paper was retrieved and 
reviewed for data appropriate for construction of, at minimum, a 2x2 table for genotype-
smoking association in controls. If an unadjusted OR for any genotype-smoking association 
could be calculated, the as much of the following information as possible was abstracted: 
SNP, genotype categories (3 genotypes, dominant and/or recessive models), smoking status 
and dose categories [ever/never, current/not current, smoker/non-smoker, ever/former/current, 
pack-years (PY), duration and/or intensity], and cell counts for all genotype and smoking 
categories. Cell counts and smoking and genotype categories were abstracted onto preprinted 
forms to reduce data entry errors.   
The following study characteristics were abstracted directly into an Excel spreadsheet 
for coding: year of publication, study design (case-control, cohort, cross-sectional, 
convenience, other), source of control group (for case-control: population, hospital, friends 
and non-blood related family, convenience, community, neighborhood, other; for cohorts: 
population, occupational, convenience, other), type of clinic that hospital- or clinic-based 
control groups were from (disease clinics, checkup clinics), matching characteristics (none, 
frequency-match, individual-match, matched on age, gender, ethnicity or other), study 
outcome (cancer [type], non-cancer disease, non-disease), full study/control group size (N), 
size of SNPxSmoking subset (N), country, percent male participants, ethnicity (% white, % 
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African American, % Asian American, % Han Chinese, % other), Hardy Weinberg 
equilibrium p-value, minor allele frequency, health exclusion criteria for study/control group 
(no exclusions, history of case cancer, history of any cancer, “cancer-free” only, other health 
conditions, “healthy” only, other), number of genes/SNPs assayed, and number of smoking 
categories.  If the HWE p-value or MAF was not given but could be calculated, it was 
calculated and included. An estimate of central tendency for participants’ age in years 
(designated “average age”) was derived for each study using, in order of preference: median 
age, mean age, weighted average across study age categories, midpoint of age range.  No 
individual-level characteristics were abstracted.   
4. Meta-analyses  
Environmental exposure:  tobacco smoking behavior, including dose and duration, 
was the environmental factor investigated.  Smoking was chosen due to public health 
importance conveyed by the high prevalence of the smoking and the strong justification for 
further gene-environment interaction studies.  Smoking status was categorized as (1) 
ever/never (referent), and (2) current/not current (referent).  Smoking amount was analyzed as 
(1) pack-years [PY, lowest non-zero category (referent) compared to highest], (2) duration 
[years, shortest non-zero category (referent) compared to longest] and (3) smoking intensity 
[cigarettes/day, lightest non-zero category (referent) compared to heaviest].  Original study 
categorizations were used when possible.  The categories “passive smoking only” and “never 
active or passive smoking” were combined into “never” for our analyses.  For analyses of 
current/not current smoking, never+former smokers and “non-smokers” (if identified as not 
current smokers) were considered not current smokers.  Pack-years of smoking (pack-years = 
number of packs smoked per day multiplied by years smoked; 20 cigarettes=1pack) were 
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analyzed as relative categories [lightest smokers vs. heaviest smokers regardless of PY 
cutpoints] and absolute categories [< specified range of PY cutpoints vs. >= the same range of 
PY cutpoints; ranges varied by SNP].  The ranges were chosen to maximize the number of 
included studies while keeping the range small enough that no study would have >1 cutpoint 
in a specified range.  Similar to PY, smoking intensity was categorized by relative (lightest vs. 
heaviest smokers regardless of cigarette/day cutpoints) and absolute (<20 vs. >= 20 
cigarettes/day) measures.  Smoking duration cutpoint range was 20-40 years, inclusive, for all 
SNPs.  
Genetic exposures:  Six polymorphisms in 3 DNA repair genes.  The six SNPs were 
XRCC1 [Arg399Gln (rs25487), Arg194Trp (rs179872), Arg280His (rs25489)], XPD 
[Lys751Gln (rs13181), Asp312Asn (rs1799793)] and XRCC3 [Thr241Met (rs861539)].  The 
three genes participate in 3 different DNA repair pathways, the BER pathway (XRCC1), the 
NER pathway (XPD), and the DSB pathway (XRCC3).  These genes were chosen for their 
relevance to cancer risk, the relatively high prevalence of several SNPs in these genes, the 
availability of published control group data, and their relevance to further interaction studies 
with tobacco smoking.  Because there were too few studies that provided the joint distribution 
of genotype and smoking using all three genotypes (homozygous common allele, 
heterozygous, homozygous for the variant allele),  all analyses were done using the dominant 
model (homozygous for the common allele as the referent vs. genotypes with any variant 
allele).  Studies where only the ORz(95% CI) for the recessive model were presented were 
included in the systematic review, but not in any of the meta-analyses. 
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Outcome measure:  Unadjusted odds ratios (ORz) and 95% confidence intervals for 
each SNP-smoking association were calculated from cell counts (Stata 9.2, using metan STB-
44: sbe24).   
Summary estimates:  Forest plots with visually weighted point estimates were used to 
graphically display individual ORz(95% CI) for each study and the summary ORz (95% CI) 
for each SNP-smoking pair.  To reduce the possibility of results being confounded by 
ethnicity (population stratification) in overall analyses and when examining the study 
characteristics likely to vary strongly by ethnicity (Hardy Weinberg equilibrium p-values and 
minor allele frequency) studies were stratified by ethnicity and treated as separate studies if 
possible. Fixed effects models were used for summary estimates unless studies were too 
heterogeneous to combine.  Cochran’s Q two-sided homogeneity p-values (α=0.10) were used 
to assess overall heterogeneity in odds ratios [189].   
Funnel plots were generated for inspection and testing.  Two tests for statistical 
significance of funnel plot asymmetry were used were used to assess the potential for 
publication bias [190].  When data were sufficient (Nstudies>=5), asymmetry was formally 
assessed using Begg and Mazumdar’s test [191] and Egger’s test [192] at α=0.10.  Funnel 
plots graph the effect size of each study against its variance (or other measure associated with 
sample size, inverse variance etc.).  Generally, as variance increases effect sizes also increase 
if all studies, both positive and negative, have been published, creating a funnel shaped plot.  
If there is an area of the plot where studies that have similar effect sizes and variance are 
missing, for instance, small studies with null or negative findings, the ‘funnel’ will be 
asymmetrical.  This could indicate a publication preference for large studies, regardless of 
results, and small studies only when the results are positive. There are other factors that can 
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cause funnel plot asymmetry but a symmetrical plot argues against publication bias.  It is 
unlikely that publication bias based entirely on the magnitude of interaction effects is a 
common occurrence.  However, it is possible that null results for main effects in small studies 
may be correlated with positive results in interaction analyses and produce some degree of 
publication bias. 
5. Study characteristic analysis  
 
Stratified analysis:  To further the goal of understanding the heterogeneity of the 
included studies, multiple study characteristics were abstracted for stratified and meta-
regression analysis.  In study characteristic analysis, the goal is to see if effect size or 
homogeneity varies, on average, by strata of a given study characteristic. For instance, 
stratified analysis will show whether studies with controls out of HWE have a summary ORz 
different than the summary ORz of studies with controls in HWE.  Cochran’s Q statistic two-
sided homogeneity p-values were used to assess heterogeneity within strata, as it is also of 
interest to see the SNP-smoking ORzs with a subgroup of studies defined by a study 
characteristic are more homogeneous than for that SNP-smoking ORz overall.  Consistent with 
the goal of study characteristic analysis, stratum-specific estimates for each subgroup of 
studies were calculated regardless of homogeneity test results. 
Stratified analysis of study design was performed for all SNP-smoking combinations, 
because this study characteristic was considered a priori the most important, given that the 
independence assumption applies population-based controls or cohorts. However, due to 
sample size considerations, the remaining study characteristics were examined only for 
XRCC1 399, XPD 751 and XRCC3 241 and only for ever-never smoking, current-not current 
smoking and pack-years of smoking.  Forest plots were done for each stratified gene-smoking 
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association examined.  Stratum-specific funnel plots were constructed for different strata of 
study characteristics where the data allowed.  Stratified random-effects meta-analyses were 
used when the overall SNP-smoking association had a Cochran’s Q p-value α<0.10, otherwise 
fixed effects meta-analysis was used, regardless of the homogeneity p-values of individual 
strata.  For purposes of comparing strata either random- or fixed-effect models will allow 
comparison.  The same method was used for all study characteristics of a given SNP-smoking 
combination to ensure comparability within SNP-smoking study characteristic analysis.  
Meta-regression:   Consistent with the goal of exploring study heterogeneity, meta-
regression was performed regardless of homogeneity of the studies included in the summary 
ORzs.  Meta-regression provides a formal comparison of the stratum-specific ORzs by study 
characteristic.  It produces a ratio of the stratum-specific ORz compared to the reference 
stratum for that study characteristic, therefore a ratio of ratios (ROR) with corresponding 95% 
CI.  Therefore, regression coefficients for each study characteristic in the meta-regression 
model indicate the direction and magnitude of the association between that study 
characteristic and the magnitude of the ORz.  Meta-regression was performed for all SNP-
smoking combinations where sample size allowed. The minimum conditions for generating 
meta-regression estimates (RORs) was that there were at least two studies in each of at least 
two strata. Because the sample size was generally small within strata multivariable regression 
(including multiple study characteristics in a single model) was not a viable modeling strategy 
and was not performed.   
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C. Gene-smoking association in CBCS and NCCCS controls 
1. Overview 
This portion of the project consisted of an empirical analysis of control group data 
from two population-based epidemiologic studies to estimate ORz for measures of smoking 
and a panel of polymorphic genes plausibly related to smoking behavior.  ORz is of interest 
because it is itself a measure of bias in the COR, an estimate of the interaction parameter from 
a case-control study (SIM).  The purpose in estimating ORz is to estimate the degree of bias in 
the COR, relative to the SIM.   
2. Study populations  
As described previously, both the CBCS and NCCCS are large population-based case-
control studies conducted in central North Carolina during the mid- to late 1990’s that have 
collected extensive data on smoking and genetic exposures. Both studies over-sampled 
African American participants. 
 
Both studies included urban, suburban and rural areas (CBCS: Ncases=2311, 
Ncontrols=2022;  NCCCS: Ncases=646, Ncontrols=1053) [175, 177-180].  CBCS controls were 
pooled controls from Phase I (N=790), Phase II (N=774) and the Carcinoma in situ (N=458) 
study.  Because the underlying study populations in the CBCS and NCCCS were similar but 
not identical, and agreement was of interest, controls were not poled across studies.  Both 
studies over-sampled African Americans.  CBCS controls are all female; NCCCS controls 
also include male participants. Potential controls were selected from NC Division of Motor 
Vehicles lists (<65 years of age) and Health Care Financing Administration lists (>=65 years 
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of age), using randomized recruitment and frequency matched on age, race and gender [181].  
CBCS participants were approximately half African American and half <50 years of age.  
NCCCS participants were sampled such that the race, age and gender distribution of randomly 
selected cases is approximately 1:1 for gender and race.  The CBCS and NCCCS used similar 
questionnaires and both have extensive data on tobacco smoking history.   
3. Statistical methods:  Estimation and evaluation of ORz 
Gene-smoking association was estimated for all genetic variants in the CBCS and 
NCCCS plausibly related to smoking behavior, including each of the DNA repair SNPs 
previously assessed in the meta-analysis. 
Environmental exposure:  In the CBCS and NCCCS smoking status was categorized 
as ever, former or current smoker. Four different comparisons of smoking status were derived 
from these: 1) ever (current + former smokers) vs. never smokers, 2) current vs. not current 
(never + former smokers) smokers, 3) current smokers vs. never smokers and 4) former vs. 
never smokers.  Three measures of smoking amount were used: duration (<10 years, 11-20 
years, >20 years), intensity (<1/2 pack/day, 1/2-1 pack/day, >1 pack/day) and pack-years (PY: 
<=35 PY, >35 PY).  Pack-years were derived from categorical variables used for packs/day 
and years smoked (pack-years are equal to the midpoint of the category for number of years 
smoked multiplied by the midpoint of the category for number of packs smoked/day).   
Genetic exposures:  A sample of polymorphisms was chosen from available genotype 
data in the CBCS and NCCCS based on potential relevance to smoking behavior and/or other 
smoking-related health effects (convenience sample). Genes selected form the CBCS were 
xenobiotic metabolism genes (CYP1A1, GSTM1, GSTP1, GSTT1, NAT1, NAT2, COMT), 
DNA repair genes (Base excision repair: APE 148, hOGG1, MYH, XRCC1; Double strand 
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break repair:  BRCA2, NBS1, XRCC2, XRCC3, XRCC4; Mismatch repair:  MGMT; Nucleotide 
excision repair: ERCC1, ERCC6, RAD23B, XPC, XPD, XPF, XPG), oxidative stress defense 
genes (MnSOD, MPO, NQO1), a cell adhesion gene (CDH1) and a  growth factor gene 
(TGFB1).  NCCCS genes included: xenobiotic metabolism genes (GSTM1, GSTT1, MEH), 
DNA repair genes (Base excision repair: ADPRT, ADPRTL2, APE 148, XRCC1; Double 
strand break repair:  NBS1, XRCC3; Mismatch repair:  MLH1, MSH3, MSH6; Nucleotide 
excision repair: RAD23B, XPC, XPD, XPF, XPG), and an oxidative stress defense gene 
(MnSOD).  Methods of collection and most genotyping have been described previously [68, 
171, 193-203].  Those homozygous for the most common allele (“no variant”) were the 
referent group (G-) and were compared to heterozygotes plus homozygotes for the less 
common allele (G+, “any variant”).   
Hardy Weinberg equilibrium was tested at α=0.05 for all polymorphisms except 
GSTM1, GSTT1, NAT1 and NAT2.  These genes were not categorized in such a way the HWE 
could be calculated.  Alleles for each of these genes were grouped into 2 functional categories 
(null/present activity for GSTTM1 and GSTT1, fast/slow metabolizers for NAT1 and NAT2) 
rather than as genotypes with the actual alleles that assort under HWE. 
Gene pathways:  Genes were classified a priori by their primary metabolic pathways 
(e.g. xenobiotic-metabolizing genes, DNA repair genes, oxidative stress defense genes etc.) 
although some genes function in multiple or overlapping pathways.  For instance, some Phase 
I and Phase II xenobiotic metabolism enzymes have both exogenous substrates and 
endogenous substrates (e.g. COMT).  All analyses considered whether there appeared to be 
patterns of association within and among gene pathways. 
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Outcome measure:  Estimates of ORz and 95% confidence intervals were generated 
using logistic regression.  Because the goal of this project was examination of the 
independence assumption and potential bias introduced into case-only estimates of interaction 
by its violation, the magnitude, not the statistical significance, of ORz was our primary 
concern.  ORzs of moderate magnitude (>=1.4 or <=0.7) were judged, for the purposes of this 
project, to be of sufficient magnitude as to cause unacceptable bias in the COR in nearly all 
research contexts.  Of course, each ORz is only one estimate of the true underlying association 
and the true level of bias could be much larger or smaller, as suggested by the width of the 
95% CI.  Consequently, estimates with very wide confidence intervals were excluded from 
consideration. Confidence interval width was the ratio of the upper bound of the 95% CI to its 
lower bound. Only ORzs with confidence limit ratios (CLR, upper bound of CI/lower bound 
of CI) less than four were included, with the exception of calculation of kappa for agreement 
between CBCS and NCCCS data (see section below on agreement) where ORzs with CLRs of 
up to 5 were used. 
Population stratification:  Because the CBCS and NCCCS have study participants 
from different ethnic groups (white and African American) it is important to consider whether 
population stratification could have a substantial impact on analyses.  Population 
stratification, and the magnitude of the bias it may introduce into association studies, has been 
debated in the literature, most prominently by Thomas and Wacholder in 2002 [182, 204].  
The term population stratification refers the fact that alleles at polymorphic sites in the 
genome can have different distributions in different populations, causing strata (subgroups) 
based on membership in these genetically distinct populations, within study populations.  This 
can cause confounding in genetic studies under certain conditions.  Specifically, if a study is 
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analyzed without regard to ethnic group and/or ancestry, and the allele of interest is more 
prevalent in some ancestrally related groups than others, and the baseline risk of the outcome 
varies among the same groups, confounding may occur. The term ‘population stratification’ 
will refer to this type of confounding from here on. Specifically, Wacholder et. al. outline 3 
conditions necessary for population stratification to occur: 1. variation in genotype across 
ethnicities 2. variation in disease rates across ethnicities (after adjustment for known risk 
factors) 3. allele frequencies that track with disease rates across ethnicities (for reasons other 
than genotype of interest).  The 4th condition they outline is actually a requirement for the 
confounding to substantially affect study results, rather than a requirement for confounding 
itself. It is that there be insufficient information on ancestry or ethnicity from study 
participants to reduce bias to an acceptable level [204]. 
Population stratification could cause bias in the estimate of control group associations 
between genetic exposures and smoking behavior (ORz) if conditions 1-3 (above) were met 
and the self-reported racial categories in the CBCS and NCCCS were insufficient to control 
for this bias. Considering first the necessary conditions for confounding of the ORz by 
population stratification, it is clear that it was possible.  A number of the allele frequencies 
measured in the CBCS and NCCCS varied by race (e.g. XRCC1 Arg399Gln [6.8% and 16.7% 
MAF in whites and African Americans respectively] and XPD Asp312Asn [6.0 and 16.1 
MAF in whites and African Americans, respectively]).  Smoking behavior also varied by race 
in this population.  Although 19% of both white and African American CBCS participants 
reported being current smokers, never and former smoking are reported by 50% and 31% of 
whites and 60% and 21% of African Americans, respectively. This satisfied, at least in broad 
terms, the first two conditions. When there are only two subgroups in the data, the third 
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condition (that allele prevalence ‘track’ with outcome prevalence) is necessarily satisfied 
when the first two conditions are met.   
The fourth condition, that the available information is not sufficient to adequately 
control for this bias, was much harder to evaluate.  Primarily, it hinged on whether the self-
reported racial categories collected for this study were an adequate proxy for 1. relevant 
genetically defined subpopulations and/or 2. the true unmeasured risk factor that causes 
differences in baseline smoking behavior. Though not conclusive, there has been some 
empirical evidence available to evaluate whether self-reported race/ethnicity is an adequate 
proxy for genetic subgroups for whites and African Americans (the two groups in the CBCS 
and NCCCS). In a large study (N=3636) that included participants from 4 self-reported ethnic 
groups, genetic cluster analysis using a panel of 326 microsatellite markers to identify clusters 
showed nearly perfect correspondence (99.86%) with self-reported ethnic group and genetic 
cluster [205].  The four ethnicities included were Caucasian, African American, East Asian 
and Hispanic.  Multiple study sites were included and there was only minimal variation by 
study site within self-reported racial group. Analysis at a finer level was able to distinguish 
separate clusters for Chinese and Japanese participants but no reliable subgroups could be 
formed within Caucasians, African Americans or Hispanics [205].   
While the Tang et. al. (2005) study provided evidence that broad self-reported racial 
and ethnic categories correspond well to genetic subgroups, at least in these study populations 
and for these markers, it did not address the possibility of varying degrees of admixture within 
these ethnic categories.  An empirical analysis of the degree of bias possible in a study of N-
Acetyltransferase 2 (NAT2) polymorphism and either male bladder cancer or female breast 
cancer using data that mimicked the allele frequencies and disease rates of the US population 
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of non-Hispanic European origin, demonstrated that bias from population substructure was of 
minimal importance  for non-Hispanic whites in studies of cancer [206].  Taken together, 
these studies [205-206] indicate that self-reported information on race, as categorized in the 
CBCS and NCCCS as white or African American, is sufficient to appropriately stratify study 
participants by race and adjust for race.   
Similar work has been done for the African American population, however, the 
historic circumstances of enforced immigration and subsequent admixture have made such 
work much more difficult and complex [207].  On an individual level, African American 
ancestry demonstrates a high degree of admixture with European ancestry as well as 
admixture of various ancestral populations in Africa.  The degree of European admixture has 
been estimated at 12%-23% [208].  This admixture could be problematic if the degree of 
admixture tracks with smoking prevalence and with a true risk factor for smoking behavior 
[204-206].  In a simulation study, Wang et. al. (2004) modeled admixture from 2-10 
ethnicities (subpopulations) to a maximum of gene prevalence differences between 
subpopulations of 5-95%, at OR=1 and OR=2.  Their results showed that bias was acceptably 
low (<10%) at most of the scenarios presented. Bias was maximal (~20%) with only 2 
ethnicities, a gene prevalence difference of 90% (5% in one group, 95% in the other group) 
and a true OR of 2.0.  The 95% percentile of bias under this scenario, however, was a more 
modest 4% (OR=2.08 vs. 2.0).  In CBCS and NCCCS data, the assumption of admixture from 
only 2 ethnicities was conservative, as it ignores admixture between African ancestral groups 
and Native Americans, but plausible on a broad scale.  There were no gene prevalence 
differences as extreme as 5% & 95% in the CBCS or NCCCS controls.  For alleles with MAF 
differences of 20% or less, which were typical in the CBCS and NCCCS, any potential bias 
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should be well below the maximum 9% (at-risk genotype differences 5-40% have bias of  2% 
at the 95th percentile).   
In conclusion, although the potential for bias by population stratification, even after 
adjustment for race, certainly exists in the CBCS and NCCCS data, the magnitude should be 
small given the self-reported racial categories.  Clearly some residual confounding by 
population stratification may have remained after controlling for race in overall analyses, but 
the information available was sufficient to stratify by race and examine race as an effect 
measure modifier before proceeding to any combined analyses.   
Consequently, race-specific analyses were done for each gene variant and smoking 
measure.  Effect measure modification by race was assessed by performing the likelihood 
ratio test comparing models with and without a race*smoking interaction term. Significant 
results for the interaction term (α=0.05) in a majority of smoking measures precluded pooling 
African American and non-African American participants for that gene variant. 
Modeling:  Unconditional logistic regression with a dichotomous representation of the 
genetic variable (homozygous for common allele=referent [G-], heterozygous + homozygous 
for less common allele=exposed [G+]) as the dependent variable was used for all modeling.  
The dominant model was used to preserve power and precision of estimates of ORz, 
especially for stratified analyses where cell sizes tended to be small for some subgroups (e.g. 
African American women in the NCCCS).  A single model of the general form logit (G+/G-) 
= α + β
 (1) E1 + β (2-i) COV (2-i) + error (where G+= positive for genetic variant, E+=positive for 
the smoking behavior, COV=any additional covariates) was used for all SNPs.   
  Each dataset was evaluated for effect measure modification by stratification on race 
(white, African American), age (CBCS: <50y, >= 50y; NCCCS: <65y, >=65y) and gender 
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(NCCCS only), respectively.  Effect measure modification would have also been assessed for 
any individual level factors identified in the meta-analysis as strong predictors of effect size, 
had there been any. Average age was a mildly suggestive as an influential study characteristic 
but would have been evaluated as a potential effect measure modifier regardless.  Age 
distributions in the CBCS and NCCCS were different, necessitating different cutpoints for the 
binary age variables.   
In order to decide whether to stratify analyses on race or gender a likelihood ratio test 
was performed comparing models with and without a race*smoking interaction term (or 
gender*smoking interaction term). Significant results for the interaction term (α=0.05) in 
three or more smoking measures precluded pooling African American and non-African 
American (or male and female) participants for that SNP.    
Although frequency matching procedures using randomized recruitment in the CBCS 
and NCCCS were based on projected case incidence, and no cases were used in the current 
analysis, the matching process distorted the prevalence of these factors in the underlying 
population, potentially affecting gene-smoking estimates.  Based on directed acyclic graphs 
(DAGs) [209], and their status as matching factors, age (continuous), race (self-report: white 
or African American) and gender (NCCCS only) were assessed as potential confounders of 
the gene-smoking relationship.  Based on the DAG (Figure V.B.1.), two additional variables 
were evaluated as potential confounders:  first degree family history of any cancer, excluding 
non-melanoma skin cancer (Y/N) and total family income (<15K, 15-<30K, 30-<50K, 
>=50K).  To order to address the possibility of missing data for family history or income 
introducing bias, ORzs from the full dataset [adjusted for age, race and gender (NCCCS)] 
were compared with identically adjusted ORzs in a dataset restricted to those with no missing 
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data.  Estimates were not appreciably different, therefore the full dataset was used to assess 
confounding by family history of any cancer or total family income.  
Percent change in β coefficients was calculated but not used to determine whether a 
covariate would be retained in the model; because of the high proportion of estimates close to 
the null (Range in CBCS: 0.5-2.5, NCCCS:  0.6-1.6) this commonly used criterion was not 
sufficiently informative.  A potential confounder was retained if the absolute value of 
difference between smoking variable β coefficients from models with and without the 
potential confounder was > 0.15 (i.e. when | β coefficient for smoking from model with 
potential confounder – β coefficient for smoking from model without potential confounder| 
>0.15 the covariate was retained).  Rather than generating potentially dozens of gene variant-
smoking-specific models, the same set of confounders was used for all gene variants for 
comparability across gene variants.  If a covariate met this criterion for any gene variant-
smoking estimate, it was retained in all models. 
After assessment of effect measure modification and confounding, an association was 
characterized by the magnitude of ORz (odds ratios >=1.4 or <0.7 were considered evidence 
of non-null association) and precision of the accompanying confidence interval. Estimates 
with CLR>4 (upper limit/lower limit) were excluded from consideration unless otherwise 
stated.  SAS 9.1 was used for all modeling [210]. 
4. Agreement 
After assessing gene-variant-smoking ORzs in the CBCS and NCCCS datasets 
separately, agreement between the two studies was assessed for the 15 polymorphisms 
included in both studies using a weighted kappa statistic [211]. The weighted kappa measures 
the degree of agreement between two or more raters that are using a multi-level ordinal scale 
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to categorize a series of subjects, beyond what would be expected due to chance alone.  The 
raters were the CBCS and NCCCS, and the “subjects” of agreement were the 15 gene-
smoking associations measured by both studies.  ORz was categorized into three categories:  
1) below the null, ORz<0.9, 2) null, 0.9<=ORz<=1.1 and 3) above the null, ORz>1.1.  Only 
ORz with confidence interval widths of <4 were assessed.  With the weighted statistic 
disagreement between 2 adjacent categories has less influence on the statistic than 
disagreement between ratings further apart on the ordinal scale. The categories of Landis 
(1997) were used to describe strength of agreement or disagreement [212].  As a sensitivity 
analyses, agreement was also assessed with the definition of the null changed to 0.8-1.2 
(inclusive) and including all data regardless of CLR.  
5. Misspecification of smoking  
This study also explored the issue of undetected bias in the COR introduced by 
misspecification of smoking during independence assumption evaluation.  When a case-
control analysis of interaction is done, all exposures are specified identically for cases and 
controls. For example, if smoking is categorized as ever-never for cases in a given model it is 
also ever-never for controls in the same model.  However, when a stand-alone case-only study 
is considered, the independence assumption must be evaluated in ancillary data, and 
exposures may be specified differently than they will be in the case-only analyses.  The most 
common specification of smoking available in the literature, ever-never, is unlikely to be the 
only measure of smoking assessed in a case-only analysis including smoking.  When the ORzs 
differ across different measures of smoking, additional bias, over and above the bias 
introduced when the measures are identical, will be introduced into the COR.  Additionally, 
the decision whether or not to proceed with a case-only study may be affected.   
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The occurrence of moderate magnitude ORzs for smoking status (ever-never or 
current-not current smoking) was compared to the occurrence of moderate magnitude ORzs 
for any measure of smoking amount (duration, intensity or PY) for each genetic variant in the 
CBCS or NCCCS.  Because the CBCS and NCCCS control data allowed estimation of ORz 
across 5 different specifications of smoking for all genetic variants, particular genetic variants 
were identified that had discrepant ORzs across different smoking measures.  Further, since 
evaluation of the independence assumption in the literature is almost exclusively done by 
significance testing, we also compared significance testing of ORz to the method used in this 
study, a method based on the precision and magnitude of ORz(95% CI). 
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V. RESULTS 
A. MANUSCRIPT 1: Smoking and selected DNA repair gene polymorphisms in control 
groups: systematic review and meta-analysis 
1. Introduction 
The case-only study design as proposed by Prentice et. al and promoted by Piegorsch 
et. al. [1-2] has been increasingly used to estimate the magnitude of statistical interaction 
between two measured exposures with respect to a given outcome, most commonly a genetic 
and an environmental exposure.  This method requires only cases, no controls or defined 
cohort.  Provided the design assumptions are met, the case-only study can estimate a specific 
form of statistical interaction, departure from constancy of rate ratios in the underlying 
population, but not main effects of the two exposures. The design assumption of interest is 
that the relevant exposures are independent in the underlying source population.  Although the 
constancy of rate ratios between different strata of exposure in the underlying source 
population is the true parameter of interest (often represented as Z=1), case-control control 
groups are frequently used to estimate Z using ORz. ORz is ideally the odds ratio from an 
unmatched density-sampled control group of a case-control study but in practice many types 
of control groups have been used. 
There are potential advantages to the case-only method in several settings.  The lack of 
requirement for a control group has obvious cost advantages, but there are methodological 
and ethical advantages as well.  Estimation of the interaction parameter from case-only 
analyses is more efficient than for a traditional case-control study (i.e. fewer cases are 
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required for similar precision of estimate) and with no need for controls, there are fewer 
participants overall [8].  Not having controls may mitigate selection biases due to, for 
example, differential recruiting success between cases and controls, or differential recall of 
environmental exposures by case-control status. Invasive procedures that are part of cases’ 
diagnosis or treatment often cannot be done ethically in healthy volunteers, especially 
vulnerable groups such as pediatric populations [9].  But these advantages come at a cost. A 
case-only study only estimates interaction on a multiplicative scale (deviation of the rate ratio 
for those having both the genetic and environmental exposures from the product of rate ratios 
for those with either the genetic or the environmental exposure, but not both).  It cannot 
estimate the independent effect of either exposure, or interaction on the additive scale 
(deviation of the rate ratio for those having both the genetic and environmental exposures 
from the sum of rate ratios for those with either the genetic or the environmental exposure). 
This  limits its use to situations in which the independent effects of the two exposures are not 
of interest, nor are synergism or antagonism of the exposures [213-214].  Control-selection 
bias is the only validity threat the case-only design avoids, in comparison with the case-
control design.  Consequently, case-only studies have been proposed by several investigators 
as a mere screening method to identify candidate gene-environment or gene-gene interactions 
[5, 16-17]. 
However, the increase in precision and avoidance of control-selection bias in the case-
only method requires a major assumption:  that the two exposures are independent in the 
source population (Z=1) [1-2].  Data simulations have demonstrated that violations of the 
independence assumption that have a small magnitude can strongly bias the case-only 
interaction parameter, increase the mean-squared error (MSE),  inflate size of Neyman-
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Pearson hypothesis tests (i.e. the actual probability of rejecting a true null hypothesis) above 
the maximum tolerable level (e.g. alpha=0.05)[5], and thereby reduce confidence interval 
coverage probabilities below their specified values (e.g. 95%).  As Z grows further from 1 in 
either direction, these problems also increase appreciably. When control-group gene-
environment (G-E) associations are of similar magnitude but opposite in direction to the 
interaction effect, a case-only study may not detect interaction effects, a Type II error [5, 
124].   
Generally, when the ‘implausibility’ of specific G-E associations is argued in 
published case-only analyses, it is considered only within the framework of causality, and 
non-causal scenarios are rarely invoked.  Arguing from the causal perspective seems unwise 
for many, if not most, of the relevant gene-environment associations in the face of the wide 
variety of gene-behavior associations considered plausible enough for investigation (e.g. 
smoking behavior or diet), and our incomplete knowledge of genetic influences on health-
related behaviors.  The strongest example of a causal independence assumption violation is 
the well-known association between aldehyde dehydrogenase 2 (ALDH2) genotype and 
alcohol consumption, in which the variant allele produces unpleasant physical reaction when 
alcohol is consumed, greatly reducing alcohol consumption in carriers [72, 74].  Similarly, 
skin pigmentation is strongly associated with sun exposure, rendering a case-only study of the 
interaction of skin pigmentation and UV exposure in cancer invalid. Genetic influences on 
smoking behavior are also an active area of research, for example the association (or lack 
thereof) between CYP2A6 and smoking behavior has received considerable attention in the 
last 15 years [87-88].   
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Gene-environment correlations in populations (sources of non-independence) can be 
non-causal as well. For example, Z can vary from the null if environmental and genetic 
exposures have been non-differentially misclassified with respect to each other, as can happen 
when population subgroups, often ethnic groups, have different gene variant prevalences and 
different patterns of environmental exposure (population stratification [4].  Non-random 
misclassification of either the genetic exposure (e.g. genotype is measured perfectly but is in 
linkage disequilibrium with the causal variant rather than actually being the etiologically 
active genotype) and the environmental exposure (e.g. heavy smokers underreport smoking 
more than light smokers) can also create an apparent association in a study population.   
Selection bias could also cause association between two exposures in a control group 
being used to estimate Z.  For instance, if smokers with a family history of the outcome are 
less likely to participate as controls than smokers without a family history or non-smokers 
with a family history, a spurious inverse control group association could be created between 
smoking and any genetic exposure related to family history.  Cohort effects could affect 
control group associations if, for instance, a genetic exposure is associated with longevity, and 
the environmental exposure is one that has changed prevalence in the population over time, 
such as smoking or dietary patterns.  When ORz is being used to estimate Z, such distortions 
of ORz can mislead investigators about the true magnitude and direction of Z in the source 
population and lead to incorrect interpretation of the COR. Chance can also play a role.  Since 
the expectation that ORz=1 when Z=1 is a large sample asymptotic approximation, as sample 
size decreases, ORz will deviate from the null with increasing frequency through random error 
alone [5].  Consequently, as Z is estimated by ORz in subgroups, and sample size drops, ORz 
has a higher and higher probability if deviating from Z by chance alone.  A prudent approach 
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to the independence assumption would be to thoroughly examine any empirical evidence and 
biologic theory for or against causal association between the relevant gene variants and 
exposure before proceeding with a case-only study. 
Smoking is an environmental exposure that is commonly measured, can be quantified, 
and is important both in gene-environment interaction research and for public health overall.  
Variation in DNA repair is thought to be important in cancer [152, 215].  Three polymorphic 
DNA repair genes, X-ray cross complementing gene 1 (XRCC1), xeroderma pigmentosum 
complementation group D [XPD, previously excision repair complementing defective 2 
(ERCC2)], and X-ray cross-complementing gene 3 (XRCC3)  which participate in the base 
excision repair (BER) pathway, the nucleotide excision repair (NER) pathway, and the double 
strand break (DSB) pathway, respectively, have single nucleotide polymorphisms that have 
been investigated in numerous studies, particularly cancer studies.  Three important non-
synonymous single nucleotide changes (SNPs) have been studied for XRCC1: Arg399Gln 
(rs25487), Arg194Trp (rs1799782), and Arg280His (rs25489) [216-217].  A single nucleotide 
change in XPD exon 10 (Asp312Asn, rs1799793) and another in exon 23 (Lys751Gln, 
rs13181) have been studied [218-219].  XRCC3 has one studied amino acid-changing variant, 
a Thr241Met variant (rs861539) [137, 219].  The BER pathway is largely responsible for 
repair of oxidative damage and the NER pathway for repair of bulky DNA adducts, both types 
of damage produced by constituents of tobacco smoke [151].  With the exception of the 
XRCC1 Arg194Trp [170] the variants are thought to code for reduced DNA repair capacity, 
particularly XRCC1 Arg280His [200], although functionality for some SNPs has not been 
definitely established [170, 172-174, 220].  Cigarette smoke  is clearly genotoxic, with 
multiple studies showing smokers have increased rates of sister chromatid exchange and 
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micronuclei formation in lymphocytes, increased DNA strand breaks in lymphocytes, buccal 
cells and urothelial cells, and for heavy smokers, oxidative damage to DNA in germ cells 
[136]. 
We undertook a systematic a systematic review and meta-analysis of DNA repair 
variation and smoking behavior in control groups, using ORz to estimate Z.  The purpose in 
estimating ORz was to estimate the degree of bias in the COR, relative to the interaction 
estimate from a case-control analysis, assuming no control-selection bias.  Heterogeneity was 
explored using stratified analysis and meta-regression of study characteristics.  The primary 
aim of this project is to evaluate the importance of the independence assumption for these 
SNPs and smoking behavior and enable investigators considering a stand-alone case-only 
study of gene-environment interaction to evaluate the independence assumption in a range of 
relevant conditions (e.g. cancer, cardiovascular disease, neurological diseases) more 
rigorously than has been done previously, potentially identifying situations in which case-only 
estimates may be more or less valid.   
2. Methods 
Data Abstraction 
PubMed, ISI Web of Science and the CDC Genomics and Disease Prevention 
(GDPInfo: http://apps.nccd.cdc.gov/genomics/GDPQueryTool/frmQueryAdvPage.asp) 
databases were searched up to March 6, 2007 for peer-reviewed literature likely to contain 
data on the joint distribution of any of the polymorphisms of interest [single nucleotide 
polymorphisms XRCC1 Arg399Gln, Arg194Trp, and Arg280His, ERCC2(XPD) Lys751Gln 
and Asp312Asn, and XRCC3 Thr241Met] and smoking behavior in non-case groups.  Non-
case groups were defined as any group not selected as the index group based on disease status 
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(e.g. cohorts, convenience samples and control groups from case-control studies).  For 
simplification non-case groups will be referred to as controls throughout this article.  There 
were no language restrictions on searches.  A list of keywords for PubMed and the ISI Web of 
Science was developed in consultation with an information specialist from UNC Health 
Science Library to ensure that searches would be as inclusive as possible.  Keywords for 
PubMed were included as MeSH terms and text words whenever possible. Keywords for 
smoking were “smoking”, “tobacco”, “tobacco smoke”, “tobacco smoke pollution”, and 
“smoker”. The SNPs were searched by combining “polymorphism” and “polymorphism, 
genetic” with the SNP-specific keywords “XRCC1”, “XPD”, "xeroderma pigmentosum group 
d protein", “ERCC2” and “XRCC3”.  ISI Web of Science keywords were “smok*” and 
“tobacco,” and “XRCC1”, “XPD”, “ERCC2” and “XRCC3”.  GDPInfo was searched using the 
advanced query and limiting by factor menu terms: “smoking behavior”, “smoking (tobacco) 
passive”, “smoking (tobacco) bidi”, “smoking (tobacco)”, “smoking (tobacco) maternal”, 
“tobacco”, “indoor air pollution”, “nicotine (nasal spray)”, and “nicotine (transdermal)”, and 
gene menu terms: “XRCC1”, “XPD”, “ERCC2” and “XRCC3”.  No disease limits were used.  
Inclusion criteria were deliberately broad.  To be included, an article had to contain 
original control group data on the joint distribution of any genotype of interest (listed above) 
and any aspect of tobacco smoking behavior.  This was most often a table with counts of 
participants cross-classifying the specific genotypes and smoking behaviors. Textual data that 
could be converted to an analogous table was also included.  Reviews, animal studies, cell 
culture studies, case reports, case-only studies, abstracts, letters and editorials were excluded.  
The articles were reviewed by the first author of this paper (EH).  
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Abstracts were screened to determine whether the study included control participants 
and relevant genotype and smoking data.  SNP designations considered equivalent are shown 
below (Table V.A.1).  
Table V.A.1  SNP designations for data abstraction 
XRCC1 XRCC1 XRCC1 XPD (ERCC2) XPD (ERCC2) XRCC3 
Arg399Gln  Arg194Trp Arg280His Lys751Gln Asp312Asn Thr241Met 
G28152A C26304T  G27466A A35931C G23591A C18067T 
exon 10 exon 6 exon 9 exon 23 exon 10 exon 7 
 rs25487 rs1799782  rs25489 rs13181 rs1799793 rs861539   
R399Q R194W R280H   K751Q D312N  T241M 
      ERCC2_18880_A>C ERCC2_6540_G>A   
 
If an abstract was not excluded by the initial screening, the paper was retrieved and 
reviewed for data appropriate for construction of, at minimum, a 2x2 table for genotype-
smoking association in controls. If an unadjusted OR for any genotype-smoking association 
could be calculated, the following data were abstracted: SNP, genotype categories (3 level 
additive, dominant and/or recessive models), smoking status and dose categories [ever/never, 
current/not current, smoker/non-smoker, ever/former/current, pack-years (PY), duration 
and/or intensity], and cell counts for all genotype and smoking categories. Cell counts and 
smoking and genotype categories were abstracted onto preprinted forms to reduce data entry 
errors.  The following study characteristics were also abstracted: year of publication, study 
design (case-control, cohort, cross-sectional, convenience, other), source of control group (for 
case-control: population, hospital, friends and non-blood related family, convenience, 
community, neighborhood, other; for cohorts: population, occupational, convenience, other), 
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type of clinic that hospital- or clinic-based control groups were from (disease clinics, checkup 
clinics), matching characteristics (none, frequency-match, individual-match, matched on age, 
gender, ethnicity or other), study outcome (cancer [type], non-cancer disease, non-disease), 
full study/control group size (N), size of SNPxSmoking subset (N), country, percent male 
participants, ethnicity (% white, % African American, % Asian American, % Han Chinese, % 
other), Hardy Weinberg equilibrium p-value, minor allele frequency, health exclusion criteria 
for study/control group (no exclusions, history of case cancer, history of any cancer, “cancer-
free” only, other health conditions, “healthy” only, other), number of genes/SNPs assayed, 
and number of smoking categories.   
An estimate of central tendency for participants’ age in years (designated “average 
age”) was derived for each study using, in order of preference: median age, mean age, 
weighted average across study age categories, midpoint of age range.  No individual-level 
characteristics were abstracted.  One non-English language article could not be evaluated. 
Selection of Study Comparisons 
Three of the included study populations had control data in more than one article; 
however different SNPs were studied [221-226].  One study population had control data for 
XRCC1 399 and smoking stratified by ethnicity in one article [227] and not stratified by 
ethnicity in another [200].  Preference was given to the larger N unless a given study 
characteristic could be best examined using ORz estimates stratified by ethnicity.  No study 
population contributed to any analysis more than once maintaining independence of 
observations.  Analyses focused on associations with genotype categorized using a dominant 
model (i.e. homozygotes of the most common allele were the referent group, compared to 
heterozygotes plus homozygotes of the minor allele) due to the small number of studies that 
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provided sufficient information to assess recessive or additive models.  Smoking behavior was 
characterized by constructing five metrics from the available control data.  Smoking status 
was categorized as (1) ever/never (referent), and (2) current/not current (referent).  Smoking 
dose was analyzed as (1) pack-years [PY, lowest non-zero category (referent) compared to 
highest], (2) duration [years, shortest non-zero category (referent) compared to longest] and 
(3) smoking intensity [cigarettes/day, lightest non-zero category (referent) compared to 
heaviest].  Original study categorizations were used when possible.  “0 PY of smoking” and 
“0 years of smoking” were considered equivalent to never smoking. The categories “passive 
smoking only” and “never active or passive smoking” were combined into “never” for our 
analyses.  Studies that did not provide sufficient data to include ‘passive only’ smoking in the 
never smoking group were excluded. For analyses of current/not current smoking, 
never+former smokers and “non-smokers” (if identified as not current smokers) were 
considered not current smokers.  Pack-years of smoking (pack-years = number of packs 
smoked per day multiplied by years smoked; 20 cigarettes=1pack) were analyzed as relative 
categories [lightest smokers vs. heaviest smokers regardless of PY cutpoints] and absolute 
categories [< specified range of PY cutpoints vs. >= the same range of PY cutpoints; ranges 
varied by SNP].  The ranges were chosen to maximize the number of included studies while 
keeping the range small enough that no study would have >1 cutpoint in a specified range.  
Similar to PY, smoking intensity was categorized by relative (lightest vs. heaviest smokers 
regardless of cigarette/day cutpoints) and absolute (<20 vs. >= 20 cigarettes/day) measures.  
Smoking duration cutpoint range was 20-40 years, inclusive, for all SNPs.  
Statistical analyses 
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For all SNP-smoking analyses, crude ORs and 95% confidence limits were calculated 
from cell counts (Stata 9.2, using metan STB-44: sbe24).  Funnel plot asymmetry, an 
indicator of possible publication bias [190], was considered suggestive of study characteristics 
associated with variance and Z. When data were sufficient (Nstudies>=5), asymmetry was 
formally assessed using Begg and Mazumdar’s test [191] and Egger’s test [192] at α=0.10.  
Cochran’s Q two-sided homogeneity p-values (α=0.10 due to low power of the test) were 
used to assess overall heterogeneity in odds ratios [189].  Where appropriate, summary odds 
ratios were estimated using Mantel Haenszel methods with fixed effects.   
Study characteristic analyses:  Key study characteristics hypothesized to influence 
variation in the strength of SNP-smoking associations among controls across studies were 
assessed using stratified meta-analysis and random-effects meta-regression, with the among-
study variance estimated by restricted maximum likelihood [228].  Stratified meta-analysis 
produces a summary ORz estimate for each stratum of a study characteristic.  Meta-regression 
provides a formal comparison of the stratified estimates in the form of an estimated ratio of 
odds ratios. 
Study characteristics were selected a priori.  They included (1) study design (case-
control, cohort, or convenience; patient-based control groups, healthy control groups), (2) 
continent, (3) ethnicity, (4) Hardy-Weinberg equilibrium p-value, (5) average age, (6) gender 
(% male), (7) study outcome (lung cancer, other cancer, non-cancer disease, non-disease), (8) 
minor allele frequency and (9) smoking prevalence.  Study design was examined for all SNP-
smoking combinations; additional study characteristics were examined for XRCC1 399, XPD 
751 and XRCC3 241. Stratified random-effects meta-analyses were used when the overall 
SNP-smoking association had a Cochran’s Q p-value α<0.10, otherwise fixed effects meta-
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analysis was used, regardless of the homogeneity p-values of individual strata.  To reduce the 
possibility of results being confounded by ethnicity (population stratification) in overall 
analyses and when examining the study characteristics likely to vary strongly by ethnicity 
(Hardy Weinberg equilibrium p-values and minor allele frequency) studies were stratified by 
ethnicity and treated as separate studies if possible.  Stata 9.2 was used for all analyses.  
Results for study characteristics were assessed for consistency across smoking categories and 
across SNPs. 
3. Results 
Eligible studies:  The literature searches identified 228 articles for evaluation. Of 
these, 55 articles were eligible for inclusion.  The primary reason for exclusion was that an 
article did not present the genotype-smoking distribution in controls (N=98, 57% of 
exclusions).  Exclusion reasons for the remainder included: review article or abstract only 
(13%), did not assess any relevant SNPs (9%), and did not have any non-cases (10%). Finally, 
of the 55 studies eligible for inclusion, five were not included in final summary estimates 
because no data were presented for dominant genetic model [46, 229], no measure of adult 
smoking behavior [230], former smokers excluded [231], or never smokers were included in 
lowest PY category [232].  No studies presented all five measures of interest for smoking 
behavior. Fifty articles representing 46 distinct study populations were included in the final 
meta-analyses (brief study descriptions in Table V.A.1a).  Table V.A.1b presents five studies 
that were included in the systematic review but not in any meta-analyses. The number of 
individual controls included in each summary estimate ranged from 11,789 (XRCC1 399 
ever/never smoking) to 305 (XPD 312 current/not current smoking).  Generally, compared to 
the total N of observations in ever-never analyses, there were ~40% fewer observations in 
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current/not current analyses, and ~20% as many in PY analyses.  The number of study 
populations included for each polymorphism was as follows: XRCC1 Arg399Gln (N=32), 
XRCC1 Arg194Trp (N=16), XRCC1 Arg280His (N=8), XPD Lys751Gln (N=16), XPD 
Asp312Asn (N=9), and XRCC3 Arg241Gln (N=13).  Thirty-seven studies presented the 
control distribution of genotype and ever/never smoking, 16 for current/ not current smoking 
and 14 for PY. Far fewer presented duration (N=4) and/or intensity (N=4).  Case-control 
studies predominated with 12 population-based [200, 222-223, 226-227, 233-239] and 23 
hospital-based [221, 224-225, 240-259], four nested [260-263] and two other case-control 
studies.  Most control groups were from cancer case-control studies (N=39), one was from a 
case-control study of rheumatoid arthritis.  Nine cohort or convenience sample studies 
examined non-cancer outcomes, predominantly measures of DNA damage (8 of 9), one 
measured genotype frequency. 
Association between DNA repair gene variants and smoking behavior.   Across SNPs 
there was more variation in ORs assessing control-only G-E associations (ORzs) for measures 
of smoking amount (PY, duration, intensity) than for measures of smoking status (ever-never, 
current-not current) (Table V.A.2).  Ten of 11 summary estimates of smoking status fell 
between 0.9-1.1.  Summary estimates for smoking amounts were distributed more broadly, 
with only five of 10 summary estimates between 0.9-1.1; the most extreme measures were 
found for duration and intensity.  Although only two of 18 genotype-smoking groups were too 
heterogeneous for a fixed effects summary estimate, nearly all groups had study estimates 
above and below the null, generally varying 2-3 fold.   
For XRCC1 399, three measures of smoking behavior were homogeneous enough for a 
summary estimate of the association between variant allele and smoking: current smoker/not 
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current (N=11), PY (N=9) and intensity (N=4).  Higher PY and heavier smoking intensity, but 
not current vs. not current smoking, were associated with XRCC1 Arg399Gln (any Gln) [OR 
(95%CI): 1.2 (1.0, 1.5) and 1.5(1.2, 1.9), respectively].  Odds ratios for XRCC1 399 and ever-
never smoking ranged from 0.7 (95% CI:  0.3, 1.7) [250] to 1.9 (95% CI:  1.0, 3.7) [238] 
(Table VIII.B.1).  After two studies were stratified by ethnicity and treated as separate studies, 
13 studies had a genotype-smoking OR >1 and 10 had an OR<1. For the other two SNPs in 
XRCC1 (194 and 280), having the variant allele was associated with longer smoking duration 
[XRCC1 194: 0.7 (0.5, 0.9), XRCC1 280: 1.2 (0.6, 2.3)] and current smoking [XRCC1 280: 
1.2 (0.6, 2.3)] though confidence intervals were wide.  For the two XPD SNPs (751, 312) 
there was considerable variation in the association between XPD 751 variant allele and higher 
PY. Study estimates ranged from 1.4 (0.8, 2.6) [221] to 0.5 (0.3, 1.0) [254] (Table VIII.B.4).  
Higher PY were associated with the variant allele for XRCC3 241 although the number of 
studies was small (N=4).   
Sensitivity analyses.  Among the studies that were assessed for current-not current 
smoking, a subset could also be assessed for never, former or current smoking (Table V.A.3).  
No consistent pattern emerged for comparisons of never smoking with former or current 
smoking.  Absolute measures of PY, intensity and duration were calculated and compared to 
relative measures for consistency. Genotype-PY estimates for absolute cutpoints (i.e. all PY 
categories below specified cutpoint range vs. all categories above that cutpoint) were 
comparable to estimates using relative categories (lowest non-zero category vs. highest) 
although strata were sparse (Table V.A.3).  Additionally, when studies with only smokers 
were dropped and never smoking was used as the reference category, results were essentially 
the same for relative and absolute measures of PY.  Genotype-smoking association between 
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XRCC1 Arg399Gln and smoking intensity (cigarettes/day) could be estimated in four studies.  
There was an association between XRCC1 399 any Gln and greater smoking intensity 
[1.5(1.2, 1.9)].  As with PY, this association was consistent across both methods of smoking 
intensity categorization (lowest study-defined category vs. highest study-defined category, 
and <20 cigarettes/day vs. >20 cigarettes/day). Estimates for the two excluded studies that had 
referent groups roughly comparable to ever/never smoking and PY [231-232] were similar to 
those for included studies (Table V.A.1b).   
Ever-never analyses included studies that did not present ever-never smoking as such, 
but had smoking amount data, usually PY, that was used to derive ever-never smoking. To see 
whether these studies differed from studies presenting only ever-never data, we excluded 
studies that did not also present smoking amount information.  There was no difference in the 
distribution of study estimates or summary estimates [XRCC1 399: range of ORs 0.8 – 1.9, 
Cochran’s Q p-value 0.02; XPD 751 summary estimate: 1.0 (0.8, 1.1)]. 
Funnel plot asymmetry.  There was no evidence of funnel plot asymmetry for overall 
genotype-smoking associations (data not shown). In formal testing, the majority of p-values 
(75%) were >=0.3.  The lowest p-value was p=0.14 for XRCC1 280 ever/never for both Begg 
and Egger tests.   
Study characteristics.  For study characteristics, stratified associations and univariate 
meta-regression were evaluated across SNPs and smoking categories.  Associations were 
evaluated primarily on the basis of consistency and direction.  Study design was examined for 
all six SNPs for ever/never, current/not current smoking and PY.  For smoking status, 
genotype-smoking associations for XRCC1 399 and 194 and XPD 751 and 312 were generally 
stronger for population-based case-control studies than for hospital-based or patient-based 
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control groups, although the magnitude of the differences was small; the range of RORs was 
0.7 to 0.9 for hospital/patient-based compared to population-based controls (referent) (Table 
V.A.4).  However, for smoking dose as measured by PY (2 evaluable SNPS, XRCC1 399 and 
XPD 751) the hospital-based/patient-based control groups showed stronger genotype-smoking 
associations than population-based control groups (range of RORs: 1.2-1.5).  When 
examining PY, for all SNPs, the genotype-smoking association for population-based control 
groups was below the null.  The remaining study characteristics were examined only for 
XRCC1 399, XPD 751 and XRCC3 241 (Tables 5, 6, and 7 respectively) due to sparse data for 
the other SNPs.   
For PY lung cancer studies were above the null for all three SNPs. Further, when 
compared to studies of other cancers the genotype-smoking association was stronger for lung 
cancer studies (referent) compared to other cancer studies [ROR= 0.8(0.5, 1.2) and 0.5(0.3, 
0.9) for XRCC1 399 and XPD 751, respectively].  All studies with PY were cancer studies. 
Older average age of study participants (>63y vs. <=59y and >median age) weakly but 
consistently showed stronger associations between ever smoking and variant allele for XRCC1 
399, XPD 751 and XRCC3 241 than did younger age. For XRCC1 399 only, this was evident 
across all three smoking categories. Also, for XRCC1 399 current-not current smokers and PY 
only, studies with lower minor allele frequencies (N=3) showed stronger associations (~2.0) 
than those with higher MAF. These three studies had only African-American or Asian 
participants. No strong and/or consistent patterns emerged for the other study characteristics 
examined: continent (North America, Europe, and Asia), ethnicity (White, African American, 
Han, multi-ethnic), HWE p-value (<0.1, >=0.1), gender (% male; all male, mixed gender, all 
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female), minor allele frequency (tertiles for each SNP), and smoking prevalence proportion 
(<=0.507, >0.507). 
4. Discussion 
This systematic review of DNA repair genotypes and smoking behavior in control data 
from 46 study populations was conducted with the goal of informing the practice of case-only 
analyses of gene-environment interaction. Results from this systematic review and meta-
analysis show considerable variation in estimates of Z for XRCC1 399 ever-never smoking 
and XPD 751 PY (Cochran Q p-values <0.1, ~3 fold range in ORs, ORs on both sides of the 
null). Even when studies were homogeneous enough for a summary estimate, point estimates 
of ORz varied as much as 5-fold. Summary estimates for individual SNPs varied across 
smoking categorizations, with larger magnitudes of association generally found for measures 
of smoking dose (PY, intensity, duration) than for smoking status (ever-never, current-not 
current).  There was a weak association between XRCC1 399 and higher smoking dose (PY, 
intensity). No study characteristics examined strongly predicted the magnitude of association 
although study outcome (lung cancer vs. other cancer for PY), study design (population-based 
vs. hospital/patient-based), and age warrant further investigation. 
A key assumption of the case-only study design for interaction is that the genotype 
and environmental exposure are independent in the underlying population [3].  Descriptively, 
any deviation from the Z=1 (estimated by ORz) introduces bias in the case-only interaction 
estimate [5].  Further, when Z ≠ 1 in population subgroups, the COR for those subgroups will 
be biased as well.  The bias introduced into the COR is in addition to other sources of bias, 
such as selection bias, information bias etc.   
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Although the validity of case-only estimates rests heavily on the independence 
assumption, literature on independence assumption verification is scant.  Data simulations 
have demonstrated that even small violations of the independence assumption can strongly 
bias the case-only interaction parameter [5].  Using data from a study of XRCC1 genotype and 
lung cancer by Ratnasinghe et. al., Albert et. al. showed that a control group association 
between genotype and pack-years of tobacco use of ORz=2.0 created bias in the case-only 
odds ratio (COR) of 105% [COR=0.9(0.4, 1.9), synergy index from case-control analysis of 
the same data (SIM)= 0.4(0.2, 1.2)] [5, 126].  Even an ORz of 1.2 biased the COR by nearly 
30%.  Another notable paper to focus on independence assumption evaluation using data 
simulation is by Gatto et. al. who elucidate conditions under which a control group is an 
appropriate proxy for the underlying study population when validating the independence 
assumption [127].   
However, little empirical work has been done on the magnitude of control-only 
associations (ORz) between DNA repair gene variations and smoking that quantitatively 
assesses this additional bias.  A population-based study (N=339) of Japanese males assessed 
association between ‘habitual smoking’ (ever/never) and a panel of 153 SNPs in 40 candidate 
genes, including the DNA repair genes OGG1 and NUDT1(MTH1) [64].  Association was 
found between smoking and 3 of 4 of the SNPs in OGG1 (0.4-0.6, borderline statistical 
significance, variant carrier vs. variant non-carrier) but no statistically significant associations 
were found for NUDT1.   
Smoking dose (PY and/or intensity) could be causally associated with variation in 
XRCC1 399, or with a polymorphism in linkage disequilibrium with XRCC1 399. There is 
evidence that the XRCC1 399 and XPD 751 variants are functional [174, 264-265].  Different 
  89
aspects of smoking behavior (smoking initiation, smoking cessation, intensity etc.) operate 
through multiple overlapping pathways [266] therefore would not be expected to be 
identically affected by DNA repair variation, which is borne out by the differing results for 
smoking status and smoking dose for several SNPs (XRCC1 399, XRCC1 280, XPD 751, 
XRCC3 241).  Although speculative, there is some evidence that variation in DNA repair 
activity may affect neurological and/or respiratory outcomes, which could in turn affect 
smoking behavior [153-155, 157, 163].  If the variants are functional, or linked to functional 
variants, heterogeneity could be due to gene-environment interaction in specific populations 
or to differing linkage disequilibrium patterns across populations.  
There are also several possible non-causal explanations for these finding. Although 
publication bias is always a concern with meta-analyses, the study goals of the contributing 
studies, visual inspection of funnel plots and formal tests of asymmetry argue against this. 
There could be similar selection bias in individual control groups, or strong selection bias in a 
subsample for studies leading to spurious results for XRCC1 399 dose estimates. This is 
possible, since just over half of the studies with dose information for XRCC1 399 were lung 
cancer studies (8 of 14) and lung cancer studies had on average higher ORzs than other cancer 
studies for XRCC1 399, XPD 751 and XRCC3 241 PY analyses.  Control groups from non-
lung cancer studies, compared to lung cancer controls (referent), showed ROR (95%CI) of 0.8 
(0.5, 1.2) and 0.5 (0.3, 0.9) for XRCC1 399 and XPD 751, respectively.  For XRCC3 241 the 
ORz (95%CI) were 0.8(0.5, 1.1) and 1.1(0.4, 2.7) for non-lung cancer controls and lung 
cancer controls, respectively.  The connection between smoking and lung cancer is well 
known, possibly leading to more variation in response rates or recall by smoking history 
and/or family history of cancer, but the direction of possible bias is unpredictable. The ORz 
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for the one XRCC1 399 study that explicitly excluded participants with smoking-related 
diseases was essentially the same as the summary estimate [243].  If heavier smokers with 
diseases/family histories related to DNA repair were overrepresented in hospital/patient-based 
controls and/or under represented in population-based control groups, ORz would likely be 
biased upward for hospital-based studies and downward for population-based studies.  This 
could conceivably cause estimates of ORz for hospital-based studies to be higher than ORz for 
population-based studies when the reverse is true in the underlying populations.  In our 
analysis, for smoking status measures, average ORzs tended to be above the null for 
population-based studies and below the null for hospital-based controls.  For PY, the reverse 
was true, with hospital-based controls having average ORzs around 1.3 and population-based 
controls slightly below the null. (Table V.A.4).  Population stratification could have 
contributed to the heterogeneity in XRCC1 399 ever-never and XPD 751 PY estimates since 
the variant alleles are found at different frequencies in different ethnic groups within the same 
study, and smoking behavior may also differ by ethnicity. Although this cannot be rigorously 
addressed without individual level data, there were no clear patterns in ORz for any SNP for 
study-level ethnicity, either by stated ethnicity, when stratified by single-ethnicity vs. multi-
ethnicity studies, or when MAF was used as a crude proxy to assign ethnicity for studies with 
unknown ethnic makeup. Finally, chance could play a role, particularly given the large 
number of associations examined and sparse data for many analyses. 
Implications for stand-alone case-only studies 
Z is a measure of the magnitude of bias in the COR. If Z=1, the case-only estimate of 
interaction is not biased by genotype-environment association in the underlying population 
[3].  Commonly, this assumption is assessed in control data from a small number of outside 
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studies, using significance testing. Significance testing alone is not sufficient for assessment 
of potential bias [7].  Rarely is Z estimated and/or adjusted for, analogous to other forms of 
bias such as confounding. Results from this project illustrate some of the pitfalls of this 
approach. For instance, for XRCC1 399 ever-never smoking, 18 of the 21 included studies 
have estimates that are not statistically significantly different than the null; considering any or 
all of these in a testing framework would lead to the conclusion that the independence 
assumption was valid and a case-only study would give an unbiased estimate of multiplicative 
interaction.    However, the range of ORzs for these 18 studies is 0.7-1.6, many with wide CIs, 
indicating the potential for substantial bias.  Similarly, although the summary ORzs for PY are 
close to the null, the upper limits of the CIs were approximately 1.5 for SNPs in XRCC1 and 
XPD and the lowest CI limit was 0.6; the range of potential bias is larger than obvious from 
examining only the magnitude of ORz. Given that less than half of the studies that collect 
control genotype and smoking information present it in publications, and that very different 
conclusions can be drawn from different subsets of studies, this common approach seems 
inappropriate.   
In the estimation framework, results from this project demonstrate the difficulty of 
using ancillary data to assess the independence assumption. Even when the Cochran’s Q p-
value is high, such as for XRCC1 399 current-not current smoking (p=0.4), point estimates of 
ORz can vary as much as 5-fold [2.1(1.1, 3.9) for African Americans [227] to 0.4(0.1, 1.2) 
[267]].  Without further information that certain study characteristics might be influential, 
there is no good way to decide which of the available ancillary control groups might best 
represent the underlying (unmeasured) population for a proposed case-only study. Further, it 
is necessary to do a broad literature search to even to be aware of the possible values of ORz 
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and range of bias in the COR.  Additionally, since both summary estimates and individual 
study estimates vary across smoking categories, it is important that the independence 
assumption be evaluated for all smoking categories that will be used in the case-only analyses.  
For investigations of dose, it will be difficult for many SNPs to locate enough published 
control group data to even assess the possible range of the magnitude of bias.  
This study has several strengths.  Using a broad comprehensive search strategy in 
collaboration with information specialists increased power to detect and investigate 
heterogeneity between studies. Sample size was large for smoking status analyses and 
relatively large for XRCC1 399 and XPD 751 PY analyses.  There was sufficient data for 
many studies to compare ORz for smoking status and smoking dose both within studies, and 
by smoking category across multiple SNPs. The fact that none of the studies was conducted 
with the goal of assessing control group associations is both a strength and a weakness of this 
systematic review.  Of the studies that collected the appropriate information only about 1/3 
presented it in such a way that it could be abstracted for this meta-analysis, limiting sample 
size, especially for measures of smoking dose.  However, publication bias was expected to be 
minimal since gene-environment interaction studies are typically not evaluated on the basis of 
control group associations.  This was as supported by the formal tests of funnel plot 
asymmetry.   
Only unadjusted odds ratios could be calculated so study estimates may be 
confounded.  No individual level data was collected. This could be problematic for age and 
ethnicity in particular. Although some study characteristics could be determined accurately 
from articles, others were more likely to be misclassified. In particular, average age of study 
participants was difficult to determine. However, the fact that age was not a central study 
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feature for any of the studies makes it likely that misclassification is non-differential with 
respect to smoking and genotype.  Several potentially informative study characteristics could 
not be examined because too few articles presented information that could be assessed using 
the same metric.  In particular, response rates, which may vary by smoking behavior and 
family/personal history of cancer [117-120], and control group exclusion criteria, were 
presented using very different levels and types of detail from study to study. Only two of the 
12 articles with multi-ethnic study populations presented data stratified by ethnicity, 
complicating interpretation of HWE p-value, ethnicity and MAF as study characteristics. Few 
studies presented enough control group information to examine multiple measures of smoking 
in the same study population, with the exception of studies that presented PY, since smoking 
status (ever-never) could nearly always be derived. Results did not change appreciably when 
studies without dose were excluded from ever-never analyses, indicating that articles that 
presented dose were not driving estimates of smoking status. 
This systematic review of control-group associations between smoking and selected 
polymorphic genes commonly used in interaction studies was conducted to accomplish 
several objectives.  The overarching goal was to enable investigators to make more effective 
use of ancillary data to evaluate the independence assumption prior to launching a stand-alone 
case-only study.  Results from this study suggest that the independence assumption is 
frequently violated and caution is warranted before proceeding with any case-only interaction 
analysis.  At a minimum, the independence assumption should be more rigorously evaluated 
than is often done.  For a case-only analysis of a case-control study, separate ORzs should be 
calculated for each anticipated COR in the relevant subgroup before proceeding.  Evaluation 
of the independence assumption for a proposed stand-alone case-only study should include, 
  94
whenever possible, results from studies similar to the current study, relevant literature 
reviews, and a thorough search for individual studies with control or cohort data to ascertain 
at least the range of ORzs, both overall and in relevant subgroups.   
Evaluation of the independence assumption for case-only interaction studies would be 
greatly improved with more transparency and finer detail and in published articles, 
accomplished perhaps by expanding supplementary online tables to include selected joint 
genotype-smoking distributions in non-case groups. With the current emphasis on pooling 
controls, our results indicate that investigators should remain cautious about proceeding with 
case-only studies without further examination of the independence assumption in individual 
studies.  If it could reliably be shown that Z=1 across individual studies, more use could be 
made of data pooling from control groups and cohorts for selected SNPs and exposures, 
especially where individual level data on potential confounders can be provided.
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5. Tables and Figures 
Table V.A.1a.  Characteristics of 50 studies included in summary estimates (46 study populations) 1 
Author &  year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses 2  
Butkiewicz 2001 Poland  
(Upper Silesia) 
Case-
control, 
hospital-
based 
56.3 (8.8)y 
[Mean(SD)] 
39-79y 
[Range] 
Controls partially selected 
from healthy males from 
groups previously recruited 
for occupational studies. Rest 
of controls are 52 members of 
4 families in Utah (CEPH 
reference families).  
Matching:  Frequency-
matched to case group on age, 
smoking habit and 
occupational exposure.  
Lung cancer XPD Asp312Asn 
Ever/never, PY 
Cao 2006 Southern China Case-control 45.7y (15.6y) 
[Mean (SD)] 
Controls were "cancer-free" 
participants from a 
community cancer screening 
program.  
Matching: Matched to cases 
on age & ethnicity. 
Nasopharyngeal 
cancer 
XRCC1 Arg399Gln 
Current sm/ not 
XRCC1 Arg194Trp 
Current sm/ not 
David-Beabes 
2001 
US  
(Los Angeles) 
Case-
control,  
population-
based 
62.9y (7.9y) 
[Mean (SD)] 
Controls selected from 
Drivers License lists (<65y) 
or Medicare lists (>=65y).  
Matching: Frequency-
matched to cases on age, 
gender & ethnicity. 
Lung cancer XRCC1 Arg399Gln 
Ever/never, Intensity 
XRCC1 Arg194Trp 
Ever/never,  Intensity 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses 2 
Duell 2001 
 
Carolina Breast 
Cancer Study  
(CBCS) 
(Same study 
population as 
Pachkowski 
2006) 3 
US  
(North Carolina) 
Case-
control,  
population-
based 
51.6y 
[Mean] 
Controls were women 
selected from Drivers License 
(<65y) or Medicare (>=65y) 
lists. African American & 
younger (<50y) cases 
oversampled. 
Matching: Frequency 
matched to cases on age & 
ethnicity.  
Breast cancer XRCC1 
Arg399Gln 
Ever/never, 
Current sm/ not 
Duell 2002 & 
Duell 2002 
(parent study) 
US 
(Northern 
California) 
Case-
control,  
population-
based 
24-54y (24%) 
55-66y (26%) 
67-73y (26%) 
74-85y (23%) * 
[Frequency 
distribution] 
 
Controls were identified by 
random digit dialing & 
Medicare lists (>=65y) & 
resided in any of 6 San 
Francisco Bay area counties .  
Matching: Frequency-
matched to case group on age 
& gender.  
Pancreatic cancer XRCC1 
Arg399Gln 4 
Duration 
Garcia-Closas 
2006 
Spain Case-
control, 
hospital-
based 
66 (10)y 
 [Mean(SD)]  
21-80y  
[Range] 
Controls were from 
participating hospitals with 
diagnoses unrelated to 
exposure(s) of interest 
(includes smoking). 
Matching: Individually 
matched to cases on age, 
gender, ethnicity and region.  
Bladder cancer XPD Asp312Asn 
Ever-never 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses  ⁯    
Han 2003 
 
(Nurse's 
Health Study) 
US Case-
control, 
nested 
57.8 y 
[Mean] 
Controls were a random 
selection from the subcohort 
of the Nurses Health Study 
that gave blood in 1989-90. 
No diagnosed cancer other 
than NMSC. 
Matching: Individually 
matched to cases on year of 
birth, menopausal status, HRT 
at blood collection, month of 
blood return, time of day of 
blood collection, fasting status 
at blood draw. 
Breast cancer XRCC1 Arg194Trp 
Ever-never 
Duration 
Harms 2004 US 
(Texas) 
Case-
control, 
hospital-
based 
57.2 (9.3) 
[Mean (SD)] 
Controls were current smokers 
who were non-case patients at 
the University of Texas 
Medical Branch in Galveston 
plus population from 
surrounding area. Meta-
analysis included only non-
Hispanic whites. 
Matching: Frequency-matched 
to case group on age, ethnicity 
and gender. 
Lung cancer, 
Subset of controls: 
DNA damage 
(chromosomal 
aberrations)  
XRCC1 Arg399Gln 
 PY 
XPD Lys751Gln 
PY 
XRCC3 Thr241Met 
PY 
Hoffmann 
2005 
Germany 2 Convenience 
sample 
27.0 (5.7) 
[smokers] 
26.3y (3.9y) 
[nonsmokers] 
[Mean (SD)] 
Healthy male smokers & 
nonsmokers (1:1) 
DNA damage 
(comet assay) 
XRCC1 Arg399Gln 
Current sm/ not 
XPD Lys751Gln 
Current sm/ not 
XRCC3 Thr241Met 
Current sm/not 
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Table 1a.  Studies included in meta-analyses (continued) 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in 
controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses  ⁯    
Hou 2002 
 
(Same study 
population as 
Ryk2006b) 
Sweden 
(Stockholm) 
Case-
control, 
hospital-
based 
68y 
[Median] 
65y (14.5y) 
[Mean (SD)] 
30-89y 
[Range] 
Healthy controls were recruited 
from Stockholm residence files 
every 6 months.  
Matching:  Frequency-matched to 
case group on age, gender, 
catchment area & smoking status 
(never/former/current).  Never-
smoking cases were over-sampled 
(50% of case group). 
Lung cancer XPD Lys751Gln 
Ever/never 
XPD Asp312Asn 
Ever/never 
Huang 2005a Poland  
(Warsaw) 
Case-
control, 
population-
based 
<50y    (12%) 
50-59y (17%) 
60-69y (39%) 
>=70y  (32%) 
[Frequency 
distribution] 
Controls randomly chosen from 
Warsaw population registry. 
Matching: Frequency-matched to 
case group on age & gender 
Gastric cancer XRCC1 Arg399Gln 
Ever/never 
PY 
XPD Lys751Gln 
Ever/never 
PY 
XRCC3 Thr241Met 
Ever/never 
PY 
Hung 2005 Eastern Europe Case-
control, 
hospital-
based 
<=40y   ( 3%) 
41-50y  (15%) 
51-60y  (31%) 
61-70y  (36%) 
>70y    (16%) 
[Frequency 
distribution] 
Controls were patients in same 
hospitals as cases (15 centers in 6 
Eastern European countries) except 
controls from Warsaw who were 
randomly sampled from the 
population register. Patients with 
tobacco-related diseases were 
excluded from control 
group.Matching: Frequency-
matched to case group on age, 
gender, center & referral area.  
Lung cancer XRCC1 Arg399Gln 
Ever/never 
PY 
XRCC1 Arg194Trp 
Ever/never 
PY 
XRCC1 Arg280His 
Ever/never 
PY 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment 
 Study 
outcome Analyses  ⁯    
Ito 2004 Japan Case-control, 
hospital-based 
62.6y (9.1y) 
[Mean (SD)] 
35-79y 
[Range] 
Controls were random sample of 
cancer-free visitors to Aichi Cancer 
Center Hospital who provided blood.  
Matching:  Frequency-matched to 
case group on age & gender. 
Lung cancer XRCC1 Arg399Gln 
Ever/neve 
Current sm/not 
PY 
Jiao 2007 US 
(Texas) 
Case-control, 
hospital-based 
(friends & 
family) 
<50y   (15%) 
50-59y (27%) 
60-69y (34%) 
>=70y (23%) 
[Frequency 
distribution] 
Controls were friends & non-
genetically related family of non-
pancreatic cancer patients.  
Matching: Frequency-matched to 
case group on age, gender & 
ethnicity 
Pancreatic 
cancer 
XPD Lys751Gln 
Ever/never 
XPD Asp312Asn 
Ever/never 
Jin 2005 China 
(Zhejiang) 
Case-control, 
nested 
62.2 (10.3)y 
[Mean (SD)] 
40-49y  (14%) 
50-59y ( 32%) 
60-69 y (28%) 
70+y     (26%) 
[Frequency 
distribution] 
Controls were randomly chosen from 
colorectal cancer screening trial with 
individually matched communities. 
No previously diagnosed 
malignancy. 
Matching: Frequency matched to 
case group on age, gender and 
habitation.   
Colorectal 
cancer 
XRCC3 Thr241Met 
Current sm/not 
Justenhoven 
2004 
 
(GENICA) 
Germany 
(Bonn) 
Case-control, 
population-based 
<50 y  (23%) 
>=50 y  (77%) 
[Frequency 
distribution] 
Controls were population-based from 
Interdisciplinary Study Group on 
Gene Environment Interactions and 
Breast Cancer in Germany 
(GENICA).  
Matching:  Individually matched to 
cases on age 
Breast cancer XPD Asp312Asn 
Ever/never 
  
100
 
Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in 
controls  
[metric] 
 Control  
ascertainment 
 Study 
outcome Analyses  ⁯    
Kelsey 2004 US 
(New 
Hampshire) 
Case-
control, 
population-
based 
62 (10) 
[Mean (SD)] 
Controls randomly selected from driver's 
license (<65 y) or Medicare (>=65y) 
records.  Some controls were shared with 
non-melanoma skin cancer study.  
Matching: Frequency-matched to cases 
on age & gender 
Bladder cancer XRCC1 Arg399Gln 
Ever/never 
Kocabas 2006 Turkey Convenience 
sample 
26-78y 
[Range] 
Healthy volunteers Genotype XRCC1 Arg399Gln 
Current sm/not 
Koyama 2005 Japan Case-control 23.6y (4.7y) 
[Mean (SD)] 
Controls were healthy individuals with no 
autoimmune disease 
Matching: Matched on ethnicity 
Rheumatoid 
arthritis 
XRCC1 Arg399Gln 
Current sm/not 
XRCC1 Arg194Trp 
Current sm/ not 
XRCC1 Arg280His 
Current sm/ not 
Lei 2002 Taiwan 5 Cohort, 
occupational 
32.4y 
(5.2y)[Mean 
(SD)] 
Controls were a subcohort of male resin 
synthesis plant workers unexposed to 
epichlorohydrin >1 ppm. 
DNA 
damage(Sister 
chromatid 
exchange) 
XRCC1 Arg399Gln 
Current sm/not 
Intensity 
Lunn 1999 US 
(North 
Carolina) 
Convenience not given Controls were participants in a 
community-based study of African 
Americans and whites who were 
heterozygous for the glycophorin A 
antigen.  Additional white & African 
Americans from the same community 
sample were added for genotype 
frequency estimation only. 
DNA damage 
(Glycophorin A 
somatic 
mutations) 
XRCC1 Arg399Gln 
Current sm/not 
XRCC1 Arg194Trp 
Current sm/ not 
XRCC1 Arg280His 
Current sm/ not 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in 
controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses  ⁯    
Matullo 2001 
 
[European  
Prospective 
Investigation into 
Cancer & Nutrition in 
Italy (EPIC-Italy)] 
Palli 2000  
(parent study) 
Italy Cohort, 
prospective 
49.8y [Mean] 
<=44y  (33%) 
45-54y (33%) 
>54y   (34%)  
[Frequency 
distribution] 
Controls were a random selection of EPIC 
participants from Northern Italy (Varese 
and Turin), Central Italy (Florence) and 
Southern Italy (Ragusa and Naples). 
Recruitment criteria varied by site and 
included blood donors, women being 
screened for breast cancer, population-based 
recruitment etc.  
DNA damage 
(DNA adducts) 
XRCC1 Arg399Gln 
Ever/never 
Current sm/not 
 XPD Lys751Gln 
Ever/never 
Current sm/not 
XRCC3 Thr241Met 
Ever/never 
Current sm/not 
Matullo 2005 Italy  
(Turin) 
Case-
control, 
hospital-
based 
34-76y 
[Range] 
Controls were a random selection of male 
patients at 2 urology clinics (benign 
diseases only) and at medical and surgical 
clinics. Patients with cancer, liver or renal 
diseases or smoking-related conditions were 
excluded. 
Matching: none 
Bladder cancer XRCC1 Arg399Gln 
Ever/never 
Current sm/not 
XPD Lys751Gln 
Ever/never 
Current sm/not 
XRCC1 Arg194Trp 
Ever/never: 
Current sm/not 
XPD Asp312Asn 
Ever/never 
Current sm/not 
XRCC3 Thr241Met 
Ever/never 
Current sm/not 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in 
controls  
[metric] 
 Control  
ascertainment 
 Study 
outcome Analyses  ⁯    
Metsola 2005 Finland Case-
control, 
hospital-
based 
53.5y [Mean] 
37-77y 
[Range] 
Controls resided in same area as cases that 
attended Kuopio University Hospital and 
were 
 randomly selected from the Finnish 
National Population Register. 
Matching: none 
Breast cancer XRCC1 Arg399Gln 
Ever/never 
PY 
 XPD Lys751Gln 
Ever/never 
PY 
XRCC1 Arg280His 
Ever/never 
PY 
Misra 2003 
 
[Alpha-
tocopherol 
Beta-carotene 
Cancer 
Prevention 
Study (ATBC 
Finland)] 
Finalnd Case-
control, 
nested 
59y  
[Median] 
55-63y  
[Range] 
Controls were from a case-control study 
nested in the ATBC Trial cohort. All were 
male smokers from southwestern Finland. 
Intervention group received alpha-
tocopherol &/or beta-carotene supplements. 
Sampling from cohort based on incidence 
density sampling & availability of blood 
samples.Matching: Individually-matched on 
age, intervention group, study clinic & date 
of blood draw. 
Lung cancer XRCC1 Arg399Gln 
Intensity 
Olshan 2002 
 
Olshan 2000 
(parent study) 
US 
(North 
Carolina) 
Case-
control, 
hospital-
based 
20-49y (27%) 
50-59y (22%) 
60-69y (33%) 
>=70y (17%) 
[Frequency 
distribution] 
Controls were surgical patients attending 
the same clinic as cases. Controls with 
aspirin triad were excluded.  Meta-analysis 
included only white controls. 
Matching:  Frequency-matched to case 
group on age & gender. 
Head & neck 
cancer 
XRCC1 Arg399Gln 
Ever/never 
XRCC1 Arg194Trp 
Ever/never 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in 
controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses  ⁯    
Pachkowski 
2006 1 
Carolina 
Breast Cancer 
Study  (CBCS) 
US  
(North Carolina) 
Case-control, 
population-
based 
<=45y (30%) 
>45y (70%)  
[Frequency 
distribution] 
Controls were women selected 
from Drivers License (<65y) or 
Medicare (>=65y) lists. African 
American & younger (<50y) cases 
oversampled. 
Matching: Frequency matched to 
cases on age & ethnicity.  
Breast cancer XRCC1 Arg399Gln 
Ever/never 
Current sm/not 
Intensity 
Duration 
XRCC1 Arg194Trp 
Ever/never 
Current sm/not 
Duration 
Intensity 
XRCC1 Arg280His 
Ever/never 
Current sm/not 
Duration 
Intensity 
Park 2002 Korea Case-control, 
hospital-based 
60.7y (8.9y) 
[Mean (SD)] 
38-86y 
[Range] 
Controls were randomly selected 
from healthy male volunteers at a 
hospital check-up clinic. 
Matching: Frequency matched to 
case group on age. 
Lung cancer XRCC1 Arg399Gln 
PY 
Patel 2005 
 
[Cancer 
Prevention 
Study II (CPS-
II) Nutrition 
cohort ] 
US Case-control, 
nested 
(Combined 
cases & 
controls) 
62y 
 [Median] 
43-75y 
 [Range] 
Controls were women from the 
CPS-II Nutrition Cohort, a 
subgroup of the CPS-II baseline 
mortality cohort. Controls were 
randomly selected cancer-free 
participants meeting case-matching 
criteria.  
Matching: Individually-matched to 
cases on age, ethnicity & date of 
blood collection. 
Breast cancer XRCC1 Arg399Gln 
Ever/never 
XRCC1 Arg194Trp 
Ever/never 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in 
controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses  ⁯    
Ramachandran 
2006 
India Case-
control, 
hospital-
based 
(friends & 
family) 
not given Controls were visitors & family to Head and 
Neck Clinic of the Thiruvananthapuram 
Regional cancer center.   
Matching: Frequency-matched to cases on 
age, gender & "habits" 6 
Head & neck 
cancer 
XRCC1 Arg399Gln 
Ever/never 
Ryk 2006 
 
(Same study 
population as 
Hou 2002) 
Sweden(S
tockholm) 
Case-
control, 
population-
based 
68y  
[Median] 
30-89y 
 [Range] 
Healthy controls were recruited from 
Stockholm residence files every 6 months. 
Matching:  Frequency-matched to case group 
on age, gender, catchment area & smoking 
status (never/former/current).  Never-smoking 
cases were over-sampled (50% of case group).  
Lung cancer XRCC1 Arg399Gln 
Ever/never 
Schabath 2005 
 
(Study 
population may 
overlap Shen 
2002) 
US 
(Texas) 
Case-
control, 
hospital-
based 
62y 
[Mean] 
Healthy control subjects were recruited from 
Kelsey-Seybold Clinics (a large private 
multispecialty physicians group, Houston). 
Matching: Frequency-matched to case group 
on age, gender & ethnicity 
Bladder cancer  XPD Lys751Gln 
Ever/never 
PY 
XPD Asp312Asn 
Ever/never 
PY 
Schneider 2005 Germany Case-
control, 
hospital-
based 
  Controls were from outpatient clinics free of 
any benign or malignant tumors & unrelated 
to cases  
Matching: none 
Lung cancer XRCC1 Arg399Gln 
Ever/never 
PY 
XRCC1 Arg194Trp 
Ever/never 
PY 
XRCC1 Arg280His 
Ever-never 
PY 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment 
 Study 
outcome Analyses  ⁯    
Shen 2000 China 
(Jiangsu 
Province) 
Case-
control, 
population-
based 
61.6y 
 [Mean] 
62y  
[Median] 
32-67y  
[Range] 
Controls were selected from closest unrelated 
neighbors in same village as cases. Controls 
were healthy & cancer-free.   
Matching: Individually-matched to cases on age, 
gender & village. 
Gastric 
cancer 
XRCC1 Arg399Gln 
Ever/never 
XRCC1 Arg194Trp 
Ever/never 
Shen 2002 
 
(Study 
population may 
overlap Schabath 
2005) 
US  
(Texas) 
Case-
control, 
hospital-
based 
56y 
[Median] 
55.8y 
[Mean] 
19-84y 
[Range] 
Controls were from a local managed care 
organization (Houston, Kelsey-Seybold). 
"Cancer-free".   Meta-analysis included only 
non-Hispanic whites. 
Matching: Frequency matched to case group on 
age, gender, ethnicity, smoking status and 
alcohol consumption. 
Head & 
neck cancer 
XRCC3 Thr241Met 
Ever/never 
Current sm/not 
Shen 2003 Italy Case-
control, 
hospital-
based 
(Cases & controls) 
63y [Mean] 
(Controls only) 
<=40y  ( 5%) 
41-50y ( 8%) 
51-60y (23%) 
61-70y (38%) 
>70y   (26%) 
[Freq distribution] 
Controls were male patients from urology depts 
of 2 main hospitals in Brescia Italy with non-
neoplastic diseases.  
Matching: Frequency-matched to case group on 
age, period of recruitment & hospital 
Bladder 
cancer 
XRCC1 Arg399Gln 
Ever/never 
PY 
XPD Lys751Gln 
Ever/never 
PY 
XRCC3 Thr241Met 
Ever/never 
PY 
Shen 2005  
 
[Same study 
population as 
Terry 2004, Long 
Island Breast 
Cancer Study 
Project 
(LIBCSP)] 
US (New 
York) 
Case-
control, 
population-
based 
<35y     ( 3%) 
35-44y  (16%) 
45-54y  (27%) 
55-64y  (26%) 
65-74y  (20%) 
75-84y  ( 7%) 
>=85y  ( 1%) 
[Frequency 
distribution] 
Controls were women identified by random digit 
dialing (<65y) & Medicare records (>=65 y) 
residing in Long Island NY in Nassau and 
Suffolk counties.Matching:  Frequency-matched 
to case group by age & ethnicity  
Breast 
cancer 
XRCC1 Arg399Gln 
Ever/never 
XRCC1 Arg194Trp 
Ever/never 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses  ⁯    
Skjelbred 2006a 
 
[European Study 
Group on 
Cytogenetic 
Biomarkers and 
Health (ESCH)] 
Norway Cohort, 
occupational 
18-71y 
[Range] 
Controls were males from ESCH cohort 
(European Study Group on Cytogenetic 
Biomarkers and Health; combined Nordic & 
Italian cohorts) + additional males. This study 
includes only the Norwegian Caucasian males 
in the Cancer Risk Biomarker group. Sample 
enriched for occupational exposures likely to 
cause chromosomal aberrations (~47% w 
possible occupational exposure to 
clastogenic/carcinogenic agents). 
DNA damage 
(chromosomal 
aberrations)  
XRCC1 Arg399Gln 
Current sm/not 
 XPD Lys751Gln 
Current sm/not 
XRCC1 Arg194Trp 
Current sm/not 
XRCC1 Arg280His 
Current sm/not 
XRCC3 Thr241Met 
Current sm/not 
Smedby 2006 
 
(Scandinavian 
Lymphoma 
Etiology Study) 
Sweden & 
Denmark 
Case-
control, 
population-
based 
59y  
[Mean] 
19-74y  
[Range] 
Controls randomly selected from population 
registries of Denmark & Sweden + regional 
pilot in Denmark. No hematologic 
malignancies. 
Matching:  Frequency-matched to case group 
on age & gender. 
Lymphoma XRCC3 Thr241Met 
Ever/never 
Current sm/not 
Stern 2001 
 
[Same study 
population as 
Stern 2002a, 
2002b(excluded)] 
US 
(North 
Carolina) 
Case-
control, 
hospital-
based 
63.3 (10.4) y 
[Mean(SD)] 
<60 y  (31.5%) 
60-70 y (41.8%) 
>70y (26.8%) 
[Frequency 
distribution] 
Controls were male urology clinic patients w 
no history of any cancer other than NMSC 
Matching: Frequency matched to case group 
on age, ethnicity, and gender 
Bladder cancer XRCC1 Arg194Trp 
Ever/never 
Duration 
Stern 2002a 
 
[Same study 
population as 
Stern 2001, 
2002b(excluded)] 
US 
(North 
Carolina) 
Case-
control, 
hospital-
based 
63.3 (10.4) y 
[Mean(SD)] 
<60 y  (31.5%) 
60-70 y (41.8%) 
>70y (26.8%) 
[Frequency 
distribution] 
Controls were male urology clinic patients w 
no history of any cancer other than NMSC 
Matching: Frequency matched to case group 
on age, ethnicity, and gender 
Bladder cancer XRCC3 Thr241Met 
Ever/never 
PY 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses  ⁯    
Terry 2004 
 
[Same study 
population as 
Shen 2005a, 
Long Island 
Breast Cancer 
Study Project 
(LIBCSP)] 
US 
(New York) 
Case-
control, 
population-
based 
<35y     ( 3%) 
35-44y  (16%) 
45-54y  (27%) 
55-64y  (26%) 
65-74y  (20%) 
75-84y  ( 7%) 
>=85y  ( 1%) 
[Frequency 
distribution] 
Controls were women identified by random 
digit dialing (<65y) & Medicare records 
(>=65 y) residing in Long Island NY in 
Nassau and Suffolk counties. 
Matching:  Frequency-matched to case 
group by age & ethnicity  
Breast cancer  XPD Lys751Gln 
Ever/never 
Current sm/not 
Tuimala 2004 Finalnd & 
Hungary 
Convenienc
e sample 
41.0y 
[Mean(SD)] 
21-64y 
 [Range] 
Controls were from 2 parent case-control 
studies: 1. Finnish office workers from 
case-control study of isocyanate asthma 2. 
Hungarian healthy blood donors and clerks 
attending pre-employment physicals from 
case-control study of head and neck cancer 
(nonsmoking drinkers excluded). Control 
groups were pooled for analysis 
[Finns(N=61) + Hungarians(N=84)].  
DNA 
damage(Chromo
somal 
abberations 
&Sister 
chromatid 
exchange) 
XRCC1 Arg399Gln 
Ever/never 
XRCC1 Arg280His 
Ever/never 
XRCC3 Thr241Met 
Ever/never 
Wilding 2005 UK Cohort, 
occupational 
~69y [Mean] 
All >50y 
Cohort consisted of retired male workers 
from nuclear facility. 
DNA damage 
(chromosomal 
aberrations)  
XRCC1 Arg399Gln 
Ever/never 
XRCC1 Arg194Trp 
Ever/never 
XRCC3 Thr241Met 
Ever/never 
Xing 2002 China 
(Beijing) 
Case-
control, 
hospital-
based 
58y (6.8) 
[Mean (SD)] 
Population controls randomly selected from 
a nutritional survey having participants 
from the same region as case patients.  
Matching: Frequency-matched to case 
group on age & gender. 
Lung cancer  XPD Lys751Gln 
Ever/never 
PY 
XPD Asp312Asn 
Ever/never 
PY 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment 
 Study 
outcome Analyses  ⁯    
Yu 2004a 
 
(Same population 
as Yu 2004b) 
China Case-
control, 
hospital-
based 
57.4y (9.4y) 
[Mean(SD)] 
<60y  (66%) 
>60 y (34%) 
[Frequency 
distribution] 
Controls were randomly selected from a pool 
of volunteers who visited the general health 
check-up division at Tongji Hospital of 
Huazhong University of Science & 
Technology clinics. 
Matching:  Frequency-matched to case group 
on age & gender 
Esophageal 
cancer 
XRCC1 Arg399Gln 
Ever/never 
Yu 2004b 
 
(Same population 
as Yu 2004a) 
China  Case-
control, 
hospital-
based 
57.4y (9.4y) 
[Mean(SD)] 
<60y  (66%) 
>60 y (34%) 
[Frequency 
distribution] 
Controls were randomly selected from a pool 
of volunteers who visited the general health 
check-up division at Tongji Hospital of 
Huazhong University of Science & 
Technology clinics. 
Matching:  Frequency-matched to case group 
on age & gender 
Esophageal 
cancer 
XPD Lys751Gln 
Ever/never 
Zhou 2002 
 
(Same study 
population as 
Zhou 2003) 
US 
(Massachus
etts) 
Case-
control, 
hospital-
based 
(friends & 
family) 
58.5y (12.4y) 
[Mean (SD)] 
19-100y 
[Range] 
<55y    (38%) 
55-64y (26%) 
>=65 y (36%) 
[Frequency 
distribution] 
Controls were friends & non-genetically 
related family of lung cancer cases at 
Massachusetts General Hospital. Also friends 
& family of non-lung cancer pts in 
cardiothoracic wards (<10%).  
Matching: none 
Lung cancer XPD Lys751Gln 
Ever/never 
PY 
XPD Asp312Asn 
Ever/never 
PY 
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Table V.A.1a.  Studies included in meta-analyses (continued) 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
Design 
Age in controls  
[metric] 
 Control  
ascertainment  Study outcome Analyses  ⁯    
Zhou 2003 
(Same study 
population as 
Zhou 2002) 
US 
(Massachusetts) 
Case-
control, 
hospital-
based 
(friends & 
family) 
58.5y (12.4y) 
[Mean (SD)] 
19-100y 
[Range] 
<55y    (38%) 
55-64y (26%) 
>=65 y (36%) 
[Frequency 
distribution] 
Controls were friends & 
non-genetically related 
family of lung cancer cases 
at Massachusetts General 
Hospital. Also friends & 
family of non-lung cancer 
pts in cardiothoracic wards 
(<10%).  
Matching: none 
Lung cancer XRCC1 Arg399Gln 
Ever/never 
PY 
Zijno 2006 Italy(Rome) Cohort, 
occupational 
43.4 y 
[Mean] 
Traffic wardens [N~133] & 
office workers [N~57]) in 
the municipality of Rome.  
Study of urban air pollutants 
and genotoxic 
endpoints.Matching: none 
DNA damage 
(Sister chromatid 
exchange) 
XPD Lys751Gln 
Current sm/not 
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Table V.A.1b.  Characteristics of 5 additional studies (5 study populations) not included in any summary estimates. 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
 
                       
Design 
Age in controls  
[metric] 
  
Control ascertainment  
& reason for exclusion  
  
Study 
outcome 
  
Analyses  ⁯    
Affatato 2004 US  
(Texas) 
Conveni
ence 
sample 
48y 
[Median] 
Volunteers from University of Texas Medical 
Branch in Galveston answering notices for 
smokers & nonsmokers for genetic studies.  
Excluded cancer history and exposure to 
potential mutagens (radiation etc.). 
Matching: none 
Exclusion: Included only never smokers and 
current smokers. Former smokers excluded. 
DNA 
damage 
(chromo-
somal 
aberrations)  
XPD Lys751Gln 
Never/ current smoker only:  
1.05 (0.39, 2.88) 
XPD  Asp312Asn 
Never/ current smoker only: 
1.31 (0.47, 3.62) 
Figueiredo 
2004 
Canada 
(Ontario) 
Case-
control, 
populati
on-
based 
45.2 (6.5) y 
Mean (SD)] 
Controls were women identified by random 
digit dialing. No history of breast cancer.  
Matching: Frequency-matched to case group 
on age. 
Exclusion: No data presented on adult 
smoking.  
Breast 
cancer 
XRCC1 Arg399Gln 
Adolescent smoking yes/no: 
1.02 (0.58, 1.79) 
XRCC3 Thr241Met 
Adolescent smoking yes/no: 
1.42 (0.80, 2.50) 
Stern 2002b 
(Same study 
population as 
Stern 2001 & 
2002a) 
US 
(North 
Carolina) 
Case-
control, 
hospital
-based 
63.4 (10.3) 
[Mean (SD)] 
<=60 y    
(31.1%) 
60-70 y   
(42.1%) 
>=70 y    
(26.8%) 
[Frequency 
distribution] 
Controls were males from urology clinics 
without a history of cancer except NMSC.  
Matching: Frequency matched to case group 
on age, gender and ethnicity. Only blacks and 
whites included in analysis. 
Exclusion: Data presented for recessive model 
only. 
Bladder 
cancer 
XPD Lys751Gln 
Ever/never (Any Lys v. Gln):  
1.76 (0.75, 4.16) 
Duration (Any Lys v. Gln):  
0.91 (0.34, 2.41) 
Stern 2006a US 
(Californi
a) 
Case-
control 
61 (7) y 
[Mean (SD)] 
Controls were from screening study for 
colorectal adenomas. No history of invasive 
cancer, past polyps.  
Matching: Individually matched to cases on 
age, gender, date and center of procedure. 
Exclusion: Data presented for recessive model 
only. 
Colorectal 
adenoma 
XPD Lys751Gln 
Ever/never (Any Lys v. Gln):  
0.72 (0.45, 1.15) 
  
111
 
Table V.A.1b.  Characteristics of 5 additional studies (5 study populations) but not included in any summary estimates (continued) 
Author &  
year 
Study name 
(abbreviation) 
  
Location 
  
 
                       
Design 
Age in 
controls  
[metric] 
  
Control ascertainment  
& reason for exclusion  
  
Study 
outcome 
  
Analyses  ⁯    
Wang 2003b US 
(Texas) 
Case-
control, 
hospital-
based 
~ 62 y 
[Mean] 
Controls were from community centers. No 
previous cancer history except NMSC. African-
American and Mexican-American controls only. 
Matching: Frequency matched to case group on 
age, gender, ethnicity & city of residence. 
Exclusion:  Never smokers included in lowest 
PY category 
Lung 
cancer 
XRCC3 Thr241Met 
PY (Never+low PY v. hi PY):  
0.21 (0.07, 0.64) 
 
Abbreviations: PY = pack-years, NMSC = non-melanoma skin cancer, y=years of age. Sm=smoker, not=not a current smoker 
1
 Fifty-five studies met overall inclusion criteria. 50 studies, representing 46 study populations, could be included in at least 1 genotype-smoking summary 
estimate. Five studies met inclusion criteria but could not be included in any genotype-smoking summary analyses. 
2 Reference groups for smoking analyses: never smoker, not a current smoker (never+former smoking), lowest non-zero PY category (v. highest), shortest non-
zero smoking duration category (v. highest) & lowest non-zero category of smoking intensity (v. highest). All genotype contrasts: homozygous for the more 
common allele (ref) v. 1 or more copies of the less common variant 
3
 Duell 2001 & Pachkowski 2006 are from the CBCS. Duell 2001 was used for analyses stratified on ethnicity, Pachkowski 2006 used for all others. 
4
 Excluded from Ever/never and Current sm/not because "never smoking" was not comparable to other studies Never/former/current categories were 1. never 
active or passive and 2. passive+cigar/pipe smoking) 
5
 Assumed because of lead author's institutional affiliation 
6
 Appears to include to smoking behavior, alcohol consumption and/or betel quid chewing. 
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Table V.A.2: DNA repair gene variation and smoking summary estimates 
 Ever-never Current-Not current  Pack-years Intensity Duration 
 N 
Q  
p-
value 
ORz  
(95% 
CI)1 N 
Q  
p-
value 
ORz  
(95% CI)2 N 
Q  
p-value 
ORz  
(95% 
CI)3 N 
Q  
p-
value 
ORz  
(95% 
CI) 4 N 
Q  
p-
value 
ORz  
(95% 
CI)5 
Gene and SNP 
XRCC1                      
Arg399
Gln 6 21 0.01 --- 12 11 0.40 
1.0  
(0.9, 1.1) 9 0.30 
1.2  
(1.0, 1.5) 4 0.49 
1.5  
(1.2, 1.9) 2 0.03 --- 12 
Arg194
Trp 7 12 0.62 
1.0  
(0.9, 1.1) 6 0.68 
1.1  
(0.9, 1.3) 2 0.73 
1.1  
(0.7, 1.6) 2 0.89 
1.1 
 (0.8, 1.6) 3 0.47 
0.7  
(0.5, 0.9) 
Arg280
His 8 5 0.47 
1.0  
(0.8, 1.2) 4 0.51 
0.7  
(0.5, 1.1) 3 0.32 
1.0 
 (0.6, 1.5) 1 -- 
0.9  
(0.5, 1.8) 1 -- 
1.2  
(0.6, 2.3) 
XPD                
Lys751
Gln 9 12 0.46 
0.9  
(0.8, 1.1) 6 0.25 
1.1  
(0.9, 1.3) 7 0.02 --- 12 0   0   
Asp312
Asn 10 9 0.79 
1.1  
(1.0, 1.2) 1 --- 
1.1  
(0.7, 1.9) 4 0.11 
1.1  
(0.8, 1.5) 0   0   
XRCC3                
Thr241
Met 11 9 0.52 
1.0  
(0.9, 1.2) 7 0.73 
0.9 (0.8, 
1.1) 4 0.67 
0.8  
(0.6, 1.2) 0     0     
Abbreviations: CI=Confidence interval, na=not applicable, PY=pack-years, ORz=control-only genotype-smoking odds ratio, Q=Cochran’s test of 
heterogeneity, N=number of studies, G+=gene is positive for any variant allele G-=negative for variant allele (referent), E+=positive for smoking measures, 
E-=negative for smoking measure (referent), N=number of studies, SNP=single nucleotide polymorphism, Arg=Arginine, Gln=Glutamine, Trp=Tryptophan, 
His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine  
1
 Fixed effects summary estimates for G+/G- vs. E+/E- . G- is homozygous for the common allele (ref), G+ is the genotype with 1 or 2 variant alleles, E- 
(ref) is never smoker and E+ is ever smoking 
2
 Fixed effects summary estimates for G+/G- vs. E+/E- . G- is homozygous for the common allele (ref), G+ is the genotype with 1 or 2 variant alleles, E- 
(ref) is not current smoker and E+ is  current smoking 
3
 Fixed effects summary estimates for G+/G- vs. E+/E- . G- is homozygous for the common allele (ref), G+ is the genotype with 1 or 2 variant alleles, E- 
(ref) is lowest non-zero PY category and E+ is highest category of PY 
4
 Fixed effects summary estimates for G+/G- vs. E+/E- . G- is homozygous for the common allele (ref), G+ is the genotype with 1 or 2 variant alleles, E- 
(ref) is lowest non-zero category of intensity (cig/day) and E+ is highest category of smoking intensity. 
5
 Fixed effects summary estimates for G+/G- vs. E+/E- . G- is homozygous for the common allele (ref), G+ is the genotype with 1 or 2 variant alleles, E- 
(ref) is lowest non-zero category of duration(yrs) and E+ is highest category of smoking duration. 
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Table V.A.2: DNA repair gene variation and smoking summary estimates (continued) 
6
 Arg/Arg v. any Gln 
7 Arg/Arg v. any Trp 
8
 Arg/Arg v. any His 
9
 Lys/lys v. any Gln 
10
 Asp/Asp v. any Asn 
11
 Thr/Thr v. any Met 
12 Studies too heterogeneous for fixed effects summary estimate 
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Table V.A.3.  Genotype-smoking associations for selected specification of current-not current smoking and pack-years of smoking 
 XRCC1  XPD  XRCC3 
 
Arg399Gln Arg194Trp Arg280His Lys751Gln Asp312Asn Thr241Met 
 N  ORz (95% CI) N ORz (95% CI) N ORz (95% CI) N ORz (95% CI) N ORz (95% CI) N ORz (95% CI) 
Current / not current smoking 
Not current (never + 
former)(ref) vs. current 
smoker 11 1.0 0.9, 1.1 6 1.1 0.9, 1.3 4 0.7 0.5, 1.1 6 1.1 0.9, 1.3 1 1.1 0.7, 1.9 7 0.9 0.8, 1.1 
Never (ref) vs. former 
smoker 4 1.1 0.9, 1.3 2 1.1 0.8, 1.4 1 1.0 0.7, 1.5 3 0.8 0.6, 1.0 1 1.3 0.7, 2.4 4 1.0 0.8, 1.3 
Never (ref) vs. current 
smoker 4 1.1 0.9, 1.4 2 1.2 0.8, 1.6 1 0.9 0.5, 1.4 3 0.9 0.7, 1.1 1 1.3 0.7, 2.3 4 0.9 0.7, 1.2 
Pack-years of smoking  
Relative PY 1 
Lightest (ref)  vs. 
heaviest smokers 2 9 1.2 1.0, 1.5 2 1.1 0.7, 1.6 3 1.0 0.6, 1.5 7 1.2 1.0, 1.5 4 1.1 0.8, 1.5 4 0.8 0.6, 1.2 
Never (0 PY)(ref) vs. 
lightest smokers 3 7 -- 6  2 0.9 0.7, 1.2 3 1.1 0.8, 1.5 6 0.9 0.8, 1.1 4 1.0 0.8, 1.3 3 1.3 0.9, 1.8 
Never (0 PY)(ref) vs. 
heaviest smokers 7 1.2 1.0, 1.4 2 1.1 0.8, 1.6 3 1.1 0.7, 1.5 6 1.0 0.8, 1.3 4 1.1 0.8, 1.4 3 1.0 0.7, 1.4 
Absolute PY 4 
Light (<cutpoint range, 
ref)  vs.  heavy 
smokers (>=cutpoint 
range) 5 6 1.2 1.0, 1.5 2 0.9 0.7, 1.3 2 1.2 0.8, 1.7 4 1.1 0.9, 1.3 3 1.0 0.8, 1.2 3 0.8 0.5, 1.1 
Never (0 PY) (ref) vs. 
(<cutpoint range, ref)  4 1.1 0.9, 1.2 2 0.8 0.7, 1.1 2 1.0 0.8, 1.4 4 0.9 0.7, 1.1 3 1.0 0.8, 1.2 2 1.4 1.0, 2.0 
Never (0 PY) (ref) vs. 
(>=cutpoint range) 4 1.3 1.0, 1.6 2 1.1 0.8, 1.5 2 1.3 0.8, 1.9 4 0.9 0.7, 1.1 3 1.0 0.8, 1.2 2 1.0 0.6, 1.6 
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Table V.A.3. Genotype-smoking associations for selected specifications of current-not current smoking and pack-years of smoking (continued) 
Abbreviations: ref=referent, PY=pack-year,  ORz=control-only genotype-smoking odds ratio, N=number of studies,  Arg=Arginine, Gln=Glutamine, 
Trp=Tryptophan, His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine 
1
 Lowest and highest study-defined PY categories, regardless of PY cutpoints. 
2
 Lowest study-defined non-zero PY category (reference) compared to highest study-defined PY category, regardless of PY cutpoints (i.e. smokers only). 
3
 Never smokers (0PY) as common referent for lowest study-defined PY category and highest study-defined PY category, regardless of PY cutpoints. 
4
 Light and heavy smokers are defined as smoking less or more, respectively, than the study-defined cutpoint within the cutpoint range for the specified 
SNP; Studies w no cutpoint in this range are excluded, no studies included multiple cutpoints in this range; Ranges for absolute PY: XRCC1 Arg399Gln 
(32-42PY) 
5
 Light includes all study-defined categories w a lower bound less than the cutpoint range for that SNP (excluding 0 PY); Heavy includes all study-defined 
categories w an upper bound greater than the cutpoint range for that SNP 
6
 Studies too heterogeneous for fixed effects summary estimate 
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Table V.A.4: Genotype-smoking associations stratified by study design 
  XRCC1 
  Arg399Gln  Arg194Trp  Arg280His 
  N 
ORz  
(95% CI) 1 
Ratio of ORs 
(95%CI) 2  N 
ORz  
(95% CI) 1 
Ratio of ORs 
(95%CI) 2  N 
ORz  
(95% CI) 1 
Ratio of ORs 
(95%CI) 2 
  Ever-never smoking 
Case-based categories 
 Case-control            
 
   Population 
   - based 8 1.1 (0.9, 1.5) Ref  4 1.0 (0.9, 1.3) Ref  2 0.9 (0.7, 1.3) Ref 
 
   Hospital- 
   based 9 1.0 (0.9, 1.2) 0.9 (0.7, 1.2)  5 0.9 (0.8, 1.1) 0.9 (0.7, 1.2)  2 1.1 (0.8, 1.4) 1.2 (0.8, 1.8) 
 
   Other 1 0.9 (0.6, 1.3) 0.8 (0.4, 1.3)  2 1.1 (0.9, 1.5) 1.1 (0.8, 1.5)  0   
 
Cohort/ 
convenience 3 1.0 (0.8, 1.4) 0.9 (0.6, 1.4)  1 0.7 (0.3, 1.4) 0.7 (0.3, 1.4)  1 0.5 (0.2, 1.1) 0.5 (0.2, 1.3) 
 
     
 
   
 
  
 
Case-control 18 1.1 (0.9, 1.2) Ref  11 1.0 (0.9, 1.2) NA  4 1.0 (0.8, 1.2) NA 
 
Other 3 1.0 (0.8, 1.4) 1.0 (0.7, 1.4)  1 0.7 (0.3, 1.4)   1 0.4 (0.2, 1.1)  
Non-case-based categories 
 Case-control             
 
     Population 
     controls 8 1.1 (0.9, 1.5) Ref  4 1.0 (0.9, 1.3) Ref  2 0.9 (0.7, 1.3) Ref 
 
     Patient  
     controls 3 6 1.1 (0.9, 1.2) 0.9 (0.7, 1.3)  5 0.9 (0.8, 1.1) 0.9 (0.7, 1.2)  2 1.1 (0.8, 1.4) 1.2 (0.8, 1.8) 
 
     Non-patient 
     controls 4 4 0.9 (0.8, 1.1) 0.8 (0.6, 1.1)  2 1.1 (0.9, 1.5) 1.1 (0.8, 1.5)  0   
 
Cohort/ 
convenience 3 1.0 (0.8, 1.4) 0.9 (0.6, 1.4)  1 0.7 (0.3, 1.4) 0.7 (0.3, 1.4)  1 0.5 (0.2, 1.1) 0.5 (0.2, 1.3) 
Health status of non-cases 
 
Not patients 5 15 1.1 (0.9, 1.3) Ref  7 1.1 (0.9, 1.2) Ref  3 0.9 (0.7, 1.1) Ref 
 
Patients 6 1.1 (0.9, 1.2) 1.0 (0.8, 1.3)  5 0.9 (0.8, 1.1) 0.9 (0.7, 1.1)  2 1.1 (0.8, 1.4) 1.3 (0.8, 1.9) 
 
Unknown 
patient status 0    0    0   
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Table V.A.4: Genotype-smoking associations stratified by study design (continued) 
  XRCC1 
  Arg399Gln  Arg194Trp  Arg280His 
  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2 
  Current-not current smoking 
Case-based categories 
 Case-control            
 
Population-
based 1 1.2 (1.0, 1.5) Ref  1 1.1 (0.8, 1.6) NA  1 0.9 (0.6, 1.4) NA 
 
Hospital-
based 3 0.9 (0.7, 1.2) 0.7 (0.5, 1.0)  2 0.9 (0.7, 1.3)   0   
 
Other 0    0    0   
 
 Unknown 1 1.6 (0.7, 3.7) 1.3 (0.5, 3.2)  1 0.9 (0.4, 2.2)   1 1.1 (0.2, 5.8)  
 
Cohort/ 
convenience 6 0.8 (0.6, 1.1) 0.7 (0.5, 1.0)  2 1.5 (0.8, 2.7)   2 0.5 (0.2, 1.0)  
 
 
 
   
 
   
 
  
 
Case-control 5 1.1 (0.9, 1.3) Ref  4 1.0 (0.8, 1.3) Ref  2 0.9 (0.6, 1.4) Ref 
 
Other 6 0.8 (0.6, 1.1) 0.8 (0.6, 1.1)  2 1.5 (0.8, 2.7) 1.5 (0.8, 2.7)  2 0.5 (0.2, 1.0) 0.5 (0.2, 1.2) 
Non-case-based categories 
 Case-control            
 
Population 
controls 1 1.2 (1.0, 1.5) Ref  1 1.1 (0.8, 1.6) NA  1 0.9 (0.6, 1.4) NA 
 
Patient 
controls 3 2 0.8 (0.6, 1.2) 0.7 (0.5, 1.0)  1 1.1 (0.6, 2.1)   0   
 
Non-patient 
controls 4 1 1.0 (0.7, 1.5) 0.8 (0.5, 1.3)  1 0.8 (0.6, 1.2)   0   
 
Unknown 1 1.6 (0.7, 3.7) 1.3 (0.5, 3.2)  1 0.9 (0.4, 2.2)   1 1.1 (0.2, 5.8)  
 
Cohort/ 
convenience 6 0.8 (0.6, 1.1) 0.7 (0.5, 1.0)  2 1.5 (0.8, 2.7)   2 0.5 (0.2, 1.0)  
Health status of non-cases          
 
Not patients 5 8 1.0 (0.9, 1.2) Ref  4 1.1 (0.8, 1.3) NA  3 0.7 (0.5, 1.1) NA 
 
Patients 2 0.8 (0.6, 1.2) 0.9 (0.6, 1.3)  1 1.1 (0.6, 2.1)   0   
 
Unknown 
patient status 1 1.6 (0.7, 3.7) 1.6 (0.7, 3.7)  1 0.9 (0.4, 2.2)   1 1.1 (0.2, 5.8)  
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Table V.A.4: Genotype-smoking associations stratified by study design (continued) 
  XRCC1 
  Arg399Gln  Arg194Trp  Arg280His 
  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2  N 
ORz (95% CI) 
1
 
Ratio of ORs 
(95%CI) 2  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2 
  Pack-years 
Case-based categories 
 
Case-control            
 
Population-
based 2 0.9 (0.6, 1.4) Ref  0  NA  1 0.5 (0.2, 1.5) NA 
 
Hospital-
based 7 1.3 (1.1, 1.6) 1.5 (0.9, 2.4)  2 1.1 (0.7, 1.6)   2 1.1 (0.7, 1.8)  
 
Other 0    0    0   
 
 Unknown 0    0    0   
 
Cohort/ 
convenience 0    0    0   
 
            
 
Case-control 9 1.2 (1.0, 1.5) NA  2 1.1 (0.7, 1.6) NA  3 1.0 (0.6, 1.5) NA 
 
Other 0    0    0   
Non-case-based categories 
 Case-control             
 
Population 
controls 2 0.9 (0.6, 1.4) Ref  0  NA  1 0.5 (0.2, 1.5) NA 
 
Patient 
controls 3 4 1.4 (1.1, 1.7) 1.5 (0.9, 2.5)  2 1.1 (0.7, 1.6)   2 1.1 (0.7, 1.8)  
 
Non-patient 
controls 4 3 1.3 (0.9, 1.8) 1.4 (0.8, 2.5)  0    0   
 
Unknown 0    0    0   
 
Cohort/ 
convenience 0    0    0   
             
Health status of non-cases 
 
Not patients 5 5 1.1 (0.9, 1.5) Ref  0  NA  1 0.5 (0.2, 1.5) NA 
 
Patients 4 1.4 (1.1, 1.7) 1.2 (0.8, 1.8)  2 1.1 (0.7, 1.6)   2 1.1 (0.7, 1.8)  
  
Unknown 
patient status 0       0       0     
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Table V.A.4: Genotype-smoking associations stratified by study design (continued) 
   XPD  XRCC3 
  
 Lys751Gln  Asp312Asn  Thr241Met 
  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2  N 
ORz (95% CI) 
1
 
Ratio of ORs 
(95%CI) 2  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2 
  Ever-never smoking 
Case-based categories         
 Case-control            
 
Population-
based 
4 
1.0 (0.8 , 1.1) Ref  2 1.3 (1.0, 1.8) Ref  2 1.0 (0.8, 1.3) Ref 
 
Hospital-
based 
7 
0.9 (0.8, 1.1) 0.9 (0.7, 1.2)  7 1.0 (0.9, 1.2) 0.8 (0.6, 1.1)  4 1.0 (0.7, 1.3) 1.0 (0.6, 1.4) 
 
Other 0    0    0   
 
Cohort/ 
convenience 1 1.0 (0.6, 1.6) 1.0 (0.6, 1.7)  0    3 1.2 (0.9, 1.6) 1.2 (0.8, 1.8) 
 
         
 
  
 
Case-control 11 0.9 (0.8, 1.1) NA  9 1.1 (1.0, 1.2) NA  6 1.0 (0.8, 1.2) Ref 
 
Other 1 1.0 (0.6, 1.6)   0    3 1.2 (0.9, 1.6) 1.2 (0.8, 1.7) 
Non-case-based categories         
 Case-control             
 
Population 
controls 
4 
1.0 (0.8 , 1.1) Ref  2 1.3 (1.0, 1.8) Ref  2 1.0 (0.8, 1.3) Ref 
 
Patient 
controls 3 
3 
0.8 (0.6, 1.1) 0.8 (0.5, 1.2)  3 1.1 (0.9, 1.3) 0.8 (0.6, 1.1)  4 1.0 (0.7, 1.3) 1.0 (0.6, 1.4) 
 
Non-patient 
controls 4 
4 
1.0 (0.8, 1.2) 1.0 (0.7, 1.4)  4 1.0 (0.8, 1.2) 0.7 (0.5, 1.1)  0   
 
Cohort/ 
convenience 1 1.0 (0.6, 1.6) 1.0 (0.5, 1.7)  0    3 1.2 (0.9, 1.6) 1.2 (0.8, 1.8) 
Health status of non-cases         
 
Not patients 5 9 1.0 (0.9, 1.1) Ref  6 1.1 (0.9, 1.3) Ref  5 1.1 (0.9, 1.3) Ref 
 
Patients 3 0.8 (0.6, 1.1) 0.8 (0.6, 1.1)  3 1.1 (0.9, 1.3) 1 (0.8, 1.2)  4 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 
 
Unknown 
patient status 0    0    0   
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Table V.A.4: Genotype-smoking associations stratified by study design (continued) 
   XPD   XRCC3  
  
 Lys751Gln  Asp312Asn  Thr241Met 
  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2  N 
ORz (95% CI) 
1
 
Ratio of ORs 
(95%CI) 2  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2 
  Current-not current smoking 
Case-based categories 
 Case-control            
 
Population-
based 1 1.0 (0.7, 1.3) NA  0    1 1.0 (0.7, 1.5) Ref 
 
Hospital-
based 1 0.7 (0.5, 1.2)   1 1.1 (0.7, 1.9) NA  2 0.9 (0.6, 1.2) 0.8 (0.5, 1.4) 
 
Other 0    0    1 2.0 (0.6, 6.6) 2.0 (0.6, 6.8) 
 
 Unknown 0    0    0   
 
Cohort/ 
convenience 4 1.4 (1.0, 1.8)   0    3 0.9 (0.6, 1.2) 0.8 (0.5, 1.4) 
 
 
 
   
 
      
 
Case-control 2 0.9 (0.7, 1.2) Ref  1 1.1 (0.7, 1.9) NA  4 1.0 (0.8, 1.2) Ref 
 
Other 4 1.4 (1.0, 1.8) 1.5 (1.0, 2.2)  0    3 0.9 (0.6, 1.2) 0.9 (0.6, 1.3) 
Non-case-based categories 
 Case-control             
 
Population 
controls 1 1.0 (0.7, 1.3) NA  0    1 1.0 (0.7, 1.5) Ref 
 
Patient 
controls 3 1 0.7 (0.5, 1.2)   1 1.1 (0.7, 1.9) NA  2 0.9 (0.6, 1.2) 0.8 (0.5, 1.4) 
 
Non-patient 
controls 4 0    0    1 2.0 (0.6, 6.6) 2.0 (0.6, 6.8) 
 
 Unknown 0    0    0   
 
Cohort/ 
convenience 4 1.4 (1.0, 1.8)   0    3 0.9 (0.6, 1.2) 0.8 (0.5, 1.4) 
Health status of non-cases         
 
Not patients 5 5 1.2 (0.9, 1.4) NA  0    5 1.0 (0.8, 1.2) Ref 
 
Patients 1 0.7 (0.5, 1.2)   1 1.1 (0.7, 1.9) NA  2 0.9 (0.6, 1.2) 0.9 (0.6, 1.3) 
 
Unknown 
patient status 0    0       
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Table V.A.4: Genotype-smoking associations stratified by study design (continued) 
   XPD   XRCC3  
  
 Lys751Gln  Asp312Asn  Thr241Met 
  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2  N 
ORz (95% CI) 
1
 
Ratio of ORs 
(95%CI) 2  N ORz (95% CI) 1 
Ratio of ORs 
(95%CI) 2 
  Pack-years 
Case-based categories 
 Case-control            
 
Population-
based 2 0.8 (0.5, 1.3) Ref  0    1 0.8 (0.4, 1.4) NA 
 
Hospital-
based 5 1.3 (0.8, 2.1) 1.5 (0.7, 3.5)  4 1.1 (0.8, 1.5) NA  3 0.8 (0.5, 1.3)  
 
Other 0    0    0   
 
Unknown 0    0    0   
 
Cohort/ 
convenience 0    0    0   
 
            
 
Case-control 7 1.1 (0.8, 1.7) NA  4 1.1 (0.8, 1.58) NA  4  NA 
 
Other 0    0    0   
Non-case-based categories 
 Case-control             
 
Population 
controls 2 0.8 (0.5, 1.3) Ref  0    1 0.8 (0.4, 1.4) NA 
 
Patient 
controls 3 2 1.0 (0.6, 1.6) 1.2 (0.5, 2.6)  1 0.9 (0.5, 1.4) NA  2 0.8 (0.5, 1.3)  
 
Non-patient 
controls 4 3 1.6 (0.8, 3.1) 2.0 (0.9, 4.3)  3 1.3 (0.9, 1.8)   1 1.1 (0.4, 2.7)  
 
Unknown 0    0    0   
 
Cohort/ 
convenience 0    0    0   
             
Health status of non-cases 
 
Not patients 5 5 1.2 (0.7, 2.0) Ref  3 1.3 (0.9, 1.8) NA  2 0.9 (0.5, 1.4) Ref 
 
Patients 2 1.0 (0.6, 1.6) 0.8 (0.3, 1.8)  1 0.9 (0.5, 1.4)   2 0.8 (0.5, 1.3) 0.9 (0.5, 1.8) 
  
Unknown 
patient status 0       0             
  
122
Table V.A.4: Genotype-smoking associations stratified by study design (continued) 
 Abbreviations: CI=Confidence interval, HWE = Hardy Weinberg equilibrium, MAF=minor allele frequency, na=not applicable, ORz=control-only genotype-
smoking odds ratio, PY=pack-years, N=number of studies, Ref=referent, Q=Cochran’s test of homogeneity, Arg=Arginine, Gln=Glutamine, Trp=Tryptophan, 
His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine 
1
 Unadjusted OR (95% CI): Genotype contrast for all SNPs is A/A (ref) vs. any a, where A is the more common allele and a is the less common; random 
effects for XRCC1 Arg399Gln ever-never & XPD Lys751Gln, fixed effects for others 
2
 Ratio of Odds Ratios: Meta-regression used to compare odds ratios in given study design stratum to the odds ratio in the designated reference stratum 
3
 Patient controls: controls are persons attending a hospital or disease clinic for treatment or diagnosis, does not include patients at wellness or check-up clinics 
4
 Non-patient controls: Case-control study participants who are not patients (i.e. not treated at hospital or disease clinic); they may be friend and family 
controls, cohort members in a nested case-control etc.; also excludes population-based controls 
5
 Non-cases that are not patients:  population-based controls, friends and/or non-blood-related family of patients, convenience, community samples or cohort 
members. 
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Table V.A.5.  XRCC1 Arg399Gln and Smoking: Overall and by study characteristics    
 
Ever-never 1 Current-Not current 2 
 PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5 N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
Overall                         
 
Not stratified by 
ethnicity w/in study 21 0.01   11 0.4   9 0.3   
 
Stratified by ethnicity 
within study 6 23 0.02   12 0.3   na    
By Study Characteristic                       
Continent                         
 North America 7 0.01 
1.1  
(0.9, 1.3) Ref 2 0.6 
1.2 
 (1.0 , 1.5) Ref 2 0.1 
1.2  
(0.8, 1.7) 
1.1  
(0.7, 1.7) 
 Europe 11 0.2 
1.1  
(0.9, 1.3) 
1.0  
(0.8, 1.3) 5 0.5 
0.8 
 (0.6, 1.0) 
0.7 
 (0.5, 0.9) 5 0.8 
1.1 
 (0.9, 1.4) Ref 
 Asia 3 0.1 
1.1 
(0.7, 1.9) 
1.0  
(0.7, 1.6) 4 0.7 
1.0  
(0.8, 1.3) 
0.8  
(0.6, 1.1) 2 0.6 
1.9  
(1.2, 2.9) 
1.7  
(1.0 , 2.7) 
Ethnicity/nationality 6                         
 
Single-ethnicity 
studies 6,7 14 0.3 
1.0  
(0.9, 1.2) Ref 4 0.1 
1.0  
(0.8, 1.2) Ref 5 0.4 
1.1  
(0.9, 1.5) Ref 
 Multi-ethnic studies 7 2 0.01 
1.2  
(0.7, 2.1) 
1.2  
(0.9, 1.7) 1 na 
0.9  
(0.2, 3.4) 
0.9  
(0.2, 3.5) 0    
 Unknown ethnicity 7 0.1 
1.1  
(0.9, 1.3) 
1.1  
(0.8, 1.4) 7 0.6 
0.9 
 (0.7, 1.1) 
0.9 
 (0.6, 1.3) 4 0.2 
1.3 
 (1.1, 1.7) 
1.2  
(0.8, 1.8) 
  
  
   
  
   
  
   
 White >=99% 8 10 0.6 
1.0  
(0.9, 1.1) Ref 2 0.2 
0.9  
(0.6, 1.2) na 5 0.4 
1.1 
 (0.9, 1.5) na 
 
African American 
>=99% 2 0.03 
1.1  
(0.5, 2.5) 
1.1  
(0.7, 1.8) 1 na 
2.1  
(1.1, 3.9)  0    
 Han >=99% 2 0.2 
1.4  
(0.8, 2.5) 
1.5  
(0.8, 2.5) 1 na 
1.0  
(0.7, 1.4)  0    
 Multi-ethnic studies 2 0.01 
1.2  
(0.7, 2.1) 
1.3  
(0.9, 1.8) 1 na 
0.9  
(0.2, 3.4)  0    
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Table V.A.5.  XRCC1 Arg399Gln and Smoking: Overall and by study characteristics   (continued) 
 
Ever-never 1 Current-Not current 2 
 PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5 N 
Q  
p-value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic                       
HWE p-value 6                         
 
Single-ethnicity 
(continuous) 13 0.2 
1.0  
(0.9, 1.2) 
0.8 
 (0.5, 1.3) 4 0.1 
1.0  
(0.8, 1.2) 
1.3 
 (0.2, 7.2) 5 0.4 
1.1  
(0.9, 1.5) 
16.9  
(0.4, 713) 
 
 
  
   
   
  
   
  
 
   p <0.05 0              
    p >=0.05, <0.50 6 0.1 
1.2  
(1.0 , 1.4) Ref 2 0.5 
1.2  
(0.8, 1.8) Ref 1 --- 
1.2  
(0.9, 1.7) na 
    p >=0.50  16 0.05 
1.1  
(0.9, 1.2) 
0.9 
 (0.7, 1.2) 10 0.3 
0.9  
(0.8, 1.1) 
0.8  
(0.5, 1.2) 8 0.2 
1.2  
(1.0 , 1.6)  
     p< 0.50  6 0.1 
1.2  
(1.0 , 1.4) Ref 2 0.5 
1.2  
(0.8, 1.8) Ref 1 --- 
1.2  
(0.9, 1.7) na 
     p>=0.50 16 0.05 
1.1  
(0.9, 1.2) 
0.9  
(0.7, 1.2) 10 0.3 
0.9  
(0.8, 1.1) 
0.8  
(0.5, 1.2) 8 0.2 
1.2  
(1.0 , 1.6)  
  
  
   
  
   
  
   
     p< 0.10  1 --- 
0.9  
(0.6, 1.3) na 0    0    
     p>=0.10 21 0.02 
1.1  
(1.0 , 1.2)  12    9    
Age                         
 
Age non-missing 20 0.01 
1.1 
 (1.0 , 1.2) 
1.0  
(1.0 , 1.0) 10 0.3 
1.0  
(0.9, 1.1) 
1.0  
(1.0 , 1.0) 9 0.3 
1.2  
(1.0 , 1.5) 
1.0  
(1.0 , 1.1) 
 
 
  
   
   
  
   
  
 <= 47.9y 9 1 --- 
0.8  
(0.4, 1.6) na 5 0.3 
0.9 
 (0.7, 1.1) Ref 0   na 
 > 47.9 y 19 0.01 
1.1  
(1.0 , 1.2)  5 0.4 
1.1  
(0.9, 1.3) 
1.2  
(0.9, 1.7) 9 0.3 
1.2 
 (1.0 , 1.5)  
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Table V.A.5.  XRCC1 Arg399Gln and Smoking: Overall and by study characteristics   (continued) 
 
Ever-never 1 Current-Not current 2 
 PY 3,4 
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5 N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic                       
Age (continued)                         
 <=59y 10 8 0.1 
1.1  
(0.9, 1.3) Ref 8 0.6 
0.9 
 (0.7, 1.1) na 3 0.1 
1.1 
 (0.8, 1.6) Ref 
 >59, <=63y 7 0.02 
1.0  
(0.8, 1.3) 
0.9  
(0.7, 1.2) 1 --- 
0.9  
(0.6, 1.3)  5 0.4 
1.3  
(1.1, 1.6) 
1.3 
 (0.8, 2.1) 
 >63y  5 0.5 
1.2  
(1.0 , 1.4) 
1.1  
(0.8, 1.5) 1 --- 
1.2  
(1.0 , 1.5)  1 --- 
0.8  
(0.2, 2.6) 
0.7  
(0.2, 2.7) 
  
  
   
  
   
  
   
 <=59y 11 8 0.1 
1.1  
(0.9, 1.3) Ref 8 0.6 
0.9  
(0.7, 1.1) Ref 3 0.1 
1.1  
(0.8, 1.6) Ref 
 >59y 12 0.02 
1.1  
(0.9, 1.3) 
1.0  
(0.8, 1.3) 2 0.2 
1.1 
(0.9, 1.4) 
1.3 
 (1.0 , 1.7) 6 0.4 
1.3  
(1.0 , 1.6) 
1.2  
(0.8, 1.8) 
  
  
   
  
   
  
   
 At or below median  12 0.1 
1 
 (0.9, 1.2) Ref 5 0.3 
0.9  
(0.7, 1.1) Ref 5 0.4 
1.2 
 (1.0 , 1.5) Ref 
 Above median 8 0.02 
1.2  
(0.9, 1.4) 1.1 (0.9, 1.4) 5 0.4 
1.1  
(0.9, 1.3) 
1.2  
(0.9, 1.7) 4 0.2 
1.3 
 (1.0 , 1.8) 
1.1  
(0.7, 1.6) 
Gender                         
 
Percent male 
(continuous) 21   
1.1  
(0.7, 1.5) 10 0.3 
1.0  
(0.9, 1.1) 
0.7 
 (0.5, 0.9) 9 0.3 
1.2  
(1.0 , 1.5) 
1.3 
 (0.6, 2.8) 
 
Percent male (mixed 
gender only) 13 0.1 
1.0  
(0.9, 1.2) 
1.4  
(0.6, 3.5) 4 0.7 
1.0  
(0.8, 1.3) 
0.9  
(0.1, 8) 6 0.1 
1.3 
 (1.0 , 1.5) 
1 
 (0.1, 
11.4) 
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Table V.A.5.  XRCC1 Arg399Gln and Smoking: Overall and by study characteristics   (continued) 
 
Ever-never 1 Current-Not current 2 
 PY 3,4 
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5 N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic                       
Gender (continued)                         
 
100% female 
participants 5 0.01 
1.1 
 (0.8, 1.4) Ref 2 0.3 
1.2 
 (0.9, 1.5) Ref 1 -- 
0.9  
(0.4, 1.8) Ref 
 
<= 69% male 
participants 12 7 0.1 
1.0  
(0.8, 1.3) 
1.0  
(0.7, 1.3) 2 0.7 
1.0  
(0.8, 1.4) 
0.9 
 (0.6, 1.3) 3 0.1 
1.1 
 (0.8, 1.5) 
1.1 
 (0.5, 2.8) 
 
> 69% male 
participants 6 0.3 
1.1 
 (0.9, 1.3) 
1.0  
(0.7, 1.4) 2 0.2 
1.0  
(0.7, 1.4) 
0.8 
 (0.5, 1.3) 3 0.2 
1.4  
(1.1, 1.8) 
1.5 
 (0.6, 3.8) 
 100% male 3 0.7 
1.2  
(0.9, 1.6) 
1.1  
(0.7, 1.7) 4 0.7 
0.7  
(0.6, 1.0) 
0.6 
 (0.4, 0.9) 2 0.7 
1.3 
 (0.8, 2.2) 
1.5 
 (0.5, 4) 
  
  
   
  
   
  
   
 All female 5 0.01 
1.1  
(0.8, 1.4) Ref 2 0.3 
1.2  
(0.9, 1.5) Ref 1 -- 
0.9 
 (0.4, 1.8) Ref 
 Mixed gender 13 0.1 
1.0  
(0.9, 1.2) 
1.0  
(0.7, 1.3) 4 0.7 
1.0  
(0.8, 1.3) 
0.9  
(0.6, 1.2) 6 0.1 
1.3 
 (1.0 , 1.5) 
1.4 
 (0.7, 2.9) 
 All male 3 0.7 
1.2  
(0.9, 1.6) 
1.1  
(0.7, 1.7) 4 0.7 
0.7  
(0.6, 1.0) 
0.6 
 (0.4, 0.9) 2 0.7 
1.3 
 (0.8, 2.2) 
1.5  
(0.6, 3.6) 
Study outcome                         
 Lung cancer 6 0.4 
1.0  
(0.9, 1.1) Ref 1 --- 
0.9  
(0.6, 1.3) Ref 6 0.2 
1.3 
 (1.1, 1.6) Ref 
 Other cancer 12 0.02 
1.2  
(1.0 , 1.4) 
1.2 
 (1.0 , 1.6) 3 0.3 
1.1  
(0.9, 1.3) 
1.2 
 (0.8, 2) 3 0.7 
1.0  
(0.7, 1.5) 
0.8 
 (0.5, 1.2) 
 Non-cancer disease 0    1 --- 
1.6 
 (0.6, 3.7) 
1.8 
 (0.7, 4.7) 0    
 Non-disease 3 0.7 
1.0  
(0.8, 1.4) 
1.1 
 (0.7, 1.6) 6 0.6 
0.8  
(0.6, 1.1) 
0.9  
(0.6, 1.5) 0    
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Table V.A.5.  XRCC1 Arg399Gln and Smoking: Overall and by study characteristics   (continued) 
 
Ever-never 1 Current-Not current 2 
 PY 3,4 
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5 N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic                  
Study Outcome (continued)                 
 Cancer 18 0.01 
1.1 
 (0.9, 1.2) Ref 4 0.3 
1.1 
 (0.9, 1.2) Ref 9 0.3 
1.2 
 (1.0 , 1.5) Ref 
 Non-cancer disease 0    1 --- 
1.6  
(0.6, 3.7) 
1.5  
(0.6, 3.7) 0    
 Non-disease 3 0.7 
1.0  
(0.8, 1.4) 
0.9 
 (0.6, 1.4) 6 0.6 
0.8  
(0.6, 1.1) 
0.8 
 (0.6, 1.1) 0    
  
  
   
  
   
  
   
 Lung cancer 6 0.4 
1.0  
(0.9, 1.1) Ref 1 --- 
0.9 
 (0.6, 1.3) na 6 0.2 
1.3  
(1.1, 1.6) Ref 
 All other 15 0.04 
1.2  
(1.0 , 1.3) 
1.2  
(1.0 , 1.5) 10 0.3 
1 
 (0.9, 1.2)  3 0.7 
1 
 (0.7, 1.5) 
0.8  
(0.5, 1.2) 
MAF 2                         
MAF (cutpoints assigned by tertiles across SNP)           
 0.10-0.27 6 0.1 
1.1 
 (0.7, 1.5) Ref 4 0.1 
1.1 
 (0.9, 1.4) Ref 2 0.6 
1.9  
(1.2, 2.9) Ref 
 >0.27-0.36 10 0.01 
1.1 
 (1.0 , 1.3) 
1.1 
 (0.8, 1.5) 4 0.4 
0.9  
(0.6, 1.4) 
0.8  
(0.5, 1.4) 7 0.5 
1.1 
 (0.9, 1.4) 
0.6 
 (0.4, 1.0) 
 >0.36-0.50 6 0.9 
1 
 (0.8, 1.2) 
1 
 (0.7, 1.4) 4 0.7 
0.8 
 (0.7, 1.1) 
0.8 
 (0.5, 1.1) 0    
MAF (cutpoints proxy for ethnicity)            
 10%-20% 3 0.1 
1 
 (0.5, 1.8) Ref 1 --- 
2.1  
(1.1, 3.9) Ref 0    
 >20%-27% 3 0.1 
1.1 
 (0.7, 1.9) 
1.1 
 (0.6, 1.9) 4 0.7 
1.0  
(0.8, 1.3) 
0.5 
 (0.2, 0.9) 2 0.6 
1.9 
 (1.2, 2.9) Ref 
 >27%-50% 16 0.04 
1.1  
(1.0 , 1.2) 
1.1  
(0.7, 1.7) 7 0.6 
0.9  
(0.7, 1.1) 
0.4  
(0.2, 0.8) 7 0.5 
1.1 
 (0.9, 1.4) 
0.6 
 (0.4, 1.0) 
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Table V.A.5.  XRCC1 Arg399Gln and Smoking: Overall and by study characteristics   (continued) 
 
Ever-never 1 Current-Not current 2 
 PY 3,4 
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5 N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic                  
MAF 2  (continued) 
                
MAF-assigned ethnicity            
    White  15 0.3 
1.1 
 (0.9, 1.2) Ref 6 0.5 
0.9 
 (0.7, 1.1) Ref 7 0.5 
1.1 
 (0.9, 1.4) Ref 
    African American 13 3 0.1 
1 
 (0.5, 1.8) 
0.9 
 (0.6, 1.5) 1  
2.1  
(1.1, 3.9) 
2.4 
 (1.2, 4.7) 0    
    Han 3 0.1 
1.1  
(0.7, 1.9) 
1.0  
(0.7, 1.5) 4 0.7 
1.0  
0.8, 1.3) 
1.1 
 (0.8, 1.6) 2 0.6 
1.9  
(1.2, 2.9) 
1.6  
(1.0 , 2.6) 
    Multi-ethnic studies 2 0.01 
1.2  
(0.7, 2.1) 
1.2  
(0.8, 1.7) 1 -- 
0.9  
0.2, 3.4) 
1 
 (0.3, 4.1) 0    
Smoking prevalence 14                         
 
Continuous 21 0.01  
1.7 
 (0.6, 4.7) 11 0.4 
1.0  
(0.9, 1.1) 
0.2 
 (0.1, 0.7) 9 0.3 
1.2 
 (1.0 , 1.5) 
0.7 
 (0.2, 2.6) 
    
   
   
  
   
  
 0-0.365 2 0.9 
0.7  
(0.5, 1.1) Ref 7 0.6 
1.1  
(0.9, 1.2) Ref 5 0.3 
1.4  
(1.1, 1.8) Ref 
 >0.365-507 3 0.3 
1.1 
 (0.9, 1.3) 
1.5 
 (0.9, 2.4) 2 0.3 
0.6  
(0.3, 1.3) 
0.6 
 (0.3, 1.3) 1 --- 
1.2  
(0.9, 1.7) 
0.9 
 (0.6, 1.3) 
 >0.507-0.602 7 0.02 
1.2  
(0.9, 1.5) 
1.6  
(1.0 , 2.6) 1 --- 
0.7 
 (0.5, 1.1) 
0.7 
 (0.5, 1.1) 3 0.3 
0.9 
 (0.6, 1.4) 
0.7 
 (0.4, 1.1) 
 >0.602-1 9 0.3 
1 
 (0.9, 1.2) 
1.4 
 (0.9, 2.3) 1 --- 
0.9 
 (0.2, 3.4) 
0.8 
 (0.2, 3.3) 0    
  
  
   
  
   
  
   
 >0-0.507 5 0.2 
1 
 (0.8, 1.2) Ref 9 0.5 
1.0  
(0.9, 1.2) Ref 6 0.4 
1.3  
(1.1, 1.6) Ref 
 >0.507-1 16 0.01 
1.1 
 (1.0 , 1.3) 
1.1 
 (0.9, 1.5) 2 0.8 
0.7  
(0.5, 1.1) 
0.7 
 (0.5, 1.1) 3 0.3 
0.9 
 (0.6, 1.4) 
0.7 
 (0.4, 1.1) 
Abbreviations: CI=Confidence interval, na=not applicable, HWE = Hardy Weinberg equilibrium PY=pack-years, ORz=control-only genotype-smoking odds 
ratio (bolded), N=number of studies, Ref=referent, Q=Cochran’s test of homogeneity, SNP=single nucleotide polymorphism, MAF=minor allele frequency, 
Arg=Arginine, Gln=Glutamine, Trp=Tryptophan, His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine 
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Table V.A.5.  XRCC1 Arg399Gln and Smoking: Overall and by study characteristics   (continued) 
1 OR=Unadjusted odds ratio for XRCC1 Arg399Gln: XRCC1 Arg/Arg (ref) vs. any Gln, never smoking (ref) vs. ever smoking, random effects estimates  
2 OR=Unadjusted odds ratio for XRCC1 Arg399Gln: XRCC1 Arg/Arg (ref) vs. any Gln, not current smoker (ref) vs. current smoker, fixed effects estimates 
3 OR=Unadjusted odds ratio for XRCC1 Arg399Gln: XRCC1 Arg/Arg (ref) vs. any Gln, lightest smokers (ref) vs. heaviest smokers [lightest excludes never 
smokers], fixed effects 
4
 PY contrast is between lightest non-zero category of pack-years (ref) vs. heaviest category of PY 
5
 Ratio of Odds Ratios: Compares odds ratio in given study characteristic stratum to the odds ratio in the designated reference stratum for that study 
characteristic by meta-regression 
6
 Studies that can be stratified by ethnicity are included as separate single-ethnicity studies; studies w 99%-100% of 1 ethnicity are classified as single-
ethnicity 
7
 Only includes studies with explicitly stated ethnic makeup 
8
 White = Caucasian, white or non-Hispanic white; African American = African American or black;  
        Han = Han, Han Chinese or ethnic Chinese; Japan, Korea and China may include ethnic minorities.
 
9
 Median of studies included in XRCC1 399 current/not current smoker analyses. 
10
 Categories based on thirds from studies included in XRCC1 399 PY analyses (<=59y, >59y-63y, >63y) 
11
 Median of all studies w age info  (all SNPs) w age info [range:23.6-69y, mean: 56.51y SD: 9.84y] 
12
 Median proportion male in all studies (all SNPs, all smoking exposures): 0.69 
13
 For 399 ever-never 1 study from Hungary is included using MAF as proxy for ethnicity 
14
 Smoking prevalence is contrast-specific (defined as "ever", "current" or "heavier PY" as appropriate)  
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Table V.A.6.  XPD Lys751Gln and Smoking: Overall and by study characteristics   
 
Ever-never 1 Current-Not current 2  PY 3,4  
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% 
CI) 5  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
Overall  
  12 0.5 
0.9  
(0.8, 1.1)   6 0.2 
1.1  
(0.9, 1.3)  7 0.019 
1.2  
(1.0, 1.5)  
By Study Characteristic             
Continent                         
 North America 4 0.4 
0.9  
(0.8, 1) Ref 1 --- 
0.9  
(0.7, 1.3) Ref 3 0.006 
1.5  
(0.7, 3.2) Ref 
 Europe 6 0.3 
1.0  
(0.8, 1.3) 
1.2  
(0.9, 1.5) 5 0.2 
1.2  
(0.9, 1.5) 
1.2  
(0.8, 1.8) 3 0.503 
1.0  
(0.7, 1.4) 
0.7  
(0.3, 1.5) 
 Asia 2 0.5 
1.0  
(0.6, 1.7) 
1.1  
(0.7, 1.9) 0    1 na 
0.8  
(0.3, 1.7) 
0.5  
(0.1, 1.9) 
Ethnicity/nationality                         
 
Single-ethnicity 
studies 6 6 0.3 
1.0  
(0.8, 1.2) Ref 1 --- 
1.2  
(0.8, 1.8) na 5 0.097 
1.4  
(0.9, 2.1) na 
 
Multi-ethnic  
studies 7 2 0.6 
0.8  
(0.7, 1.0) 
0.8  
(0.6, 1.1) 1 --- 
0.9  
(0.7, 1.3)  1 --- 
0.8  
(0.5, 1.3)  
 Unknown ethnicity 4 0.7 
1.0  
(0.8, 1.3) 
1.1  
(0.8, 1.4) 4 0.1 
1.1  
(0.8, 1.5)  1 --- 
0.8  
(0.4, 1.4)  
  
  
    
  
   
  
   
 White >=99% 8 4 0.2 
1.0  
(0.8, 1.2) Ref 1 --- 
1.2  
(0.8, 1.8) na 4 0.181 
1.6  
(1.0, 2.4) na 
 
African American 
>=99% 0   
1.0  
(0.6, 1.8) 0    0    
 Han >=99% 2 0.5 
1.0  
(0.6, 1.7) 
0.8  
(0.6, 1.1) 0    1 --- 
0.8  
(0.3, 1.7)  
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Table V.A.6.  XPD Lys751Gln and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4  
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic  
HWE p-value                          
 
Continuous (single 
ethnicity)  6 0.3 
1.0  
(0.8, 1.2) 
0.8  
(0.5, 1.2) 1 --- 
1.2  
(0.8, 1.8) na 5 0.097 
1.4  
(0.9, 2.1) 
2.2  
(0, 93.7) 
 
 
  
    
   
  
  
   
 HWE p <0.05 1 --- 
1.1  
(0.8, 1.7) Ref 2 0.6 
1.3  
(0.9, 1.8) Ref 0   na 
 
HWE p >=0.05, 
<0.50 4 0.6 
1.1  
(0.8, 1.4) 
1.0  
(0.6, 1.6) 1 --- 
0.7  
(0.5, 1.2) 
0.6  
(0.3, 1.2) 1 --- 
0.8  
(0.4, 1.4)  
 HWE p >=0.50  7 0.4 
0.9  
(0.8, 1.0) 
0.8  
(0.5, 1.2) 3 0.2 
1.1  
(0.9, 1.4) 
0.9  
(0.5, 1.5) 6 0.022 
1.2  
(0.8, 1.9)  
  
  
    
  
   
  
   
 HWE p <0.50 5 0.8 
1.1  
(0.9, 1.4) Ref 3 0.2 
1.0  
(0.8, 1.4) Ref 1 --- 
0.8  
(0.4, 1.4) Ref 
 HWE p >=0.50  7 0.4 
0.9  
(0.8, 1.0) 
0.8  
(0.6, 1.0) 3 0.2 
1.1  
(0.9, 1.4) 
1.1  
(0.7, 1.9) 6 0.022 
1.2  
(0.8, 1.9) 
1.6  
(0.5, 4.4) 
  
  
    
  
   
  
   
 HWE p <0.10 2 0.9 
1.1  
(0.8, 1.5) Ref 2 0.6 
1.3  
(0.9, 1.8) Ref 1 --- 
0.8  
(0.4, 1.4) na 
 HWE p >=0.10  10 0.4 
0.9  
(0.8, 1.0) 
0.8  
(0.6, 1.1) 4 0.1 
1.0  
(0.8, 1.3) 
0.8  
(0.5, 1.2) 6 0.022 
1.2  
(0.8, 1.9) 
 
 
Age                         
 
Age non-missing 
(continuous) 12 0.5 
0.9  
(0.8, 1.1) 
1.0  
(1.0, 1.0) 6 0.2 
1.1  
(0.9, 1.3) 
1.0  
(1.0, 1.0) 7 0.019 
1.1  
(0.8, 1.7) 
1.0  
(0.9, 1.1) 
 
 
   
   
   
  
   
  
 <= 47.9y 9 0   na 3 0.5 
1.4  
(1.0, 1.9) Ref 0   na 
 > 47.9 y 12 0.5 
0.9  
(0.8, 1.1) 
0  
(0, 0) 3 0.4 
0.9  
(0.7, 1.2) 
0.7  
(0.5, 1.0) 7 0.019 
1.1  
(0.8, 1.7)  
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Table V.A.6.  XPD Lys751Gln and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4  
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic  
Age (continued)                         
 <=59y 10 7 0.6 
0.9  
(0.8, 1.0) Ref 6 0.2 
1.1  
(0.9, 1.3) na 4 0.054 
1.4  
(0.8, 2.4) Ref 
 >59, <=63y 4 0.2 
1.0  
(0.8, 1.2) 
1.1  
(0.8, 1.4) 0    3 0.362 
0.9  
(0.6, 1.2) 
0.6  
(0.3, 1.2) 
 >63y  1 --- 
1.4  
(0.8, 2.6) 
1.5  
(0.8, 2.9) 0    0    
  
  
    
  
   
  
   
 <=59y 11 7 0.6 
0.9  
(0.8, 1.0) Ref 6 0.2 
1.1  
(0.9, 1.3) na 4 0.054 
1.4  
(0.8, 2.4) Ref 
 >59y 5 0.2 
1.0  
(0.8, 1.2) 
1.1  
(0.9, 1.4) 0    3 0.362 
0.9  
(0.6, 1.2) 
0.6  
(0.3, 1.2) 
  
  
    
  
   
  
   
 At or below median  6 0.5 
0.9  
(0.8, 1.1) Ref 3 0.5 
1.4  
(1.0, 1.9) Ref 4 0.054 
1.4  
(0.8, 2.4) Ref 
 Above median 6 0.3 
1.0  
(0.8, 1.1) 
1.1  
(0.9, 1.4) 3 0.4 
0.9  
(0.7, 1.2) 
0.7  
(0.5, 1.0) 3 0.362 
0.9  
(0.6, 1.2) 
0.6  
(0.3, 1.2) 
Gender                         
 
Percent male 
(continuous) 12 0.5 
0.9  
(0.8, 1.1) 
1.0  
(0.7, 1.4) 6 0.2 
1.1  
(0.9, 1.3) 
1.1  
(0.7, 2) 7  
0  
(0, 0) 
0.8  
(0.2, 3.4) 
 
Percent male, mixed 
gender only 8 0.9 
1.0  
(0.9, 1.2) 
0.8  
(0.3, 2.4) 2 0.3 
1.5  
(1.0, 2.3) na 5 0.006 
1.2  
(0.7, 2) 
0  
(0, 0.1) 
 
 
   
   
  
   
  
   
 
100% female 
participants 2 0.1 
0.9  
(0.7, 1.1) Ref 1 --- 
0.9  
(0.7, 1.3) na 1 --- 
0.9  
(0.4, 1.9) Ref 
 
<= 69% male 
participants 12 5 0.7 
1.0  
(0.9, 1.2) 
1.2  
(0.9, 1.5) 1 --- 
1.3  
(0.7, 2.2)  3 0.024 
1.5  
(0.7, 3.1) 
1.7  
(0.5, 5.6) 
 
> 69% male 
participants 3 0.7 
0.9  
(0.7, 1.3) 
1.1  
(0.7, 1.5) 1 --- 
1.9  
(1.0, 3.8)  2 0.970 
0.8  
(0.5, 1.2) 
0.8  
(0.2, 2.9) 
 100% male 2 0.2 
0.7  
(0.5, 1.1) 
0.8  
(0.5, 1.3) 3 0.2 
1.0  
(0.8, 1.4)  1 --- 
1.3  
(0.7, 2.5) 
1.4  
(0.3, 6.1) 
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Table V.A.6.  XPD Lys751Gln and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4  
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic  
Gender (continued)                         
 All female 2 0.1 
0.9  
(0.7, 1.1) Ref 1 --- 
0.9  
(0.7, 1.3) Ref 1 na 
0.9  
(0.4, 1.9) na 
 Mixed gender 8 0.9 
1.0  
(0.9, 1.2) 
1.1  
(0.9, 1.5) 2 0.3 
1.5  
(1.0, 2.3) 
1.6  
(0.9, 2.7) 5 0.006 
1.2  
(0.7, 2)  
 All male 2 0.2 
0.7  
(0.5, 1.1) 
0.8  
(0.5, 1.3) 3 0.2 
1.0  
(0.8, 1.4) 
1.1  
(0.7, 1.7) 1 na 
1.3  
(0.7, 2.5)  
Study outcome                         
 Lung cancer 3 0.5 
1.0  
(0.8, 1.2) Ref 0    3 0.080 
1.6  
(0.8, 3.1) Ref 
 Other cancer 8 0.2 
0.9  
(0.8, 1.1) 
0.9  
(0.7, 1.2) 2 0.4 
0.9  
(0.7, 1.2) Ref 4 0.565 
0.9  
(0.7, 1.2) 
0.5  
(0.3, 0.9) 
 Non-cancer disease 0     0    0    
 Non-disease 1 --- 
1.0  
(0.6, 1.6) 
1.0  
(0.6, 1.7) 4 0.7 
1.3  
(1.0, 1.8) 
1.5  
(1.0, 2.2) 0    
  
  
    
  
   
  
   
 Cancer 11 0.4 
0.9  
(0.8, 1.1) na 2 0.4 
0.9  
(0.7, 1.2) Ref 7 0.019 
1.1  
(0.8, 1.7) na 
 Non-cancer disease 0     0    0    
 Non-disease 1 na 
1.0  
(0.6, 1.6)  4 0.7 
1.3  
(1.0, 1.8) 
1.5  
(1.0, 2.2) 0    
  
  
    
  
   
  
   
 Lung cancer 3 0.5 
1.0  
(0.8, 1.2) Ref 0   na 3 0.080 
1.6  
(0.8, 3.1) Ref 
 All other 9 0.3 
0.9  
(0.8, 1.1) 
0.9  
(0.7, 1.2) 6 0.2 
1.1  
(0.9, 1.3)  4 0.565 
0.9  
(0.7, 1.2) 
0.5  
(0.3, 0.9) 
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Table V.A.6.  XPD Lys751Gln and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4  
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% 
CI) 5  N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic  
MAF                          
 
MAF non-missing 12 0.5 
0.9  
(0.8, 1.1) 
1.3  
(0.3, 6.2) 6 0.2 
1.1  
(0.9, 1.3) 
0  
(0, 
3772.6) 7   
1.2  
(0, 45.7) 
MAF (cutpoints assigned by median across SNP)  
 0.01-0.37 7 0.5 
0.9  
(0.8, 1.0) Ref 2 0.3 
1.0  
(0.7, 1.3) Ref 5 0.016 
1.3  
(0.8, 2.1) Ref 
 >0.37-0.50 5 0.7 
1.1  
(0.9, 1.4) 
1.2  
(1.0, 1.6) 4 0.2 
1.1  
(0.9, 1.5) 
1.1  
(0.7, 1.8) 2 0.768 
0.8  
(0.5, 1.3) 
0.7  
(0.3, 1.5) 
MAF (cutpoints proxy for ethnicity)  
 1%-15% 2 0.5 
1.0  
(0.6, 1.7) Ref 0   na 1 --- 
0.8  
(0.3, 1.7) na 
 >15%-50% 10 0.3 
0.9  
(0.8, 1.0) 
0.9  
(0.6, 1.6) 6 0.2 
1.1  
(0.9, 1.3)  6 0.015 
1.2  
(0.8, 1.8)  
MAF-assigned ethnicity 
    White  8 0.4 
1.0  
(0.9, 1.2) Ref 5 0.2 
1.2  
(0.9, 1.5) na 5 0.052 
1.3  
(0.9, 2.1) na 
    African American  0     0    0    
    Han 2 0.5 
1.0  
(0.6, 1.7) 
1.0  
(0.6, 1.7) 0   na 1 --- 
0.8  
(0.3, 1.7) na 
 
   Multi-ethnic 
studies 2 0.6 
0.8  
(0.7, 1.0) 
0.8  
(0.6, 1.0) 1 --- 
0.9  
(0.7, 1.3)  1 --- 
0.8  
(0.5, 1.3)  
Smoking prevalence 13                         
 
Continuous 12 0.5 
0.9  
(0.8, 1.1) 
0.3  
(0.1, 1.1) 6 0.2 
1.1  
(0.9, 1.3) 
2  
(0.5, 8.6) 7   
0.3  
(0, 7.8) 
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Table V.A.6.  XPD Lys751Gln and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4  
  N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% 
CI) 5  N 
Q  
p-value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) N 
Q  
p-
value 
ORz 
(95% CI) 
Ratio of 
ORs 
( 95% CI) 
By Study Characteristic  
Smoking prevalence (continued) 13                 
 0-0.365 1 --- 
1.3  
(0.8, 1.9) Ref 4 0.1 
1.0  
(0.8, 1.3) Ref 2 0.009 
1.3  
(0.5, 3.6) Ref 
 >0.365-507 2 0.7 
1.2  
(0.8, 1.7) 
0.9  
(0.5, 1.6) 1 --- 
1.6  
(0.6, 4.2) 
1.5  
(0.5, 4.6) 3 0.918 
0.8  
(0.5, 1.1) 
0.6  
(0.3, 1.3) 
 >0.507-0.602 6 0.5 
0.9  
(0.8, 1.1) 
0.7  
(0.5, 1.1) 1 --- 
1.2  
(0.8, 1.8) 
1.1  
(0.6, 2.2) 2 0.359 
1.5  
(0.9, 2.6) 
1.2  
(0.5, 2.9) 
 >0.602-1 3 0.3 
0.9  
(0.7, 1.1) 
0.7  
(0.4, 1.1) 0    0    
  
  
    
  
   
  
   
 >0-0.507 3 0.9 
1.2  
(0.9, 1.6) Ref 5 0.2 
1.0  
(0.8, 1.3) na 5 0.010 
1.0  
(0.6, 1.6) Ref 
  >0.507-1 9 0.5 
0.9  
(0.8, 1.0) 
0.7  
(0.5, 1.0) 1 --- 
1.2  
(0.8, 1.8)  2 0.359 
1.5  
(0.9, 2.6) 
1.6  
(0.7, 3.9) 
Abbreviations: CI=Confidence interval, na=not applicable, HWE = Hardy Weinberg equilibrium, PY=pack-years, ORz=control-only genotype-smoking odds 
ratio, ), N=number of studies, Ref=referent, Q=Cochran’s test of homogeneity, SNP=single nucleotide polymorphism, Arg=Arginine, Gln=Glutamine, 
Trp=Tryptophan, His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine 
1
 OR=Unadjusted odds ratio for XPD Lys751Gln:  Lys/Lys (ref) vs. any Gln, never smoking (ref) vs. ever smoking, fixed effects 
2 OR=Unadjusted odds ratio for XPD Lys751Gln: Lys/Lys (ref) vs. any Gln, not current smoker (ref) vs. current smoker, fixed effects 
3 OR=Unadjusted odds ratio for XPD Lys751Gln: Lys/Lys (ref) vs. any Gln, lightest non-zero smokers (ref) vs. heaviest smokers; stratified random effects 
4 PY contrast is between lightest non-zero category of pack-years (ref) vs. heaviest category of PY 
5
 Ratio of Odds Ratios: Compares OR in given study characteristic stratum to the OR in the designated reference stratum for that study characteristic by meta-
regression 
6
 Studies w 99%-100% of 1 ethnicity are classified as single-ethnicity 
7
 Only includes studies with explicitly stated ethnic makeup 
8
 White = Caucasian, white or non-Hispanic white; African American = African American or black; Han = Han, Han Chinese or ethnic Chinese 
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Table V.A.6.  XPD Lys751Gln and Smoking: Overall and by study characteristics  (continued) 
9 Median of studies included in XRCC1 751 current/not current smoker analyses. 
10
 Categories based on thirds from studies included in XRCC1 399 PY analyses (<=59y, >59y-63y, >63y) 
11 Median of all studies w age info  (all SNPs) w age info [range:23.6-69y, mean: 56.7y SD: 9.8y] 
12 Median proportion male in all studies (all SNPs, all smoking exposures): 0.69 
13 Smoking prevalence is contrast-specific (defined as "ever", "current" or "heavier PY" as appropriate)  
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Table V.A.7.  XRCC3 Thr241Met and Smoking: Overall and by study characteristics   
 
Ever-never 1 Current-Not current 2  PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  
Overall                         
  9 0.5 
1.0 
(0.9, 1.2)   7 0.7 
0.9  
(0.8, 1.1)   4 0.7 
0.8  
(0.6, 1.2)  
By Study Characteristic             
Continent                         
 North America 2 0.1 
0.9  
(0.6, 1.3) Ref 1 --- 
0.8  
(0.5, 1.2) na 2 0.3 
0.7  
(0.4, 1.3) Ref 
 Europe 7 0.7 
1.1  
(0.9, 1.3) 
1.1  
(0.8, 1.7) 5 0.9 
0.9  
(0.7, 1.1)   2 0.6 
0.9  
(0.6, 1.4) 
1.2  
(0.6, 2.5) 
 Asia 0     1 --- 
2.0  
(0.6, 6.6)   0    
Ethnicity/nationality                 
 
Single-
ethnicity 
studies 6 3 0.7 
0.8  
(0.6, 1.1) Ref 3 0.3 
0.8  
(0.6, 1.1) Ref 2 0.9 
1.0 
(0.6, 1.7) na 
 
Multi-ethnic 
studies 7 2 0.2 
1.0 
(0.7, 1.3) 
1.2  
(0.8, 1.9) 1 --- 
1.0 
(0.7, 1.5) 
1.2  
(0.7, 2) 1 --- 
0.6  
(0.3, 1.2)  
 
Unknown 
ethnicity 4 0.9 
1.2  
(1.0, 1.5) 
1.5  
(1.0, 2.2) 3 0.7 
0.9  
(0.7, 1.3) 
1.1  
(0.7, 1.7) 1 --- 
0.8  
(0.4, 1.4)  
  
  
    
 
    
 
   
 
White  
>=99% 8 3 0.7 
0.8  
(0.6, 1.1) Ref 2 0.9 
0.8  
(0.6, 1.1) Ref 2 0.9 
1.0 
(0.6, 1.7) na 
 
African 
American 
>=99% 0     0     0    
 Han >=99% 0     1 --- 
2.0  
(0.6, 6.6)   0    
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Table V.A.7.  XRCC3 Thr241Met and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  
By Study Characteristic             
HWE p-value                         
 
Continuous 
(single 
ethnicity)  3 0.7 
0.8  
(0.6, 1.1) 
1.0 
(0.3, 3.4) 3 0.3 
0.8  
(0.6, 1.1) 
0.4  
(0.1, 1.6) 2 0.9 
1.0 
(0.6, 1.7)  
 
 
  
    
 
    
 
   
 HWE p <0.05 0     1 --- 
2.0  
(0.6, 6.6) na 0   na 
 
HWE p 
>=0.05, <0.50 2 0.3 
1.1  
(0.8, 1.6) Ref 0     2 0.6 
0.9  
(0.6, 1.4)  
 HWE p >=0.50  7 0.4 
1.0 
(0.8, 1.2) 
0.9  
(0.6, 1.4) 6 0.9 
0.9  
(0.7, 1.1)   2 0.3 
0.7  
(0.4, 1.3)  
  
  
    
 
    
 
   
 HWE p <0.50 2 0.3 
1.1  
(0.8, 1.6) Ref 1 --- 
2.0  
(0.6, 6.6) na 2 0.6 
0.9  
(0.6, 1.4) na 
 HWE p >=0.50  7 0.4 
1.0 
(0.8, 1.2) 
0.9  
(0.6, 1.4) 6 0.9 
0.9  
(0.7, 1.1)   2 0.3 
0.7  
(0.4, 1.3)  
  
  
    
 
    
 
   
 HWE p <0.10 0   na 1 --- 
2.0  
(0.6, 6.6) na 0   na 
 HWE p >=0.10  9 0.5 
1.0 
(0.9, 1.2)   6 0.9 
0.9  
(0.7, 1.1)   4 0.7 
0.8  
(0.6, 1.2)  
Age                         
 
Age non-
missing 9 0.5 
1.0 
(0.9, 1.2) 
1.0 
(1.0, 1.0) 7 0.7 
0.9  
(0.8, 1.1) 
1.0 
(1.0, 1.0) 4 0.7 
0.8  
(0.6, 1.2) 
0.9  
(0.8, 1.1) 
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Table V.A.7.  XRCC3 Thr241Met and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  
By Study Characteristic             
Age                         
 <= 47.9y 9 1 ---  na 2 0.6 
0.8  
(0.6, 1.1) Ref 0   na 
 > 47.9 y 8 0.4 
1.0 
(0.9, 1.2)   5 0.6 
1.0 
(0.8, 1.2) 
1.2  
(0.8, 1.9) 4 0.7 
0.8  
(0.6, 1.2)  
  
  
    
 
    
 
   
 <=59y 10 5 0.3 
1.0 
(0.8, 1.2) Ref 6 0.9 
0.9  
(0.7, 1.1) na 1 --- 
1.1  
(0.4, 2.7) na 
 >59, <=63y 2 0.3 
1.1  
(0.8, 1.6) 
1.1  
(0.8, 1.7) 1 --- 
2.0  
(0.6, 6.6)   2 0.6 
0.9  
(0.6, 1.4)  
 >63y  2 0.5 
1.2  
(0.8, 1.7) 
1.2  
(0.8, 1.9) 0     1 --- 
0.6  
(0.3, 1.2)  
  
  
    
 
    
 
   
 <=59y 11 5 0.3 
1  
(0.8, 1.2) Ref 6 0.9 
0.9  
(0.7, 1.1) na 1 --- 
1.1  
(0.4, 2.7) na 
 >59y 4 0.7 
1.1  
(0.9, 1.5) 
1.2  
(0.8, 1.6) 1 --- 
2.0  
(0.6, 6.6)   3 0.5 
0.8  
(0.5, 1.1)  
  
  
    
 
    
 
   
 
At or below 
median  5 0.3 
1.0 
(0.8, 1.2) Ref 4 0.8 
0.8  
(0.7, 1.1) Ref 3 0.8 
0.9  
(0.6, 1.4) na 
 Above median 4 0.7 
1.1  
(0.9, 1.5) 
1.2  
(0.8, 1.6) 3 0.5 
1.0 
(0.8, 1.4) 
1.2  
(0.8, 1.8) 1 --- 
0.6  
(0.3, 1.2)  
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Table V.A.7.  XRCC3 Thr241Met and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  
By Study Characteristic             
Gender                         
 
Percent male 
(continuous) 9 0.5 
1.0 
(0.9, 1.2) 
1.0 
(0.4, 2.4) 7 0.7 
0.9  
(0.8, 1.1) 
0.6  
(0.3, 1.5) 4 0.7 
0.8  
(0.6, 1.2) 
1.1  
(0.1, 8.6) 
 
Percent male, 
mixed gender 
only 6 0.3 
1  
(0.9, 1.3) 
1.1  
(0.1, 12.6) 4 0.5 
1.0 
(0.8, 1.3) 
0.1  
(0, 3.4) 
 
   
 
 
   
   
  
   
  
  
 
100% female 
participants 0     0     0   na 
 
<= 69% male 
participants 12 4 0.1 
1.0 
(0.8, 1.2) Ref 4 0.5 
1.0 
(0.8, 1.3) Ref 2 0.6 
0.9  
(0.5, 1.4)  
 
> 69% male 
participants 2 0.5 
1.2  
(0.8, 1.9) 
1.2  
(0.7, 2) 0     1 --- 
0.6  
(0.3, 1.2)  
 100% male 3 0.8 
1.0 
(0.8, 1.4) 
1.0 
(0.7, 1.5) 3 0.8 
0.8  
(0.6, 1.1) 
0.9  
(0.6, 1.3) 1 --- 
1.0 
(0.5, 1.9)  
  
  
    
 
    
 
   
 All female 0     0     0    
 Mixed gender 6 0.3 
1.0 
(0.9, 1.3) Ref 4 0.5 
1.0 
(0.8, 1.3) Ref 3 0.6 
0.8  
(0.5, 1.1) na 
 All male 3 0.8 
1.0 
(0.8, 1.4) 
1.0 
(0.7, 1.4) 3 0.8 
0.8  
(0.6, 1.1) 
0.9  
(0.6, 1.3) 1 --- 
1.0 
(0.5, 1.9)  
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Table V.A.7.  XRCC3 Thr241Met and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  
By Study Characteristic             
Study outcome                         
 Lung cancer 0     0     1 --- 
1.1  
(0.4, 2.7) na 
 Other cancer 5 0.4 
1  
(0.8, 1.2) Ref 4 0.5 
1.0 
(0.7, 1.2) Ref 3 0.5 
0.8  
(0.5, 1.1)  
 
Non-cancer 
disease 0     0     0    
 Non-disease 4 0.7 
1.2  
(0.9, 1.6) 
1.2  
(0.8, 1.7) 3 0.7 
0.9  
(0.6, 1.2) 
0.9  
(0.6, 1.3) 0    
  
  
    
 
    
 
   
 Cancer 5 0.4 
1.0 
(0.8, 1.2) na 4 0.5 
1.0 
(0.7, 1.2) Ref 4 0.7 
0.8  
(0.6, 1.2) na 
 
Non-cancer 
disease 0     0     0    
 Non-disease 4 0.7 
1.2  
(0.9, 1.6)   3 0.7 
0.9  
(0.6, 1.2) 
0.9  
(0.6, 1.3) 0    
  
  
    
 
    
 
   
 Lung cancer 0     0   na 1 --- 
1.1  
(0.4, 2.7) na 
 All other 9 0.5 
1.0 
(0.9, 1.2) na 6 0.7 
0.9  
(0.8, 1.1)   3 0.5 
0.8  
(0.5, 1.1)  
MAF                          
 
MAF non-
missing 9 0.5 
1.0 
(0.9, 1.2) 
0.9  
(0, 235.8) 7 0.7 
0.9  
(0.8, 1.1) 
0.2  
(0, 4.6) 4 0.7 
0.8  
(0.6, 1.2) 
0  
(0, 45050) 
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Table V.A.7.  XRCC3 Thr241Met and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  
By Study Characteristic             
MAF (continued)  
    
    
    
    
MAF (cutpoints assigned by median across SNP) 
 0.01-0.37 5 0.3 
1.0 
(0.8, 1.3) Ref 2 0.1 
0.9  
(0.6, 1.4) Ref 4 0.7 
0.8  
(0.6, 1.2) na 
 >0.37-0.50 4 0.5 
1.0 
(0.8, 1.3) 
1.0 
(0.7, 1.4) 5 0.9 
0.9  
(0.7, 1.1) 
1.0 
(0.6, 1.7) 0    
MAF (cutpoints proxy for ethnicity) 
 1%-15% 0   Ref 1 --- 
2.0  
(0.6, 6.6) na 0   na 
 >15%-50% 9 0.5 
1.0 
(0.9, 1.2)   6 0.9 
0.9  
(0.7, 1.1)   4 0.7 
0.8  
(0.6, 1.2)  
MAF-assigned ethnicity 
    White  7 0.5 
1.1  
(0.9, 1.3) Ref 5 0.9 
0.9  
(0.7, 1.1) na 3 0.8 
0.9  
(0.6, 1.4) na 
 
   African 
American  0     0     0    
    Han 0     1 --- 
2.0  
(0.6, 6.6)   0    
 
   Multi-ethnic 
studies 2 0.2 
1.0 
(0.7, 1.3) 
0.9  
(0.7, 1.3) 1 --- 
1.0 
(0.7, 1.5)   1 --- 
0.6  
(0.3, 1.2)  
Smoking prevalence 13                 
 
Continuous 9 0.5 
1.0 
(0.9, 1.2) 
0.1  
(0, 1.8) 7 0.7 
0.9  
(0.8, 1.1) 
0.5  
(0.1, 3.1) 4 0.7 
0.8  
(0.6, 1.2) 
2.4  
(0.1, 56.6) 
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Table V.A.7.  XRCC3 Thr241Met and Smoking: Overall and by study characteristics  (continued) 
 
Ever-never 1 Current-Not current 2  PY 3,4 
  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of ORs 
( 95% CI) 5  N 
Q  
p-
value 
ORz  
(95% CI) 
Ratio of 
ORs 
( 95% CI) 5  
By Study Characteristic             
Smoking prevalence (continued) 13 
    
    
    
    
 0-0.365 0     4 0.8 
0.9  
(0.7, 1.2) Ref 1 --- 
0.8  
(0.4, 1.4) na 
 >0.365-507 0     2 0.1 
1.1  
(0.5, 2.3) 
1.1  
(0.5, 2.5) 1 --- 
0.6  
(0.3, 1.2)  
 >0.507-0.602 4 0.8 
1.2  
(0.9, 1.5) Ref 1 --- 
0.8  
(0.6, 1.2) 
0.9  
(0.6, 1.4) 2 0.9 
1.0 
(0.6, 1.7)  
 >0.602-1 5 0.4 
0.9  
(0.7, 1.1) 
0.8  
(0.6, 1.1) 0     0    
  
  
    
 
    
 
   
 >0-0.507 0   na 6 0.7 
0.9  
(0.8, 1.2) na 2 0.5 
0.7  
(0.4, 1.1) na 
 >0.507-1 9 0.5 
1.0 
(0.9, 1.2)   1 --- 
0.8  
(0.6, 1.2)   2 0.9 
1.0 
(0.6, 1.7)   
Abbreviations: CI=Confidence interval, na=not applicable, HWE = Hardy Weinberg equilibrium, PY=pack-years, ORz=control-only genotype-smoking 
odds ratio, ), N=number of studies, Ref=referent, Q=Cochran’s test of homogeneity, SNP=single nucleotide polymorphism, Arg=Arginine, Gln=Glutamine, 
Trp=Tryptophan, His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine 
1
 OR=Unadjusted odds ratio for XRCC3 Thr241Met:  Thr/Thr (ref) vs. any Met, never smoking (ref) vs. ever smoking, fixed effects 
2 OR=Unadjusted odds ratio for XRCC3 Thr241Met:  Thr/Thr (ref) vs. any Met, not current smoker (ref) vs. current smoker, fixed effects 
3 OR=Unadjusted odds ratio for XRCC3 Thr241Met:  Thr/Thr (ref) vs. any Met, lightest non-zero smokers (ref) vs. heaviest smokers; stratified random 
effects 
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Table V.A.7.  XRCC3 Thr241Met and Smoking: Overall and by study characteristics  (continued) 
4 PY contrast is between lightest non-zero category of pack-years (ref) vs. heaviest category of PY 
5
 Ratio of Odds Ratios: Compares odds ratio in given study characteristic stratum to the odds ratio in the designated reference stratum for that study 
characteristic by meta-regression 
6
 Studies w 99%-100% of 1 ethnicity are classified as single-ethnicity 
7
 Only includes studies with explicitly stated ethnic makeup 
8
 White = Caucasian, white or non-Hispanic white; African American = African American or black; Han = Han, Han Chinese or ethnic Chinese 
9 Median of studies included in XRCC1 751 current/not current smoker analyses. 
10
 Categories based on thirds from studies included in XRCC1 399 PY analyses (<=59y, >59y-63y, >63y) 
11 Median of all studies w age info  (all SNPs) w age info [range:23.6-69y, mean: 56.7y SD: 9.8y] 
12 Median proportion male in all studies (all SNPs, all smoking exposures): 0.69 
13 Smoking prevalence is contrast-specific (defined as "ever", "current" or "heavier PY" as appropriate)  
 
 
  
145
 
 
Figure V.A.1:  Weighted Forest Plot for XRCC1 399 and ever-never smoking 
Odds ratio
.1 1 10
Study
 % Weight
 Odds ratio
 (95% CI)
 1.93 (1.00,3.72) Shen 2000   1.0
 0.78 (0.57,1.07) David-Beabes 2001   7.0
 1.11 (0.70,1.76) Matullo 2001b   2.7
 1.16 (0.61,2.21) Olshan 2002   1.3
 1.53 (0.82,2.86) Shen 2003   1.2
 0.97 (0.77,1.23) Zhou 2003  11.1
 0.80 (0.55,1.18) Ito 2004   4.6
 0.90 (0.62,1.31) Kelsey 2004   4.6
 0.83 (0.43,1.61) Tuimala 2004   1.5
 1.09 (0.57,2.08) Yu 2004a   1.4
 1.86 (1.23,2.80) Huang 2005a   2.6
 1.04 (0.86,1.25) Hung 2005b  16.9
 1.09 (0.67,1.77) Matullo 2005   2.4
 0.75 (0.50,1.13) Metsola 2005   4.2
 0.88 (0.60,1.28) Patel 2005   4.5
 1.23 (0.85,1.77) Schneider 2005   4.0
 1.57 (1.24,2.00) Shen 2005a   8.2
 1.11 (0.69,1.78) Wilding 2005   2.5
 1.21 (1.00,1.46) Pachkowski 2006  15.7
 0.72 (0.31,1.69) Ramachandran 2006   1.0
 0.84 (0.44,1.62) Ryk 2006b   1.5
 1.09 (1.01,1.18) Overall (95% CI)
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Figure V.A.2.  Funnel plot for XRCC1 399 and ever-never smoking 
 
Begg's funnel plot with pseudo 95% confidence limits
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B. MANUSCRIPT 2:  Association of DNA repair and metabolic gene polymorphisms with 
tobacco smoking in controls from two population-based case-control studies:  Carolina 
Breast Cancer Study and North Carolina Colon Cancer Study 
1. Introduction 
The case-only study design as proposed by Prentice et. al [1] and popularized by Piegorsch 
et. al. and Khoury et. al . [2-3] has been used increasingly over the last 20 years to estimate the 
magnitude of statistical interaction between two exposures, most often gene-environment 
interaction (GxE) in cancer studies.  This method requires only cases, no population controls or 
defined cohort.  Potential advantages of the design are reduced cost and increased precision [8].  
Also, no invasive procedures are needed for healthy volunteers, especially in vulnerable 
populations (e.g. children) [9].  It has been proposed as a screening method to identify candidate 
gene-environment or gene-gene interactions and/or genes that may be etiologically important for 
further investigation [5, 16-17].  Because further investigation in more rigorous full-scale studies 
of genes identified in case-only studies requires significant additional money and time, it is 
important to evaluate the assumptions of case-only method. 
Provided the design assumptions are met, in particular the independence assumption (i.e. 
that the genetic and environmental factors are independent in the population that produced the 
cases), the case-only study estimates statistical interaction that deviates from the null in a 
multiplicative model but not the independent effects of the genetic or environmental factors or 
their joint effects on the additive scale.  When this design assumption is not met, bias is introduced 
into the case-only estimate of interaction (COR) [5].  Traditionally, case-control studies have been 
used to detect statistical interaction. The relationship between gene-environment interaction 
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estimated by the case-only odds ratio and the same gene-environment interaction estimated by a 
case-control study can be expressed as follows (Equation1): 
 
OR gene*env, case-only = OR gene*envr, case-control /(OR gene, case-control * OR envr, case-control)   *  Z  
 
where Z is the association between the gene and the environmental exposure in the control group 
of a case-control study [3].  The quantity [OR gene*envr, case-control /(OR gene, case-control * OR envr, case-
control)] is sometimes referred to as the synergy index on a multiplicative scale, or SIM.  When 
there is no association between the genetic exposure and the environmental exposure in the 
population (i.e. Z=1), the COR is equivalent to the deviation from a multiplicative relationship 
between the genetic and environmental exposures (i.e. COR = SIM).  Using these abbreviations, 
the relationship can be expressed succinctly as (Equation 2):  
COR = SIM * ORz 
where ORz is the control only G-E odds ratio used to estimate Z, the underlying population G-E 
association. 
Data simulations have demonstrated that even small violations of the independence 
assumption can strongly bias the case-only interaction parameter [5].  Using logistic models, 
Albert et. al. varied the magnitude of control group G-E association to explore the effect of 
independence assumption violation on case-only interaction estimates.  As expected from 
Equation 2, as values of ORz increased above the null, the COR was increasingly and 
proportionally biased away from the SIM.  Using data from a study of XRCC1 genotype and lung 
cancer by Ratnasinghe et. al., Albert et. al. showed empirically that the magnitude of ORz equaled 
the magnitude of bias introduced into the COR relative to the SIM due to violation of the 
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independence assumption violation:  ORz=2.03 for genotype and pack-years of tobacco use 
created a bias in the COR of 105% relative to the SIM [COR=0.90 (0.41,1.94), SIM= 0.44 (0.17, 
1.16)] [126].  In another example, an ORz of 1.2 representing the association between genotype 
and alcohol drinking status (ever/never) biased the COR by nearly 30%, which exceeds a 
commonly used threshold for an acceptable level of confounding bias (10%).  Further, violations 
of the independence assumption may cause the Type II error rate (false negative) to be high.  
When control-group G-E associations are of similar magnitude but opposite in direction to the 
interaction effect,  a case-only study may fail to detect interaction effects [5, 124].  Because the 
case-only study has been suggested as a useful screening tool to identify candidate genes for 
further investigation, a high Type II error rate would be problematic.  Little work has been done to 
explore this possibility.      
Although the validity of case-only estimates rests heavily on the independence assumption, 
and case-only studies, particularly stand-alone case-only studies, have some advantages over 
traditional study designs for interaction analysis, the literature specific to control group 
associations of interest for interaction studies is scant.  In the traditional population-based case-
control study cases and controls are sampled from the same underlying population. However, 
many investigators use data from a different population than the cases came from to evaluate the 
independence assumption.  The assumption that Z=1 can only be evaluated if both exposures have 
been measured in the same underlying population at risk or, in the context of a case-control study 
drawn from the population at risk, estimated by ORz in the controls, [2] or finally, by a suitable 
proxy for either of the preceding groups.   
The current study aims to address at least one of the gaps in the existing literature, by 
contributing results from large population-based control associations.  We explored gene-smoking 
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control group associations in two population-based case-control studies, the Carolina Breast 
Cancer Study (CBCS) and the North Carolina Colon Cancer Study (NCCCS).  The SNPs chosen 
are often used to study gene-smoking interaction and/or smoking behavior. They include SNPs in 
DNA repair genes (repair of genetic damage from smoking), xenobiotic metabolism genes 
(activation of procarcinogens and excretion of toxic intermediates), and cell cycle control genes.  
Both studies oversampled African Americans, and the NCCCS has both male and female 
participants, so issues of effect modification and/or confounding by age, race and gender were 
addressed. Finally, all genes were grouped by the function of the gene pathway they participated 
in, and any patterns by pathway were noted.   
2. Methods 
Study populations 
CBCS and NCCCS 
Population-based controls from the CBCS and the NCCCS were used to estimate ORz for 
gene-smoking associations. The Carolina Breast Cancer Study and the North Carolina Colon 
Cancer Study are population-based case-control studies conducted in central North Carolina 
during the mid- to late 1990’s which included urban, suburban and rural areas (CBCS: 
Ncases=2311, Ncontrols=2022;  NCCCS: Ncases=646, Ncontrols=1053) [175, 177-180].  CBCS controls 
were pooled controls from Phase I (N=790), Phase II (N=774) and the Carcinoma in situ (N=458) 
study.  The CBCS controls were not pooled with NCCCS controls.  Both studies over-sampled 
African Americans.  CBCS controls are all female; NCCCS controls also include male 
participants. Potential controls were selected from NC Division of Motor Vehicles lists (<65 years 
of age) and Health Care Financing Administration lists (>=65 years of age), using randomized 
recruitment and frequency matched on age, race and gender [181].  CBCS participants were 
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approximately half African American and half <50 years of age.  NCCCS participants were 
sampled such that the race, age and gender distribution of randomly selected cases is 
approximately 1:1 for gender and race.  The CBCS and NCCCS used similar questionnaires and 
both have extensive data on tobacco smoking history.   
A sample of polymorphisms was chosen from available genotype data in the CBCS and 
NCCCS based on potential relevance to smoking behavior and/or other smoking-related health 
effects. Genes selected form the CBCS were xenobiotic metabolism genes (CYP1A1, GSTM1, 
GSTP1, GSTT1, NAT1, NAT2, COMT), DNA repair genes (Base excision repair: APE 148, 
hOGG1, MYH, XRCC1; Double strand break repair:  BRCA2, NBS1, XRCC2, XRCC3, XRCC4; 
Mismatch repair:  MGMT; Nucleotide excision repair: ERCC1, ERCC6, RAD23B, XPC, XPD, 
XPF, XPG), oxidative stress defense genes (MnSOD, MPO, NQO1), a cell adhesion gene (CDH1) 
and a  growth factors gene (TGFB1).  NCCCS genes included: xenobiotic metabolism genes 
(GSTM1, GSTT1, MEH), DNA repair genes (Base excision repair: ADPRT, ADPRTL2, APE 148, 
XRCC1; Double strand break repair:  NBS1, XRCC3; Mismatch repair:  MLH1, MSH3, MSH6; 
Nucleotide excision repair: RAD23B, XPC, XPD, XPF, XPG), and an oxidative stress defense gene 
(MnSOD).  Methods of collection and genotyping have been described previously [68, 171, 193-
203, 268]. 
Statistical methods 
Hardy Weinberg equilibrium was tested at α=0.05 for all polymorphisms except GSTM1, 
GSTT1, NAT1 and NAT2.  Estimates of ORz and 95% confidence intervals were generated using 
logistic regression with a dichotomous representation of the genetic variable (homozygous for 
common allele=referent [G-], heterozygous + homozygous for less common allele=exposed [G+]) 
as the dependent variable.  A single model of the general form logit (G+/G-) = α + β
 (1) E1 + β (2-i) 
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COV (2-i) + error (where G+= positive for genetic variant,  E+=positive for the smoking behavior, 
COV=any additional covariates) was used for all SNPs.  Those homozygous for the most common 
allele (“no variant”) were the referent group (G-) and were compared to heterozygotes plus 
homozygotes for the less common allele (G+, “any variant”). 
In the CBCS and NCCCS smoking status was categorized as ever, former or current 
smoker. Three measures of smoking dose were used: duration (<10 years, 11-20 years, >20 years), 
intensity (<1/2 pack/day, 1/2-1 pack/day, >1 pack/day) and pack-years (PY: <=35 PY, >35 PY).  
Pack-years were derived from categorical variables used for packs/day and years smoked (pack-
years are equal to the midpoint of the category for number of years smoked multiplied by the 
midpoint of the category for number of packs smoked/day).   
Each dataset was evaluated for ORz effect measure modification using stratification on 
race (white, African American), age (CBCS: <50y, >= 50y; NCCCS: <65y, >65y) and gender 
(NCCCS only), respectively.  Based on directed acyclic graphs [209], and their status as matching 
factors, age (continuous), race (white or African American) and gender (NCCCS only) were 
included as potential confounders of the gene-smoking relationship.  In order to decide whether to 
stratify analyses on race, a likelihood ratio test was performed comparing models with and without 
a race*smoking interaction term. Significant results for the interaction term (α=0.05) in a majority 
of smoking measures precluded pooling African American and non-African American participants 
for that SNP.  Because sample size was often low for African Americans, crossover (ORzs on 
opposite sides of the null) was also examined to better characterize any differences by race. 
Although matching procedures were based on projected case incidence, and no cases were 
used in the current analysis, the matching process distorted the prevalence of these factors in the 
underlying population, potentially affecting gene-smoking estimates; consequently we adjusted for 
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all matching factors (race, age and gender).  Based on DAGs, two additional variables were 
evaluated as potential confounders:  first degree family history of any cancer, excluding non-
melanoma skin cancer (Y/N) and total family income (<$15K, >=$15K-<$30K, >=$30K-<$50K, 
>=$50K).  Percent change in β coefficients was calculated but not used to determine whether a 
covariate would be retained in the model; because of the high proportion of estimates close to the 
null (Range in CBCS: 0.5-2.5, NCCCS:  0.6-1.6) this commonly used criterion was not 
sufficiently informative.  A potential confounder was retained if the absolute value of difference 
between smoking variable β coefficients from models with and without the potential confounder 
was > 0.15 (i.e. when | β coefficient for smoking from model with potential confounder – β 
coefficient for smoking from model without potential confounder| >0.15 covariate is retained).  
For consistency, if a covariate met this criterion for any polymorphism-smoking estimate, it was 
retained in all models. After assessment of effect measure modification and confounding, an 
association was characterized by magnitude of ORz (odds ratios >=1.4 or <0.7 were considered 
evidence of non-null association) and precision of the accompanying confidence interval. 
Estimates with confidence limit ratios >4 (CLR, upper CI limit/lower CI limit) were excluded 
from consideration unless otherwise stated.  SAS 9.1 was used for all modeling [210]. 
After assessing the CBCS and NCCCS datasets separately, agreement between the two 
studies was assessed for the 15 polymorphisms included in both studies using a weighted kappa 
statistic [211].  The weighted kappa measures the degree of agreement between two or more raters 
that are using a multi-level ordinal scale to categorize a series of subjects, beyond what would be 
expected due to chance alone.  Here the raters were the CBCS and NCCCS, and the “subjects” of 
agreement were the 15 gene-smoking associations measured by both studies.  ORz was categorized 
into three categories:  1) below the null, ORz<0.9, 2) null, 0.9<=ORz<=1.1 and 3) above the null, 
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ORz>1.1.  With the weighted statistic disagreement between 2 adjacent categories is considered 
less important than disagreement between ratings further apart on the ordinal scale. Because 
distributions of race, age and gender differed across the two studies, restricted datasets were 
created and compared. These datasets were restricted to white women 40-74 years of age. Due to 
reduced sample size in the NCCCS restricted dataset precision requirements were relaxed 
(estimates with CLR <5 were included) to provide sufficient estimates for a comparison of most 
polymorphisms and several major smoking behaviors.  SAS 9.1 was used to calculate weighted 
kappa statistics [210]. 
Misspecification of smoking exposure occurs when the independence assumption is 
evaluated with one measure of smoking (e.g. ever-never) but the case-only analysis is performed 
on a different measure of smoking (e.g. duration of smoking).  Any difference in ORz between 
smoking measures leads to undetected bias in the COR.  We examined the frequency of 
differences in ORzs for smoking status (ever-never, current-not current smoking) and measures of 
smoking amount (duration, intensity and PY).  We also compared the consequence of using the p-
value for ORz(95%CI) vs. using the magnitude of ORz as a decision tool when evaluating the 
independence assumption. 
3. Results 
The study populations used in this analysis were drawn from largely overlapping source 
populations of white and African American residents of central and eastern North Carolina.  
Although the underlying source population is essentially the same, the two population-based study 
populations varied substantially by gender and sample size due to sampling criteria (Table V.B.1).  
CBCS cases in Phases I and II were diagnosed with invasive breast cancer and CIS cases had 
breast carcinoma in situ.  The invasive study oversampled women <50 years of age and African 
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American women; CIS did not.  Controls were frequency-matched by race and age (+/- 5 years) to 
the respective case groups.  Response rates were 55% overall for Phases I (1993-1996) and II 
(1996-2001), and 65.2% for CIS (1996-2001) [178, 193, 269].  The overall response rate for the 
pooled CBCS controls was 57% (N=2022). The response rate for DNA samples was 90%.  
Prevalence of current smoking was similar across CBCS control subgroups (Phase I: 21%, Phase 
II: 19%) and the CIS (17%).  CIS controls were slightly older than invasive study controls 
(Median age:  Phase I 49y, Phase II 50y, CIS 53y). Controls from the NCCCS were older than 
CBCS controls and included both men and women.  Consistent with gender and age differences in 
smoking prevalence in the US [270-271], there were a higher proportion of never smokers and a 
shorter average smoking duration in CBCS controls compared to the NCCCS.   
Table V.B.2 provides the rs# and official name for each SNP included in the analysis, as 
well noting the most common allele for each in the CBCS and NCCCS datasets.  The common 
allele for the full dataset was used as the referent even when the common allele differed by race. 
SNPs where the common allele differed by race are noted in Table V.B.2.  In the CBCS, 38 
polymorphisms in 29 genes were evaluated; 17 genes were DNA repair genes.   In the NCCCS, 25 
polymorphisms and four haplotypes from 19 genes were evaluated.  Fifteen genes were DNA 
repair genes.  For the 15 polymorphisms included in both studies, two were in metabolic genes, 12 
were in nine DNA repair genes, and one was in an oxidative stress gene.   
Allele frequencies and HWE p-values for CBCS and NCCCS controls, stratified by race, 
are presented in Table VIII.B.1.  Within race only four SNPs (3%) were out of Hardy Weinberg 
equilibrium (α=0.05), two in CBCS controls (CYP1A1 in non-African Americans, XRCC3 241 in 
African Americans) and two in NCCCS controls (RAD23B and XPF 415 in non-African 
Americans) approximately what one would expect by chance alone. HWE can not be calculated 
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for GSTM1, GSTT1, NAT 1 and NAT2 because these polymorphisms are categorized by enzymatic 
activity (present or absent [null] for GSTs; rapid or slow for NATs) rather than as discrete alleles.  
Percent ‘any variant’ was consistent between the CBCS and NCCCS within race; the sole 
exception was GSTT1 (CBCS:  16.4% and 16.6% null, in non-African Americans and African 
Americans, respectively; NCCCS: 29.6% and 33.3% null, in non-African Americans and African 
Americans, respectively).  Tables 4a-d and 5a-d present overall and race-, age- and gender-
stratified ORz for CBCS and NCCCS, respectively. All results are adjusted for race, age 
[continuous] and gender unless stratified by same.  All ORz sufficiently precise for evaluation 
(CLR <4) were between 0.4 and 2.5.   
All models were adjusted for matching variables (race, age and gender) unless stratified or 
restricted by same.  Approximately half of the polymorphisms showed joint confounding by race 
and age (difference of |>0.15| in β coefficients), almost entirely former smoking and/or >35 PY in 
the CBCS, although no absolute difference in β coefficients exceeded 0.4 for ORzs w CLR <4.  
Unadjusted and race-, age-, and gender-adjusted estimates did not vary substantially in the 
NCCCS.  Confounding by race and age were more marked in measures of smoking dose than 
smoking status, but did not vary by functional gene category.  Based on directed acyclic graphs 
[209], family history of any cancer and family income were identified as potential confounders, 
but neither changed estimates substantially in either dataset.  They were not included in any 
models. 
CBCS 
In the CBCS overall, three SNPs showed consistency across smoking categories with 
moderate ORzs (defined as an ORz>=1.4 or <=0.7) in at least one smoking status category (ever, 
former or current) and at least one smoking dose category (duration, intensity or pack-years):  
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CYP1A1 M2, GSTP1, and XPF 662 (Tables 4a-d).  An additional five SNPs had two or more 
moderate ORzs in any smoking category:  COMT, CDH1, XRCC1 194, BRCA2 372, and MGMT 
84.  Finally, two SNPs, CYP1A1 M4 and ERCC6 1213, showed moderate ORzs in more than one 
level of a single measure of smoking behavior (e.g. moderate ORzs in two levels of smoking 
duration but no other measures of smoking).  Only estimates with a CLR < 4 were considered 
precise enough for evaluation.  
Xenobiotic metabolizing genes were slightly overrepresented among the SNPs showing 
moderate associations with smoking behavior (Range: 0.5 - 2.5).  DNA repair genes were 
overrepresented among the weaker associations (0.7-1.6).  Among the metabolism genes, CYP1A1 
M2 was positively associated with smoking status and <35 PY (vs. never). No other smoking 
categories were evaluable for CYP1A1 M2 due to low precision. GSTP1 was positively associated 
with former, short duration, moderate intensity and low PY of smoking but inversely associated 
with current smoking and high PY of smoking.  COMT was inversely associated with high 
intensity and >35 PY of smoking, but not with any measures of smoking status. Among DNA 
repair genes, XPF 662, XRCC1 194, BRCA2 372, and MGMT 84 showed associations with 
smoking behavior particularly for measures of smoking amount (duration, dose or PY).  Of the 21 
evaluable DNA repair genes, six were associated with high PY, with four of them (ERCC6 1230, 
ERCC1 8092 and XRCC4 -28073, MnSOD) associated only with PY but not smoking status, 
duration or intensity.   
Within smoking categories, one SNP showed a moderate magnitude ORz for ever smoking 
(CYP1A1 M2); one other metabolism gene and two DNA repair genes (both NER) showed 
moderate associations with current smoking. For duration, two metabolism SNPs (GSTP1 and 
NAT1) and two DNA repair SNPs (OGG1 and XRCC1 194) had moderate magnitude ORzs for 
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<10yrs and three others had moderate magnitude ORzs for 11-20 years (BRCA2 372, XPF 662, and 
CDH1). Only one SNP was associated with the longest duration of smoking (MGMT 84). Eleven 
SNPs were associated with either low or high PY, including five that were not associated with any 
other measure of smoking.   
When the CBCS ORzs were stratified by race, there was little evidence of heterogeneity 
nor did any strong patterns by race emerge.  Using p-values to evaluate effect measure 
modification by race, approximately 6% of the likelihood ratio tests for a race-smoking interaction 
term were significant at α=0.05, about what would be expected by chance.  There was no pattern 
of significant interaction by race for any given smoking measure.  Only NQO1 was significant for 
interaction for more than one smoking measure; ORz differed significantly for all smoking 
measures and was inverse for African Americans and positive for non-African Americans.  
 To further highlight more extreme differences, we examined crossover (ORzs on opposite 
sides of the null) to evaluate effect measure modification by race.  Seven SNPS showed 
substantial variation by race in at least one smoking category (GSTT1, COMT, XRCC1 194, NBS1 
185, XRCC4 -28073, ERCC1 8092 and NQO1).  GSTT1 and COMT were inverse in whites and 
positive in African Americans.  For SNPs that varied by race, the direction of association for each 
stratum was consistent across smoking categories.  When estimates were stratified by age (< 50 yr, 
>=50 yrs) there was minor variation; it was consistently less than variation by race. 
 Misspecification of smoking exposure (i.e. using status to evaluate the independence 
assumption then conducting a case-only analysis of a smoking amount measure) strongly affected 
the frequency that bias would be introduced into the COR.  In the CBCS, for smoking status, there 
were four SNPs with positive moderate magnitude ORzs (CYP1A1 M2 for ever smoking; CYP1A1 
M4, ERCC6 1213, and XPF 662 for current smoking).  For smoking amounts (duration, intensity 
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or PY), nine had positive moderate magnitude ORzs (Table V.B.9).  However, of these nine SNPs, 
only one also had a positive moderate magnitude ORzs for smoking status (CYP1A1 M2).  One 
SNP with an inverse moderate magnitude ORz for smoking status (GSTP1 and current smoking) 
showed largely inverse moderate magnitude ORzs for smoking amounts.  None of the other six 
SNPs with inverse moderate magnitude ORzs for any measure of smoking amount had moderate 
magnitude ORzs for smoking status.  
Using the magnitude of ORz as an indicator of independence assumption violation 
identified more instances that bias would be introduced into the COR than using significance 
testing.  Of the 22 positive moderate magnitude ORzs in the CBCS, nine were statistically 
significant at α=0.05. There were three statistically significant positive ORzs of smaller magnitude.  
There were 11 inverse ORzs of moderate magnitude, six of which were statistically significant. 
One smaller magnitude ORz was statistically significant. 
           NCCCS   
              In the NCCCS controls, using the same criteria for moderate magnitude association as 
listed for the CBCS, five SNPs in four genes (MEH 113, MEH 139, GSTM1, POLD1 119, MSH3 
940) and three haplotypes of GST, were moderately associated with smoking behavior (Tables 5a-
d).  MEH 113 and MEH 139 were both inversely associated with smoking for at least one smoking 
status category and one smoking amount category.  The bulk of moderate ORzs in the metabolic 
genes can be attributed to the two SNPs in the MEH gene. POLD1 119, a DNA repair gene, was 
most consistently associated with smoking across categories. Weak and/or suggestive associations 
were found for XPC 939, XRCC1 194, XRCC3 241, XPD751 and MSH6 39.  As in the CBCS, 
metabolism genes were overrepresented in the stronger associations and DNA repair genes in the 
weaker associations.  Associations between minor alleles for metabolism SNPs and smoking were 
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consistently inverse whereas association between smoking and DNA repair SNPs were both 
positive and inverse. 
Within smoking categories, three of the four metabolism gene SNPs (GSTM1, MEH 113 & 
139) were inversely associated with smoking status (ever, former or current smoking); three DNA 
repair SNPs showed moderate magnitude inverse ORzs for smoking status (ever & current 
smoking: POLD 119, current smoking:  MSH3 940 and MSH6 39).  Short and moderate duration 
smoking showed both positive and inverse ORzs, whereas the ORz for smoking >20 yrs was near 
the null for all SNPs except MEH 139. All measures of amount (duration, intensity and PY) 
showed some clustering of positive associations in MMR and NER DNA repair genes, and inverse 
associations for metabolic genes and BER DNA repair genes. Only one SNP (POLD 119) showed 
an association with low PY, although there were six associated with high PY (MEH 113, MEH 
139, POLD 119, MSH3 1036, XPC 499 and XPC 939), two of which had no association with any 
other smoking measure (MSH3 1036, XPC 499).  
When the data were stratified by gender, estimates for ever smoking were slightly more 
likely to be positive or more strongly positive for women than for men, although this was not true 
for other measures of smoking status. Results were similar for smoking duration >20y, however 
low precision in estimates for short and moderate duration meant few comparisons across gender 
could be made. For smoking intensity, stratification by gender produced associations on opposite 
sides of the null more often than for other smoking categories although precision limited 
comparisons for the heaviest smokers. For low PY, estimates for women were again more likely to 
be positive, or more strongly positive, than estimates for men. High PY could not be evaluated.  
Only MSH3 940 differed significantly by gender across more than one smoking measure.  ORzs 
for ever, duration and PY were higher among women than men when positive or closer to the null 
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when inverse. MSH3 1036 showed the same pattern however the LRT for gender was not 
significant for any measure of smoking at α=0.05.   
No strong patterns emerged after stratification by race, although estimates were often on 
opposite sides but still close to the null.  The exception was GSTT1 where stratification by race 
produced moderate inverse associations in whites and moderate positive associations in African 
Americans for most evaluable smoking measures (ever, current, and intensity). Results for 
duration and high PY were generally not evaluable by race due to poor precision.  Approximately 
3% of the likelihood ratio tests for a race-smoking interaction term were significant at α=0.05, 
about what would be expected by chance.  There was no pattern of significant interaction by race 
for any given smoking measure. GSTT1 was the only gene with more than one statistically 
significant (at α=0.05) race*smoking interaction term: ever smoking, never/former/current 
smoking and PY; it was generally positive for African Americans and inverse for non-African 
Americans. Where evaluable, stratification by age (<65y, >=65y) yielded ORzs that were more 
similar across strata than gender- or race-stratified ORzs.   
The effect of misspecification of the smoking variable in the independence assumption was 
assessed as in the CBCS (Table V.B.9).  In the NCCCS, for smoking status, there were six SNPs 
with moderate magnitude ORzs, all inverse (MEH 113, POLD 119 with ever smoking, GSTM1 
null, MEH 139, MSH3 940, and MSH6 39 with current smoking). Three of the four GST 
haplotypes showed moderate magnitude ORzs with smoking status.  For smoking amount, there 
were 11 SNPs or haplotypes with positive moderate magnitude associations; only 1 showed a 
similar result for smoking status.  Only half of the SNPs with inverse moderate magnitude ORzs 
for any smoking amount measure category also had inverse moderate magnitude ORzs for 
smoking status (5 of 9).   
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In the NCCCS, there were 22 positive moderate magnitude ORzs; three were statistically 
significant. Of the 35 inverse moderate magnitude ORzs, six were statistically significant. There 
were no statistically significant ORzs between 0.7 and 1.4. 
            CBCS and NCCCS  
              Comparing CBCS and NCCCS results for the 15 SNPs measured in both studies (Table 
V.B.6), no SNP had ORz >=1.4 or <=0.7 in both studies. With the null defined as between 0.9-1.1 
(inclusive), the weighted kappa for agreement was -0.07 (95% CI: -0.19, 0.06), indicating slight 
disagreement (Table V.B.10) [212].  When CBCS and NCCCS datasets were restricted to white 
women 40-74 years of age to improve comparability (Table V.B.7), results were only evaluable in 
the NCCCS for ever, former, long duration, moderate intensity and low PY of smoking, for 13 or 
fewer SNPs, even with the limits for precision relaxed to include estimates with CLR <5.  Under 
these conditions, the kappa for agreement was 0.22 (95% CI: -0.01, 0.46), usually considered 
slight agreement [212].  Changing the definition of the null to 0.8-1.2 (inclusive) or including all 
data regardless of CLR did not change results.  
4. Discussion 
The aim of the current project was to assess the magnitude of associations between a 
convenience sample of SNPs in two population-based control groups and multiple measures of 
smoking behavior.  The primary motivation was to evaluate any gene-smoking associations in 
light of the bias that would be introduced into a case-only analysis of gene-environment 
interaction when the independence assumption is violated.  
Odds ratios for the control groups (ORzs) in the current study were of moderate magnitude 
[>=1.4 or <=0.7] in at least one of the six smoking behavior measures for approximately half of 
the SNPs examined in each of these population-based control groups (CBCS: 45%, NCCCS: 
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59%).  This analysis focused on this magnitude of association because an ORz  of >=1.4 would 
inflate the corresponding SIM (interaction term from a case-control study), if positive, by >=40%.  
This is a substantive degree of bias in most contexts and could easily mislead researchers into 
concluding G-E interaction exists when it doesn’t or that G-E interaction is much stronger than it 
actually is.  Alternatively, G-E interaction may be missed completely when the SIM is inverse and 
the ORz is positive. The converse is true for ORzs <=0.7.  These moderate magnitude ORzs were 
found across all functional categories of putative gene function. For most DNA repair gene SNPs, 
particularly BER and DSB genes, both studies showed a preponderance of moderate magnitude 
ORzs in categories of smoking dose (pack/day, years smoked or PY) rather than smoking status 
(ever, former, current). In contrast, metabolic gene SNPs had moderate magnitude ORzs in both 
status and dose measures.  There were too few SNPs in other functional categories to observe any 
patterns.   
Metabolic genes and smoking behavior 
There is an extensive epidemiologic literature on smoking and metabolic genes, [i.e. those 
coding for enzymes that metabolize nicotine or other tobacco smoke constituents such as 
polycyclic aromatic hydrocarbons (PAH)] [145-146].  Variation in these genes can alter enzyme 
activity, regulation or expression [144] plausibly increasing or decreasing risk of disease or 
influencing smoking behaviors, such as the number cigarettes consumed daily or years as a 
smoker.  Of the seven metabolic genes included the CBCS data, five (CYP1A1, GSTM1, GSTP1, 
NAT1 and COMT) showed moderate association in at least one measure of smoking.  Only 
CYP1A1 was moderately associated with ever smoking.  In the NCCCS, all three metabolic genes 
(GSTM1, GSTT1, and MEH) showed moderate association with at least one measure of smoking.   
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The COMT Val158Met SNP (rs4680) is the only SNP in the current study that has been 
extensively studied with respect to its possible influence on smoking behavior, [147].  Results 
have been equivocal with two recent large population-based European studies coming to different 
conclusions [148-149].  Omdivar et. al. found a 20% reduction in incident smoking cessation for 
carriers of the low activity form of the allele (Met carriers) whereas Breitling et. al. found no 
association [OR=0.97 (0.83, 1.12)].  Results from the CBCS were consistent with Met carriers 
having slightly reduced duration and PY of smoking (ORz=0.9 and 0.5 for <=35PY and >35PY; 
ORz=1.0, 0.8 and 0.8 for <10y, 11-20y and >20y, respectively).  
For CYP1A1, Chen et. al. demonstrated that having at least one CYP1A1*2A allele was 
associated with smoking reduction and increased quitting during pregnancy [2.2(1.0,4.6) and 
1.7(1.0,2.9), respectively] [150].  CBCS results for women <50y were consistent with higher 
quitting for those with an M1 allele. (ORz=1.5 and 1.1, former and current smoking, respectively).  
For GSTM1, Chen et. al. found no association between GSTM1 null and less smoking, whereas 
results from the NCCCS showed less smoking (ORz for women=1.6, 0.7 and 1.0 for <1/2     
pack/day, ½-1 pk/day and >1 pk/day, respectively).  Findings for GSTP1, GSTT1 and MEH have 
not been reported previously. 
DNA repair genes and smoking  
Studies that have examined DNA repair genes and smoking behavior are scarce.  The 
population-based candidate gene study of habitual smoking by Lui et. al included several DNA 
repair genes in addition to the metabolic genes discussed earlier [64].  Again, ORzs were presented 
only for statistically significant DNA repair gene SNPs. Only one was in the current study, OGG1 
[ORz =0.6 (0.4, 1.0) for ever smoking].  There was no association with ever smoking for the 
OGG1 SNP in the CBCS [ORz =1.0 (0.9, 1.3)].   
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A recent meta-analysis of gene-smoking association assessed XRCC1 399, 194 and 280.  
Several of the summary ORzs were of moderate magnitude (ORz>=1.4 or <=0.7):  XRCC1 194 and 
longer duration ORz =0.7 (0.5, 0.9), XRCC1 280 and current smoking ORz= 0.7 (0.5, 1.1), and 
XRCC1 399 and greater intensity ORz=1.5(1.2, 1.9).  Summary estimates included CBCS data; 
however, the control group data from the other included studies were consistent with CBCS results 
[224, 233, 260, 262, 272-275].  Findings for the other DNA repair SNPs in the CBCS and NCCCS 
[XPF, MSH3 (stratified by gender), and POLD1] have not been reported previously. 
Two SNPs in the current project varied strongly by race, NQO1 and GSTT1. For NQO1, an 
oxidative stress response gene, ORz was consistently positive in non-African Americans, and 
inverse among African Americans, notably for current smoking (ORz for non-African 
American=1.4, African American=0.7) and smoking >20 y (ORz for non-African American=1.4, 
African American=0.6).  NQO1 is thought to be a susceptibility factor for coronary heart disease, 
and cancer, particularly with environmental exposures such as smoking and benzene, respectively 
[276-277].  In contrast, GSTT1, a Phase 2 metabolic gene, was generally inverse for non-African 
Americans and positive for African Americans. A number of the relevant exposures (e.g. benzene, 
pesticides, quinone-based chemotherapy) may differ by race or SES, and could plausibly be 
related to changes in smoking behavior that vary by race.  
Smoking behavior in controls 
Several SNPs in the CBCS and NCCCS stood out with moderate magnitude ORzs in at 
least one status category and at least one level of a dose measure (pack/day, years smoked, PY).  
In the CBCS these were: CYP1A1 M2 (positive), GSTP1 (positive & inverse), and XPF 662 
(positive). In the NCCCS five SNPs had comparable signals:  MEH 113 and 139, GSTM1, POLD1 
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119, and MSH3 940.  The metabolic genes generally had inverse ORzs, as did POLD1 119, a DNA 
repair gene.  POLD1 119 showed the most consistent results across smoking measures. 
In the CBCS, COMT, CDH1, XRCC1 194, BRCA2 372, and MGMT 84 showed moderate 
associations in more then one smoking measure; CYP1A1 M4 and ERCC6 1213 showed 
association in more than one level of a single smoking measure.  In the NCCCS several genes also 
showed weaker signals:  XPC 939, XRCC1 194, XRCC3 241, XPD 751 and MSH6 39. 
Even given the wealth of smoking behaviors, genetic variations and populations studied, 
and the biological plausibility of smoking behavior being influenced by toxic intermediates in 
xenobiotic metabolism pathways, it is difficult to find studies of smoking in controls or population 
samples to compare with the current study [54, 64, 125] (Table V.B.8).  Smits et. al. used pooled 
control group data from the International Collaborative Study on Genetic Susceptibility to 
Environmental Carcinogens (GSEC) to estimate ORzs between polymorphisms in five metabolic 
genes (CYP 1A1, GSTT1, GSTM1, GSTP1 and NAT2) and six measures of smoking (ever, former, 
current, cig/day, years smoked and PY) (Table V.B.8).  Total sample size for each gene varied 
(GSTM1:  N=10,719 to GSTP1:  N=2,792); however, less than half of controls had information on 
smoking amount. Results were adjusted for study, age, sex and ethnicity.  Results for these five 
genes and smoking status were most often at or near the null.  Overall, they were broadly similar 
to CBCS and NCCCS results, even though controls pooled across multiple studies would not 
necessarily be expected to have an ORz similar to that of any given study.  Despite this, there were 
differences that have implications for the validity and interpretation of case-only interaction 
estimates.  For example, in GSEC controls the overall ORz for GSTP1 and current smoking was 
just above the null, but in the CBCS it was below the null. For female GSEC controls, the ORz was 
similar to the CBCS, but the ORz for non-hospital controls was above the null.  GSEC and CBCS 
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ORzs for GSTP1 were even further apart for former smokers (Table V.B.8).  Variation in ORz 
between pooled controls from small to moderate sized studies (GSEC) and the two relatively large 
population-based control groups in the current study, as well as the variation between subgroups in 
the pooled controls, suggest that the ORz should be considered specific to each underlying 
population rather than an estimate of some ‘universal’ ORz for that SNP and smoking measure.  
The GSTP1 results, in particular, imply that increasing sample size by pooling is not sufficient to 
compensate for lack of controls from the relevant underlying population.  
Finally, in the largest population-based candidate gene study of smoking to date (N=339), 
Lui et. al. examined a panel of 153 SNPs in 40 candidate genes potentially involved in tobacco 
consumption in a sample of Japanese men 40-49 years of age [64].  Lui et. al. found significant 
associations for 14 SNPs and current smoking (referent=not current smoker).  ORzs were 
presented only when statistically significant. The ORz for MEH was consistent with NCCCS 
although the specific SNPs were different:  MEH rs2292566 [64]: ORz=0.4 (0.2, 0.8)];  MEH 113 
& 139 (NCCCS):  ORz=0.8 (0.5, 1.1) and 0.6 (0.4, 0.9) respectively]. 
In an evaluation of the independence assumption for gene-smoking associations in controls 
Hamajima et. el. [125] calculated ORz(95%CI) in four published control groups [278-281] for ever 
smoking and SNPs in CYP2E1, NAT2, and CYP1A1.  None of the ORzs were significant at α=0.10, 
however, the magnitude of ORzs ranged from 2.3 (CYP2E1) to 0.6 (CYP2E1); ORzs for NAT2 
(slow) and CYP1A1 (M2) were 0.6 and 0.7, respectively.  Although the authors noted that the 
magnitude of the ORz was the amount of bias introduced into the COR, they concluded, on the 
basis of statistical significance, that these SNPs could be used with smoking in a case-only study 
of interaction.   
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In the literature, quantitative approaches have ultimately relied almost exclusively on 
statistical significance regardless of whether the independence assumption was being evaluated in 
a control group from the same study population as the cases or in ancillary data (i.e. data external 
to the published study),.  For instance, in Egan et. al. (2003) the magnitude of gene-environment 
associations varied from 0.5 to 1.1, and in Marcus et. al. (2000), it was 0.5 to 1.8, nonetheless the 
only associations considered problematic were the statistically significant ones ones [21, 52].  This 
is in contrast to methods of assessing bias in common practice, where the magnitude of the change 
in the estimate of interest is of primary concern [214]. 
Implications for case-only studies 
Based on the magnitude of the gene-smoking associations observed in the CBCS and 
NCCCS (ORz >=1.4 or <=0.7), a case-only interaction estimate would be biased for at least one 
level of smoking behavior in at least one of the six measures examined (ever, former, current, 
cig/day [3 level], years smoked [3 level], PY [2 level]) for approximately half of the SNPs 
examined in these population-based control groups (CBCS: 45%, NCCCS: 59%).  For most 
functional categories except metabolism gene SNPs, moderate magnitude ORzs were most often 
found for measures of smoking dose (cig/day, years smoked, PY) rather than smoking status (ever, 
former, current). These results need to be replicated in other population-based control series or 
other relevant samples.   
Nonetheless, some implications for the conduct of case-only studies are clear.  Smoking 
status measures are more easily extracted from the published literature than measures of smoking 
amount.  Consequently, ever-never and current-not current smoker are most often used to check 
the independence assumption (Hodgson in preparation).  Results from the current study show that 
the magnitude of ORz is not reliably close to the null for many of these SNPs, making them 
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unsuitable for a case-only interaction analysis.  These results also clearly show that for many 
SNPs evaluating the independence assumption using smoking status is insufficient evidence of no 
association for measures of smoking amount such as duration, intensity and PY, the measures of 
interest for many case-only analyses. Very few SNPs with moderate magnitude ORzs in any 
category of smoking amount had comparable magnitude ORzs for measures of smoking status in 
either control group (CBCS: 25%, NCCCS: 13%).  Similarly, making a decision based solely on 
the p-value of ORz would result in approximately half of the moderate magnitude association in 
the CBCS controls being missed and around 80% of the moderate magnitude ORzs in the NCCCS 
being missed.  This was observed across all gene categories in both control groups. 
Strengths and Limitations  
The primary strengths of this study are the population-based design and sample size. The 
independence assumption for case-only analyses is a large sample assumption that pertains 
specifically to G-E associations in the population that underlies the sample of cases.  Using a 
control group rather than a population sample meant that the true parameter (RRz) could only be 
estimated; ORz was a proxy for RRz.  However, ORz is the information most easily available in the 
literature, and most often used to evaluate the independence assumption, making it the most 
relevant measure to examine to inform the practice of case-only study design.   
We were able to use individual level data such as race, gender and age to check for 
potential effect measure modification and confounding, something not generally possible when 
checking the independence assumption using the published literature.  Genotype prevalence varies 
by race for many metabolic and DNA repair genes; smoking behaviors vary by race, gender and 
age [270-271, 282-283]. Consequently it is important to be able to address the effect of race, 
gender and age on the gene-smoking association when evaluating the independence assumption. 
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Both studies had information on smoking intensity, duration and PY, often the exposures of 
interest in a case-only interaction analysis, but not often available in the published literature, at 
least for controls. Both the CBCS and NCCCS oversampled African Americans making subgroup 
analyses by race feasible for most SNPs.  The CBCS and NCCCS are drawn from essentially the 
same underlying population: largely overlapping geographic areas, during approximately the same 
time period, using the same sampling methods, enhancing comparability of the two control 
groups.  Because the current study was a convenience sample of SNPs originally chosen for their 
relevance to two different cancers, there were a limited number of SNPs included in both studies. 
A further limitation was that for African American women 40-74 years of age in the NCCCS, very 
few SNPs and smoking measures meet our precision criteria thus it was not possible to assess 
agreement between the two studies for this restricted group.  
Selection bias could have distorted the true gene-smoking relationship in the controls if 
joint smoking and genetic status are associated with reduced or increased participation rates.  Bias 
due to nonparticipation by smoking status alone may be non-differential with respect to the gene-
smoking association because potential participants are unaware of their gene status. However if 
participation rates also vary by family history (or any proxy for G+), ORz would be driven away 
from the true ORz in an unpredictable direction, depending on the participation rates of smokers 
with or without a family history (e.g. if smokers with a family history of cancer refuse 
participation more often than other groups, a true positive ORz could be driven downward, even 
below the null, but if the non-participation rate in smokers with no family history is even higher 
the ORz will increase away from the null).  However, the population prevalence of current 
smoking in the CBCS (20%) was similar to NC women in the 2001 BRFSS (23%), while former 
smokers and never smokers, respectively, are only slightly over- and under-represented in the 
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CBCS (CBCS: 29%, BRFSS: 20%, CBCS: 51%, BRFSS: 57%) [195, 271], arguing that selection 
bias due to the joint distribution of smoking and gene status is likely to be small.   
The precise biological functions of most of the SNPs in this study were unknown, limiting 
causal interpretations of any associations found.  Population stratification could have caused some 
residual confounding despite adjustment for self-reported race.  Any associations could have been 
due to chance or to polymorphisms in linkage disequilibrium with the assayed polymorphisms.  
Linkage disequilibrium can vary across ethnicities; however, with the one exception noted 
(NQO1), results did not vary substantively by race.  Additionally, agreement was substantially 
enhanced when the CBCS and NCCCS datasets were restricted by gender, race and age.  If the 
SNP-smoking associations in the control groups were due entirely to chance, agreement would not 
be expected to improve solely due to restriction by race, age and gender. 
Conclusions 
Our findings show that the gene-smoking ORzs in population controls are often of 
sufficient magnitude that these associations would produce unacceptable bias in the COR in a 
case-only study of GxE interaction.  Thus, caution is warranted when using the case-only method.  
A stand-alone case-only study should be conducted only when the independence assumption can 
be verified with appropriate empirical data.  Appropriate data means either population-specific 
data or, if sufficient published data are available, ORzs within a narrow, pre-specified range of 
acceptable bias, across a wide variety of population-based studies. This data is needed for every 
smoking metric that proposed for the case-only analyses. In the short term, it would be extremely 
useful to have more detailed control group information available from large population-based 
studies for a variety of genes.  Specifically, it would be useful to have more detailed data on 
smoking metrics (duration, intensity, etc.) than is usually presented, ideally stratified by race and 
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gender.  Given that many studies already collect much more detailed information on smoking 
behavior in controls than is actually presented in a paper, these data could relatively easily be 
archived as supplemental tables online.  Other exposures whose effect might be modified be 
genetic variation (e.g. air pollution, infectious diseases, alcohol consumption, chemotherapeutics) 
should also be examined. 
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5. Tables and Figures 
 
Table V.B.1. Characteristics of CBCS and NCCCS control groups  
  Full CBCS and NCCCS  Non-African American women, 40-74 y 
  CBCS  NCCCS  CBCS  NCCCS 
  N  %  N  %  N  %  N  % 
Total N 2022    1053    1107    222   
Gender                 
 Female 2022  100  535  50.8  1107  100  222  100 
 Male 0    518  49.2  0    0   
Race                
 White 1 1234  61.0  616  58.5  1107  100  222  100 
 African American 788  39.0  437  41.5  0    0   
Age at selection (years)               
 Mean +/-SD 52.6 +/-11.2    66.1+/-9.5    55.1+/- 10.0    63.5+/-8.2   
 Median 50    68    53    66   
 Range 21-74    40-81    40-74    41-74   
Smoking behavior                
 Smoking Status                
 Never 1087  53.8  450  42.9  558  50.4  119  53.6 
 Former 547  27.1  412  39.2  344  31.1  76  34.2 
 Current 388  19.2  188  17.9  205  18.5  27  12.2 
  2022    1050    1107    222   
 Duration (years)                
 <10  271  29.1  128  21.4  143  15.0  30  29.4 
 11-20 235  25.3  130  21.7  265  27.8  18  17.6 
 >20  424  45.6  340  56.9  546  57.2  54  52.9 
  930    598    954    102   
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Table V.B.1. Characteristics of CBCS and NCCCS control groups (continued)  
  Full CBCS and NCCCS  Non-African American women, 40-74 y 
  CBCS  NCCCS  CBCS  NCCCS 
  N  %  N  %  N  %  N  % 
 Intensity (pack/day)               
 <1/2  329  35.4  188  31.6  161  29.5  31  30.1 
 1/2 - 1 324  34.8  223  37.5  189  34.7  42  40.8 
 >1  277  29.8  184  30.9  195  35.8  30  29.1 
  930    595    545    103   
 Pack-years 2                
 N 925    593    542    102   
 Mean +/- SD 17.5 +/-17.3    27.1+/-27    20.7+/-18.3    26.3+/-27.4   
 Median 11.6    18.8    19.1    21   
 Range 0.1-80    0.1-137.5    79.8    124.8   
                 
 <=35 pack-years 783  84.6  424  71.5  431  79.5  71  69.6 
 >35 pack-years 142  15.4  169  28.5  111  20.5  31  30.4 
  925    593    542    102   
                                  
Abbreviations:  CBCS=Carolina Breast Cancer Study, NCCCS=North Carolina Colon Cancer Study, SD=standard deviation, 
N=number of controls 
1
 Participants reporting non-African American race (98% white for CBCS, 98.9% white in NCCCS) 
2
 Smokers only 
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Table V.B.2. Gene variants in CBCS and NCCCS 
Gene & 
codon/ 
nucleotide 
position rs#  
Common1 
allele (amino 
acid) 
Variant1 
allele 
(amino 
acid) 
Nucleotide 
common/ 
variant  Gene name and official abbreviation 2  Study 
ADPRT 762 rs1136410   Val Ala T/C   poly (ADP-ribose) polymerase 1 [PARP1]  NCCCS 
ADPRTL2   
328 3         C/T   poly (ADP-ribose) polymerase 2 [PARP2]  NCCCS 
APE1 148 rs1130409   Asp Glu T/G   
APEX nuclease (multifunctional DNA repair 
enzyme) 1 [APEX1]  Both 
BRCA2    
intron 24 rs206340   -- -- G/A   breast cancer 2, early onset [BRCA2]  CBCS 
BRCA2 372 rs144848   Asn His A/C   breast cancer 2, early onset [BRCA2]  CBCS 
CDH1 -160 rs16260   -- -- C/A   cadherin 1, type 1, E-cadherin (epithelial) [CDH1]  CBCS 
COMT 158 4 rs4680   Val Met G/A   catechol-O-methyltransferase [COMT]  CBCS 
CYPIA1 M1  
(CYP1A1*2A) rs4646903   (*1A) (*2A) T/C   
cytochrome P450, family 1, subfamily A, 
polypeptide 1 [CYP1A1]  CBCS 
CYPIA1 M2 
(CYP1A1*2C) rs1048943   Ile (*1A) Val A/G   
cytochrome P450, family 1, subfamily A, 
polypeptide 1 [CYP1A1]  CBCS 
CYPIA1 M3 
(CYP1A1*3) rs4986882   (*1A) (*3) T/C   
cytochrome P450, family 1, subfamily A, 
polypeptide 1 [CYP1A1]  CBCS 
CYPIA1 M4 
(CYP1A1*4) rs1799814   Thr (*1A) Asn C/A   
cytochrome P450, family 1, subfamily A, 
polypeptide 1 [CYP1A1]  CBCS 
ERCC1 nt8092 rs3212986   Gln Lys C/A   
excision repair cross-complementing rodent repair 
deficiency, complementation group 1 (includes 
overlapping antisense sequence) [ERCC1]  CBCS 
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Table V.B.2. Gene variants in CBCS and NCCCS (continued) 
Gene & 
codon/ 
nucleotide 
position rs#  
Common1 
allele (amino 
acid) 
Variant1 
allele 
(amino 
acid) 
Nucleotide 
common/ 
variant  Gene name and official abbreviation 2  Study 
ERCC6 1213 rs2228527     Arg Gly A/G   
excision repair cross-complementing rodent repair 
deficiency, complementation group 6 [ERCC6]  CBCS 
ERCC6 1230 rs4253211   Arg Pro G/C   
excision repair cross-complementing rodent repair 
deficiency, complementation group 6 [ERCC6]  CBCS 
GSTM1 5     present null     glutathione S-transferase mu 1 [GSTM1]  Both 
GSTP1 105 6 rs1695   Ile Val A/C   glutathione S-transferase pi 1 [GSTP1]  CBCS 
GSTT1 5     present null     glutathione S-transferase theta 1 [GSTT1]  Both 
MEH 113 rs1051740   Tyr His T/C   
epoxide hydrolase 1, microsomal (xenobiotic) 
[EPHX1]  NCCCS 
MEH 139 rs55784606   His Tyr C/T   
epoxide hydrolase 1, microsomal (xenobiotic) 
[EPHX1]  NCCCS 
MGMT 84 rs12197   Leu Phe C/T   
O-6-methylguanine-DNA methyltransferase 
[MGMT]  CBCS 
MLH1 219 rs1799977   Ile Val A/G   
mutL homolog 1, colon cancer, nonpolyposis type 
2 (E. coli) [MLH1]  NCCCS 
MNSOD 16 7 rs4880   Val Ala T/C   superoxide dismutase 2, mitochondrial [SOD2]  Both 
MPO -463 rs2333227   -- -- G/A   myeloperoxidase [MPO]  CBCS 
MSH3 1036 rs26279   Thr Ala A/G   mutS homolog 3 (E. coli) [MSH3]  NCCCS 
MSH3 940 rs184967   Arg Gln G/A   mutS homolog 3 (E. coli) [MSH3]  NCCCS 
MSH6 39 rs1042821   Gly Glu G/A   mutS homolog 6 (E. coli) [MSH6]  NCCCS 
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Table V.B.2. Gene variants in CBCS and NCCCS (continued) 
Gene & 
codon/ 
nucleotide 
position rs#  
Common1 
allele (amino 
acid) 
Variant1 
allele 
(amino 
acid) 
Nucleotide 
common/ 
variant  Gene name and official abbreviation 2  Study 
MYH 324 rs3219489   Gln His G/C   mutY homolog (E. coli) [MUTYH]  CBCS 
NAT1 rs1057126   (*10, rapid) (Non *10) T/A   
N-acetyltransferase 1 (arylamine N-
acetyltransferase) [NAT1]  CBCS 
NAT2 Reference   (*4, rapid) (*5,*6,*7,*14,slow)   
N-acetyltransferase 2 (arylamine N-
acetyltransferase) [NAT2]  CBCS 
NBS1 185 rs1805794   Glu Gln G/C   Nijmegen breakage syndrome 1 (nibrin) [NIB]  Both 
NQO1 187 rs1800566   Pro Ser C/T   NAD(P)H dehydrogenase, quinone 1 [NQO1]  CBCS 
OGG1 326 rs1052133   Ser Cys C/G   8-oxoguanine DNA glycosylase [OGG1]  CBCS 
POLD1 119 rs1726801   Arg His G/A   
polymerase (DNA directed), delta 1, catalytic 
subunit 125kDa [POLD1]  NCCCS 
RAD23B rs1805329   Ala Val C/T   RAD23 homolog B (S. cerevisiae) [RAD23B]  Both 
TGFB1 rs1800470   Leu Pro T/C   transforming growth factor, beta 1 [TGFB1]  CBCS 
XPC 499 rs2228000    Ala Val C/T   
xeroderma pigmentosum, complementation group 
C [XPC]  NCCCS 
XPC 939 rs2228001   Lys Gln A/C   
xeroderma pigmentosum, complementation group 
C [XPC]  Both 
XPD 312 rs1799793   Asp Asn G/A   
excision repair cross-complementing rodent repair 
deficiency, complementation group 2 [ERCC2]  Both 
XPD 751 rs13181   Lys Gln A/C   
excision repair cross-complementing rodent repair 
deficiency, complementation group 2 [ERCC2]  Both 
XPF 415 rs1800067   Arg Gln G/A   
excision repair cross-complementing rodent repair 
deficiency, complementation group 4 [ERCC4]  Both 
XPF 662 rs2020955   Ser Pro T/C   
excision repair cross-complementing rodent repair 
deficiency, complementation group 4 [ERCC4]  CBCS 
XPG 1104 rs17655    Asp His G/C   
excision repair cross-complementing rodent repair 
deficiency, complementation group 5 [ERCC5]  Both 
XRCC1 194 rs1799782   Arg Trp C/T   
X-ray repair complementing defective repair in 
Chinese hamster cells 1 [XRCC1]  Both 
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Table V.B.2. Gene variants in CBCS and NCCCS (continued) 
Gene & 
codon/ 
nucleotide 
position rs#  
Common1 
allele 
 (amino acid) 
Variant1 
allele 
(amino 
acid) 
Nucleotide 
common/ 
variant  Gene name and official abbreviation 2  Study 
XRCC1 280 rs25489   Arg His G/A   
X-ray repair complementing defective repair in 
Chinese hamster cells 1 [XRCC1]  Both 
XRCC1 399 rs25487   Arg Gln G/A   
X-ray repair complementing defective repair in 
Chinese hamster cells 1 [XRCC1]  Both 
XRCC2 188 rs3218536    Arg His G/A   
X-ray repair complementing defective repair in 
Chinese hamster cells 2 [XRCC2]  CBCS 
XRCC3 241 rs 861539   Thr Met C/T   
X-ray repair complementing defective repair in 
Chinese hamster cells 3 [XRCC3]  Both 
XRCC4 -
28073 8 rs2075685   T G T/G   
X-ray repair complementing defective repair in 
Chinese hamster cells 4 [XRCC4]   CBCS 
Abbreviations:  CBCS=Carolina Breast Cancer Study, NCCCS=North Carolina Colon Cancer Study, SD=standard deviation, N=number of controls, 
SNP=single nucleotide polymorphism, Ala=alanine, Arg=arginine, Asp=aspartic acid, Asn=asparagine , Glu=glutamic acid, Gln=glutamine,  Gly=glycine, 
His=histidine,  Ile=isoleucine, Leu=leucine, Lys=lysine, Met=methionine, Pro=proline, Phe=phenylalanine, Thr=threonine, Trp=tryptophan, Tyr=tyrosine, 
Ser=serine, Val=valine; C=cytosine, A=adenine, G=guanine, T=thymine 
1
 Analyzed as common and variant as defined by frequency in CBCS/NCCS datasets. The less frequent allele varied by race where noted. 
2
 http://www.ncbi.nlm.nih.gov/sites/entrez (accessed 5/13/2009) 
3 ADPRTL2 328: Less frequent nucleotide was C in African Americans, T in non-African Americans 
4 COMT: less frequent allele was Met in African Americans, Val in non-African Americans 
5 Present (referent) or null 
6 GSTP1: Less frequent allele was Ile in African Americans, Val in non-African Americans 
7
 MnSOD (CBCS & NCCCS): Less frequent allele was Ala in African Americans, Val in non-African Americans 
8
 XRCC4 -28073: Less frequent nucleotide was G in African Americans, T in non-African Americans 
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Table V.B.3a.  Gene variant-smoking status associations in the CBCS, overall and by race 1,2 
Gene pathway/  
SNP 5 
Ever smokers 3 Current smokers 4 
ORz 2 NAA AA <50y >=50y ORz NAA AA <50y >=50y 
Xenobiotic metabolism 6   
  
      
CYPIA1 M1 1.0 0.8 1.1 1.3 0.7 1.0 0.8 1.1 1.0 1.0 
CYPIA1 M2 1.8 1.6 -1 -1 -1 #### -1   -1 -1 
CYPIA1 M3 0.9 -1 1.0 -1 -1 #### ### 1 -1 -1 
CYPIA1 M4 1.3 1.5 -1 -1 -1 2.5 2.9 0 -1 -1 
GSTM1 1.0 1.2 0.8 1.1 1.0 1.1 1.0 1.1 1.3 0.7 
GSTP1 1.2 1.4 0.8 1.2 1.2 0.7 0.7 0 0.7 0.7 
GSTT1 1.0 0.7 1.5 0.9 1.1 1.1 0.9 0 0.9 -1 
NAT1 0.9 1.1 0.8 1.0 1.0 1.2 1.2 0 1.5 -1 
NAT2 0.9 1.1 0.9 1.1 1.0 1.3 2.1 1 1.5 -1 
COMT 0.8 0.6 1.2 1.0 0.7 0.9 0.7 1.3 0.9 0.9 
DNA repair  
  
      
    Base excision repair  
  
      
APE1 148 1.1 1.3 0.9 1.3 1.0 1.2 1.3 1.0 1.3 1.0 
hOGG1 1.0 1.0 1.1 1.1 1.0 0.9 1.0 0.8 1.0 0.8 
MYH 324 1.0 1.0 0.8 1.0 0.9 0.8 0.9 0.8 0.8 0.8 
XRCC1 194 1.1 1.0 1.3 1.2 1.1 1.1 0.9 1.5 1.0 1.3 
XRCC1 280 0.9 0.9 0.9 0.7 1.1 0.9 0.8 0 0.8 -1 
XRCC1 399 1.0 1.1 1.1 1.1 1.1 1.2 1.2 1.4 1.2 1.3 
    Double strand break repair               
BRCA2 24 0.9 0.9 0.9 0.9 0.9 0.9 0.8 1.1 0.9 0.9 
BRCA2 372 1.2 1.2 1.2 1.0 1.4 1.2 1.1 1.2 1.0 1.4 
NBS1 185 1.2 1.3 1.0 1.4 1.1 1.0 1.1 1.1 1.2 0.9 
XRCC2 188 0.9 0.8 -1 1.0 0.9 0.9 0.9 1 1.1 -1 
XRCC3 241 0.9 0.9 1.0 1.0 0.9 1.2 1.2 1.2 1.2 1.2 
XRCC4 -28073 1.2 1.2 1.3 1.5 1.0 1.2 1.1 1.4 1.5 1.0 
    Mismatch repair                 
MGMT 84 0.9 0.9 1.0 1.0 0.9 0.8 0.9 0.7 0.8 0.8 
    Nucleotide excision repair             
ERCC1 8092 1.0 0.9 1.1 1.0 0.9 1.0 0.8 1.1 0.8 1.1 
ERCC6 1213 1.2 1.4 1.0 1.3 1.2 1.6 1.7 1.4 1.6 1.5 
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Table V.B.3a.  Gene variant-smoking status associations in the CBCS, overall and by race 1,2 (continued) 
Gene pathway/  
SNP 5 
Ever smokers 3 Current smokers 4 
ORz 2 NAA AA <50y >=50y ORz NAA AA <50y >=50y 
    Nucleotide excision repair (continued)       
  
    
ERCC6 1230 0.9 0.9 1.2 1.0 0.8 1.1 1.1 1 1.6 0.8 
HRAD23B 1.1 1.1 1.0 1.2 1.0 1.2 1.3 0 1.1 1.3 
XPC 939 0.9 0.9 1.0 0.9 1.0 1.0 1.1 0.9 1.0 1.0 
XPD 312 1.0 1.0 1.1 1.1 1.1 1.1 1.1 1.0 1.0 1.2 
XPD 751 1.2 1.2 1.1 1.1 1.3 1.2 1.1 1.3 1.0 1.4 
XPF 415 1.0 1.1 -1 1.0 1.0 1.0 0.9 0 0.7 1.2 
XPF 662 1.1 ### 1.2 1.0 1.4 1.4 ### 1.4 1.5 1.3 
XPG 1104 0.9 1.0 0.7 0.9 0.9 0.8 0.8 0.9 0.9 0.8 
Cell adhesion                 
CDH1 0.8 0.8 0.8 0.9 0.8 0.8 0.8 0.9 0.9 0.8 
Cell growth                 
TGFB1 1.1 1.1 1.1 1.3 0.9 0.8 0.8 0.9 0.9 0.7 
    Oxidative stress defense             
MnSOD 1.0 0.9 1.0 1.1 0.8 0.9 0.8 0.9 0.8 0.9 
MPO 1.0 1.2 0.9 0.8 1.4 1.0 1.2 0.8 0.9 1.3 
NQO1 7 -99 1.3 0.8 1.2 1.0 1.0 1.3 0.7 1.2 1.0 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, NAA=Non African-American (98% white), AA=African American, PY=pack-
years, SNP=single nucleotide polymorphism, y=years 
1 Odds ratios are race and age adjusted unless stratified by race or age, respectively 
2
 Odds ratio not displayed if 95% confidence limit ratio (upper limit/lower limit) >4 
3
 Referent is never smokers for all smoking categories unless otherwise noted 
4
 Referent is  not-current smokers (former + never) 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 
referent=present 
6 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7
 Could not be pooled for some measures of smoking. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  <=0.7  
  >=1.4  
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Table V.B.3a.  Gene variant-smoking status associations in the CBCS, overall and by race 1,2 (continued) 
Gene pathway/  
SNP 5 
Former smokers 3 Current smokers 3 
ORz NAA AA <50y >=50y ORz NAA AA <50y >=50y 
Xenobiotic metabolism 6   
            
      
CYPIA1 M1 1.0 0.8 1.1 1.5 0.6 1.0 0.8 1.2 1.1 0.8 
CYPIA1 M2 2.1 -1   -1 -1 #### -1 0 -1 -1 
CYPIA1 M3 #### -1 0 -1 -1 #### ### 0 -1 -1 
CYPIA1 M4 #### -1 0 -1 -1 #### -1 0 -1 -1 
GSTM1 1.0 1.3 0 0.9 1.1 1.1 1.1 1.0 1.3 0.8 
GSTP1 1.8 1.9 0 1.9 1.5 0.8 0.9 0 0.8 -1 
GSTT1 0.9 0.7 0 -1 -1 1.1 -1 0 -1 -1 
NAT1 0.8 1.0 0 0.7 1.1 1.1 1.3 0 1.4 -1 
NAT2 0.8 0.9 0 0.9 0.9 1.2 -1 0 1.4 -1 
COMT 0.8 0.6 1.1 1.0 0.7 0.9 0.6 1.3 0.9 0.8 
DNA repair  
                    
    Base excision repair  
                  
APE1 148 1.1 1.2 0.8 1.2 1.0 1.2 1.4 1.0 1.4 1.0 
hOGG1 1.1 1.0 1.3 1.1 1.1 1.0 1.0 0.8 1.0 0.9 
MYH 324 1.1 1.1 1.0 1.2 1.0 0.9 0.9 0.7 0.9 0.8 
XRCC1 194 1.1 1.1 1.2 1.3 1.0 1.2 1.0 1.5 1.1 1.3 
XRCC1 280 0.9 1.0 0 0.7 1.2 0.9 0.8 0 0.8 -1 
XRCC1 399 1.0 1.0 0.9 0.9 1.0 1.2 1.2 1.4 1.2 1.3 
    Double strand break repair    
      
  
BRCA2 24 1.0 1.0 0.8 1.0 0.9 0.9 0.8 1.0 0.9 0.9 
BRCA2 372 1.2 1.2 1.2 1.0 1.4 1.3 1.2 1.3 1.0 1.5 
NBS1 185 1.2 1.4 0.9 1.4 1.1 1.1 1.2 1.0 1.4 0.9 
XRCC2 188 0.9 0.9 0 0.9 1.0 0.8 0.8 0 1.0 -1 
XRCC3 241 0.8 0.8 0.9 0.9 0.8 1.1 1.1 1.2 1.2 1.1 
XRCC4 -28073 1.1 1.2 1.1 1.3 1.0 1.3 1.2 1.5 1.6 1.0 
    Mismatch repair  
MGMT 84 1.1 1.0 1.2 1.2 1.0 0.8 0.9 0.7 0.9 0.8 
    Nucleotide excision repair  
ERCC1 8092 1.0 0.9 1.0 1.2 0.8 1.0 0.8 1.1 0.9 1.0 
ERCC6 1213 1.0 1.1 0.8 1.0 1.0 1.6 1.8 1.3 1.6 1.5 
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Table V.B.3a.  Gene variant-smoking status associations in the CBCS, overall and by race 1,2 
Gene pathway/  
SNP 5 
Former smokers 3 Current smokers 3 
ORz NAA AA <50y >=50y ORz NAA AA <50y >=50y 
    Nucleotide excision repair  (continued) 
ERCC6 1230 0.8 0.8 1 0.7 0.8 1.0 1.0 1 1.4 0.7 
HRAD23B 1.0 1.0 1.2 1.2 0.9 1.2 1.3 0 1.1 1.3 
XPC 939 0.9 0.8 1.1 0.8 0.9 1.0 1.0 0.9 0.9 1.0 
XPD 312 1.0 1.0 1.2 1.1 1.0 1.1 1.1 1.1 1.0 1.2 
XPD 751 1.1 1.2 1.0 1.1 1.2 1.2 1.2 1.2 1.0 1.5 
XPF 415 1.1 1.1 0 1.2 0.9 1 0.9 0 0.8 1.2 
XPF 662 1.0 ### 1.1 0.7 1.4 1.3 ### 1.4 1.3 1.5 
XPG 1104 1.0 1.1 0.7 0.9 1.0 0.8 0.9 0.8 0.8 0.8 
Cell adhesion                     
CDH1 0.8 0.9 0.7 0.9 0.8 0.8 0.8 0.9 0.9 0.7 
Cell growth                     
TGFB1 1.2 1.3 1.2 1.6 1.0 0.9 0.8 1.0 1.1 0.7 
    Oxidative stress defense                     
MnSOD 1.1 1.0 1.0 1.3 0.8 0.9 0.8 0.9 0.9 0.8 
MPO 1.0 1.2 1.0 0.8 1.3 1.0 1.2 0.8 0.8 1.4 
NQO1 7 1.0 1.2 0.8 1.2 1.0 1.0 1.4 0.7 1.2 1.0 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, NAA=Non African-American (98% white), AA=African American, 
PY=pack-years, SNP=single nucleotide polymorphism, y=years 
1 Odds ratios are race and age adjusted unless stratified by race or age, respectively 
2
 Odds ratio not displayed if 95% confidence limit ratio (upper limit/lower limit) >4 
3
 Referent is never smokers for all smoking categories unless otherwise noted 
4
 Referent is  not-current smokers (former + never) 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 
referent=present 
6 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7
 Could not be pooled for some measures of smoking. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  <=0.7   >=1.4        
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Table V.B.3b.  Gene variant-smoking duration association in the CBCS, overall and by race 1,2 
  <=10 years 3 11-20 years >20 years 
Gene pathway/  
SNP 5  ORz 2 NAA AA <50y >=50y ORz NAA AA <50y >=50y ORz NAA AA <50y >=50y 
Xenobiotic metabolism 6  
CYPIA1 M1 1.0 1.2 1.0 1.3 -1.0 1.3 -1.0 -1.0 1.4 -1.0 0.8 0.7 0.9 -1.0 0.6 
CYPIA1 M2 ### -1.0 -.0 -1.0 -1.0 #### -1.0 -1.0 -1.0 -1.0 #### -1.0 -.0 -1.0 -1.0 
CYPIA1 M3 ### #### -.0 -1.0 -1.0 #### #### -1.0 -1.0 -1.0 #### -1.0 -.0 -1.0 -1.0 
CYPIA1 M4 ### -1.0 ## -1.0 -1.0 #### -1.0 #### -1.0 -1.0 #### -1.0 -.0 -1.0 -1.0 
GSTM1 1.1 1.3 -.0 1.0 -1.0 1.0 0.9 -1.0 1.4 -1.0 1.0 1.3 -.0 -1.0 1.1 
GSTP1 1.9 1.8 -.0 -1.0 -1.0 1.0 1.2 -1.0 0.9 -1.0 1.0 1.3 -.0 -1.0 1.2 
GSTT1 ### -1.0 -.0 -1.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0 1.0 -1.0 -.0 -1.0 1.3 
NAT1 0.6 -1.0 -.0 -1.0 -1.0 1.1 -1.0 -1.0 -1.0 -1.0 1.1 1.2 -.0 -1.0 -1.0 
NAT2 0.8 -1.0 -.0 -1.0 -1.0 0.9 -1.0 -1.0 -1.0 -1.0 1.1 1.5 -.0 -1.0 1.1 
COMT 1.0 -1.0 -.0 -1.0 -1.0 0.8 0.5 -1.0 0.6 -1.0 0.8 0.7 -.0 -1.0 0.8 
DNA repair                               
    Base excision repair                             
APE1 148 1.2 1.2 1.0 1.4 0.9 1.1 1.3 0.9 1.1 1.1 1.1 1.3 0.9 1.4 1.0 
hOGG1 1.4 1.1 1.9 1.3 1.3 1.1 1.1 1.0 1.2 0.8 0.9 0.9 0.8 0.7 1.0 
MYH 324 1.0 1.1 0.8 1.0 1.0 1.0 0.9 1.1 1.0 0.8 1.0 1.1 0.7 1.1 0.9 
XRCC1 194 1.4 1.4 1.4 1.5 1.5 0.9 0.7 -1.0 1.4 -1.0 1.1 1.0 1.3 0.9 1.2 
XRCC1 280 0.8 0.8 1.0 -1.0 -1.0 0.9 -1.0 -1.0 -1.0 -1.0 1.0 1.1 -1.0 -1.0 1.1 
XRCC1 399 0.8 0.8 0.8 0.8 1.0 1.1 1.2 0.9 1.0 1.3 1.2 1.1 1.5 1.7 1.1 
    Double strand break repair                           
BRCA2 24 0.9 1.1 0.7 0.9 0.9 1.0 0.9 1.3 1.0 0.9 0.9 0.8 0.9 0.8 0.9 
BRCA2 372 1.0 1.0 1.1 0.9 1.3 1.5 1.7 0.9 1.2 1.6 1.3 1.1 1.6 1.0 1.4 
NBS1 185 1.2 1.2 1.0 1.3 0.9 1.3 1.3 1.5 1.8 1.0 1.1 1.4 0.7 1.1 1.1 
XRCC2 188 0.9 0.7 1.0 1.0 -1.0 0.9 0.9 -1.0 -1.0 -1.0 0.9 0.9 -1.0 1.2 0.8 
XRCC3 241 0.8 0.8 0.9 0.8 0.8 0.8 0.9 0.8 1.1 0.7 1.1 0.9 1.2 1.2 0.9 
XRCC4 1394 1.1 1.0 1.7 1.4 1.0 1.0 1.1 1.1 1.7 0.7 1.3 1.4 1.1 1.3 1.2 
    Mismatch repair  
MGMT 84 1.3 1.3 1.1 1.1 1.4 1.0 0.9 1.4 1.0 1.1 0.7 0.8 0.6 0.9 0.7 
  
184
 
 
 
Table V.B.3b.  Gene variant-smoking duration association in the CBCS, overall and by race 1,2 (continued) 
  <=10 years 3 11-20 years >20 years 
Gene pathway/  
SNP 5  ORz 2 NAA AA <50y >=50y ORz NAA AA <50y >=50y ORz NAA AA <50y 
>=50
y 
    Nucleotide excision repair                           
ERCC1 8092 1.0 1.0 0.9 1.1 0.7 1.1 0.8 1.7 1.2 0.8 0.9 0.9 0.9 0.8 1.0 
ERCC6 1213 1.2 1.1 1.3 1.3 1.0 1.2 1.3 1.0 1.2 1.1 1.2 1.5 0.9 1.3 1.2 
ERCC6 1230 0.8 0.8 1.0 1.0 0.8 0.9 0.8 -1.0 0.8 1.0 1.0 0.9 -1.0 1.5 0.8 
HRAD23B 1.2 1.0 -.0 1.5 0.7 0.9 0.8 -1.0 0.8 0.9 1.2 1.3 0.8 1.2 1.1 
XPC 939 1.0 1.1 0.9 0.9 1.3 0.9 0.7 1.2 0.9 0.8 0.9 0.9 0.8 0.8 0.9 
XPD 312 0.9 1.0 0.8 0.9 0.8 1.2 1.1 1.5 1.3 1.2 1.1 1.1 1.2 1.1 1.1 
XPD 751 0.9 1.1 0.7 0.9 1.1 1.3 1.3 1.3 1.3 1.2 1.3 1.2 1.3 1.1 1.3 
XPF 415 1.1 1.3 -.0 1.3 -1.0 0.9 0.9 -1.0 -1.0 -1.0 1.0 1.0 -1.0 1.0 1.0 
XPF 662 1.1 #### 1.2 0.9 -1.0 1.4 #### 1.4 1.0 -1.0 1.0 #### 1.2 -1.0 1.1 
XPG 1104 0.9 1.1 0.7 0.9 1.0 1.0 1.2 0.8 1.0 1.1 0.9 1.0 0.7 0.8 0.9 
Cell adhesion                               
CDH1 0.9 0.9 0.7 0.9 0.8 0.7 0.7 0.7 0.7 0.8 0.8 0.8 0.9 1.0 0.8 
Cell growth                               
TGFB1 1.3 1.4 1.2 1.5 1.2 1.1 1.1 1.0 1.2 0.9 1.0 0.9 1.0 1.2 0.8 
    Oxidative stress defense                           
MnSOD 1.0 1.0 0.8 1.1 0.8 1.0 0.8 1.3 1.1 0.7 1.0 0.9 1.0 1.0 0.9 
MPO 0.9 1.2 0.7 0.6 1.8 1.1 1.0 1.0 1.0 1.0 1.1 1.3 1.0 0.9 1.4 
NQO1 7 
  
1.2 0.8 1.1 1.0 1.0 1.3 1.1 1.2 1.2 1.1 1.4 0.6 1.4 0.9 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, NAA=Non African-American (98% white), AA=African American, PY=pack-years, 
SNP=single nucleotide polymorphism, y=years 
1 Odds ratios are race and age adjusted unless stratified by race or age, respectively 
2
 Odds ratio not displayed if 95% confidence limit ratio (upper limit/lower limit) >4 
3
 Referent is never smokers for all smoking categories unless otherwise noted 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 referent=present 
6 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7 Could not be pooled for some measures of smoking. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  <=0.7   >=1.4        
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Table V.B.3c.  Gene variant-smoking intensity association in the CBCS, overall and by race 1,2 
  <1/2 pack/day 3 1/2 - 1 pack/day >1 pack/day 
Gene pathway/  
SNP 5  ORz 2 NAA AA <50y >=50y ORz NAA AA <50y >=50y ORz NAA AA <50y >=50y 
Xenobiotic metabolism 6  
CYPIA1 M1 0.9 0.8 1.0 1.3 -1.0 1.0 -1.0 1.3 1.2 -1.0 1.0 1.0 -1.0 -1.0 -1.0 
CYPIA1 M2 #### -1.0 -.0 -1.0 -1.0 #### -1.0 -1.0 -1.0 -1.0 #### -1.0 -1.0 -1.0 -1.0 
CYPIA1 M3 #### ### 1.0 -1.0 -1.0 #### -1.0 -1.0 -1.0 -1.0 #### #### -1.0 -1.0 -1.0 
CYPIA1 M4 #### -1.0 -.0 -1.0 -1.0 #### -1.0 ### -1.0 -1.0 #### -1.0 -1.0 -1.0 -1.0 
GSTM1 0.9 1.0 -.0 1.2 -1.0 0.9 1.1 -1.0 1.0 -1.0 1.3 1.4 -1.0 1.1 1.5 
GSTP1 1.2 1.5 1.0 1.4 -1.0 1.8 2.1 -1.0 -1.0 -1.0 0.9 0.9 -1.0 -1.0 -1.0 
GSTT1 1.3 -1.0 -.0 -1.0 -1.0 1.1 -1.0 -1.0 -1.0 -1.0 #### -1.0 -1.0 -1.0 -1.0 
NAT1 0.8 -1.0 -.0 -1.0 -1.0 1.2 -1.0 -1.0 -1.0 -1.0 0.9 1.1 -1.0 -1.0 -1.0 
NAT2 0.8 -1.0 -.0 -1.0 -1.0 1.0 -1.0 -1.0 -1.0 -1.0 1.1 1.5 -1.0 -1.0 -1.0 
COMT 0.9 0.5 1.5 1.3 0.6 1.2 -1.0 -1.0 0.9 -1.0 0.6 0.5 -1.0 -1.0 -1.0 
DNA repair                               
    Base excision repair                             
APE1 148 1.3 1.3 1.3 1.8 1.0 0.9 1.2 0.6 1.2 0.8 1.2 1.4 0.8 1.0 1.4 
hOGG1 0.9 0.8 1.1 1.1 0.8 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.0 1.0 1.0 
MYH 324 1.0 1.0 0.9 1.0 0.9 0.9 1.0 0.7 1.0 0.8 1.0 1.0 1.3 1.1 1.0 
XRCC1 194 1.2 1.4 0.9 1.4 1.0 1.0 0.6 1.9 1.1 0.8 1.2 1.2 -1.0 1.2 1.4 
XRCC1 280 0.9 0.9 1.0 -1.0 1.4 1.0 0.8 -1.0 0.8 -1.0 0.8 0.9 ### -1.0 -1.0 
XRCC1 399 0.9 1.0 0.9 0.8 1.1 1.1 1.2 1.3 1.2 1.2 1.1 1.1 1.6 1.4 1.0 
    Double strand break repair                           
BRCA2 24 0.8 1.0 0.7 0.8 0.9 1.0 0.9 1.3 1.1 0.9 0.9 0.9 1.0 0.8 1.0 
BRCA2 372 1.1 0.9 1.5 1.1 1.1 1.2 1.2 1.0 0.8 1.5 1.6 1.6 -1.0 1.2 1.8 
NBS1 185 1.1 1.2 1.0 1.2 1.0 1.2 1.4 1.0 1.2 1.2 1.2 1.4 1.0 1.7 1.0 
XRCC2 188 0.8 0.7 1.0 1.0 -1.0 0.8 0.7 -1.0 0.8 0.8 1.1 1.1 -1.0 1.1 1.2 
XRCC3 241 0.9 0.7 1.2 1.0 0.8 0.9 1.1 0.8 1.1 0.8 0.8 0.9 0.8 0.8 0.9 
XRCC4 1394 1.1 0.9 1.4 1.5 0.9 1.2 1.1 1.6 1.8 1.0 1.2 1.5 0.7 1.2 1.3 
    Mismatch repair  
MGMT 84 1.1 1.1 1.1 1.3 0.9 0.8 0.9 0.7 0.6 1.1 0.9 0.8 1.2 1.1 0.8 
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Table V.B.3c.  Gene variant-smoking intensity association in the CBCS, overall and by race 1,2  (continued) 
  <1/2 pack/day 3 1/2 - 1 pack/day >1 pack/day 
Gene pathway/  
SNP 5  ORz 2 NAA AA <50y >=50y ORz NAA AA <50y >=50y ORz NAA AA <50y >=50y 
    Nucleotide excision repair                           
ERCC1 8092 1.0 0.9 1.0 1.2 0.7 1.0 1.1 1.0 1.0 1.1 0.9 0.7 1.5 0.8 0.9 
ERCC6 1213 1.3 1.3 1.2 1.7 1.0 1.3 1.4 1.3 1.3 1.5 1.0 1.3 -1.0 1.0 1.1 
ERCC6 1230 1.0 1.0 1.0 1.1 1.0 1.0 0.9 -1.0 1.2 0.8 0.8 0.8 -1.0 0.9 0.7 
HRAD23B 1.0 1.0 1.0 1.3 0.8 1.1 1.1 -1.0 1.1 1.0 1.2 1.2 -1.0 1.1 1.2 
XPC 939 1.1 1.0 1.2 1.1 1.1 0.8 0.8 0.8 0.8 0.8 0.9 0.9 0.9 0.8 1.1 
XPD 312 1.0 1.0 1.0 1.1 0.9 1.1 1.1 1.1 1.2 1.1 1.1 1.0 1.6 0.9 1.2 
XPD 751 1.1 1.3 1.1 1.0 1.4 1.2 1.2 1.2 1.2 1.1 1.2 1.3 1.0 1.0 1.3 
XPF 415 0.9 0.9 1.0 1.2 -1.0 1.0 0.9 -1.0 0.9 1.0 1.1 1.3 -1.0 0.9 1.5 
XPF 662 1.4 ### 1.6 1.5 1.7 0.9 #### 0.9 0.7 1.3 0.9 #### 1.0 -1.0 -1.0 
XPG 1104 0.9 1.0 0.8 1.1 0.8 0.9 1.1 0.6 0.8 1.0 0.9 1.0 0.7 0.8 1.1 
Cell adhesion                               
CDH1 0.9 1.0 0.8 1.0 0.8 0.8 0.8 0.8 0.9 0.8 0.7 0.7 -1.0 0.7 0.7 
Cell growth                               
TGFB1 1.2 1.2 1.1 1.4 1.1 1.1 1.1 1.0 1.3 0.9 0.9 0.9 1.0 1.2 0.8 
    Oxidative stress defense                           
MnSOD 1.0 0.9 0.9 1.0 0.8 1.0 0.8 1.1 1.0 0.9 1.0 1.0 0.8 1.2 0.8 
MPO 1.0 1.4 0.8 0.7 1.5 1.0 1.1 1.0 0.8 1.4 1.1 1.1 1.2 1.0 1.2 
NQO1 7 
  
1.2 0.8 1.1 0.9 1.2 1.5 1.0 1.5 1.1 0.9 1.2 -1.0 1.0 1.0 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, NAA=Non African-American (98% white), AA=African American, PY=pack-years, 
SNP=single nucleotide polymorphism, y=years 
1 Odds ratios are race and age adjusted unless stratified by race or age, respectively 
2
 Odds ratio not displayed if 95% CI width (upper limit/lower limit) >4 
3
 Referent is never smokers for all smoking categories unless otherwise noted 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 
referent=present 
6 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7
 Could not be pooled. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  <=0.7   >=1.4        
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Table V.B.3d.  Gene variant-PY association in the CBCS, overall and by race 1,2 
  <=35 PY  >35PY 
Gene pathway/  
SNP 5  ORz 2 NAA AA <50y >=50y ORz NAA AA <50y >=50y 
Xenobiotic 
metabolism 6                     
CYPIA1 M1 1.0 0.8 1.1 1.3 0.6 999.0 -1.0 -1.0 -1.0 -1.0 
CYPIA1 M2 1.6 -1.0 -.0 -1.0 -1.0 -99.0 -99.0 -1.0 -9.0 -1.0 
CYPIA1 M3 1.0 -1.0 1.0 -1.0 -1.0   -1.0 -1.0 -1.0 -1.0 
CYPIA1 M4 99.0 -1.0 -.0 -1.0 -1.0 -99.0 0.6 -1.0 -1.0 0.8 
GSTM1 0.9 1.0 0.8 1.0 0.8 1.7 -1.0 -1.0 -1.0 -1.0 
GSTP1 1.4 1.6 0.8 1.2 1.4 0.7 -1.0 -1.0 -1.0 -1.0 
GSTT1 1.0 0.8 1.4 0.8 1.4 -99.0 1.1 -1.0 -1.0 1.0 
NAT1 0.9 1.1 0.9 1.1 1.0 -99.0 -1.0 -1.0 -1.0 -1.0 
NAT2 0.9 1.0 1.0 1.0 0.9 -99.0 1.2 -1.0 1.2 1.0 
COMT 0.9 0.6 1.3 1.0 0.9 0.5 -1.0 -1.0 -1.0 -1.0 
DNA repair                     
    Base excision repair                   
APE1 148 1.1 1.2 1.0 1.3 1.0 1.3 1.8 -1.0 -1.0 1.1 
hOGG1 1.1 1.0 1.2 1.1 1.0 0.9 1.1 -1.0 -1.0 1.0 
MYH 324 1.0 1.0 0.8 1.0 0.9 1.0 1.1 -1.0 1.3 1.0 
XRCC1 194 1.1 0.9 1.3 1.3 0.9 1.6 1.5 -1.0 -1.0 1.7 
XRCC1 280 0.9 0.8 1.0 0.6 1.3 -99.0 -1.0 -99.0 -1.0 -1.0 
XRCC1 399 1.0 1.1 1.0 1.0 1.1 1.0 0.9 -1.0 -1.0 0.9 
    Double strand break repair                 
BRCA2 24 0.9 1.0 0.9 0.9 0.9 0.8 0.7 -1.0 -1.0 0.9 
BRCA2 372 1.2 1.2 1.2 1.0 1.3 1.6 1.5 -1.0 -1.0 2.0 
NBS1 185 1.2 1.4 1.0 1.4 1.1 1.0 1.2 -1.0 1.2 1.0 
XRCC2 188 0.9 0.8 -.0 0.9 0.8 1.1 1.1 -1.0 -1.0 -1.0 
XRCC3 241 0.9 0.9 1.0 1.1 0.8 0.8 0.8 -1.0 -1.0 0.9 
XRCC4 1394 1.1 1.1 1.3 1.4 1.0 1.5 1.6 -1.0 -1.0 1.3 
    Mismatch repair                     
MGMT 84 1.0 1.0 1.0 1.0 1.0 0.5 0.6 -1.0 -1.0 0.6 
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Table V.B.3d.  Gene variant-PY association in the CBCS, overall and by race 1,2 (continued) 
  <=35 PY  >35PY 
Gene pathway/  
SNP 5  ORz 2 NAA AA <50y >=50y ORz NAA AA <50y >=50y 
    Nucleotide excision repair                 
ERCC1 8092 1.0 1.0 1.1 1.1 0.9 0.7 0.6 -1.0 -1.0 0.8 
ERCC6 1213 1.3 1.4 1.1 1.3 1.3 0.8 1.1 -1.0 -1.0 0.8 
ERCC6 1230 0.9 0.9 1.0 1.1 0.9 0.7 0.7 -1.0 -1.0 0.6 
HRAD23B 1.1 1.1 1.0 1.2 1.0 1.2 1.3 -1.0 -1.0 1.1 
XPC 939 0.9 0.8 0.9 0.9 0.9 1.1 1.2 -1.0 -1.0 1.2 
XPD 312 1.1 1.1 1.1 1.1 1.1 0.9 0.9 -1.0 -1.0 1.0 
XPD 751 1.2 1.3 1.1 1.1 1.3 1.1 1.1 -1.0 0.8 1.2 
XPF 415 1.0 1.0 -.0 1.1 0.9 1.0 1.2 999.0 -1.0 1.4 
XPF 662 1.2 999.0 1.3 1.1 1.5 999.0 999.0 -1.0 -1.0 -1.0 
XPG 1104 0.9 1.0 0.7 0.9 0.9 1.2 1.5 -1.0 -1.0 1.2 
Cell adhesion                     
CDH1 0.8 0.8 0.8 0.8 0.8 0.9 0.9 -1.0 1.4 0.8 
Cell growth                     
TGFB1 1.1 1.1 1.0 1.3 1.0 0.8 0.9 -1.0 -1.0 0.8 
Oxidative stress defense                 
MnSOD 1.0 0.8 1.0 1.0 0.8 1.4 1.5 -1.0 -1.0 1.1 
MPO 1.0 1.2 0.9 0.8 1.4 1.1 1.1 -1.0 1.3 1.1 
NQO1 7 
  
1.3 0.8 1.2 1.0 1.1 1.4 -1.0 -1.0 0.9 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, NAA=Non African-American (98% 
white), AA=African American, PY=pack-years, SNP=single nucleotide polymorphism, y=years 
1 Odds ratios are race and age adjusted unless stratified by race or age, respectively 
2
 Odds ratio not displayed if 95% CI width (upper limit/lower limit) >4 
3
 Referent is never smokers for all smoking categories unless otherwise noted 
4
 Pack-years= midpoint of category for number of years smoked x midpoint of category for number of 
packs smoked/day 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less 
common alleles, GSTM1 & GSTT1 referent=present 
6 Primary functional category; gene may function in additional pathways e. g. COMT in estrogen 
metabolism 
7
 Could not be pooled. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
 
 = ORz <=0.7 
 
 = ORz >=1.4 
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Table V.B.4a.  Gene variant-smoking status associations in the NCCCS, overall and by gender and race 1,2 
  
Gene pathway/  
Gene variant 5  
Ever Current vs. not current 
ORz 2 W M NAA AA <65y >=65y ORz W M NAA AA <65y >=65y 
Xenobiotic metabolism 6  
GST hap C 7 1.2 1.3 1.1 1.0 1.7 1.4 1.1 1.0 1.4 0.9 0.7 1.5 1.0 1.1 
GST hap A 8 1.4 1.6 1.2 0.9 2.2 1.8 1.1 1.5 ## 1.4 -1.0 2.3 1.5 1.4 
GST hap B 8 0.8 0.8 0.6 0.7 ## -1.0 0.7 0.6 ## ## -1.0 -1.0 -1.0 -1.0 
GST hap D 8 1.3 1.3 1.3 1.2 1.7 1.6 1.1 0.9 ## 0.7 0.8 -1.0 1.0 0.8 
GSTM1 1.0 1.0 1.0 1.0 1.1 1.0 1.0 0.7 1.1 0.5 0.8 0.7 0.7 0.8 
GSTT1 9 
  
1.0 0.9 0.7 1.5 1.0 0.9 
  
1.1 1.1 0.7 1.8 1.0 1.3 
MEH 113 0.7 0.7 0.8 0.8 0.7 0.7 0.9 0.8 0.6 0.6 0.7 0.5 0.5 0.8 
MEH 139 0.8 1.3 1.0 1.0 1.5 1.1 1.2 0.6 1.0 0.7 0.8 -1.0 0.8 0.9 
DNA repair                             
POLD1 119 0.7 1.2 0.9 1.1 ## 1.3 0.9 0.8 1.1 0.8 1.1 -1.0 1.2 0.7 
   Base excision repair                         
ADPRT 762 1.1 1.3 0.9 1.1 ## 1.1 1.1 1.2 1.8 0.9 1.1 -1.0 1.3 1.1 
ADPRTL2 328 1.1 1.2 1.0 1.2 ## 1.1 1.1 1.1 ## 1.0 1.2 -1.0 1.0 1.1 
APE1 148 1.1 1.3 1.0 1.2 1.0 1.1 1.1 1.0 1.2 0.9 1.2 0.9 0.8 1.3 
XRCC1 194 0.8 0.6 ## 0.8 0.9 -1.0 0.8 0.9 ## ## -1.0 -1.0 -1.0 -1.0 
XRCC1 280 1.3 ## ## 1.2 ## -1.0 -1.0 -1.0 ## ## -1.0 -1.0 -1.0 -1.0 
XRCC1 399 1.1 1.3 0.9 1.1 1.0 0.8 1.3 1.0 0.8 1.1 0.9 1.0 0.7 1.3 
   Double strand break repair                     
NBS1 185 0.9 0.7 0.7 0.7 0.7 0.6 0.8 0.8 0.7 0.9 1.4 0.6 0.9 0.7 
XRCC3 241 0.9 0.7 1.1 0.8 1.1 0.9 0.9 1.1 1.2 1.1 1.2 1.1 1.2 1.1 
   Mismatch repair                           
MLH1 219 1.1 0.7 1.3 0.8 1.3 1.6 0.8 0.8 0.9 1.3 0.9 1.4 1.2 1.1 
MSH3 1036 1.1 1.8 0.8 1.2 1.3 1.4 1.1 1.0 0.9 0.6 0.6 -1.0 1.0 -1.0 
MSH3 940 1.2 1.1 0.7 0.9 0.8 0.8 0.9 0.7 0.8 0.6 0.6 0.7 0.8 0.6 
MSH6 39 0.9 0.8 1.0 0.9 0.9 1.0 0.8 0.7 0.8 0.8 0.6 1.2 0.9 0.8 
  
190
 
 
 
 
Table V.B.4a.  Gene variant-smoking status associations in the NCCCS, overall and by gender and race 1,2  (continued) 
  
Gene pathway/  
Gene variant 5  
Ever Current vs. not current 
ORz 2 W M NAA AA <65y >=65y ORz W M NAA AA <65y >=65y 
   Nucleotide excision repair                     
RAD23B 1.1 0.6 0.9 0.7 0.9 0.9 0.7 1.0 0.4 1.0 0.8 0.7 0.8 0.7 
XPC 499 0.8 0.9 0.8 0.8 1.3 1.1 0.8 1.1 1.0 1.1 0.9 -1.0 1.1 1.0 
XPC 939 1.2 1.3 1.1 1.3 1.1 1.0 1.3 1.0 1.2 0.8 1.1 0.8 0.8 1.1 
XPD 312 1.0 1.1 0.9 1.0 1.0 1.1 1.0 0.9 0.9 0.8 0.9 -1.0 1.1 0.7 
XPD 751 1.2 1.4 1.1 1.2 1.2 1.4 1.2 1.0 1.1 0.9 0.8 1.3 1.1 0.9 
XPF 415 1.0 ## 1.7 1.1 ## -1.0 1.1 1.3 ## 1.5 1.7 -1.0 -1.0 -1.0 
XPG 1104 1.0 1.1 0.8 0.9 1.0 1.4 0.8 1.2 1.2 1.2 1.1 1.4 1.7 0.9 
   Oxidative stress defense                       
MNSOD 1.0 1.2 0.9 1.1 1.0 1.2 0.9 1.1 0.8 1.1 1.1 0.9 0.9 1.1 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, W=women, M=Men, NAA=Non African-American (98% white), 
AA=African American, PY=pack-years, y=years 
1
 Odds ratios are race, age and gender adjusted unless stratified by race, age or gender, respectively 
2 Odds ratio not displayed if confidence limit ratio >4 
3 Referent is never smokers for all smoking categories unless otherwise noted 
4 Referent is  not-current smokers (former + never) 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 
referent=present 
6 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7 GST hap C = haplotype of GSTT1 present & GSTM1 present (referent) vs. all other GSTT1 & GSTM1 combinations of present and 
null combined 
8 GST hap A=GSTT1 null & GSTM1 present, GST hap B=GSTT1 null & GSTM1 null, GST hap D=GSTT1 present & GSTM1 null; GST 
hap C is referent 
11 Pack-years= midpoint of category for number of years smoked x midpoint of category for number of packs smoked/day 
9
 Could not be pooled for some measures of smoking. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  = ORz <=0.7 
  = ORz  >=1.4 
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Table V.B.4b.  Gene variant-smoking status associations in the NCCCS, overall and by gender and race 1,2 
Former Current 
Gene 
pathway/  
Gene variant 5  ORz 2 W M NAA AA <65y >=65y ORz W M NAA AA <65y >=65y 
Xenobiotic metabolism 6                       
GST hap C 7 1.3 1.2 1.2 1.0 1.6 1.5 1.1 1.2 1.5 1.0 0.8 1.9 1.2 1.1 
GST hap A 8 1.3 1.5 1.1 0.9 1.7 -1.0 1.0 1.7 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 
GST hap B 8 0.9 -1.0 -1.0 0.8 -1.0 -1.0 0.7 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 
GST hap D 8 1.4 1.3 1.5 1.2 -1.0 1.8 1.2 1.1 -1.0 0.9 0.9 -1.0 -1.0 -1.0 
GSTM1 1.2 1.0 1.2 1.1 1.3 1.2 1.1 0.8 1.1 0.6 0.8 -1.0 0.8 0.8 
GSTT1 0.9 1.0 0.8 0.8 1.2 1.0 0.8   1.1 1.0 0.6 2.0 1.0 1.1 
MEH 113 0.8 0.8 0.9 0.8 0.9 0.8 0.9 0.7 0.6 0.6 0.6 0.5 0.4 0.7 
MEH 139 0.9 1.3 1.1 1.1 -1.0 1.3 1.2 0.6 1.1 0.8 0.8 -1.0 0.9 1.0 
DNA repair 
POLD1 119 0.7 1.2 1.0 1.1 -1.0 1.3 1.0 0.7 -1.0 0.8 1.2 -1.0 1.3 -1.0 
   Base excision repair                         
ADPRT 762 1.0 1.1 0.9 1.1 -1.0 1.0 1.1 1.2 -1.0 0.8 1.1 -1.0 1.2 -1.0 
ADPRTL2 328 1.1 1.1 1.0 1.2 -1.0 1.1 1.1 1.1 -1.0 1.0 1.3 -1.0 1.1 1.2 
APE1 148 1.1 1.3 1.0 1.2 1.0 1.3 1.0 1.1 1.3 0.9 1.3 0.9 0.9 1.3 
XRCC1 194 0.8 0.6 -1.0 0.7 -1.0 -1.0 0.8 0.8 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 
XRCC1 280 1.3 -1.0 -1.0 1.3 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 -1.0 
XRCC1 399 1.1 1.5 0.8 1.2 0.9 0.9 1.3 1.0 0.9 1.0 1.0 -1.0 0.6 1.5 
   Double strand break repair                     
NBS1 185 0.9 0.7 0.8 0.6 0.8 0.6 0.8 0.8 -1.0 0.7 1.1 0.5 0.7 0.7 
XRCC3 241 0.8 0.7 1.1 0.7 1.1 0.8 0.9 1.0 1.0 1.1 1.0 1.2 1.1 1.0 
  Mismatch repair  
MLH1 219 1.2 0.7 1.3 0.8 1.2 1.6 0.7 0.9 0.8 1.5 0.8 1.5 1.5 0.9 
MSH3 1036 1.1 2.1 0.9 1.4 1.5 1.5 1.3 1.0 -1.0 -1.0 0.7 -1.0 -1.0 -1.0 
MSH3 940 1.4 1.2 0.8 1.0 0.8 0.8 1.0 0.8 0.8 0.6 0.7 0.7 0.7 0.6 
MSH6 39 1.0 0.8 1.0 1.0 0.8 1.1 0.8 0.7 0.8 0.9 0.6 1.1 0.9 0.8 
  
192
 
 
 
Table V.B.4b.  Gene variant-smoking status associations in the NCCCS, overall and by gender and race 1,2 (continued) 
Former Current 
Gene 
pathway/  
Gene variant 5  ORz 2 W M NAA AA <65y >=65y ORz W M NAA AA <65y >=65y 
   Nucleotide excision repair                       
RAD23B 1.1 0.7 0.9 0.7 1.0 1.0 0.7 1.0 0.4 1.0 0.7 0.7 0.8 0.6 
XPC 499 0.8 0.9 0.7 0.7 -1.0 1.0 0.7 1.0 0.9 0.9 0.8 -1.0 1.1 0.9 
XPC 939 1.3 1.3 1.2 1.3 1.2 1.1 1.3 1.1 1.4 0.9 1.3 0.9 0.9 1.2 
XPD 312 1.1 1.2 0.9 1.0 1.1 1.1 1.1 0.9 1.0 0.8 0.9 -1.0 1.2 0.7 
XPD 751 1.3 1.5 1.1 1.3 1.1 1.4 1.2 1.1 1.3 0.9 1.0 1.3 1.3 1.0 
XPF 415 0.9 -1.0 -1.0 0.9 -1.0 -1.0 1.1 1.2 -1.0 -1.0 1.6 -1.0 -1.0 -1.0 
XPG 1104 0.9 1.1 0.8 0.9 0.9 1.1 0.8 1.2 1.2 1.0 1.0 1.4 1.8 0.8 
   Oxidative stress defense                       
MNSOD 1.0 1.4 0.8 1.1 1.0 1.4 0.9 1.1 0.9 1.0 1.1 0.9 1.0 1.0 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, W=women, M=Men, NAA=Non African-American (98% white), 
AA=African American, PY=pack-years, y=years 
1 Odds ratios are race, age and gender adjusted unless stratified by race, age or gender, respectively 
2 Odds ratio not displayed if confidence limit ratio >4 
3 Referent is never smokers for all smoking categories unless otherwise noted 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 
referent=present 
6 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7 GST hap C = haplotype of GSTT1 present & GSTM1 present (referent) vs. all other GSTT1 & GSTM1 combinations of present and null 
combined 
8 GST hap A=GSTT1 null & GSTM1 present, GST hap B=GSTT1 null & GSTM1 null, GST hap D=GSTT1 present & GSTM1 null; GST hap C is 
referent 
11 Pack-years= midpoint of category for number of years smoked x midpoint of category for number of packs smoked/day 
9
 Could not be pooled for some measures of smoking. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  = ORz <=0.7 
  = ORz >=1.4 
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Table V.B.4c.  Gene variant-smoking duration association in the NCCCS, overall and by gender and race 1,2 
<10y 11-20y >20 y 
Gene 
pathway/  
Gene 
variant 5  ORz 2 W M NAA AA Y O ORz W M NAA AA Y O ORz W M NAA AA Y O 
Xenobiotic metabolism 6                                      
GST hap C 7 1.5 1.6 1.4 1.3   1.2 1.1 - 0.9 1.0  1.1 1.0 1.2 1.2 1.1 0.8  1.1 1.0 
GST hap A 8 1.6  1.0 -1.0   1.0 1.3 1  -1.0  -1.0 -1.0 1.4 1.6 1.2 0.7    
GST hap B 8 -1.0  -.0 -1.0   -.0 -1.0 1  -1.0  -1.0 -1.0 0.7 1.0 -1.0 0.6    
GST hap D 8 1.7  -.0 1.6   1.0 1.1 1  1.1  -1.0 -1.0 1.2 1.3 1.2 1.0    
GSTM1 1.3 1.2 1.3 1.2   1.1 0.9 1 0.8 1.0  0.8 1.0 1.0 1.0 1.0 1.0  0.8 1.0 
GSTT1 1.0 1.3 0.8 0.8   0.9 1.0 - 1.0 0.9  1.1 0.9 0.9 1.0 0.9 0.6  1.1 0.9 
MEH 113 0.7 1.1 1.0 1.0   1.4 0.7 1 0.9 0.8  0.9 0.7 0.8 0.6 0.7 0.7  0.9 0.7 
MEH 139 1.0 1.2 1.4 1.4   1.3 0.8 1 0.8 1.0  -1.0 1.5 0.7 1.3 0.9 0.9   1.5 
DNA repair                                    
POLD1 119 0.7 1.0 -.0 1.2   -.0 0.9 0  0.9  -1.0 -1.0 0.7 1.2 1.0 1.2    
   Base excision repair                                
ADPRT 762 1.2  1.0 1.4   -.0 0.7 1  0.7  -1.0 -1.0 1.2 1.5 1.0 1.1    
ADPRTL2 
328 1.0  0.7 1.1   0.9 1.0  1.2 1.2  -1.0 -1.0 1.2 1.3 1.0 1.3    
APE1 148 1.4  0.8 1.3   1.3 1.1 1 1.8 1.2  1.0 1.2 1.0 1.3 0.8 1.2  1.0 1.2 
XRCC1 194 -1.0  1.0 -1.0   -1. -.0 1  -1.0  -1.0 -1.0 0.9 1.0 -1.0 0.8    
XRCC1 280 -1.0  1.0 -1.0   -1. -1.0 1  -1.0  -1.0 -1.0 1.2 1.0 -1.0 -1.0    
XRCC1 399 1.3 1.1 1.3 1.3   1.7 1.2 0 0.9 1.2  -1.0 1.8 1.0 1.2 0.8 1.0   1.8 
   Double strand break repair                               
NBS1 185 0.9 -1.0 1.0 -1.0   -.0 1.2 1 0.9 -1.0  -1.0 -1.0 0.8 0.6 0.7 0.8    
XRCC3 241 0.7 0.5 1.1 0.7   0.7 0.7 . 0.7 0.6  1.0 0.5 1.0 0.9 1.3 0.9  1.0 0.5 
                                      
MLH1 219 1.4  1.1 0.8   0.9 1.0 1  1.0  -1.0 1.0 1.1 0.6 1.2 0.8   1.0 
MSH3 1036 1.0  -.0 1.2   1.2 1.1 0  1.2  -1.0 1.5 1.0 1.4 0.8 1.2   1.5 
MSH3 940 1.2 1.0 -.0 1.0   0.7 1.6 0 1.0 0.9  -1.0 1.3 1.1 1.2 0.7 0.9   1.3 
MSH6 39 0.8 0.9 1.0 1.0  0.9 1.0 0.9 0 1.2 1.1  1.7 1.0 0.9 0.6 0.9 0.8  1.7 1.0 
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Table V.B.4c.  Gene variant-smoking duration association in the NCCCS, overall and by gender and race 1,2 (continued) 
<10y 11-20y >20 y 
Gene 
pathway/  
Gene 
variant 5  
OR
z
 2
 W M NAA 
A
A Y O ORz W M NAA AA Y O ORz W M NAA AA Y O 
   Nucleotide excision repair                                     
RAD23B 1.2 0.5 1.0 0.8  1.1 0.5 0.8  1.0 0.7  0.9 0.7 1.1 0.7 0.9 0.7  0.9 0.7 
XPC 499 0.8 1.0 0.7 0.7   0.6 0.9  0.7 0.7   1.3 0.9 0.8 0.9 0.8   1.3 
XPC 939 1.0 0.9 1.1 0.9  0.7 1.3 1.1  1.2 1.2 1.0 1.0 1.1 1.3 1.8 1.1 1.6 1.0 1.0 1.1 
XPD 312 1.3 1.1 1.3 1.2   1.3 1.0  0.9 1.0   0.8 0.9 1.1 0.8 0.9  - 0.8 
XPD 751 1.5 1.9 1.2 1.6   1.4 1.5  1.3 1.8  1.3 1.8 1.0 1.2 0.9 1.0  1.3 1.8 
XPF 415 1.0 -.0 -1.0 -1.0   -1.0 -1.0      -1. 1.1 -1.0 -1.0 1.2   -1.0 
XPG 1104 0.7 1.0 0.8 0.8   0.7 0.8  0.6 0.6  1.3 0.5 1.2 1.5 1.0 1.1  1.3 0.5 
   Oxidative stress defense                              
MNSOD 1.0 1.2 0.8 1.1  1.2 0.9 1.4  0.8 1.1  1.3 0.9 0.9 1.1 0.9 1.1  1.3 0.9 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, W=women, M=Men, NAA=Non African-American (98% white), AA=African American, 
PY=pack-years,  Y: <65 years of age, O: >=65 years of age 
1 Odds ratios are race, age and gender adjusted unless stratified by race, age or gender, respectively 
2 Odds ratio not displayed if confidence limit ratio >4 
3 Referent is never smokers for all smoking categories unless otherwise noted 
5
 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 referent=present 
6
 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7 GST hap C = haplotype of GSTT1 present & GSTM1 present (referent) vs. all other GSTT1 & GSTM1 combinations of present and null combined 
8
 GST hap A=GSTT1 null & GSTM1 present, GST hap B=GSTT1 null & GSTM1 null, GST hap D=GSTT1 present & GSTM1 null; GST hap C is referent 
11
 Pack-years= midpoint of category for number of years smoked x midpoint of category for number of packs smoked/day 
9 Could not be pooled for some measures of smoking. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  = ORz <=0.7 
  = ORz >=1.4 
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Table V.B.4d.  Gene variant-smoking intensity association in the NCCCS, overall and by gender and race 1,2 
<1/2 pack/day 1/2 - 1 pack/day >1 pack/day 
Gene 
pathway/  
Gene 
variant 5  ORz 2 W M NAA 
A
A Y O ORz W M NAA AA Y O ORz W M NAA AA Y O 
Xenobiotic metabolism 6  
GST  
hap C 7 1.7 2.5 1.3 1.3 2.3 2.0 1.6 1.0 0.8 1.0 0.7 1.3 1.5 0.7 1.2 1.1 1.2 1.1 1.3 1.5 0.7 
GST  
hap A 8 1.8      1.7 1.2 -.0 1.2 -1.0 -.0 -1.0 0.7 1.3 1.0 -.0 -1.0 1.0 -1. 0.7 
GST 
 hap B 8 1.1 1.0 -.0 -1.0 1.0 1.0 -1.0 0.5 -1. 1.0 -1.0 -.0 -1.0 -1.0 0.9 -.0 -.0 -1.0 -.0 -1.0 -1.0 
GST 
 hap D 8 1.9 -.0 -.0 1.6 1.0 1.0 1.5 1.0 0.9 1.1 0.9 -.0 -1.0 0.8 1.3 -.0 1.2 1.3 -.0 -1.0 0.8 
GSTM1 1.4 1.6 1.2 1.3 1.5 1.7 1.2 0.8 0.7 0.8 0.8 -.0 0.8 0.8 1.1 1.0 1.1 1.1 -.0 0.8 0.8 
GSTT1 1.1 1.7 0.7 0.8 1.7 1.0 1.2 0.8 0.8 0.9 0.6 1.3 1.3 0.6 0.9 -.0 1.0 0.7 1.3 1.3 0.6 
MEH 113 0.9 0.9 0.9 0.8 0.9 0.8 1.0 0.7 0.7 0.9 0.8 0.7 0.6 0.9 0.6 -.0 0.7 0.7 0.7 0.6 0.9 
MEH 139 0.9 1.1 1.0 1.1 1.0 -1.0 1.2 0.8 1.6 0.9 1.0 -1. 1.2 1.1 0.6 -.0 1.1 1.0 -.0 1.2 1.1 
DNA repair  
POLD1 
119 0.6 1.1 1.3 1.2 -.0 -1.0 1.0 0.8 1.3 0.8 1.1 1.0 1.1 1.0 0.6 1.0 0.8 1.0 -.0 1.1 1.0 
   Base excision repair                                       
ADPRT 
762 1.1 1.2 10 1.1 -.0 -10 1.0 1.1 1.3 0.9 1.1 -1. 1.3 1.0 1.1 -0 0.8 1.0 -0 1.3 1.0 
ADPRTL2 
328 0.9 0.9 0.8 1.1 1.0 -1.0 0.9 1.2 1.4 1.0 1.2 -.0 1.0 1.3 1.2 -.0 1.1 1.3 -.0 1.0 1.3 
APE1 148 1.1 1.5 0.8 1.2 0.9 1.2 1.0 1.2 1.3 1.2 1.3 1.2 1.4 1.2 1.1 1.0 1.0 1.2 1.2 1.4 1.2 
XRCC1 
194 0.7 -0 -.0 -1.0 -.0 -1.0 -1.0 0.7 1.0 -.0 -1.0 -.0 -1.0 -1.0 1.1 -.0 -.0 1.0 -.0 -1.0 -1.0 
XRCC1 
280 -1.0 1.0 -.0 -1.0 -.0 -1.0 -1.0 -1.0 1.0 10 -1.0 -.0 -1.0 -1.0 -1.0 -.0 -.0 -1. -.0 -1.0 -1.0 
XRCC1 
399 1.2 1.5 1.0 1.4 1.1 0.8 1.6 1.2 1.2 1.0 1.2 -.0 1.0 1.3 0.8 1.0 0.7 0.9 -.0 1.0 1.3 
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Table V.B.4d.  Gene variant-smoking intensity association in the NCCCS, overall and by gender and race 1,2 (continued) 
<1/2 pack/day 1/2 - 1 pack/day >1 pack/day 
Gene 
pathway/  
Gene 
variant 5  ORz 2 W M NAA AA Y O 
OR
z W M NAA AA Y O ORz W M NAA AA Y O 
   Double strand break repair  
NBS1 185 1.0 0.6 0.6 -1.0 0.6 1.0 0.7 0.8 0.8 0.8 0.8 0.8 0.8 0.8 1.0 1.0 0.8 0.6 0.8 0.8 0.8 
XRCC3 
241 0.9 0.7 1.1 0.7 1.2 0.7 1.0 0.8 0.9 0.8 0.8 1.0 1.0 0.8 1.1 0.7 1.4 1.0 1.0 1.0 0.8 
MLH1 
219 1.1 0.7 1.9 0.9 1.4 -.0 0.8 1.2 0.6 1.4 0.9 1.2 1.2 0.9 1.2 1.0 1.0 0.8 1.2 1.2 0.9 
MSH3 
1036 0.8 1.4 0.7 1.2 -.0 1.0 0.9 1.1 1.6 0.7 1.0 -.0 1.6 0.9 1.3 1.0 0.9 1.5 -1. 1.6 0.9 
MSH3 940 1.1 1.2 0.5 1.0 0.7 0.8 0.8 1.2 0.8 0.9 0.9 0.9 0.8 0.9 1.6 -.0 0.8 1.0 0.9 0.8 0.9 
MSH6 39 0.8 1.0 1.0 0.9 1.0 1.2 0.9 0.9 0.6 1.0 0.8 0.8 0.9 0.8 0.9 1.1 1.0 1.0 0.8 0.9 0.8 
   Nucleotide excision repair 
RAD23B 1.2 0.7 1.2 0.8 1.1 1.3 0.8 1.0 0.6 0.9 0.7 0.7 0.9 0.6 0.9 1.0 0.8 0.6 0.7 0.9 0.6 
XPC 499 1.0 1.3 0.8 0.8 -.0 -1.0 1.0 0.8 0.8 0.7 0.7 -.0 -1.0 0.7 0.8 -.0 0.9 0.7 -.0 -1.0 0.7 
XPC 939 1.2 1.0 1.4 1.3 1.2 1.1 1.3 1.4 1.6 1.2 1.4 1.3 1.2 1.5 1.0 -.0 0.8 1.2 1.3 1.2 1.5 
XPD 312 1.1 0.8 1.3 1.1 1.1 -1.0 1.1 0.9 1.5 0.7 1.0 -.0 0.8 1.0 1.0 -.0 0.9 1.0 1.0 0.8 1.0 
XPD 751 1.4 1.4 1.3 1.5 1.3 1.4 1.4 1.0 1.3 0.8 1.0 0.9 0.7 1.2 1.4 -.0 1.2 1.3 0.9 0.7 1.2 
XPF 415 -1.0 -.0 -.0 -1.0 -.0 -1.0 -1.0 1.2 1.0 -.0 1.3 -.0 -1.0 1.4 1.0 -.0 -.0 0.9 -.0 -.0 1.4 
XPG 1104 0.9 1.0 0.8 0.8 1.0 0.8 0.9 1.1 0.9 1.1 1.0 1.2 1.5 0.8 1.0 -.0 0.7 1.0 1.2 1.5 0.8 
   Oxidative stress defense                                     
MNSOD 1.1 0.8 0.8 1.1 0.7 1.0 0.7 1.0 1.5 0.8 1.0 1.3 1.4 0.9 0.9 2.2 0.9 1.3 1.3 1.4 0.9 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, W=women, M=Men, NAA=Non African-American (98% white), AA=African American, 
PY=pack-years, y=years 
1 Odds ratios are race, age and gender adjusted unless stratified by race, age or gender, respectively; Odds ratio not displayed if 95% confidence limit ratio 
(upper limit/lower limit) >4 
2 Odds ratio not displayed if confidence limit ratio >4 
3 Referent is never smokers for all smoking categories unless otherwise noted 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 referent=present 
6 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7 GST hap C = haplotype of GSTT1 present & GSTM1 present (referent) vs. all other GSTT1 & GSTM1 combinations of present and null combined 
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Table V.B.4d.  Gene variant-smoking intensity association in the NCCCS, overall and by gender and race 1,2 (continued) 
8 GST hap A=GSTT1 null & GSTM1 present, GST hap B=GSTT1 null & GSTM1 null, GST hap D=GSTT1 present & GSTM1 null; GST hap C is referent 
11 Pack-years= midpoint of category for number of years smoked x midpoint of category for number of packs smoked/day 
9 Could not be pooled for some measures of smoking. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  = ORz <=0.7 
  = ORz >=1.4 
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Table V.B.4e.  Gene variant-pack-years of smoking association in the NCCCS, overall and by gender and race 1,2 
<=35 PY  >35PY 
Gene pathway/  
Gene variant 5  ORz 2 W M NAA AA <65y >=65y ORz W M NAA AA <65y >=65y 
Xenobiotic metabolism 6                         
GST hap C 7 1.3 1.6 1.1 1.1 1.7 1.5 1.2 1.0 1.0 1.1 0.8 -1.0 -1.0 1.0 
GST hap A 8 1.5 1.9 1.2 1.0 2.1 -1.0 1.2 1.2 -.0 1.0 -1.0 -1.0 -1.0 -1.0 
GST hap B 8 0.8 1.2 -.0 0.8 -.0 -1.0 -1.0 -1.0 1.0 -.0 -1.0 -1.0 -1.0 -1.0 
GST hap D 8 1.4 1.6 1.3 1.3 1.8 1.8 1.2 1.0 -.0 1.2 1.0 -1.0 -1.0 0.9 
GSTM1 1.1 1.3 1.0 1.1 1.1 1.1 1.1 0.9 -.0 1.0 0.9 -1.0 -1.0 1.0 
GSTT1 
  
1.2 0.8 0.8 1.4 1.1 0.9 
  
-.0 0.9 0.6 -1.0 -1.0 0.9 
MEH 113 0.8 0.7 0.9 0.8 0.8 0.7 1.0 0.7 -1. 0.6 0.7 -1.0 -1.0 0.6 
MEH 139 0.8 1.4 1.0 1.1 1.4 1.2 1.2 0.6 1.0 1.0 0.9 -1.0 -1.0 1.2 
DNA repair                             
POLD1 119 0.7 1.1 0.9 1.0 -.0 1.2 0.9 0.6 1.0 1.0 1.2 -1.0 -1.0 1.0 
   Base excision repair                         
ADPRT 762 1.1 1.2 1.0 1.2 1.0 1.0 1.2 1.0 1.0 -.0 1.0 -1.0 -1.0 0.9 
ADPRTL2 328 1.1 1.2 1.0 1.2 1.0 1.0 1.1 1.2 -.0 1.0 1.2 -1.0 -1.0 1.2 
APE1 148 1.1 1.2 0.9 1.2 1.0 1.1 1.0 1.2 1.0 1.0 1.4 -1.0 -1.0 1.3 
XRCC1 194 0.8 0.5 -.0 0.7 0.9 -1.0 0.7 0.8 -.0 -.0 -1.0 -1.0 -1.0 -1.0 
XRCC1 280 1.2 1.0 -.0 -1.0 1.0 -1.0 -1.0 -1.0 -.0 -.0 -1.0 
-
99.0 -1.0 -1.0 
XRCC1 399 1.2 1.2 1.0 1.3 1.0 0.8 1.4 0.9 -.0 0.7 0.9 -1.0 -1.0 1.0 
   Double strand break repair                       
NBS1 185 1.0 0.7 0.8 0.7 0.7 0.7 0.8 0.8 -.0 0.6 -1.0 -1.0 -1.0 0.7 
XRCC3 241 0.8 0.8 0.9 0.7 1.1 0.9 0.8 1.1 1.0 1.5 1.1 -1.0 -1.0 1.2 
                              
MLH1 219 1.2 0.8 1.6 1.0 1.3 1.8 0.9 1.0 -.0 1.0 0.6 -1.0 -1.0 0.6 
MSH3 1036 1.0 1.7 0.8 1.1 1.3 1.4 1.1 1.5 1.0 0.8 1.3 -1.0 -1.0 1.3 
MSH3 940 1.2 0.9 0.7 0.9 0.8 0.8 0.9 1.3 1.0 0.7 1.0 -1.0 -1.0 1.1 
MSH6 39 0.8 0.9 1.0 1.0 0.9 1.1 0.9 1.0 1.0 0.9 0.7 -1.0 -1.0 0.7 
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Table V.B.4e.   
Gene variant-pack-years of smoking association in the NCCCS, overall and by gender and race 1,2 (continued) 
<=35 PY  >35PY 
Gene pathway/  
Gene variant 5  ORz 2 W M NAA AA <65y >=65y ORz W M NAA AA <65y >=65y 
   Nucleotide excision repair                        
RAD23B 1.0 0.6 1.0 0.7 0.9 0.9 0.7 1.1 1.0 0.8 0.7 -1.0 -1.0 0.5 
XPC 499 0.9 1.1 0.8 0.8 1.3 1.0 0.9 0.7 1.0 0.8 0.6 -1.0 -1.0 0.6 
XPC 939 1.1 1.1 1.1 1.2 1.1 1.0 1.3 1.5 1.0 1.1 1.6 -1.0 -1.0 1.6 
XPD 312 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.8 0.9 -1.0 -1.0 0.8 
XPD 751 1.2 1.4 1.1 1.3 1.1 1.2 1.3 1.2 1.0 1.0 1.0 -1.0 -1.0 0.9 
XPF 415 0.9 10 -.0 1.0 1.0 -1.0 1.1 1.1 1.0 -.0 1.1 -1.0 -1.0 -1.0 
XPG 1104 0.9 0.9 0.8 0.8 1.0 1.1 0.8 1.3 1.0 0.9 1.3 -1.0 -1.0 0.8 
   Oxidative stress defense                        
MNSOD 1.1 1.1 0.8 1.0 0.9 1.2 0.8 0.8 1.0 1.1 1.5 -1.0 -1.0 1.4 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, W=women, M=Men, NAA=Non African-American (98% white), 
AA=African American, PY=pack-years, y=years 
1
 Odds ratios are race, age and gender adjusted unless stratified by race, age or gender, respectively 
2 Odds ratio not displayed if confidence limit ratio >4 
3 Referent is never smokers for all smoking categories unless otherwise noted 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & 
GSTT1 referent=present 
6 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
7 GST hap C = haplotype of GSTT1 present & GSTM1 present (referent) vs. all other GSTT1 & GSTM1 combinations of present and 
null combined 
8 GST hap A=GSTT1 null & GSTM1 present, GST hap B=GSTT1 null & GSTM1 null, GST hap D=GSTT1 present & GSTM1 null; GST 
hap C is referent 
11 Pack-years= midpoint of category for number of years smoked x midpoint of category for number of packs smoked/day 
9 Could not be pooled for some measures of smoking. LRT p-value for race*smoking interaction term <0.05 
Bold = Overall ORz 
  = ORz <=0.7 
  = ORz >=1.4 
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Table V.B.5: Gene variant-smoking associations in CBCS and NCCCS 
 Smoking Status Duration Intensity Pack-years 
 Ever smoking 
(ORz) 5,6 
Current 
smokers  
(Ref: Not 
Current) 7 
Former 
smokers  
(ORz) 
Current 
smokers  
(ORz) 
<=10y  
(ORz) 
11-20y  
(ORz) 
>20y  
(ORz) 
<1/2pk  
(ORz) 
1/2 - 1 pk  
(ORz) 
>1 pk  
(ORz) 
<=35 PY 
10
 
(ORz)) 
>35PY  
(ORz) 
Gene 
pathway 9 / 
gene 
variant 8 B 3 C 4 B C B C B C B C B C B C B C B C B C B C B C 
Xenobiotic metabolism 6 
GSTM1 1.0 1.0 1.1 0.7 1.0 1.2 1.1 0.8 1.1 1.3 1.0 0.9 1.0 1.0 0.9 1.4 0.9 0.8 1.3 1.1 0.9 1.1 1.7 0.9 
GSTT1 1.0 1.0 1.1 1.1 0.9 0.9 1.1 1.1 -0.9 1.0 1.0 1.0 1.0 0.9 1.3 1.1 1.1 0.8 -0.9 0.9 1.0 1.0 -0.9 0.9 
DNA repair 
   Base excision repair 
APE1 148 1.1 1.1 1.2 1.0 1.1 1.1 1.2 1.1 1.2 1.4 1.1 1.1 1.1 1.0 1.3 1.1 0.9 1.2 1.2 1.1 1.1 1.1 1.3 1.2 
XRCC1 194 1.1 0.8 1.1 0.9 1.1 0.8 1.2 0.8 1.4 -1.0 0.9 -1.0 1.1 0.9 1.2 0.7 1.0 0.7 1.2 1.1 1.1 0.8 1.6 0.8 
XRCC1 280 0.9 1.3 0.9 -1.0 0.9 1.3 0.9 -1.0 0.8 -1.0 0.9 -1.0 1.0 1.2 0.9 -1.0 1.0 -1.0 0.8 -1.0 0.9 1.2 -0.9 -1.0 
XRCC1 399 1.0 1.1 1.2 1.0 1.0 1.1 1.2 1.0 0.8 1.3 1.1 1.2 1.2 1.0 0.9 1.2 1.1 1.2 1.1 0.8 1.0 1.2 1.0 0.9 
   Double strand break repair 
NBS1 185 1.2 0.9 1.0 0.8 1.2 0.9 1.1 0.8 1.2 0.9 1.3 1.2 1.1 0.8 1.1 1.0 1.2 0.8 1.2 1.0 1.2 1.0 1.0 0.8 
XRCC3 241 0.9 0.9 1.2 1.1 0.8 0.8 1.1 1.0 0.8 0.7 0.8 0.7 1.1 1.0 0.9 0.9 0.9 0.8 0.8 1.1 0.9 0.8 0.8 1.1 
   Nucleotide excision repair 
HRAD23B 1.1 1.1 1.2 1.0 1.0 1.1 1.2 1.0 1.2 1.2 0.9 0.8 1.2 1.1 1.0 1.2 1.1 1.0 1.2 0.9 1.1 1.0 1.2 1.1 
XPC 939 0.9 1.2 1.0 1.0 0.9 1.3 1.0 1.1 1.0 1.0 0.9 1.1 0.9 1.3 1.1 1.2 0.8 1.4 0.9 1.0 0.9 1.1 1.1 1.5 
XPD 312 1.0 1.0 1.1 0.9 1.0 1.1 1.1 0.9 0.9 1.3 1.2 1.0 1.1 0.9 1.0 1.1 1.1 0.9 1.1 1.0 1.1 1.0 0.9 1.0 
XPD 751 1.2 1.2 1.2 1.0 1.1 1.3 1.2 1.1 0.9 1.5 1.3 1.5 1.3 1.0 1.1 1.4 1.2 1.0 1.2 1.4 1.2 1.2 1.1 1.2 
XPF 415 1.0 1.0 1.0 1.3 1.1 0.9 1.0 1.2 1.1 1.0 0.9 -1.0 1.0 1.1 0.9 -1.0 1.0 1.2 1.1 1.0 1.0 0.9 1.0 1.1 
XPG 1104 0.9 1.0 0.8 1.2 1.0 0.9 0.8 1.2 0.9 0.7 1.0 0.8 0.9 1.2 0.9 0.9 0.9 1.1 0.9 1.0 0.9 0.9 1.2 1.3 
   Oxidative stress defense 
MNSOD 1.0 1.0 0.9 1.1 1.1 1.0 0.9 1.1 1.0 1.0 1.0 1.4 1.0 0.9 1.0 1.1 1.0 1.0 1.0 0.9 1.0 1.1 1.4 0.8 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, PY=pack-years, met=metabolism, Ph=Phase, CBCS=B=Carolina Breast Cancer Study, 
NCCCS=C=North Carolina Colon Cancer Study, y=years, pk=packs/day 
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Table V.B.5: Gene variant-smoking associations in CBCS and NCCCS (continued) 
3 All odds ratios from CBCS (B) are race and age adjusted 
4 All odds ratios from NCCCS (C) are race, age and gender adjusted 
5
 Odds ratio not displayed if 95% confidence limit ratio (upper limit/lower limit) >4 
6
 Referent is never smokers for all smoking categories unless otherwise noted 
7
 Referent is  not-current smokers (former + never) 
8 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 referent=present 
9 Primary functional category; gene may function in additional pathways e.g. COMT in estrogen metabolism 
10
 Pack-years= midpoint of category for number of years smoked x midpoint of category for number of packs smoked/day 
Bold = Overall ORz 
 = ORz <=0.7 
 = ORz >=1.4 
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Table V.B.6. Gene-variant - smoking associations 1 in CBCS & NCCCS: Non-African American female controls 40-74 years of age 
  Smoking 2 Status Duration (years) Intensity  (pack/day) Pack-years 3 
  
Ever 
smoking  
(ORz) 1,4 
Current 
smokers  
(Ref: Not 
Current) 5 
Former 
smokers  
(ORz) 
Current 
smokers  
(ORz) 
<=10y  
(ORz) 
11-20y  
(ORz) 
>20y  
(ORz) 
<1/2pk  
(ORz) 
1/2 - 1 
pk  
(ORz) 
>1 pk  
(ORz) 
<=35 
PY 
(ORz) 
>35PY  
(ORz) 
SNP 7 B8 C9 B C B C B C B C B C B C B C B C B C B C B C 
CBCS 
Xenobiotic metabolism 6 
CYPIA1 M1 0.8   0.9   0.7   0.8   1.0   1.0   0.7   0.7   0.6   1.0   0.7   1.1 
  
CYPIA1 M2 1.5   -1.0   2.0   -1.0   1.0   1.0   -.0   1.0   1.0   -.0   -.0   -.0 
  
CYPIA1 M3 -1.0   ###   10   ###   ###   ###   1.0   ##   1.0   ###   -.0   ### 
  
CYPIA1 M4 1.6   3.1   1.0   2.8   1.0   1.0   1.0   1.0   1.0   -.0   1.2   -.0 
  
GSTP1 1.5   0.8   2.0   1.0   2.0   1.5   1.3   1.8   2.2   0.9   1.9   0.7 
  
NAT1 1.2   1.3   1.1   1.4   1.0   1.3   1.2   1.0   1.7   1.0   1.2   -.0 
  
NAT2 1.1   2.0   0.9   1.9   1.0   1.1   1.5   0.8   1.2   1.3   0.9   -.0 
  
COMT 0.6   0.7   0.6   0.6   1.0   0.4   0.7   0.5   0.8   0.5   0.7   0.5 
  
DNA repair 
hOGG1 1.0   0.9   1.0   0.9   1.1   1.1   0.9   0.8   1.1   1.1   1.0   1.0 
  
MYH 324 1.0   0.9   1.1   0.9   1.2   0.8   1.1   1.0   1.0   1.0   1.0   1.1 
  
BRCA2 24 0.9   0.8   1.0   0.8   1.0   0.8   0.9   1.0   0.8   0.9   1.0   0.7 
  
BRCA2 372 1.3   1.2   1.3   1.3   1.2   1.8   1.2   0.9   1.3   1.7   1.2   1.6 
  
XRCC2 188 0.8   0.7   0.8   0.7   0.5   0.9   0.9   0.6   0.6   1.0   0.7   1.0 
  
XRCC4 -
28073 1.1   1.1   1.1   1.1   0.7   1.0   1.5   0.9   1.1   1.4   1.0   1.7 
  
MGMT 84 1.0   1.0   0.9   1.0   1.3   0.9   0.8   1.0   1.0   0.8   1.0   0.6 
  
ERCC1 
8092 0.9   0.8   0.9   0.8   0.9   0.8   0.9   0.9   1.1   0.8   1.0   0.7 
  
ERCC6 
1213 1.4   1.8   1.2   1.9   1.2   1.4   1.5   1.3   1.4   1.4   1.5   1.1 
  
ERCC6 
1230 0.8   1.0   0.7   0.9   0.7   0.8   0.9   0.8   0.9   0.7   0.8   0.6 
  
Other 
CDH1 0.8   0.9   0.8   0.8   0.9   0.8   0.8   1.0   0.8   0.8   0.8   0.9 
  
TGFB1 0.9   0.7   1.1   0.7   1.3   0.9   0.8   1.1   1.0   0.8   1.0   0.8 
  
MPO 1.3   1.2   1.3   1.3   1.4   1.0   1.4   1.5   1.2   1.2   1.3   1.2 
  
NQO1 1.4   1.4   1.3   1.6   1.2   1.4   1.5   1.2   1.6   1.3   1.4   1.4 
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Table V.B.6. Gene-variant - smoking associations 1 in CBCS & NCCCS: Non-African American female controls 40-74 years of age (continued) 
  Smoking 2 Status Duration (years) Intensity  (pack/day) Pack-years 3 
  
Ever 
smoking  
(ORz) 1,4 
Current 
smokers  
(Ref: Not 
Current) 5 
Former 
smokers  
(ORz) 
Current 
smokers  
(ORz) 
<=10y  
(ORz) 
11-20y  
(ORz) 
>20y  
(ORz) 
<1/2pk  
(ORz) 
1/2 - 1 
pk  
(ORz) 
>1 pk  
(ORz) 
<=35 
PY 
(ORz) 
>35PY  
(ORz) 
SNP 7 B8 C9 B C B C B C B C B C B C B C B C B  C B C B C 
NCCCS 
Xenobiotic metabolism 6 
MEH 113   0.6       0.6             -10 0.4   -1.   0.5       0.5     
MEH 139   1.0       1.0             -.0 1.1   1.0   1.3       1.2     
GST hap C 10   0.7       0.7             1.0 0.6   1.0   0.4       1.0     
GST hap A 11   -.0       -.0             -.0 -.0   1.0   1.0       -.0     
GST hap B 12   -.0       -.0             -.0 -.0   1.0   -.0       -.0     
GST hap D 13   1.1       1.0             1.0 0.9   1.0   -.0       1.4     
DNA repair 
POLD1 119   1.5       1.4             -.0 1.5   1.0   1.7       1.6     
ADPRT 762   1.7       1.4             1.0 1.7   -.0   1.9       1.7     
ADPRTL2 328   1.1       1.2             -.0 1.0   -.0   1.0       1.2     
MLH1 219   0.6       0.6             -.0 0.5   -.0   1.0       0.7     
MSH3 1036   2.2       2.7             -.0 1.0   -1.   -.0       2.1     
MSH3 940   1.5       1.6             -.0 1.7   -.0   -.0       1.1     
MSH6 39   0.7       0.7             -.0 0.6   -.0   0.5       0.8     
XPC 499   0.7       0.7             -.0 0.6   -.0   0.6       0.8     
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Table V.B.6. Gene-variant - smoking associations 1 in CBCS & NCCCS: Non-African American female controls 40-74 years of age (continued) 
  Smoking 2 Status Duration (years) Intensity  (pack/day) Pack-years 3 
  
Ever 
smoking  
(ORz)  1,4 
Current 
smokers  
(Ref: Not 
Current) 5 
Former 
smokers  
(ORz) 
Current 
smokers  
(ORz) 
<=10y  
(ORz) 
11-20y  
(ORz) 
>20y  
(ORz) 
<1/2pk  
(ORz) 
1/2 - 1 
pk  
(ORz) 
>1 pk  
(ORz) 
<=35 PY 
(ORz) 
>35PY  
(ORz) 
SNP 7 B 8 C 9 B C B C B C B C B C B C B C B C B C B C B C 
CBCS and NCCCS 
Xenobiotic metabolism 6 
GSTM1 1.1 0.8 0.9   1.3 0.8 1.0   1.4   0.9   1.2 0.7 1.0   1.0   1.4   1.0 1.1 1.7   
GSTT1 0.7 0.5 0.9   0.7 0.6 0.8           0.8 1.0     1.1       0.8 0.6     
DNA repair 
APE1 148 1.3 1.3 1.3   1.2 1.2 1.4   1.2   1.3   1.3 1.0 1.3   1.2   1.5   1.2 1.4 1.8   
XRCC1 
194 1.0 1.0 0.9   1.1 1.0 1.0   1.4   0.7   1.0 1.0 1.2   0.6   1.4   0.9 -.0 1.5   
XRCC1 
280 0.9 1.0 0.8   1.0 1.0 0.8   0.9       1.1 1.0 0.8   0.9   0.9   0.8 -.0 1.2   
XRCC1 
399 1.1 1.6 1.3   1.0 1.8 1.3   0.9   1.3   1.2 1.8 1.1   1.3   1.0   1.2 1.6 0.9   
NBS1 185 1.3 0.7 1.0   1.4 0.7 1.2   1.3   1.3   1.4 0.6 1.1   1.4   1.4   1.4 0.8 1.1   
XRCC3 
241 0.9 0.5 1.2   0.8 0.4 1.1   0.8   1.0   0.9 0.6 0.8   1.1   0.8   0.9 0.5 0.8   
HRAD23B 1.1 0.6 1.5   0.9 0.8 1.4   0.8   0.8   1.3 0.6 0.9   1.1   1.2   1.0 0.6 1.2   
XPC 939 0.9 1.7 1.1   0.9 1.6 1.0   1.2   0.8   0.9 2.4 1.2   0.8   0.9   0.9 1.4 1.2   
XPD 312 1.1 1.7 1.1   1.0 1.7 1.1   1.0   1.1   1.1 1.8 1.0   1.1   1.1   1.1 1.4 0.9   
XPD 751 1.2 1.9 1.1   1.3 2.1 1.2   1.1   1.3   1.3 1.5 1.3   1.1   1.3   1.3 1.6 1.1   
XPF 415 1.2 -.0 1.1   1.1 -.0 1.2  1.4   1.1   1.0 1.0 0.9   1.1  1.5   1.1 -1. 1.3   
XPG 1104 1.0 1.1 0.8   1.1 1.0 0.9   1.1   1.1   1.0 1.6 1.0   1.1   1.0   0.9 0.6 1.4   
Other 
MnSOD 0.9 1.5 0.9   1.0 1.6 0.9   1.1   0.7   1.0 1.2 0.9   0.8   1.1   0.8 1.3 1.6   
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, PY=pack-years, CBCS=Carolina Breast Cancer Study, NCCCS=North Carolina Colon 
Cancer Study, y=years, pk=packs/day, SNP=single nucleotide polymorphism, B=Breast cancer (CBCS), C=colon cancer (NCCCS) 
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Table V.B.6. Gene-variant - smoking associations 1 in CBCS & NCCCS: Non-African American female controls 40-74 years of age (continued) 
1
 OR=Odds ratio; OR not presented if 95% confidence limit ratio >5 (upper limit/lower limit>5) 
2
 Referent is never smokers for all ORz unless otherwise noted 
3
 Pack-years= number of years smoked x packs smoked/day [20cigarettes=1 pack] 
4 All ORz are age adjusted (continuous) 
5
 Referent is not-current smokers (former + never) 
6 Primary functional category, gene may function in additional pathways e. g. COMT in estrogen metabolism 
7 SNP referent = homozygous for common allele (compared to heterozygotes + homozygous for less common alleles); ref=present for GSTM1 & GSTT1; 
ref=rapid for NAT1 and NAT2. 
8
 B=CBCS (breast cancer study) 
9
 CO=NCCCS (colon cancer study) 
10
 GST hap C = haplotype of GSTT1 present & GSTM1 present (referent) vs. all other GSTT1 & GSTM1 combinations of present and null 
11 GST hap A=haplotype of GSTT1 null & GSTM1 present ; GST hap C is referent 
12 GST hap B=haplotype of GSTT1 null & GSTM1 null; GST hap C is referent 
13 GST hap D=haplotype of GSTT1 present & GSTM1 null; GST hap C is referent 
Bold = Overall ORz 
  = ORz <=0.7 
  = ORz >=1.4 
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Table V.B.7. Gene variant-smoking status association in GSEC, CBCS and NCCCS controls  
  Ever  Former 
Gene 4 GSEC 1  CBCS 2  NCCCS 3  GSEC 1  CBCS 2  NCCCS 3 
  
ORz 95% CI  ORz 95% CI  ORz 95% CI  ORz 95% CI  ORz 95% CI  ORz 95% CI 
CYP1A1                        
 All 0.9 0.8 1.1      --    0.9 0.7 1.1      --   
 Women 1.1 0.9 1.4  1.0 0.7 1.3  --    1.1 0.8 1.6  1.0 0.6 1.4  --   
 
Non-
hospital 0.9 0.7 1.1  1.0 0.7 1.3  --    0.8 0.7 1.1  1.0 0.6 1.4  --   
GSTM1                        
 All 0.9 0.9 1.0      1.0 0.8 1.4  0.9 0.8 1.1      1.2 0.8 1.6 
 Women 0.9 0.8 1.1  1.0 0.7 1.4  1.0 0.7 1.6  0.8 0.7 1.0  1.0 0.7 1.5  1.0 0.6 1.6 
 
Non-
hospital 0.9 0.8 1.0  1.0 0.7 1.4  1.0 0.8 1.4  1.0 0.8 1.1  1.0 0.7 1.5  1.2 0.8 1.6 
GSTT1                        
 All 1.0 0.9 1.2      1.0 0.7 1.3  1.1 0.9 1.3      0.9 0.7 1.3 
 Women 0.8 0.7 1.0  1.0 0.6 1.5  1.0 0.7 1.6  0.9 0.7 1.3  0.9 0.6 1.6  1.0 0.6 1.6 
 
Non-
hospital 1.3 1.1 1.5  1.0 0.6 1.5  1.0 0.7 1.3  1.3 1.0 1.7  0.9 0.6 1.6  0.9 0.7 1.3 
GSTP1                        
 All 1.1 0.9 1.2      --    1.0 0.8 1.2      --   
 Women 0.8 0.6 1.1  1.2 0.8 1.7  --    0.8 0.6 1.2  1.8 1.1 2.6  --   
 
Non-
hospital 1.1 0.9 1.3  1.2 0.8 1.7  --    1.0 0.8 1.3  1.8 1.1 2.6  --   
NAT2                        
 All 1.0 0.9 1.2      --    1.1 0.9 1.3      --   
 Women 1.1 0.9 1.3  0.9 0.7 1.5  --    1.3 1.0 1.8  0.8 0.6 1.4  --   
  
Non-
hospital 0.9 0.7 1.0   0.9 0.7 1.5   --       1.0 0.8 1.2   0.8 0.6 1.4   --     
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Table V.B.7. Gene variant-smoking status association in GSEC, CBCS and NCCCS controls (continued) 
  Current             
Gene 4 GSEC 1  CBCS 2  NCCCS 3             
  
ORz 95% CI  ORz 95% CI  ORz 95% CI             
CYP1A1                        
 All 1.0 0.9 1.2      --               
 Women 1.3 0.98 1.7  1.0 0.6 1.4  --               
 
Non-
hospital 1.0 0.8 1.2  1.0 0.6 1.4  --               
GSTM1                        
 All 0.9 0.8 1.0      0.8 0.5 1.2             
 Women 1.0 0.8 1.2  1.1 0.7 1.6  1.1 0.6 2.1             
 
Non-
hospital 0.9 0.8 1.0  1.1 0.7 1.6  0.8 0.5 1.2             
GSTT1                        
 All 1.0 0.8 1.2      1.1 0.7 1.6             
 Women --    1.1 0.6 1.7  1.1 0.6 2.1             
 
Non-
hospital 1.2 1.0 1.6  1.1 0.6 1.7  1.1 0.7 1.6             
GSTP1                        
 All 1.1 0.9 1.3      --               
 Women 0.7 0.4 1.0  0.8 0.5 1.2  --               
 
Non-
hospital 1.1 0.9 1.4  0.8 0.5 1.2  --               
NAT2                        
 All 0.9 0.8 1.1      --               
 Women 1.0 0.8 1.3  1.2 0.8 2.1  --               
  
Non-
hospital 0.8 0.6 0.9   1.2 0.8 2.1   --                             
Abbreviations: ORz =odds ratio in controls, CI=confidence interval, CBCS=Carolina Breast Cancer Study, NCCCS=North Carolina Colon Cancer 
Study, GSEC= Collaborative Study on Genetic Susceptibility to Environmental Carcinogens 
1 Adjusted for study, gender, age and ethnicity (Smits 2004) 
2
 Adjusted for age and race 
3 Adjusted for gender, age and race unless stratified by gender 
4 Smits 2004: Referent is "wild-type" (WT) (i.e. med type homozygotes) vs. having >=1 variant allele; CYP1A1: M1 is the variant allele, NAT2: *4 
allele is variant allele (rapid acetylator); GST and GSTM referents are genotypes with >= 1 allele vs. deletion of both alleles (variant=null);  
Bold =  ORz 
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Table V.B.8.  Misspecification for Gene variant-smoking status associations (ORz 1) in the CBCS and NCCCS 
  Status Duration Intensity Pack-years 9 
Gene pathway 6 / 
Gene variant 5  Ever 3 Current 4 Former Current 
<=10 
years 
11-20 
years 
>20 
years  
<1/2 
pk/day 
1/2 - 1 
pk/day 
>1 
pk/day 
<=35 
PY  
>35 
PY 
CBCS 1,2 
Xenobiotic metabolism 6                       
CYPIA1 M1 1.0 1.0 1.0 1.0 1.0 1.3 0.8 0.9 1.0 1.0 1.0 990 
CYPIA1 M2 1.8 -999.0 2.1 10 -999.0 -9.0 -99.0 -99.0 -999.0 -999.0 -999.0 1.6 -9.0 
CYPIA1 M3 0.9 -999.0 -999.0 -999.0 999.0 -99.0 -99.0 -999.0 -999.0 -999.0 1.0   
CYPIA1 M4 1.3 2.5 10 -999.0 -999.0 999.0 -99.0 -99.0 -999.0 -999.0 -999.0 -99.0 9.0 
GSTM1 1.0 1.1 1.0 1.1 1.1 1.0 1.0 0.9 0.9 1.3 0.9 1.7 
GSTP1 1.2 0.7 1.8 10 0.8 1.9 10 1.0 1.0 1.2 1.8 0.9 1.4 0.7 
GSTT1 1.0 1.1 0.9 1.1 999.0 1.0 1.0 1.3 1.1 -999.0 1.0 -90 
NAT1 0.9 1.2 0.8 1.1 0.6 1.1 1.1 0.8 1.2 0.9 0.9 9.0 
NAT2 0.9 1.3 0.8 1.2 0.8 0.9 1.1 0.8 1.0 1.1 0.9 9.0 
COMT 0.8 0.9 0.8 0.9 1.0 0.8 0.8 0.9 1.2 0.6 10 0.9 0.5 10 
DNA repair                         
    Base excision repair                       
APE1 148 1.1 1.2 1.1 1.2 1.2 1.1 1.1 1.3 0.9 1.2 1.1 1.3 
hOGG1 1.0 0.9 1.1 1.0 1.4 1.1 0.9 0.9 1.1 1.1 1.1 0.9 
MYH 324 1.0 0.8 1.1 0.9 1.0 1.0 1.0 1.0 0.9 1.0 1.0 1.0 
XRCC1 194 1.1 1.1 1.1 1.2 1.4 0.9 1.1 1.2 1.0 1.2 1.1 1.6 
XRCC1 280 0.9 0.9 0.9 0.9 0.8 0.9 1.0 0.9 1.0 0.8 0.9 
-
999.0 
XRCC1 399 1.0 1.2 1.0 1.2 0.8 1.1 1.2 0.9 1.1 1.1 1.0 1.0 
    Double strand break repair                     
BRCA2 24 0.9 0.9 1.0 0.9 0.9 1.0 0.9 0.8 1.0 0.9 0.9 0.8 
BRCA2 372 1.2 10 1.2 1.2 1.3 1.0 1.5 10 1.3 10 1.1 1.2 1.6 10 1.2 1.6 10 
NBS1 185 1.2 1.0 1.2 1.1 1.2 1.3 1.1 1.1 1.2 1.2 1.2 1.0 
XRCC2 188 0.9 0.9 0.9 0.8 0.9 0.9 0.9 0.8 0.8 1.1 0.9 1.1 
XRCC3 241 0.9 1.2 0.8 1.1 0.8 0.8 1.1 0.9 0.9 0.8 0.9 0.8 
XRCC4 -28073 1.2 1.2 1.1 1.3 1.1 1.0 1.3 1.1 1.2 1.2 1.1 1.5 
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Table V.B.8.  Misspecification for Gene variant-smoking status associations (ORz 1) in the CBCS and NCCCS (continued) 
  Status Duration Intensity Pack-years 9 
Gene pathway 6 / 
Gene variant 5  Ever 3 Current 4 Former Current 
<=10 
years 
11-20 
years 
>20 
years  
<1/2 
pk/day 
1/2 - 1 
pk/day 
>1 
pk/day 
<=35 
PY  
>35 
PY 
CBCS 1,2 
    Mismatch repair                       
MGMT 84 0.9 0.8 1.1 0.8 1.3 1.0 0.7 10 1.1 0.8 0.9 1.0 0.5 10 
    Nucleotide excision repair                     
ERCC1 8092 1.0 1.0 1.0 1.0 1.0 1.1 0.9 1.0 1.0 0.9 1.0 0.7 
ERCC6 1213 1.2 1.6 10 1.0 1.6 10 1.2 1.2 1.2 1.3 1.3 1.0 1.3 10 0.8 
ERCC6 1230 0.9 1.1 0.8 1.0 0.8 0.9 1.0 1.0 1.0 0.8 0.9 0.7 
HRAD23B 1.1 1.2 1.0 1.2 1.2 0.9 1.2 1.0 1.1 1.2 1.1 1.2 
XPC 939 0.9 1.0 0.9 1.0 1.0 0.9 0.9 1.1 0.8 0.9 0.9 1.1 
XPD 312 1.0 1.1 1.0 1.1 0.9 1.2 1.1 1.0 1.1 1.1 1.1 0.9 
XPD 751 1.2 1.2 1.1 1.2 0.9 1.3 1.3 1.1 1.2 1.2 1.2 1.1 
XPF 415 1.0 1.0 1.1 1.0 1.1 0.9 1.0 0.9 1.0 1.1 1.0 1.0 
XPF 662 1.1 1.4 1.0 1.3 1.1 1.4 1.0 1.4 0.9 0.9 1.2 -99.0 
XPG 1104 0.9 0.8 1.0 0.8 0.9 1.0 0.9 0.9 0.9 0.9 0.9 1.2 
Other                         
CDH1 0.8 0.8 0.8 0.8 0.9 0.7 10 0.8 0.9 0.8 0.7 10 0.8 10 0.9 
TGFB1 1.1 0.8 1.2 0.9 1.3 1.1 1.0 1.2 1.1 0.9 1.1 0.8 
MnSOD 1.0 0.9 1.1 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.4 
MPO 1.0 1.0 1.0 1.0 0.9 1.1 1.1 1.0 1.0 1.1 1.0 1.1 
NQO1 1.0 1.0 1.0 1.0 1.0 1.0 1.1 1.0 1.2 0.9 1.0 1.1 
NCCCS 1,2 
Xenobiotic metabolism 6  
GST hap C 7 1.2 1.0 1.3 1.2 1.5 1.1 1.2 1.7 10 1.0 1.2 1.3 1.0 
GST hap A 8 1.4 1.5 1.3 1.7 1.6 1.3 1.4 1.8 10 1.2 1.3 1.5 1.2 
GST hap B 8 0.8 0.6 0.9 -1.0 -1.0 -1.0 0.7 1.1 0.5 10 0.9 0.8 -1.0 
GST hap D 8 1.3 0.9 1.4 1.1 1.7 1.1 1.2 1.9 10 1.0 1.3 1.4 1.0 
GSTM1 1.0 0.7 1.2 0.8 1.3 0.9 1.0 1.4 0.8 1.1 1.1 0.9 
GSTT1 1.0 1.1 0.9 1.1 1.0 1.0 0.9 1.1 0.8 0.9 1.0 0.9 
  
210
 
Table V.B.8.  Misspecification for Gene variant-smoking status associations (ORz 1) in the CBCS and NCCCS (continued) 
  Status Duration Intensity Pack-years 9 
Gene pathway 6 / 
Gene variant 5  Ever 3 Current 4 Former Current 
<=10 
years 
11-20 
years 
>20 
years  
<1/2 
pk/day 
1/2 - 1 
pk/day 
>1 
pk/day 
<=35 
PY  
>35 
PY 
NCCCS 1,2 
Xenobiotic metabolism 6 (continued) 
MEH 113 0.7 0.8 0.8 0.7 0.7 0.7 0.8 0.9 0.7 0.6 10 0.8 0.7 10 
MEH 139 0.8 0.6 10 0.9 0.6 10 1.0 0.8 0.7 10 0.9 0.8 0.6 10 0.8 0.6 10 
DNA repair                         
POLD1 119 0.7 0.8 0.7 0.7 0.7 0.9 0.7 10 0.6 10 0.8 0.6 0.7 0.6 
   Base excision repair                       
ADPRT 762 1.1 1.2 1.0 1.2 1.2 0.7 1.2 1.1 1.1 1.1 1.1 1.0 
ADPRTL2 328 1.1 1.1 1.1 1.1 1.0 1.0 1.2 0.9 1.2 1.2 1.1 1.2 
APE1 148 1.1 1.0 1.1 1.1 1.4 1.1 1.0 1.1 1.2 1.1 1.1 1.2 
XRCC1 194 0.8 0.9 0.8 0.8 -1.0 -1.0 0.9 0.7 0.7 1.1 0.8 0.8 
XRCC1 280 1.3 -1.0 1.3 -1.0 -1.0 -1.0 1.2 -1.0 -1.0 -1.0 1.2 -1.0 
XRCC1 399 1.1 1.0 1.1 1.0 1.3 1.2 1.0 1.2 1.2 0.8 1.2 0.9 
   Double strand break repair                     
NBS1 185 0.9 0.8 0.9 0.8 0.9 1.2 0.8 1.0 0.8 1.0 1.0 0.8 
XRCC3 241 0.9 1.1 0.8 1.0 0.7 0.7 1.0 0.9 0.8 1.1 0.8 1.1 
   Mismatch repair                       
MLH1 219 1.1 0.8 1.2 0.9 1.4 1.0 1.1 1.1 1.2 1.2 1.2 1.0 
MSH3 1036 1.1 1.0 1.1 1.0 1.0 1.1 1.0 0.8 1.1 1.3 1.0 1.5 
MSH3 940 1.2 0.7 1.4 0.8 1.2 1.6 1.1 1.1 1.2 1.6 1.2 1.3 
MSH6 39 0.9 0.7 1.0 0.7 0.8 0.9 0.9 0.8 0.9 0.9 0.8 1.0 
   Nucleotide excision repair                     
RAD23B 1.1 1.0 1.1 1.0 1.2 0.8 1.1 1.2 1.0 0.9 1.0 1.1 
XPC 499 0.8 1.1 0.8 1.0 0.8 0.9 0.9 1.0 0.8 0.8 0.9 0.7 
XPC 939 1.2 1.0 1.3 1.1 1.0 1.1 1.3 1.2 1.4 1.0 1.1 1.5 
XPD 312 1.0 0.9 1.1 0.9 1.3 1.0 0.9 1.1 0.9 1.0 1.0 1.0 
XPD 751 1.2 1.0 1.3 1.1 1.5 1.5 1.0 1.4 1.0 1.4 1.2 1.2 
XPF 415 1.0 1.3 0.9 1.2 1.0 -1.0 1.1 -1.0 1.2 1.0 0.9 1.1 
XPG 1104 1.0 1.2 0.9 1.2 0.7 0.8 1.2 0.9 1.1 1.0 0.9 1.3 
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Table V.B.8.  Misspecification for Gene variant-smoking status associations (ORz 1) in the CBCS and NCCCS (continued) 
  Status Duration Intensity Pack-years 9 
Gene pathway 6 / 
Gene variant 5  Ever 3 Current 4 Former Current 
<=10 
years 
11-20 
years 
>20 
years  
<1/2 
pk/day 
1/2 - 1 
pk/day 
>1 
pk/day 
<=35 
PY  
>35 
PY 
NCCCS 1,2 
Other                         
MNSOD 1.0 1.1 1.0 1.1 1.0 1.4 0.9 1.1 1.0 0.9 1.1 0.8 
Abbreviations: ORz=odds ratio in controls, CI=confidence interval, PY=pack-years, y=years, pk/day=packs/day, CBCS=Carolina Breast Cancer 
Study, NCCCS=North Carolina Colon Cancer Study, SNP=single nucleotide polymorphism 
1
 Odds ratio not displayed if 95% confidence limit ratio (upper limit/lower limit) >4 
2 Odds ratios are race and age-adjusted for CBCS; race, age and gender-adjusted for NCCCS  
3
 Referent is never smokers for all smoking categories unless otherwise noted 
4
 Referent is  not-current smokers (former + never) 
5 SNP referent = homozygous for common allele, compared to heterozygotes + homozygous for less common alleles, GSTM1 & GSTT1 
referent=present 
6 Primary functional category; gene may function in additional pathways eg COMT in estrogen metabolism 
7 GST hap C = haplotype of GSTT1 present & GSTM1 present (referent) vs. all other GSTT1 & GSTM1 combinations of present and null combined 
8 GST hap A=GSTT1 null & GSTM1 present, GST hap B=GSTT1 null & GSTM1 null, GST hap D=GSTT1 present & GSTM1 null; GST hap C is 
referent 
9
 Pack-years= midpoint of category for number of years smoked x midpoint of category for numer of packs smoked/day 
10
 Statistically significant at alpha=0.05 
Bold = ORz significant at alpha=0.05 
  = ORz <=0.7 
  = ORz >=1.4 
  = 0.7<ORz<1.4 and significant at alpha=0.05 
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Table V.B.9.  
 Agreement between CBCS and NCCCS gene variant-smoking associations 
  Kappa 1  95% CI  N 
Full CBCS and NCCCCS       
 Null=ORz: 0.9-1.1 CLR<4 -0.07  -0.19 0.06  165 
Restricted CBCS and NCCCCS: white women 40-74 y    
 Null=ORz: 0.9-1.1 CLR<5 0.22  -0.01 0.46  52 
 Null=ORz: 0.8-1.2 CLR<5 0.19  0.01 0.36  52 
 Null=ORz: 0.9-1.1 CLR<20 2 0.16  0.02 0.30  163 
 Null=ORz: 0.8-1.2 CLR<20 0.20  0.09 0.31  163 
Abbreviations:  CBCS=Carolina Breast Cancer Study, NCCCS=North Carolina Colon Study, 
CI=confidence interval, CLR=Confidence limit ratio (upper limit/lower limit), N=number of 
observations with CLR<5 
1
 Weighted kappa statistic 
2
 At CLR>20 all data was included except subgroups with empty cells 
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VI. CONCLUSIONS AND DICUSSION 
A. Findings and implications for stand-alone case-only studies 
For the interaction estimate from a case-only study (COR) to be equal to the interaction 
estimate from a case-control study (SIM) in the same population, there must be no association 
between the relevant exposures in the source population (Z=1).  The COR will be biased to the 
degree that Z, or a proxy for Z such as the odds ratio from a control group (ORz), is not equal to 
one.  This assumption, that the interacting exposures analyzed in a case-only study are 
independent in the population at risk (Z=1), is commonly called the independence assumption.  
The overall goal of the dissertation was to examine the case-only independence assumption in two 
different types of empirical control data, study-level data found in the literature and individual-
level data from two population-based control groups. Three main conclusions emerged from the 
results of the studies detailed in Chapters V-A and V-B.  First, the heterogeneity in ORz across 
studies is too great to warrant the assumption that Z = 1 for the studied DNA repair gene variants 
and smoking measures.   
Results from the systematic review and meta-analysis of DNA repair SNPs and smoking 
behavior (Chapter V-A) showed substantial variation in ORz across the 55 included studies for all 
SNP-smoking ORzs.  The magnitude of many individual study ORzs was sufficient to bias the 
COR to an unacceptable degree (moderate magnitude ORz defined as ORz<=0.7 or >=1.4).  The 
proportion of studies with at least one moderate magnitude gene-smoking ORz ranged from 0.38 
(XRCC1 280) to 0.63 (XRCC3 241).  In addition, XRCC1 399 / ever-never smoking and XPD 751 / 
PY were too heterogeneous for summary estimates [ranges, OR (95% CI): 0.7 (0.4, 1.2) – 1.9 (1.2, 
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2.8) and 0.8 (0.5, 1.3) – 2.3 (0.8, 6.1), respectively).  Even when studies were relatively 
homogeneous (p-value for Cochran’s Q > .10), ORzs for the studies in the meta-analysis varied 
from 2- to 5-fold.  Further, nearly all SNP-smoking combinations had ORzs both above and below 
the null.  These results show that it is insufficient to look at a one or a small number of control 
groups to assess the potential magnitude or direction of bias that may be introduced into a case-
only interaction estimate (COR) when the independence assumption is violated. 
Our analysis of study characteristics in Chapter V-A suggests that the independence 
assumption must be evaluated in a population-specific manner unless there is clear evidence that Z 
is reliably close to the null across multiple populations.  An important step prior to conducting a 
case-only study is deciding what ancillary control data is most appropriate for evaluating the 
independence assumption.  For instance, if certain study design characteristics can be identified a 
priori that are more valid for evaluating the independence assumption (e.g. population-based 
versus hospital controls), then only studies with that characteristic should be used to evaluate the 
independence assumption.  Analysis of study characteristics can clarify whether or not population-
based studies are homogeneous within specific strata even when there is overall heterogeneity or 
heterogeneity across other strata.  Study characteristics chosen a priori as potentially influencing 
the magnitude or heterogeneity of ORz may also be used to identify situations where the ORzs vary 
across strata (e.g. male participants, female participants or mixed gender studies).  However, in 
our data, no study characteristic was identified as a major source of heterogeneity.  Study outcome 
(lung vs. other cancer), study design (population-based vs. hospital/patient-based controls), and 
average age of study participants were suggestive but did not show consistent correlations with 
ORz values.  Therefore, there were no study characteristics that stood out strongly enough to be a 
reliable guide for decision-making. 
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Subgroup analysis of the CBCS and NCCCS control groups in Chapter V-B supported the 
meta-analysis study characteristics analysis.  There was little variation in ORz across strata of age, 
race or gender, consistent with the uninformative nature of the study-level variables average age, 
ethnicity or gender proportion in Chapter V-A.  Results from the meta-analysis suggest it is 
inappropriate to estimate Z using a limited number of control groups with similar study 
characteristics.  Unless further research identifies new study characteristics that may be influential, 
a broad sample of studies is necessary to determine the likely range of bias that may be introduced 
by the unmeasured Z. 
The second conclusion is that heterogeneity of ORzs across smoking measures precludes 
the use of one measure of smoking (e.g. ever-never smoking) to evaluate the independence 
assumption, particularly when analyses of multiple smoking measures (e.g. dose, duration) are 
planned in a case-only study.  Results from Chapters V-A and V-B support this conclusion.  The 
CBCS/NCCCS control group analyses confirmed the variability in ORz values across measures of 
smoking within two population-based control groups.  Consequently, the independence 
assumption needs to be assessed for each exposure measure that will be used in the case-only 
analysis.  Taken together, our results do not support the independence of DNA repair SNPs and 
smoking behavior, either across studies or smoking measures, nor do they support the 
independence of the xenobiotic metabolism genes CYP1A1, GSTM1, GSTP1, NAT1, COMT or 
MEH and smoking across smoking measures. 
The third conclusion is that no strong patterns were apparent when genes were categorized 
by the biological pathways in which they participate.  Neither study showed substantial clustering 
of moderate magnitude ORzs by gene category, with 25% and 18% of the xenobiotic metabolizing 
genes and DNA repair genes, respectively, consistently null across all categories and both studies.  
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There was, however, a suggestion that xenobiotic metabolism genes were more likely than DNA 
repair genes to exhibit variants with multiple moderate magnitude gene-smoking ORzs.  Our 
results clearly indicate that the independence assumption must be assessed for each gene variant, 
rather than by gene category, for the proposed case-only analysis to be valid.  
Taken together, these studies show that a systematic approach to assessing the 
independence association is essential prior to conducting a case-only analysis of gene-smoking 
interaction.  Results from both studies showed that moderate magnitude ORzs (>=1.4 or <=0.7), 
sufficient to cause bias of >10% in the COR, occur in numerous control groups and for multiple 
measures of smoking, particularly measures of smoking duration, intensity or PY.  This systematic 
approach should include conducting a thorough literature search for published systematic reviews, 
studies of appropriately pooled data, and studies with relevant control data as this information is 
necessary to establish at least the likely range of ORzs.  A sensitivity analysis should be conducted 
with available data.  In addition, searching for information on the target population of interest is 
critical.  In the absence of appropriate population-specific data, a validation study should be 
considered. Further, results show that assessing the independence assumption only for ever-never 
smoking is insufficient, if the proposed case-only analysis is to include any other measures of 
smoking behavior.  At present, control group data on other smoking measures can be difficult or 
impossible to find in the published literature. 
Finally, smoking interaction is an area of interest for many non-cancer outcomes (e.g. 
cardiovascular disease) and many of the genes assessed in the current project are not cancer-
specific (e.g. COMT and CYP1A1).  The utility and implications of these results are not limited to 
cancer research.   
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B. Strengths of the systematic review and meta-analysis 
There are several notable strengths to the systematic review and meta-analysis of DNA 
repair genes and smoking presented in Chapter V-A.  The literature search was extensive, using 
three publicly available databases, and facilitated by consultation with an information specialist.  
Sample size was relatively large (N=55 studies overall), despite the paucity of published control 
group data on the joint distribution of DNA repair genotypes and smoking.  For some SNPs there 
were sufficient data to examine smoking duration and intensity, the components of PY.  This is 
important since the smoking measure of interest for a proposed case-only study is likely be 
something other than ever-never smoking, the crudest and most commonly presented measure of 
smoking for control groups in the literature. Further, for most studies that presented data on 
smoking amount, we were able to construct at least one measure of smoking status and compare 
results within the same study, confirming that the direction and magnitude of ORz for smoking 
status and smoking amount often differ within the same study population.   
The large number of studies increased our ability to detect and investigate heterogeneity 
between studies and improved precision when study results were sufficiently homogeneous to 
warrant summary estimates.  We were able to examine numerous study characteristics (continent, 
ethnicity, average age, proportion male, HWE p-value, study outcome, minor allele frequency, and 
smoking prevalence) using a variety of metrics, in an effort to discover the source(s) of 
heterogeneity.  Although no characteristic was shown to be a major source of heterogeneity, this in 
itself is useful information for investigators with only published or ancillary data for evaluation of 
the independence assumption.   
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Visual inspection and tests of funnel plot asymmetry supported our expectation that 
publication bias would be minimal, given that control group associations are not generally 
considered when publication decisions are made.   
C. Limitations of the systematic review and meta-analysis 
Because no individual level data on controls was available in the literature, only 
unadjusted estimates of ORz could be calculated from published control group data using the joint 
distribution of genotype and smoking.  Consequently, ORzs could be confounded.  Additionally, 
results only apply at the level of the study, even when a characteristic is an individual level 
variable at collection, such as age or gender.  This is analogous to the ecologic fallacy.  For 
instance, conclusions that apply to studies with a higher average age for participants do not 
necessarily apply to the older participants within that study, and in fact could be due entirely to the 
younger individuals in the study.  
Some study characteristics were difficult to determine accurately from published reports, in 
particular age and ethnicity.  Although a consistent rubric for central tendency of age (“average” 
age) was applied, and all studies but one gave some indication of participant age, the level of 
detail varied widely and some studies are likely to be misclassified.  Participants’ ethnicity was 
often not reported.  However, results did not differ according to study-reported ethnicity, ethnicity 
assigned by continent and ethnicity assigned by MAF.  Since participation can vary by smoking 
status [117-120], it would have been informative to have included response rates as a study 
characteristic. However, too few studies presented comparable data on response rates to assess this 
characteristic. 
  219
D. Strengths of the control group analyses 
The strengths of the control group analysis of genetic variation and smoking using CBCS 
and NCCCS data presented in Chapter V-B complemented the strengths of the systematic review 
and offset some of its limitations.  Both the CBCS and NCCCS control groups are large and 
population-based.  The target population for the independence assumption is the population from 
which the cases arise.  In these two studies, the control groups come from essentially the same 
underlying population, albeit from partially overlapping geographic areas and time periods.  The 
studies used the same sampling scheme, oversampling African Americans using DMV records and 
HCFA lists, so that there was adequate sample size to perform subgroup analysis by race. 
Because gene-smoking interaction is of interest in breast and colon cancer, there were 
sufficient data to examine multiple genes in different metabolic pathways plausibly related to 
smoking behavior.  The CBCS and NCCCS had data for 38 and 25 relevant gene variants, 
respectively.  Fifteen of the variants were assayed in both studies so agreement between studies 
with essentially the same underlying population could be examined.  Additionally, the gene 
variants were in several different pathways, primarily xenobiotic metabolizing genes and DNA 
repair genes, giving additional insight into whether genes in a common pathway might have 
similar associations with smoking. 
The sample size, level of detail in the smoking information and inclusion of more than one 
ethnic group are notable strengths of this study.  Confounding by race, age, gender, family history 
of any cancer and family income were also evaluated.  Confounder evaluation is important since 
only unadjusted ORzs are available from the published literature and the independence assumption 
applies to the unconfounded G-E association.  Both studies had detailed data on smoking behavior 
so ORz could be calculated for multiple metrics for smoking status (ever-never and current-not 
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current smoking) and amount (duration, intensity and PY).  In contrast, for the meta-analysis no 
individual level data was available, nor could ORz be calculated for all five smoking measures for 
any single study. 
E. Limitations of the control group analyses 
Selection bias in the CBCS or NCCCS could have biased ORzs.  If non-response by 
eligible controls was associated with smoking behavior and with gene status, ORzs could be biased 
in an unpredictable direction; however, prevalence of current smoking in the CBCS was similar to 
that in North Carolina during this time period.  Participants are very unlikely to know their 
genotype, although it is possible that knowing one’s family history of cancer (a crude proxy for 
genotype) could affect participation.   
Some misclassification of smoking behavior is likely and could have affected results.  
Smoking data is self-reported; there are no biological measures of smoking behavior in the CBCS 
or NCCCS.  Given that the negative health effects of smoking are well known, it is unlikely that 
controls would over-estimate their tobacco consumption. If a proportion of current smokers were 
misclassified as not current smokers (former+never), and misclassification was non-differential by 
genotype, ORzs for current smoking would be biased away from the null.  However, if smoking 
misclassification is similar to estimates in the literature for the general population (<2%-13%) 
[284-287], the magnitude of bias was small at the ORzs, smoking and genotype prevalences 
typical in CBCS and NCCCS control groups.  For measures of smoking with more than two 
categories, such as current/former/never, duration or intensity, the direction of bias is 
unpredictable. If misclassification was differential by genotype, the direction of bias is 
unpredictable.  However, participants are unaware of their genotypes; therefore it is unlikely that 
any misclassification is differential by genotype. 
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Population stratification could have caused some residual confounding despite adjustment 
for race.  Stratification by race did not reveal any systematic differences in ORzs however.   
The gene variants included in this study were a convenience sample of genetic data from 
parent studies of cancer rather than candidate genes from a study designed to investigate smoking 
behavior. As such, genes thought to be important in smoking behavior, but not in breast or colon 
cancer, could not be assessed.   
Precise gene function is unknown for the majority of gene variants.  This limits 
interpretation of gene-smoking associations but is a limitation common to many studies of genetic 
exposures at this point in time.  Further, gene variants could be in linkage disequilibrium with 
causal variants, rather than being the true causal variant. Finally, chance could have played a role 
in the associations found.  However, using strict criteria for confidence limit ratios reduced the 
number of imprecise estimates considered, therefore reducing the role of chance in these results. 
F. Future directions 
In the short term, it would be extremely useful to have more detailed control group 
information publicly available from large population-based studies for a variety of genes and 
exposures.  Any environmental factor (i.e. non-genetic factor) whose effect might be modified by 
genetic variation should be included in the accessible databases.  This should include, but not be 
limited to smoking, alcohol consumption, BMI, air pollution levels, occupational exposures and 
birth/prenatal exposures such as birthweight, and common medication use such as NSAIDS.  Just 
as ever-never smoking ORzs did not predict ORzs for smoking amounts, this data must be 
available at approximately the same level of detail as the proposed case-only analyses to be a valid 
test of the independence assumption.  
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At present, control group data on smoking measures other than ever-never can be difficult 
or impossible to find in the published literature.  The results from the CBCS and NCCCS analysis 
confirm that this information often differs from ORz for smoking status.  It would be useful to 
have more detailed data on smoking amounts (duration, intensity, time since cessation for former 
smokers, age of initiation, nicotine dependence indices, etc.) than is usually presented, ideally 
stratified by race, age and gender.  Given that many studies already collect much more detailed 
information on smoking behavior in controls than is actually presented in a paper, these data could 
relatively easily be archived as supplemental tables online.  Other important information (hospital-
based vs. population-based, inclusion or exclusion criteria, response rates) is already given in most 
papers, although the data on response rates would need to be presented in some standard format to 
be useful. As mentioned, there are numerous other potentially useful data that could be made 
available for more rigorous evaluation of the independence assumption for case-only studies.    
Long term, population-based studies specifically designed to address gene-smoking 
associations are needed.  To be most useful for evaluating the independence assumption, 
additional smoking phenotypes should be included, ideally including biological measures of 
current smoking status, and a broader panel of SNPs.  SNPs chosen for this purpose should 
plausibly be of interest for gene-smoking interaction in disease, rather than only those genes 
currently being studied for their likely influence on smoking behavior.  For instance, well-
designed studies focused on specific aspects of smoking behavior abound but rarely include DNA 
repair genes, a class of genes of great interest for gene-smoking interaction in cancer (etiology and 
treatment), heart disease and neurological diseases.  Recent genome-wide association studies 
(GWAS) have raised the possibility that the search for the genetic underpinnings of all parts of the 
smoking trajectory, from initiation to dependence to cessation, may need to be broadened [288].  
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Designing gene-smoking studies to accommodate genes of interest in additional fields of wide 
public health impact such as cancer and heart disease would be an efficient use of scientific 
resources.  As suggested by [289] genotyping chips would facilitate such multi-purpose studies if 
SNPs relevant to gene-smoking interaction were routinely included.  These studies would serve 
the purposes of elucidating the etiology of tobacco dependence and cessation, while decreasing the 
number of case-only studies with unacceptable levels of bias and improving the accuracy of 
estimates of interaction from case-only studies. 
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VII. APPENDICES 
A. Informed consent 
Informed consent was obtained for the CBCS and NCCCS parent studies. There was no further 
participant contact or information gathering. This analysis was exempted as “not human subjects 
research” by the Public Health Institutional Review Board (IRB) Dec 22, 2005. IRB number: 05-2821.
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B. Supplementary tables and figures: Manuscript 1 
 
 
Table VIII.B.1. Association between XRCC1 Arg399His and smoking : Individual study results 
Author and Year Never/ever Current/Not current Pack-years 1 Intensity 2 Duration 3 
 
ORz  
(95%CI) 
ORz  
 (95%CI) 
ORz  
 (95%CI) 
ORz  
 (95%CI) 
ORz  
 (95%CI) 
Cao 2006   0.99 (0.68, 1.45)       
David-Beabes 2001 
All: 0.78 (0.57,1.07) 
Wh: 0.87 (0.59, 1.28) 
AA: 0.69 (0.39, 1.22)     1.52 (1.05, 2.22)   
Duell 2001 4 
Wh: 1.16 (0.77, 1.73) 
AA: 1.65 (0.95, 2.88) 
All: 1.48 (1.08, 2.02) 
Wh: 1.10 (0.67, 1.81) 
AA: 2.08 (1.11, 3.91) 
All: 1.35 (0.93, 1.98)     --- 
Duell 2002         0.86 (0.59, 1.24) 
Harms 2004     0.53 (0.20, 1.37)     
Hoffmann 2005   0.43 (0.15, 1.19)       
Huang 2005a 1.86 (1.23, 2.80)   0.90 (0.49, 1.67)     
Hung 2005b 1.04 (0.86, 1.25)   1.24 (0.92, 1.69)     
Ito 2004 0.80 (0.55, 1.18) 0.88 (0.58, 1.32) 2.02 (1.21, 3.40)     
Kelsey 2004 0.90 (0.62, 1.31)         
Kocabas 2006   0.87 (0.46, 1.67)       
Koyama 2005   1.55 (0.65, 3.72)       
Lei 2002   0.93 (0.34, 2.55)   0.36 (0.05, 2.34)   
Lunn 1999   0.88 (0.23, 3.49)       
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Table VIII.B.1. Association between XRCC1 Arg399His and smoking : Individual study results (continued) 
Author and Year Never/ever Current/Not current Pack-years 1 Intensity 2 Duration 3 
 ORz (95%CI) ORz (95%CI) ORz (95%CI) ORz (95%CI) ORz (95%CI) 
Matullo 2001b 1.11 (0.70, 1.76) 1.14 (0.68, 1.91)       
Matullo 2005 1.09 (0.67, 1.77) 0.80 (0.50, 1.29)       
Metsola 2005 0.75 (0.50, 1.13)   0.91 (0.45, 1.84)     
Misra 2003       1.41 (0.76, 2.62)   
Olshan 2002 1.16 (0.61, 2.21)         
Pachkowski 2006 4 1.21 (1.00, 1.46) 1.22 (0.96, 1.54)   1.61 (1.15, 2.27) 1.48 (1.07, 2.05) 
Park 2002     1.52 (0.65, 3.55)     
Patel 2005 0.88 (0.60, 1.28)         
Ramachandran 
2006 0.72 (0.31,1.69)         
Ryk 2006b 0.84 (0.44, 1.62)         
Schneider 2005 1.23 (0.85, 1.77)   0.77 (0.23, 2.60)     
Shen 2000 1.93 (1.00, 3.72)         
Shen 2003 1.53 (0.82, 2.86)   1.24 (0.66, 2.34)     
Shen 2005a 1.57 (1.24, 2.00)         
Skelbred 2006a   0.74 (0.50, 1.08)       
Tuimala 2004 0.83 (0.43, 1.61)         
Wilding 2005 1.11 (0.69, 1.78)         
Yu 2004a 1.09 (0.57, 2.08)         
Zhou 2003 0.97 (0.77, 1.23)   1.40 (0.93, 2.10)     
Abbreviations: ORz=control-only genotype-smoking odds ratio, 95% CI= 95% confidence interval, ref=referent, Arg=Arginine, 
Gln=Glutamine, Trp=Tryptophan, His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine 
1
 Pack-years: lightest non-zero category (ref) vs. heaviest 
2
 Intensity (packs/day): lightest non-zero category (ref) vs. heaviest 
3
 Duration (years): shortest non-zero category (ref) vs. longest 
4
 Duell 2001 used in stratified analyses; Pachkowski 2006 used for non-stratified analyses 
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Table VIII.B.2.  
Association between XRCC1 Arg194Trp and smoking : Individual study results 
Author and Year Never/ever Current/Not current Pack-years 1 Intensity 2 Duration 3 
 ORz (95%CI) ORz (95%CI) ORz (95%CI) ORz (95%CI) ORz (95%CI) 
Cao 2006   0.83 (0.57, 1.22)       
David-Beabes 2001 
All:  1.28 (0.79, 2.06) 
Wh: 1.37 (0.74, 2.54) 
AA:  1.14 (0.53, 2.44)     1.13 (0.66, 1.93)   
Han 2003 1.11 (0.81, 1.53)       0.68 (0.40, 1.18) 
Hung 2005b 0.97 (0.75, 1.26)   1.1 (0.73, 1.64)     
Koyama 2005   0.91 (0.38, 2.19)       
Lunn 1999   2.08 (0.10, 41.62)       
Matullo 2005 0.98 (0.52, 1.84) 1.14 (0.62, 2.11)       
Olshan 2002 1.07 (0.45, 2.53)         
Pachkowski 2006 1.13 (0.86, 1.48) 1.14 (0.81, 1.60)   1.08 (0.67, 1.73) 0.74 (0.47, 1.15) 
Patel 2005 1.20 (0.72, 2.01)         
Schneider 2005 0.60 (0.36, 1.00)   
0.76 (0.09, 
6.12)     
Shen 2000 0.87 (0.46, 1.66)         
Shen 2005a 0.85 (0.59, 1.21)         
Skelbred 2006a   1.45 (0.80, 2.64)       
Stern 2001 1.20 (0.57, 2.56)       0.34 (0.11, 1.07) 
Wilding 2005 0.68 (0.33, 1.39)         
Abbreviations: ORz=control-only genotype-smoking odds ratio, 95% CI= 95% confidence interval, ref=referent, Arg=Arginine, 
Gln=Glutamine, Trp=Tryptophan, His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine 
1
 Pack-years: lightest non-zero category (ref) vs. heaviest 
2
 Intensity (packs/day): lightest non-zero category (ref) vs. heaviest 
3
 Duration (years): shortest non-zero category (ref) vs. longest 
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Table VIII.B.3.  
Association between XRCC1 Arg280His and smoking: Individual study results 
Author and Year Never/ever Current/Not current Pack-years 1 Intensity 2 Duration 3 
 ORz (95%CI) ORz (95%CI) ORz (95%CI) ORz (95%CI) ORz (95%CI) 
Hung 2005b 1.09 (0.79, 1.50)   1.19 (0.73, 1.93)     
Koyama 2005   1.06 (0.19, 5.81)       
Lunn 1999   0.38 (0.03, 4.69)       
Metsola 2005 0.87 (0.49, 1.54)   0.54 (0.20, 1.50)     
Pachkowski 2006 0.95 (0.67, 1.35) 0.88 (0.55, 1.38)   0.93 (0.48, 1.81) 1.20 (0.64, 2.26) 
Schneider 2005 1.06 (0.57, 2.00)   0.40 (0.02, 6.97)     
Skelbred 2006a   0.46 (0.21, 1.02)       
Tuimala 2004 0.45 (0.18, 1.11)         
Abbreviations: ORz=control-only genotype-smoking odds ratio, 95% CI= 95% confidence interval, ref=referent, Arg=Arginine, 
Gln=Glutamine, Trp=Tryptophan, His=Histidine, Met=methionine, Asp=Aspartic acid, Asn=Asparagine 
1
 Pack-years: lightest non-zero category (ref) vs. heaviest 
2
 Intensity (packs/day): lightest non-zero category (ref) vs. heaviest 
3
 Duration (years): shortest non-zero category (ref) vs. longest 
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Table VIII.B.4.  
Association between XPD Lys751Gln and smoking : Individual study results 
Author and Year Never/ever Current/Not current Pack-years 1 
 ORz (95%CI) ORz (95%CI) ORz (95%CI) 
Harms 2004     2.27 (0.84, 6.11) 
Hoffmann 2005   1.57 (0.58, 4.25)   
Hou 2002 1.40 (0.75, 2.62)     
Huang 2005a 1.11 (0.73, 1.69)   0.78 (0.42, 1.44) 
Jiao 2007b 1.13 (0.75, 1.71)     
Matullo 2001b 0.97 (0.60, 1.57) 1.25 (0.72, 2.17)   
Matullo 2005 0.86 (0.51, 1.44) 0.74 (0.46, 1.22)   
Metsola 2005 1.26 (0.82, 1.93)   0.90 (0.43, 1.88) 
Schabath 2005 0.89 (0.62, 1.29)   0.75 (0.45, 1.25) 
Shen 2003 0.52 (0.26, 1.03)   1.31 (0.70, 2.46) 
Skelbred 2006a   1.21 (0.82, 1.80)   
Terry 2004 0.78 (0.61, 0.99) 0.95 (0.70, 1.29)   
Xing 2002a 0.91 (0.50, 1.63)   0.77 (0.34, 1.73) 
Yu 2004b 1.35 (0.52, 3.54)     
Zhou 2002 0.93 (0.74, 1.19)   2.15 (1.38, 3.33) 
Zinjo 2006   1.91 (0.96, 3.81)   
Abbreviations: ORz=control-only genotype-smoking odds ratio, 95% CI= 95% confidence interval, 
ref=referent, Arg=Arginine, Gln=Glutamine, Trp=Tryptophan, His=Histidine, Met=methionine, 
Asp=Aspartic acid, Asn=Asparagine 
1
 Pack-years: lightest non-zero category (ref) vs. heaviest 
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Table VIII.B.5.  
Association between XPD Asp312Asn and smoking : Individual study results 
Author and Year Never/ever Current/Not current Pack-years 1 
 ORz (95%CI) ORz (95%CI) ORz (95%CI) 
Butkiewicz 2001 1.04 (0.42, 2.58)   0.63 (0.21, 1.91) 
Garcia-Closas 2006 1.04 (0.80, 1.34)     
Hou 2002 1.48 (0.79, 2.78)     
Jiao 2007b 1.16 (0.77, 1.74)     
Justenhoven 2004 1.31 (0.95, 1.81)     
Matullo 2005 1.30 (0.79, 2.16) 1.12 (0.68, 1.86)   
Schabath 2005 1.01 (0.71, 1.45)   0.86 (0.52, 1.42) 
Xing 2002a 0.79 (0.42, 1.47)   0.66 (0.27, 1.61) 
Zhou 2002 0.98 (0.78, 1.25)   1.58 (1.05, 2.40) 
Abbreviations: ORz=control-only genotype-smoking odds ratio, 95% CI= 95% confidence interval, 
ref=referent, Arg=Arginine, Gln=Glutamine, Trp=Tryptophan, His=Histidine, Met=methionine, 
Asp=Aspartic acid, Asn=Asparagine 
1
 Pack-years: lightest non-zero category (ref) vs. heaviest 
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Table VIII.B.6.  
Association between XRCC3 Thr41Met and smoking : Individual study results 
Author and Year Never/ever Current/Not current Pack-years 1 
 ORz (95%CI) ORz (95%CI) ORz (95%CI) 
Harms 2004     1.06 (0.41, 2.73) 
Hoffmann 2005   0.63 (0.22, 1.77)   
Huang 2005a 1.24 (0.82, 1.85)   0.79 (0.43, 1.44) 
Jin 2005   2.04 (0.63, 6.60)   
Matullo 2001b 1.40 (0.87, 2.25) 1.03 (0.60, 1.77)   
Matullo 2005 1.11 (0.68, 1.81) 0.94 (0.58, 1.52)   
Shen 2002 0.70 (0.44, 1.14) 0.78 (0.49, 1.23)   
Shen 2003 0.83 (0.43, 1.63)   1.00 (0.52, 1.92) 
Skelbred 2006a   0.82 (0.56, 1.20)   
Smedby 2006 0.87 (0.61, 1.23) 1.03 (0.70, 1.51)   
Stern 2002a 1.36 (0.78, 2.40)   0.58 (0.29, 1.18) 
Tuimala 2004 1.03 (0.51, 2.08)     
Wilding 2005 1.06 (0.66, 1.70)     
Abbreviations: ORz=control-only genotype-smoking odds ratio, 95% CI= 95% confidence interval, 
ref=referent, Arg=Arginine, Gln=Glutamine, Trp=Tryptophan, His=Histidine, Met=methionine, 
Asp=Aspartic acid, Asn=Asparagine 
1
 Pack-years: lightest non-zero category (ref) vs. heaviest 
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C. Supplementary tables and figures: Manuscript 2 
 
 
Table VIII.C.1.  Genotype prevalence and Hardy-Weinberg equilibrium in CBCS and NCCCS 
SNP 
CBCS NCCCS 
Non-African American African American Non-African American African American 
No 
var  1 
Any 
var 1  
% with 
any var 
HWE  
p-
value 
No 
var 
Any 
var  
% with 
any var 
HWE  
p-
value 
No 
var  
Any 
var  
% with 
any var 
HWE  
p-
value 
No 
var  
Any 
var  
% with 
any var 
HWE  
p-
value 
ADPRT 
762 -- -- -- -- -- -- -- -- 386 153 28.4% 0.94 295 30 9.2% 0.15 
ADPRTL2 
328 -- -- -- -- -- -- -- -- 226 302 57.2% 0.99 29 285 90.8% 0.68 
APE1 148 300 836 73.6% 0.41 251 426 62.9% 0.89 153 387 71.7% 0.21 116 208 64.2% 0.71 
BRCA2 24 695 439 38.7% 0.08 408 268 39.6% 0.28 -- -- -- -- -- -- -- -- 
BRCA2 
372 579 556 49.0% 0.7 510 165 24.4% 0.89 -- -- -- -- -- -- -- -- 
CDH1 610 522 46.1% 0.91 492 182 27.0% 0.28 -- -- -- -- -- -- -- -- 
COMT 86 293 77.3% 0.92 110 153 58.2% 0.84 -- -- -- -- -- -- -- -- 
CYPIA1 
M1  325 90 21.7% 0.53 165 115 41.1% 0.58 -- -- -- -- -- -- -- -- 
CYPIA1 
M2 378 39 9.4% 0.3 274 11 3.9% 0.74 -- -- -- -- -- -- -- -- 
CYPIA1 
M3 413 2 0.5% <.001 227 5 2.2% 0.07 -- -- -- -- -- -- -- -- 
CYPIA1 
M4 377 40 9.6% 0.3 278 7 2.5% 0.83 -- -- -- -- -- -- -- -- 
ERCC1 
8092 656 478 42.2% 0.71 342 340 49.9% 0.99 -- -- -- -- -- -- -- -- 
ERCC6 
1213 713 417 36.9% 0.75 465 213 31.4% 0.83 -- -- -- -- -- -- -- -- 
ERCC6 
1230 887 244 21.6% 0.41 643 35 5.2% 0.49 -- -- -- -- -- -- -- -- 
GSTM1 2 177 192 52.0% -- 187 72 27.8% -- 258 289 52.8% -- 245 82 25.1% -- 
GSTP1 141 207 59.5% 0.23 54 193 78.1% 0.14 -- -- -- -- -- -- -- -- 
GSTT1 2 312 61 16.4% -- 216 43 16.6% -- 385 162 29.6% -- 218 109 33.3% -- 
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Table VIII.C.1.  Genotype prevalence and Hardy-Weinberg equilibrium in CBCS and NCCCS (continued) 
SNP 
CBCS NCCCS 
Non-African American African American Non-African American African American 
No 
var  1 
Any 
var 1  
% with 
any var 
HWE  
p-
value 
No 
var 
Any 
var  
% with 
any var 
HWE  
p-
value 
No 
var  
Any 
var  
% with 
any var 
HWE  
p-
value 
No 
var  
Any 
var  
% with 
any var 
HWE  
p-
value 
GST  
hap C 2,3 -- -- -- -- -- -- -- -- 179 368 67.3% -- 163 164 50.2% -- 
GST 
 hap A 2,3 -- -- -- -- -- -- -- -- 79 179 69.4% -- 82 163 66.5% -- 
GST  
hap B 2,3 -- -- -- -- -- -- -- -- 83 179 68.3% -- 27 163 85.8% -- 
GST  
hap D 2,3 -- -- -- -- -- -- -- -- 206 179 46.5% -- 55 163 74.8% -- 
hOGG1 652 483 42.6% 0.42 474 204 30.1% 0.45 -- -- -- -- -- -- -- -- 
MEH 113 -- -- -- -- -- -- -- -- 258 288 52.7% 0.37 198 127 39.1% 0.12 
MEH 139 -- -- -- -- -- -- -- -- 343 203 37.2% 0.17 135 191 58.6% 0.95 
MGMT 84 867 269 23.7% 0.12 504 174 25.7% 0.1 -- -- -- -- -- -- -- -- 
MLH1 
219 -- -- -- -- -- -- -- -- 253 286 53.1% 0.83 274 51 15.7% 0.58 
MNSOD 266 869 76.6% 0.27 196 481 71.0% 0.08 138 408 74.7% 0.55 105 220 67.7% 0.15 
MPO 699 435 38.4% 0.93 296 382 56.3% 0.37 -- -- -- -- -- -- -- -- 
MSH3 
1036 -- -- -- -- -- -- -- -- 287 256 47.1% 0.48 139 183 56.8% 0.73 
MSH3 940 -- -- -- -- -- -- -- -- 402 145 26.5% 0.26 264 59 18.3% 0.99 
MSH6 39 -- -- -- -- -- -- -- -- 393 149 27.5% 0.78 207 113 35.3% 0.34 
MYH 324 627 505 44.6% 0.19 367 306 45.5% 0.65 -- -- -- -- -- -- -- -- 
NAT1 2 103 170 62.3% -- 145 47 24.5% -- -- -- -- -- -- -- -- -- 
NAT2 2 109 165 60.2% -- 116 79 40.5% -- -- -- -- -- -- -- -- -- 
NBS1 185 518 618 54.4% 0.66 400 281 41.3% 0.53 242 293 54.8% 0.39 183 140 43.3% 0.86 
NQO1 742 389 34.4% 0.28 457 217 32.2% 0.83 -- -- -- -- -- -- -- -- 
POLD1 
119 -- -- -- -- -- -- -- -- 452 77 14.6% 0.58 171 149 46.6% 0.56 
RAD23B 756 377 33.3% 0.52 604 75 11.0% 0.41 335 193 36.6% <0.01 293 29 9.0% 0.4 
TGFB1 457 673 59.6% 0.79 224 451 66.8% 0.19 -- -- -- -- -- -- -- -- 
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Table VIII.C.1.  Genotype prevalence and Hardy-Weinberg equilibrium in CBCS and NCCCS (continued) 
SNP 
CBCS NCCCS 
Non-African American African American Non-African American African American 
No 
var  1 
Any 
var 1  
% with 
any var 
HWE  
p-
value 
No 
var 
Any 
var  
% with 
any var 
HWE  
p-
value 
No 
var  
Any 
var  
% with 
any var 
HWE  
p-
value 
No 
var  
Any 
var  
% with 
any var 
HWE  
p-
value 
XPC 499 -- -- -- -- -- -- -- -- 300 246 45.1% 0.8 278 47 14.5% 0.16 
XPC 939 400 723 64.4% 0.97 338 341 50.2% 0.19 192 350 64.6% 0.74 150 174 53.7% 0.71 
XPD 312 489 644 56.8% 0.64 517 158 23.4% 0.45 233 302 56.4% 0.62 259 63 19.6% 0.82 
XPD 751 445 688 60.7% 0.53 393 286 42.1% 0.85 212 324 60.4% 0.42 187 135 41.9% 0.86 
XPF 415 980 153 13.5% 0.27 642 31 4.6% 0.54 466 81 14.8% 0.046 309 16 4.9% 0.65 
XPF 662 249 1 0.4% 0.97 434 240 35.6% 0.2 -- -- -- -- -- -- -- -- 
XPG 1104 661 472 41.7% 0.69 231 443 65.7% 0.51 341 202 37.2% 0.26 101 218 68.3% 0.53 
XRCC1 
194 987 148 13.0% 0.43 593 89 13.0% 0.95 477 61 11.3% 0.53 277 43 13.4% 0.2 
XRCC1 
280 1030 99 8.8% 0.86 642 39 5.7% 0.58 503 44 8.0% 0.27 310 15 4.6% 0.67 
XRCC1 
399 480 642 57.2% 0.24 493 183 27.1% 0.36 222 318 58.9% 0.95 251 74 22.8% 0.07 
XRCC2 
188 982 152 13.4% 0.52 653 25 3.7% 0.62 -- -- -- -- -- -- -- -- 
XRCC3 
241 435 697 61.6% 0.09 421 255 37.7% 0.01 206 332 61.7% 0.89 204 120 37.0% 0.96 
XRCC4 
 -28073 244 889 78.5% 0.56 212 463 68.6% 0.2 -- -- -- -- -- -- -- -- 
Abbreviations: CBCS=Carolina Breast Cancer Study, NCCCS=North Carolina Colon Study, HWE=Hardy Weinberg Equilibrium, var=variant 
1 See Table 2 for definitions of common vs. variant alleles for each SNP, common=higher frequency in overall dataset. 
2
 Percent with allele present (present=referent) or not present (null) instead of % no variant allele & % any variant allele 
3
 p=present, n=null; Haplotypes for GSTT1 and GSTM1: GST hap A=GSTT1(n)/GSTM1(p), GST hap B=GSTT1(n)/GSTM1(n), GST hap C = 
GSTT1(p)/GSTM1(p) [referent], GST hap D=GSTT1(p)/GSTM1(n) 
Bold = p-value <0.05 
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Figure VIII.B.1. Directed acyclic graph of variable relationships in controls 
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